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Abdominal aortic aneurysm (AAA) is a common disorder and a major cause of
death. Pathological processes involved in AAA formation include inflammation,
proteolysis, angiogenesis and apoptosis. It has also a strong familial
predisposition with linkage studies identifying chromosomes 19q13 and 4q31 as
susceptible loci. AAA is likely to be a polygenic disorder.
Aims
 The aims of this study were to carry out a whole transcriptome analysis in order
to identify novel genes and pathways that are differentially expressed between
aneurysmal (AAA), atheromatous (AOD) and normal (NA) aortic tissue and to
confirm a set of these differentially expressed genes using quantitative real time
polymerase chain reaction (qRT-PCR).
Methods
RNA samples were prepared from full thickness aortic walls obtained during
open repair of AAA, aortic bypass for AOD and transplant patients for NA. The
quality of the RNA was assessed using the Bioanalyzer 2100 (Agilent) and
Nanodrop. RNA was then reverse transcribed to cDNA which was then
hybridised to the Human Genome (HG) -U133 plus 2.0 microarray (Affymetrix)
that interrogates the whole human genome. The robustness of the genearray
was assessed using data output quality control as defined by Affymetrix.
Statistical analysis was then carried out using the GeneSpring software. Genes
22
were considered to be significantly differentiated if they had at least a two-fold
change and a P-value < 0.05 following Benjamini-Hochberg multiple correction
testing. Genes were then classified according to their molecular functions. A set
of consistently differentially expressed genes were confirmed using qRT-PCR
with Taqman probes on a larger sample size compared with the microarray
experiment. All pathway and network analysis on the differentially expressed
genes were conducted using MetaCore software Version 6.3 (GeneGo, Inc).
Results
A total of 3320 genes and 233 genes were differentially expressed when
comparing AAA with NA and AAA with AOD respectively.  There was a
predominance of inflammatory and proteolytic genes in AAA wall. Genes with
differential expression were identified on chromosome 19q13, a locus that has
been genetically linked with AAA. These included CD79A and SpiB transcription
factor which were upregulated in AAA. Both genes are involved in inflammatory
pathways. Of the nine genes confirmed on qRT-PCR, eight showed similar
trends to that in the microarray experiment. On pathway analysis, immune and
inflammatory themes predominate.
Conclusions
This study reveals the differential expression of 233 genes in AAA compared with
AOD. This includes a number of novel genes that have not been previously
linked to AAA, some of which lie on chromosome 19q13, a locus that has been
genetically linked with AAA. The analysis also confirms a number of genes that
are already reported to be differentially expressed in AAA compared with NA or
23
AOD. Currently, there is no diagnostic test that can predict the growth rate of
AAA and no drug to modulate its growth. The novel genes and pathways






The word aneurysm is derived from the Greek word ‘aneurusma’ meaning
widening. In the Oxford Dictionary it is defined as ‘an excessive localized swelling
of the wall of an artery’. However in clinical practice, it is important to define exact
measurements to determine what constitutes ‘swelling’ and ‘dilatation’ so that
diagnostic and therapeutic targets can be set.
The diameter of the infrarenal aorta has been studied in necropsy and ultrasound
screening. The average diameter is 2.10 cm1 and is known to enlarge with age,
race, sex and body surface area but these effects are small though statistically
significant2-4.
McGregor et al proposed a definition of an abdominal aortic aneurysm as an
aorta with an infrarenal diameter of greater than 30mm5. In 1991, the Society for
Vascular Surgery and the International Society for Cardiovascular Surgery Ad
Hoc Committee on Standards in Reporting proposed as a criterion that the
infrarenal diameter should be 1.5 times the expected normal diameter6. The
disorder is conventionally diagnosed if the aortic diameter is 30mm or more.
26
1.2 Epidemiology
The prevalence of AAA can be inferred from necropsy and population-based
screening programmes. Studies with high necropsy rates showed a prevalence
of 0.6% to 3.2%7-12. In table 1.1, a survey of the necropsy studies is presented.
There has been a tendency for AAA to increase in frequency over time. The age-
and sex-specific frequencies of AAA were only calculated in two of the listed
necropsy studies7;8. In both studies, the total aneurysm frequency was twice as
high in men as in women and the aneurysms tend to appear later in woman.
27
Table 1.1 Necropsy-based studies of abdominal aortic aneurysm13
































45 838 3.2 2.0 Yes
Ultrasound scanning is a cheap, acceptable and non-invasive method of
screening for AAA.  It has an estimated sensitivity and specificity of 98 and
99%15, respectively. Four large randomised control trials16-19 have so far been
carried out. Of the 125,183 men over 65 years old that were screened, the
overall prevalence rate was 5.5%.
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Age 64–73 65-83 65-74 65-80
No.
Participants
12 639 38 704 67 800 6040
Follow-up
(years)
9.6 3.6 7 15
Attenders (%) 77 63 80 73
AAA
prevalence
4.0% 7.2% 4.9% 7.7%
1.3 Population screening
Population screening for AAA has only relatively recently started in the UK. It has
been estimated that a single ultrasound scan in males over the age of 65 years
would detect 90% of aneurysms at risk of rupture21. The MASS trial has provided
good evidence that the prevalence of aneurysm-related death is significantly
reduced in a screened male population aged 65-74 years, with a 53% reduction
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in those who attended for screening16. The MASS trial data also showed that
over four years the mean incremental cost-effectiveness ratio for screening was
£28400 per life year gained, equivalent to approximately £36000 per quality
adjusted life-year. It was estimated that this would fall to approximately £8,000
per life year gained at 10 years22. The case for population-based screening for
AAA is therefore convincing.
1.4 Clinical presentation
Most AAAs are asymptomatic. They are found on routine medical examination
when a central abdominal pulsatile mass is discovered during abdominal
palpation. They cause severe abdominal pain and hypovolaemic shock when
they rupture. Many patients develop symptoms of chronic back pain as a result of
pressure on the lumbar vertebrae, which may be eroded. Thrombosis, distal
embolisation and rupture into the intestine or vena cava are rare complications23.
1.5 Risk Factors
The aetiology of AAA is multi-factorial. Positive associations with AAA include
age24-26, smoking, hypertension and chronic obstructive airway disease25-30
whereas diabetes and black race are negatively associated28. Genetics also
plays an important part in the pathogenesis of AAA. Since Clifton31 in 1977
described AAA in three elderly male siblings in the absence of an associated
connective tissue disorder, other series have confirmed familial clustering with
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aneurysms found in 11-20% of first degree relatives32-39. The risk is more
pronounced in males than in females (25% vs. 7%)35. There is approximately a 7-
fold increase in the prevalence of AAA in male siblings of affected individuals
compared with controls and an 18-fold increase of AAA in male siblings of
affected individuals aged over 60 years40;41. Patients with a family history tend to
present younger and have a greater rate of rupture providing further evidence of
a genetic component42. Familial predisposition is therefore a strong risk factor in
the development of AAA.
A monogenic disorder resulting in AAA has not been found. There are however
monogenic diseases that have been associated with aortic aneurysms and
dissections (TAAD) including Marfan’s syndrome43, Ehler’s Danlos type IV,
autosomal dominant cutis laxa (caused by mutations in the elastin gene44) and
autosomal recessive cutis laxa (caused by fibulin-4 gene mutations45).
1.6 Management of AAA
1.6.1 Historical
In 1555, Vesalius was the first to diagnose an AAA. Astley Cooper was first to
ligate the abdominal aorta for a ruptured iliac aneurysm in 1817. In 1923, Matas
performed the first successful aortic ligation in a patient with AAA and introduced
the concept of endoaneurysmorrhaphy. Others attempted to induce thrombosis
of AAA by inserting intraluminal wires. In 1948, Rea wrapped reactive cellophane
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around the neck and the anterolateral surfaces of an aneurysm to induce a
fibrotic reaction and thereby limit expansion. Nissen used this technique in 1949
to treat the symptomatic AAA of Albert Einstein, who survived 6 years before
succumbing to rupture. The first successful and durable management of AAA
was described by Charles Dubost in 195146.
1.6.2 Surgical management
Surgery is the mainstay of treatment for AAA. Two forms of repair are currently
available for the elective management of AAA. Standard open surgical repair has
been in widespread use for the last 50 years. Recently endovascular repair of
AAA has been increasingly used as it is less invasive. Most AAA never rupture14,
so deciding when to electively repair an AAA and by what method, can be
difficult.
i) Repair vs. Surveillance for small AAA.
Necropsy9 and clinical studies9;47 have shown that the risk of rupture of AAA
increases with aortic diameter. It has been recommended that aneurysm > 5.5
cm should be electively repaired. The management of small aneurysms i.e. 4.0-
5.5 cm has been addressed in two randomised control trials: UKSAT48 and
ADAM14;49. Both trials compared all-cause mortality after immediate elective open
repair of AAA with a policy of imaging surveillance with repair of AAAs that
enlarged greater than 5.5 cm or become symptomatic. Early surgery did not
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provide a long-term advantage in both trials and ultrasonographic surveillance
was recommended for AAA ranging from 4.0 to 5.5 cm.
ii) Open repair vs. Endovascular repair.
Four trials50-53 have reported outcomes of open repair versus endovascular repair
of large AAAs in patients who were candidates for both procedures. They have
shown reduced operative mortality and early improvement in quality of life with
endovascular repair but did not find a difference in mid-term all-cause mortality or
quality of life. Endovascular repair is associated with more re-interventions and
requires periodic imaging for the remainder of the patients’ life. Longer term
follow-ups are required to determine the relative effects of the two procedures on
all-cause mortality.
iii) Endovascular repair versus observation in patients who are unfit for
open repair
EVAR-254 was the only randomized trial to compare endovascular repair with
observation for patients who are unfit for open repair. There was no survival
benefit from endovascular repair despite its minimally invasive approach.
iv) Endovascular repair versus surveillance in patients with small
abdominal aortic aneurysms
Endovascular repair of AAA is associated with a lower mortality than open
surgical repair50. Further, retrospective reviews of EVAR databases have shown
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that endovascular repair of small AAAs are associated with a better outcome
than large AAAs. About 1.9–3.2%48;49 of small AAAs will rupture while on
surveillance. The PIVOTAL trial is a multicentre randomised study comparing
outcomes between endovascular repair of small AAAs (4.0-5.0 cm) and
surveillance55.
Figure 1.1 Open repair of AAA (black arrow).
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Figure 1.2 Angiogram showing endovascular repair of AAA. A) AAA prior to
stent deployment B) AAA after stent insertion
A B
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1.6.3 Medical management of AAA
Medical treatment of AAA is still at an experimental stage. Current medical
treatments used in human trials are discussed below.
i) Beta-blockers
Beta-blockers have been shown to improve cardiac morbidity and mortality
following major vascular surgery in high risk cardiac patients56. Its
haemodynamic effect on systolic blood pressure is also potentially beneficial in
controlling AAA expansion. Propanolol has also been shown to be beneficial in
animal models of aneurysmal disease based on its biochemical effects on matrix
proteins57;58. Propanolol was investigated in two large multicentre randomised
control trials15;59 for AAA. However, it was poorly tolerated in both trials and there
was no reduction in AAA growth rate. Propanolol also had a significant negative
effect on quality of life59 as would be expected from the poor compliance rates in
both studies.
ii) MMP inhibitors
Tetracyclines are non-specific MMP inhibitors whose mechanism of action is
similar to endogenous tissue inhibitor of metalloproteinases (TIMPs) and is
unrelated to their anti-microbial action60;60;61. Tetracyclines have also been shown
to have a profound but selective effect on vascular inflammation and reduce
aortic wall neutrophil derived proteases and cytotoxic T-cell content62.
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The use of doxycycline in reducing AAA expansion in man has so far had mixed
results. A small randomised control trial (RCT) involving 32 patients suggested
that  there may be a positive effect of treatment on AAA size over an 18-month
period61, while a prospective multicentre study showed no significant change in
AAA expansion over 6 months33. Compliance was high in both trials.
Tetracycline’s efficacy in reduction of AAA growth needs to be proven in a large
RCT over a longer period (given the non-linear nature of aneurysm expansion)
before it can be recommended as a therapeutic agent.
iii) Angiotensin Converting Enzyme (ACE) inhibitors
ACE inhibitors reduce formation of angiotensin II and are therefore potent
antihypertensive. They have therefore been investigated as a potential
therapeutic agent in slowing AAA expansion as high blood pressure is associated
with AAA development. ACE inhibitors have also been shown to upregulate
collagen synthesis and decrease aortic stiffness63;64. However, post-hoc analysis
of the UK aneurysm trial data showed no relationship between the use of ACE
inhibitors and decreased expansion rate of small AAA64. A retrospective study
analysing ruptured and non-ruptured aortic aneurysms over a 10-year period
showed that use of ACE inhibitors may protect against rupture65. Their effect on
collagen synthesis could explain the decreased risk of ruptured AAA in patients
receiving them. The AARDVARK trial (funded by the National Institute for Health
Research, UK) is currently investigating the potential aneurysm-related benefits
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of perindopril, an ACE inhibitor, in patients found to have small AAAs at
screening.
iv) Statins
Statins exhibit both anti-inflammatory and anti-proteolytic properties both of
which play important roles in the pathophysiology of AAA. Their use has been
associated with decreased levels of MMP-3, MMP-966 and cysteine proteases67
in explant biopsies of AAA. AAA expansion is inhibited  and even reduced68 in
patients receiving statins. Mortality was also decreased68. All patients with
abdominal aortic aneurysms are considered to be at risk of a major
cardiovascular event and should be started on a statin69. The elucidation of the
exact mechanism of action of the statin could lead to the development of specific
inhibitors of AAA growth.
v) Anti-inflammatory agents
Anti-inflammatory agents are thought to decrease AAA expansion through
inhibition of COX-2. This decreases the amount of PGE2, which in turn inhibits
the production of MMPs70. Non-steroidal anti-inflammatory drugs have been
shown to decrease AAA expansion from 3.2 to 1.5mm/year71. COX-2 inhibitors
are, however, unlikely to be investigated further as potential therapeutic agents
because of their association with thrombotic events, notably myocardial
infarctions72-74. The use of steroids and cyclosporine for long-term control of AAA
expansion is unpractical because of their immunosuppressant effects.
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vi) Other drugs
Rapamycin is a macrolide antibiotic with an immunosuppressant effect that has
been shown to be effective in reducing aneurysm growth in an elastase-induced
model of AAA in rats75. Human trials are awaited. Roxithromycin, an antibiotic
with bactericidal action against Chlamydia has been shown to be effective in
reducing the expansion rate of AAA in a RCT, but this effect was only sustained
for a year76. Disodium cromoglycate, an inhibitor of mast cell degranulation,
reduced aortic expansion by 40% in an elastase-induced mouse AAA model,
accompanied by the inhibition of recruitment of mast cells and macrophages77.
Similarly, treatment with tranilast, another mast cell degranulation inhibitor,
attenuated AAA progression in a CaCl2-induced rat AAA model78. Rosiglitazone,
a peroxisome proliferator activated receptor gamma agonist (PPARγ), reduced
aortic expansion and rupture in angiotensin-II induced hypercholesterolemic
mouse model. Decrease in aortic expansion is associated with decreased
expression of inflammatory mediators79. Rosiglitazone is unlikely to be used in
human trials for AAA due to its cardiovascular side-effects. However,
pioglitazone another PPARγ agonist is a potential therapeutic target due to its
more favourable side-effect profile80.
vii) Gene Therapy
Gene therapy is still at an experimental stage in the prevention of AAA
development. Elastase-induced AAA development in rats was successfully
inhibited using chimeric decoy oligodeoxynucleotides (ODN) against NF-κB and
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Ets with a reduction of MMP expression81. Adenoviral transfection of TGF-β1
promotes the stability of expanding AAA82. Endovascular seeding of syngeneic
vascular smooth muscle cells (VSMCs) in aneurysmal aortic xenografts in rats
restores the healing capabilities of proteolytically injured extracellular matrix in
aneurysmal aortas, and stops expansion83 . These results are encouraging in
that possible drug targets have been identified. There are, however, limitations to
gene therapy for AAA. It is short-lived (transgene expression of TGF-β1 is
exhausted by 28 days)82  so that multiple rounds of gene therapy may be
required for the treatment of AAA and it has the potential to elicit an adverse
immune response. In addition, there is always the fear that any viral vector, once
inside the patient, may recover its ability to cause disease. It may also be naïve
to think that sporadic AAA is treatable using single gene therapy, as it is a
polygenic disorder. The development of novel less immunogenic vectors,
capable of carrying multiple genes, would be required for gene therapy to be
considered a viable option for the treatment of AAA.
1.7 PATHOGENESIS OF AAA
1.7.1 Structure of the abdominal aortic wall
The abdominal aorta has three distinct histological layers: intima, media and
adventitia. The luminal side of the tunica intima is lined by a layer of endothelial
cells. The tunica media has a lamellar structure consisting of smooth muscle
cells, elastin, collagen and ground substance. The tunica adventitia is composed
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of loose connective tissue with fibroblasts and associated collagen fibres, as well
as nutrient microvessels (the vasa vasora).
Elastin and collagen form the major components of the extracellular matrix.
Elastin is laid down in a lamellar structure within the media and constitutes about
30% of the dry weight of the aorta84. Most of the elastin in arteries is present as
the insoluble tropoelastin monomers that are cross-linked by lysine residues. It is
produced during early development and its production is complete by maturity.
Elastin then remains fairly stable with an estimated half-life of 40 to 70 years85.  It
provides support in both circumferential and longitudinal directions and
distributes tensile strengths uniformly along the aortic wall85;86. It also provides
elastic recoil to the dilated aortic wall.
Collagen is present mainly as triple helical type I and type III fibrillar collagen in a
ratio of 2:1 in the aortic wall. They are the main components of the outer layer of
the adventitia87, where they provide tensile strength and stiffness to the arterial
wall87. Unlike elastin that can stretch up to 70%88 of its initial length, collagen can
only stretch up to 2-4% of its uncoiled form88.
1.7.2 Extracellular matrix turnover
Histological examination of AAA wall has shown that it is mainly a disease of the
media and to a lesser extent the adventitia. It is characterised by a decrease in
the thickness of the media, disruption of the medial connective tissue structure
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and the loss of elastin87. This disturbs the integrity of the lamellar structure of the
media that is important in preventing aneurysm formation87. Elastolysis and
lamellar disruption are the goals of the elastase infusion used to induce aortic
dilatation in animal models89. Aneurysm formation is not only characterised by a
change in the ratio of the constituents of the extracellular matrix (with an increase
in collagen and a decrease in elastin)90, but also by the presence of immature,
un-linked forms of both collagen and elastin90.
These changes in the media have been the focus of much AAA research in an
attempt to unravel the pathogenesis of this disease. Biomechanical studies of
arteries subjected to endarterectomy have, however, demonstrated that the
aortic adventitia could tolerate both longitudinal and radial stress energy91 and
suggesting that the integrity of the aortic wall might also rely on the collagen rich
outer media and adventitia.
1.7.3 Inflammation and auto-immune response
Inflammation plays an important role in the pathophysiology of AAA
development. The walls of aortic aneurysms contain large number of
inflammatory cells including lymphocytes, macrophages and plasma cells92 as
well as deposition of immunoglobulin G. Further in-vivo evidence of AAA as an
inflammatory disease is the presence of inflammatory cells in the aortic wall of
elastase-infusion model of AAA at day 7 when aortic dilatation is maximal
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compared with day 1 when there is minimal dilatation and no inflammatory
response93.
Autoimmunity involves the breakdown of self immunoregulatory processes and
tolerance leading to generation of an immune response against self-antigens.
Another mechanism is ‘molecular mimicry’ whereby common antigenic epitopes
are shared between a microorganism and a self-antigen. A response against the
microorganism may lead to a similar response against the self-antigen sharing
common epitopes with the microorganism. Molecular mimicry is responsible for
several autoimmune diseases94. There is sufficient evidence to suggest that AAA
is an antigen-driven autoimmune disease as discussed below.
Global gene expression profiles of AAA tissue reveal large number of genes
related to the immune system. Microarray based gene expression studies of AAA
wall compared with NA show that there are a number  of differentially expressed
genes involved in immune responses95;96. This further highlights the role of
inflammatory pathways in the pathogenesis of AAA.
Immunohistochemical examination of AAA wall has shown extensive
mononuclear cell infiltrates in the adventitia and to a lesser extent the media of
AAA97-101. A predominance of CD3+ve T - cells was noted in the adventitia of
AAA compared with AOD and NA. CD19+ve B - cells and CD11c +ve
macrophages were present in the adventitia of all pathological tissues100. In
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another study characterising vascular associated lymphoid tissue in AAA wall,
the predominance of T-cells was also noted, although over 50% of samples
showed typical lymphoid follicles with B-cell germinal centres100.  AOD is
however a disease of the intima rather than the adventitia. Atherosclerotic
plaques of AAA wall were also found to have a significant proportion of CD4 T-
cells, NK cells and NK T-cells97.
1.7.3.1 TH1 TH2 responses The immune response is either cell-mediated (Th1
response) or humorally-mediated (Th2 response). Inflammatory cells found in the
walls of aortic aneurysms release cytokines that modulate the cellular and
humoral immune response. Th1 cytokines such as IFN-, IL-2, IL-12, IL-15 and
IL-18 are elevated in the blood and aortic tissues of patients with AAA102. Serum-
IFN- correlates with the rate of aneurysm progression103. Th2 cytokines such as
IL-4, 5, 8 and 10 regulate the immune response and smooth muscle cell
apoptosis102-104.The latter is a feature of aneurysm development.
Aneurysm development involves a complex interaction between Th1 and Th2
immune responses105. Th1 cytokines potentiate early atherosclerotic
development106 while Th2 cytokines are present in the AAA wall in late stages of
human AAA disease105. A Th1 response promotes aneurysm formation by
inducing the expression of matrix-degrading proteinases, while a Th2 response
suppresses macrophage MMP production and limits  aneurysm formation107. IL-4
antagonism (i.e. antagonism of a Th2 response) attenuates the formation of
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aortic aneurysm in a murine aortic transplantation model105. Schimizu at al
explain their conflicting results with other studies by postulating that a Th1
response is essential for recruitment of inflammatory cells and atheroma
formation, but without a Th2 response the lesion progresses towards aortic
occlusive disease105. Triggering of a Th2 response leads to extracellular matrix
degradation and aneurysm formation. Such triggers include risk factors for AAA
such as smoking and aging105.
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Figure 1.3 Hypothetical scheme of Th1/Th2 response in aneurysm
development. 105
1.7.3.2 Antigen activation in wall of AAA Mononuclear cells infiltrating AAAs
express early activation (CD69), intermediate activation (CD25, CD38) and late
activation (CD45) antigens. The expression of these antigens suggests active
ongoing inflammation in these lesions108.
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1.7.3.3 Autoantibodies and AAA B cells and plasma cells are localised in the
walls of AAAs and express CD69 and CD80 activation markers109. Levels of IgA
and IgG positive B-cells are higher in AAA lesions compared with the same cells
found in the peripheral blood of the same patient109. Walton et al showed
increased concentration of B-cell infiltrate in the adventitia of AAA wall. However,
they failed to show a restricted usage of immunoglobulin genes from the DNA
isolated from the aneurysmal wall. This indicates that the B-cell adventitial
infiltrate is not an autoimmune response to a limited repertoire of tissue
antigens110.
Immunosuppressive drugs such as rapamycin75, methyl prednisolone, and
cyclosporine111 reduce the rate of growth of AAA in animal models. This further
supports the possibility that AAA is an autoimmune disease.
1.7.3.4 Putative self and non-self antigens involved in cellular and antibody
responses in AAA Several possible self and non-self antigens have been
identified in AAA wall that may be involved in the pathogenesis of aneurysm
development (summarised in Table 1.3). These antigens may be able to initiate
AAA by molecular mimicry as described above.
Chlamydia pneumoniae is among the most widely studied non-self antigen. Its
presence in the walls of AAA has been shown by immunohistochemical analysis
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and tissue culture. However, polymerase chain reactions have failed to show the
presence of Chlamydia pneumoniae DNA112.
Table 1.3 Putative antigens that may elicit cellular and humoral responses
in AAA113
Self antigens Non-self antigens
Elastin and Elastin fragments108 Chlamydia Pneumoniae108
Collagen type I108 Cytomegalovirus108
Collagen type III108 Salmonella108
AAAP-40114;115 Treponema palladium108
Oxidised low-density lipoprotein108
1.8 Proteolysis and extra-cellular matrix remodelling
Abdominal aortic aneurysm formation is characterised by a breakdown of the
extracellular matrix in the aortic wall, which consists mainly of elastin and
collagen. Elastinolysis is pertinent to vessel dilatation, whilst collagenolysis plays
an important role in aneurysmal rupture85.
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1.8.1 Matrix metalloproteinases
MMPs are a family of zinc- and calcium-dependent proteases with proteolytic
activity against components of the extra-cellular matrix. There are 25 known
MMPs out of which 23 are present in humans116.
All MMPs have a similar structure consisting of a protease domain and an
ancillary domain connected by a flexible proline-rich hinge peptide except for
MMP-7 (matrilysin-1) and MMP-26 (matrilsin-2). These MMPs lack the ancillary
domain. The protease domain contains a signal peptide, a pro-domain and the
catalytic module. The ancillary domain is most commonly a domain similar to
sequences in the heme-binding protein hemopexin and the soluble fibronectin-
related protein vitronectin117;118
49
Figure 1.4 Basic domain structure of the matrix metallopeptidases.118
Due to their high proteolytic activity, MMPs are strictly regulated at three levels:
intra-cellular transcription, extra-cellular pro-enzyme activation and inhibition by
endogenous tissue inhibitors of MMPs (TIMPs)119. The major activator of MMPs
is plasmin, which is the product of the action of plasminogen activators on
plasminogen120. The elastin specific MMPs and their inhibitors: MMP-2, MMP- 3,
MMP-8, MMP-9, MMP-12 and TIMPs are of particular interest in AAA
pathophysiology120.
MMP-2 and -9 are the most extensively studied MMPs in patients with AAA.
MMP-2 levels  in the AAA wall correlate positively with increasing AAA
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diameter121. MMP-9 is suggested to be responsible for continued expansion and
rupture of aneurysms and is less prevalent in smaller aneurysms121;122. Its
primary source is inflammatory cells infiltrating the arterial adventitia, and it has
been immunolocalised to both macrophages and B cells121. Unlike either MMP-2
or -9,  MMP-3 mRNA is upregulated by more than 80-fold in AAA wall compared
with levels in AOD wall123.
MMP-8, a potent type I collagenase, was found to be elevated at the protein level
in ruptured AAA wall compared to unruptured AAA wall122. Similar result was not
reproducible at the transcription level123 reflecting the fact that MMP-8 may be
stored as preformed protein granules and thus mRNA levels may not be
representative of protein concentration.
MMP-12 is produced by macrophage and degrades collagen, elastin and
laminin124. MMP-12 has been identified in the wall of AAA but not in AOD or NA
walls124. Extracted MMP-12 from AAA wall also showed in-vitro activity125. MMP-
13 is localised to VSMCs and degrades collagen126. It has been associated with
AAA rupture126.
TIMPs constitute a family of four glycoproteins (TIMP-1,-2,-3 and -4) that inhibit
MMP and ADAM activity by binding to the catalytic sites of these enzymes127.
Among these four TIMPs, only TIMP-1 has been shown to have a protective
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effect against AAA development by inhibiting both MMP-1 and MMP-9127. These
have been confirmed in animal models of AAA128;129.
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Table 1.4 MMPs and TIMP associated with the pathogenesis of AAA130
Mediators Cells of origin Role in AAA
MMP-1 Fibroblasts  Collagenase: AAA rupture
MMP-2 VSMC fibroblasts Elastin degradation
MMP-3 Macrophages Elastin and collagen degradation






MMP-12 Macrophages Elastin degradation
MMP-13 VSMCs Collagenase: AAA rupture
MMP-14 Macrophages / VSMCs Activates proMMP-2
TIMP - 1 Various cell lines
Protective role by inhibiting MMP -1, -9
and ADAM-10
1.8.2 Cysteine proteases
Cathepsins are a large family of lysosomal cysteine proteases that play a vital
role in mammalian cellular turnover. They have  potent collagenase and elastase
activities131. Cathepsin S is one of the most potent elastase known131, while
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Cathepsin K cleaves the triple helix of collagens I and III132. Both enzymes  are
localised within smooth muscle cells and macrophages within atherosclerotic
plaques132. Cathepsins D, H and L are involved in the degradation of structural
proteins and there is greater activity in AAA wall and mural thrombus than in
normal aortic wall133-135. Deficiency of cystatin C, an inhibitor of cysteine
protease, is associated with increased aneurysm size and expansion rate136.
1.8.3 Serine Proteases
Cleavage of the plasma protein, plasminogen, by plasminogen activators
generates plasmin, which is the classical fibrinolytic enzyme (Figure 1.5). This
reaction is controlled by the plasminogen activator inhibitor (PAI-1). Plasmin
activates MMPs137 and in this way may have an indirect role in extracellular
matrix degradation during  AAA development86;134;138. AAA wall contains
significant levels of both plasminogen activators (tPA and uPA)134. Expression of
PAI-1 at the transcriptional level in AAA wall has also been shown to be
significantly lower compared with AOD wall139. Plasma levels of plasmin-
antiplasmin complexes correlate positively with progression of small AAA to large
AAA requiring surgical intervention140.
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Figure 1.5 The plasminogen-plasmin system. Plasminogen is converted
into its active form plasmin by uPA and tPA. Plasmin promotes matrix
degradation through activation of MMP and growth factors. Plasminogen













Healthy infrarenal aortic media unlike the thoracic aorta is devoid of vasa
vasorum141. Medial neovascularisation is, however, a consistent histopathological
feature of AAA wall (Figure 1.6) and has been spatially correlated with
destruction of elastin and chronic inflammation142.
Figure 1.6 A) Normal aorta – extensive network of vasa vasorum in
adventitia (arrows) with some vessels extending into media. B) AAA –
neovascularization of the media (arrowheads) originating from adventitial
vasa vasorum (arrows)143.
It has therefore been proposed that these new vessels have a sustaining or even
a causal role in the pathophysiology of aneurysms by secreting proteases that
destabilise the extracellular matrix144 and also possibly acting as a conduit for
more inflammatory cells. Immunohistochemical studies confirm localisation of
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proteinases such as MMP-2 and MMP-1144 in the neovascular endothelium.
Upregulation of angiogenic genes, VEGF, IL-8 and PROK-2145, has been
associated with aneurysm development and rupture. It has also been shown that
inhibition of ets-, an essential transcription factor for angiogenesis and a potential
upstream pharmacologic target for MMP-9, results in the prevention of AAA
progression in an elastase-induced rat model of this condition146.
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1.10 Apoptosis
The medial layer of AAA tissue shows decreased VSMCs density and increased
apoptosis147;148.
Figure 1.7 VSMCs stained with anti-α-SMC actin monoclonal antibodies in
A. Normal aorta B. AOD and C. AAA. The abundance of SMC in the media of
normal aorta and AOD is contrasted with decrease in medial SMC in AAA
(arrow)147.
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Initiation of apoptosis occurs through either an intrinsic or extrinsic pathway,
leading to activation of caspases that regulate DNA degradation149. The extrinsic
pathway involves inflammation mediated by macrophages, lymphocytes and
death ligands. The intrinsic pathway is secondary to DNA instability and oxidative
stress149. Fas, its ligand FasL, perforin and elevated cellular production of p53
and p21 have been implicated in inflammation-mediated apoptosis in AAA150.
Other mechanisms involved in apoptosis of VSMCs in AAA include:
overexpression of TGF-β1150 and inhibition of Rho-kinase, a key activator of
apoptosis151.
VSMCs contribute to vascular tone and synthesis of extracellular matrix. They
also limit proteolysis by confining inflammation to the aortic adventitia152. Their
depletion can promote AAA formation through elimination of a cell population that
is capable of connective tissue repair.
1.11 Atherosclerosis and AAA
Atherosclerosis is invariably associated with the development of AAA because of
the consistent finding of atheroma in the walls of the aneurysms153. This view has
been challenged in recent years.
i) Atherosclerosis is a major risk factor for athero-occlusive disease and not all
patients with atherosclerosis develop aortic aneurysm.
ii) Atherosclerosis is an intimal disease, whereas in the abdominal aorta,
aneurysms are caused by medial damage.
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iii) AAA is familial, under genetic influences and is unrelated to the lipid-related
risk factors associated with atherosclerosis154.
iv) Experimental models of hyperlipidemia in rabbits produce extensive aortic
atherosclerosis but do not result in aneurysm formation in the aorta155.
1.12 Oxidative Stress Theory
Reactive oxygen species (ROS) are formed during normal metabolism but their
formation is increased under stress conditions such as localised inflammatory
processes. The oxidative stress generated can result in progressive cell and
tissue damage. ROS involvement in the pathogenesis of AAA is evidenced by
reduced levels of antioxidants and increased lipid peroxidation in AAA wall when
compared with normal aortic wall156;157. Potential sources of ROS include large
numbers of infiltrating leukocytes (particularly macrophages), VSMCs, fibroblasts
and endothelial cells that are all capable of forming superoxide via different
pathways158.
ROS can modulate the recruitment of inflammatory cells into the aortic wall of
AAA by regulating the activities of cytokines and chemokines159. These
inflammatory cells are important sources of proteolytic enzymes such as MMPs
that are capable of degrading the aortic wall160;161.  ROS play an important role in
the pathogenesis of hypertension162;163 which is an important risk factor in the
development of AAA164. Another mechanism by which ROS can cause AAA
development is through SMC apoptosis165.
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Figure 1.8 Mechanisms by which ROS may promote AAA formation.
Proaneurysmal effects of ROS are shown in dashed lines158.
1.13 Haemodynamic factors and biomechanical wall
stress
The higher incidence of aneurysms in the infra-renal aorta compared with the
thoracic aorta can be partly explained by its lower elastin concentration,
reduction in its luminal diameter and an increase in turbulence caused by
bifurcation of the aorta into iliac arteries166. The resultant turbulent flow can









The change in flow from laminar to turbulent has been shown to profoundly
amplify the cellularity of experimental aneurysm wall168 and to differentially
regulate AAA gene expression169. There is an increase in intramural vascular
inflammation, reduction in endothelial cell stability and production of reactive
oxygen species169.
Laplace law states that in a simple cylinder or sphere the wall tension (T) is equal
to the pressure (P) times the radius (R) of the conduit i.e. T = P × R. The risk of
rupture increases with the size of the distension and the pressure within the
sphere or cylinder. AAA formation is accompanied by an increase in wall stress
and a decrease in wall strength which lead to further increases in the size of the
AAA that eventually leads to rupture170-172. This simplistic model does not,
however, explain why rupture occurs in  about 3% of patients with a small
aneurysm (i.e. < 5cm)173. AAA wall is complexly shaped with variable
curvatures174. The wall stress is highly dependent on the shape (e.g. profile,
tortuosity and asymmetry) of the specific AAA175;176. AAA of different diameters
can have similar wall stress distribution making it difficult to predict wall stress
without complex mathematical analysis (Figure 1.9).
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Figure 1.9 Wall stress distribution for 2 AAA and 1 nonaneurysmal aorta
(bottom). Two views are shown for each aorta. Maximum diameter of top
left AAA is 5.5 cm and top right is 6.4 cm. All subjects had normal blood
pressure. Despite their differing sizes, peak wall stress was essentially
similar in both AAA177.
Most AAA walls are also lined by intraluminal thrombus (ILT) and its
biomechanical behaviour should be considered in evaluating AAA wall stress.
Ultrasound measures of ILT in AAA have shown that it is incompressible and
undergoes non-linear strains177. ILT may therefore be mechanically protective by
providing a cushioning effect to the AAA wall177 (Figure 1.10).
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Numerous formulae have been developed to predict AAA wall stress and
possibly rupture. These models are however not ready for  clinical application
and patient management at this stage177.
Figure 1.10 Comparison of 3D wall stress distribution between AAA model
with and without ILT showing the cushioning effect of ILT177.
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1.14 Genetics of AAA
Abdominal aortic aneurysms are probably caused by a complex interaction
between several genes and environmental factors, each of which has a different
effect on disease susceptibility. A number of approaches have been used in an
attempt to identify the disease-susceptibility genes in AAA. These include:
i) candidate gene studies;
ii) linkage studies;
iii) genomewide association studies;
iv) gene expression studies.
1.14.1 Candidate gene studies
The rationale behind candidate gene studies involves the selection of genes for
investigation based on an educated guess and what is known about their roles in
vascular biology. The major advantage of these association studies is that they
are easy to design; they use independent patients who can be collected easily;
and the mode of inheritance of the disease does not need to be specified. Two
approaches have been described: DNA sequencing and single nucleotide
polymorphisms (SNPs) as markers. In DNA sequencing, the coding, non-coding
and promoter regions of a gene are sequenced in the patient’s DNA to identify
new variants. Most association studies however use SNPs as markers178.
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Plausible genes that have been studied in the context of AAA development are
discussed below.
1.14.1.1 Genes in aortic wall structure
Elastin (ELN) Mutations in the ELN gene have not been found to be significant
in abdominal aortic aneurysm in a study of 99 unrelated Italian patients with
AAA179. The G/A polymorphism was found to be significant only in Canadian
patients with a family history of AAA180. ELN mutations CL-16 and CL-13  were
also found to be associated with thoracic aneurysm in patients with autosomal
dominant cutis laxa181. From these studies, it can be concluded that ELN may
play a role in familial AAA as opposed to sporadic AAA.
Collagen type 3A1 (COL3A1) COL3A1 is located on chromosome 2q31. In
large studies, mutations of this gene have not been identified with sporadic or
familial AAA182. A single base mutation in type III procollagen gene (glycine to
arginine at position 619) was common among subjects in one family with AAA179.
Variation between this SNP and AAA needs further investigation.
Fibrillin-1 Fibrillin-1 2/3 genotype is thought to be an important determinant of
increased aortic stiffness in first degree relatives of patients with AAA183. This
genotype variant is associated with hypertension and may explain the increased
incidence of AAA183;184. The abnormal fibrillin may also weaken the structure of
the aortic wall or affect the signalling of transforming growth factor beta
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(TGFβ)185, which is an important mediator of tissue remodelling. Mutations in
TGFβ receptors type 1 or 2 can cause familial thoracic aortic aneurysm with
dissection186.
Fibulin-5 Fibulin-5 is an elastin binding protein187 and its deficiency leads to
fragmented elastin in mice188. Cutis laxa results from mutations in the fibulin-5
gene189. Due to its role in elastolysis, fibulin-5 gene is of interest in the
pathogenesis of AAA. One genetic association study on AAA using three SNPs
in the fibulin-5 gene showed no association with AAA190.
1.14.1.2 Genes involved in remodeling of aortic wall
MMPs There are a number of polymorphisms in the genes for MMPs and their
inhibitors TIMPs (Table 1.5). While some MMP polymorphisms have been
associated with AAA, none of them have successfully predicted AAA expansion.
The differing result with the MMP-9 polymorphism may be explained by the
heterogeneity of different population groups.
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Table 1.5 Candidate MMP and TIMP genes in AAA
Candidate gene Association Sample size Populations
MMP-1 Association between single
nucleotide polymorphism and AAA
22 Japan191
MMP-2 No association between -1306 C >
T polymorphism and AAA
expansion
455 UK192
MMP-3 No association between -1171 5A
> 6A polymorphism and AAA
expansion
Association between single
nucleotide polymorphism of MMP-3
and AAA
Association between 5A allele of
MMP3 and AAA










MMP-9 No association between -1562 C >












MMP-12 No association between -82 A > G
polymorphism and AAA expansion
455 UK192
TIMP-1 Association between single




TIMP-2 No association between single




TIMP-3 Association between Single





Cysteine proteases There is no data regarding an association between
cathepsin polymorphisms and AAA.  Deficiency of cystatin C, the major
extracellular inhibitor of cysteine proteases, is associated with increased
aneurysm size and expansion rate136. Homozygosity for the A allele of cystatin C,
associated with reduced cystatin C levels,  is weakly associated with AAA
growth196.
Serine Proteases AAA wall contains significant levels of plasminogen activators
(tPA and uPA)134. A single nucleotide polymorphism (4G>5G) in the gene
expressing their main inhibitor, PAI-1, has been associated with raised PAI-1
expression for the 4G allele197. A study of 190 patients with AAA showed a higher
frequency of the -675 5G insertion allele of the 4G>5G polymorphism in patients
with familial AAA only198. Another study involving 460 unrelated patients failed to
show a relationship between this polymorphism and AAA, but found that the
5G/5G genotype had the fastest aneurysm growth rate199.
1.14.1.3 Genes of the cardiovascular system
ACE and Angiotensin II type I receptor (ATIR) genes Genes for angiotensin
converting enzymes (ACE) and angiotensin II type I receptor are plausible
candidate genes for AAA as they are expressed in human aneurysmal aorta200
and their polymorphisms have been associated with other cardiovascular
disease201. Increased angiotensin II levels may lead to remodelling of vascular
tissue202, but its role in aortic dilatation remains unknown. Possible mechanisms
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include promotion of hypertension and altered shear stress203, activation of
growth factors and inflammation either through the induction of cytokines and
VCAM-1 expression204, or activation of NF-kβ-dependent gene expression205.
A significant association between the ACE ID polymorphism and AAA was
established in both normotensive and hypertensive patients, but no relationship
was found with variants of the ATIR gene206. A similar association has been
reported in 56 normotensive and 68 hypertensive patients with AAA207. The ACE
polymorphism may therefore be a potential therapeutic target.
Apolipoprotein B (APOB), Apolipoprotein E (APOE) and Cholesterol Ester
Transfer Protein (CETP) Both ApoB and ApoE are associated with increased
risk of atherosclerosis. In a study investigating the association of the Xbal
polymorphism of ApoB gene in patients with AAA with and without additional
popliteal artery aneurysms, no differences in allele frequencies were reported183.
ApoE knockout mice develop atherosclerosis and AAA after infusion with
angiotensin II. The E2, E3 and E4 alleles of this gene were investigated in
patients with small AAA. Though the E3/E4 genotype was associated with a
significant decrease in AAA expansion rate compared with the E3/E3 genotype in
a small study208, these findings were however not replicated in a larger study209.
There was no association between microsatellite polymorphism of the cholesteryl
ester transfer protein gene (CETP) and AAA210.
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1.14.1.4 Genes involved in methionine metabolism
Methylenetetrahydrofolate reductase (MTHFR) A mutation in the MTHFR gene
is associated with increased levels of homocysteine211 which results in increased
elastolytic activity in the arterial wall and possible AAA formation212. Two studies
including 58 Italian patients213 and 63 Polish patients 214 with AAA showed an
association between the C677T allele of the MTHFR gene and AAA
development. This was not, however, reproduced in a later New Zealand study
involving 428 AAA patients215.
Other genes coding for enzymes involved in methionine metabolism Giusti
et al.216 investigated 56 polymorphisms in 17 candidate genes involved in
methionine metabolism in patients with AAA (n=423) and controls (n=423). After
adjustment for cardiovascular risk factors and chronic obstructive airway disease,
a significant association was found between AAA and haplotypes of
adenosylhomocysteinase (AHCY), folate hydrolase (FOLH1),
methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR), nicotinamide-N-
methyltransferase (NNMT), paraoxonase 1(PON1) and thymidylate synthetase
(TYMS). These results need to be confirmed in a larger study.
Haptoglobin Three studies have investigated the association of the haptoglobin
gene variant and AAA. Two small studies involving 28 families210 and 52
patients217 with AAA showed no association with the haptoglobin gene variant. A
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larger study involving 83 patients218 showed that the HP 2-1 genotype was
associated with increased AAA expansion compared with HP 1-1 and HP 2-2
genotypes. Serum elastase activity and CRP levels were also higher in patients
with HP 2-1 genotype.
1.14.1.5 Genes involved in inflammation
Inflammation is an important pathophysiological process in AAA development92.
Inflammatory cells including leukocytes, macrophages and plasma cells capable
of releasing a number of cytokines have been immunolocalised in AAA wall92.
Several inflammatory-related genes have thus been investigated in AAA.
Interleukins Interleukin-1, -6 and -10 have been studied in AAA. IL-1 regulates
inflammatory pathways, is involved in extracellular matrix remodelling through
induction of MMPs and promotes VSMCs apoptosis. However, no association
has been found between polymorphisms in IL-1 gene and AAA. IL-6 is a pro-
inflammatory cytokine. Though increased levels of interleukin-6 have been
identified in patients with AAA, no association has been found with the -174 G/C
polymorphism of the interleukin-6 gene219. IL-10 is an anti-inflammatory cytokine
and the G-allele instead of the A–allele has been associated with a reduction in
IL-10 production220. No association of either allele with AAA was found221.
Chemokines Chemokine receptor 5 (CCR5) is associated with atherosclerotic
disease222. A higher frequency of a 32 base pair deletion in the CCR5 gene allele
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has been shown in AAA patients compared with patients with atherosclerotic
disease223. However, there was no difference in this allele between AAA patients
and controls224.
Human Leukocyte antigen locus (HLA-), Tumour Necrosis Factor (TNF) and
PPAR-γ No significant association has been found between the HLA genes and
AAA225. TNF is a pro-inflammatory cytokine whose expression is increased in
individuals with the A-allele compared with those with the G-allele226. However, a
genetic association study showed no association between the A-allele and
patients with AAA227. PPAR-γ downregulates the expression of osteoprotegerin
(OPG) in mouse model228. Levels of OPG are increased in aortic biopsies229.
Two polymorphisms in the PPAR-γ gene were studied in 4227 men out of whom
699 had an AAA230. PPAR-γ 1347C>T polymorphism was associated with
increased AAA growth.
1.14.1.6 Genes involved in signalling pathways
Transforming growth factor β (TGFβ) Variants in TGFβ1, -2, -3 and their
receptors lead to VSMCs apoptosis and thus may be involved in AAA
development231. Mutations in TGFβ receptor are associated with thoracic aortic
aneurysm186. No association has been found between TGFβ1 or its receptor and
AAA231;232. Two large case-control studies232;233 showed an association between
two SNPs (rs1036095 and rs4522809) of TGFβ-2 receptor and AAA.
Polymorphisms in TGFβ3 and its receptor were not associated with AAA234.
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Oestrogen receptor 1 and 2 and Progesterone receptor The incidence of AAA
is higher in man and post-menopausal women. Thus the sex hormones may play
a role in AAA development. Oestrogen receptor-1 and -2 and progesterone
receptor (PGR) variants were not associated with AAA.235;236
Most of the candidate gene studies described above do not have sufficient
samples to detect statistically significant association between a particular gene
variant and AAA. Sporadic and familial AAA also seem to have different
predisposing genes. Study design is further compounded by the genetic
heterogeneity expressed in AAA tissues in patients from different population
groups.
1.14.2 Linkage studies
Genetic linkage studies identify relationships between the chromosomal location
of known genes and disease phenotype in families in which the disease
segregates. The entire genome is analysed. They are of limited use in AAA as in
most cases only one generation is affected because the parents have died or the
children are too young to have developed AAA.  The presumed mode of
inheritance also needs to be defined, which in AAA is likely to be
heterogeneous237. To overcome some of these problems, an affected sib-pair
analysis can be carried out238.
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A major locus for familial AAA was mapped to chromosome 19q13.3 in three
Dutch families with familial AAA239. No evidence of linkage to this chromosome
was however detected in a further analysis of 101 affected sib-pairs in the same
study. Linkage analysis involving patients from different countries identified
chromosomes 19q13 (LOD score 4.75, p=0.00014) and 4q31 (LOD score 3.73,
p=0.00012) as possible loci for AAA240. Although chromosome 19q was mapped
in both studies, the loci did not overlap. This possibly reflects the genetic
heterogeneity indicating that at least 2 different genes may be responsible in
AAA. These regions are candidate regions for AAA susceptibility genes and the
specific disease-causing gene polymorphism(s) now needs to be identified.
Linkage of 19q13 has also been made with intracranial aneurysmal disease in a
cohort of Finnish patients241. Plausible candidate genes on chromosome 19q13
that may have a role in AAA development include: plasminogen activator
urokinase receptor (uPAR), which has a role in the localised degradation of the
extracellular matrix and whose levels are raised in AAA wall134 ; calpain 12
(involved in SMC apoptosis)242 and LIR9 (cross-linking of LIR9 on monocytes
causes the release of inflammatory cytokines IL1B, TNF-alpha and IL-6 243 that
may be important in the inflammatory process in aneurysmal wall).
A recent association study using SNPs of common genetic variants on
chromosome 19q13 in two independent case-control sets showed no differences
in allele frequency in patients with AAA and controls. This can be explained by
the fact that sporadic and familial AAA may have different genetic basis244.
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1.14.3 Genomewide association studies
Genomewide association study (GWAS) is an unbiased approach of studying the
association between markers i.e. SNPs across the genome and disease. This
approach is hypothesis free (i.e. there is no existing hypothesis about the
association between a disease and a particular gene or locus)245. Three GWAS
on AAA has been reported.
The first GWAS246 for AAA was carried out using pooled DNA samples from 123
AAA cases and 112 controls matched for age, gender and smoking history using
Affymetrix 500K SNP arrays. A candidate AAA-associated haplotype was
identified on chromosome 3p12.3. Four SNPs in this region were strongly
associated with AAA on individual genotyping. One SNP in this region
(rs7635818) located near the contactin-3 gene was confirmed in a larger sample
size and the association was even greater in smokers who are at high risk of
developing AAA. This study is however underpowered and a further study247
genotyping the rs7635818 in 567 patients with AAA and 552 controls could not
confirm any association.
The second GWAS on AAA identified an association between the A allele of
rs7025486 located within the DAB2IP gene on chromosome 9q33.2 and AAA248.
This association was also found with other vascular diseases such as early onset
myocardial infarction, peripheral arterial disease and pulmonary embolism but
not with intracranial aneurysm or ischaemic stroke. There was no association
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between this SNP and common risk factors for vascular diseases such as
smoking, lipid levels, obesity, type-2 diabetes or hypertension.
The most recent GWAS on AAA was carried out with 1866 patients with AAA and
5435 controls and replication of promising signals in 2871 additional cases and
32,687 controls and performed a further follow-up study of 1491 AAA and 11,060
controls249. In the discovery study, nine loci were found to be associated with
AAA. In the replication stage the lead SNP at one of these loci, rs1466535,
located on chromosome 12q13.3 showed significant association with AAA and
this was confirmed on the follow-up study. The rs1466535 is located within intron
1 of the low-density-lipoprotein receptor-related protein-1 (LRP-1). No
association was seen between rs1466535 and the 12q13.3 locus in independent
association studies of coronary artery disease, blood pressure, diabetes or
hyperlipidaemia, suggesting that this locus is specific to AAA249. The C allele of
the rs1466535 demonstrated a trend towards increased expression of LRP-1
gene. The rs146635 is a biologically plausible genetic variant specifically
associated with AAA.
The main weaknesses of genomewide association studies are that a large
number of common variants are identified and most of them have a modest effect
in influencing the disease. Their real strength however lies in the discovery of
novel biologic pathways underlying the pathogenesis of AAA.
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1.14.4 Gene expression studies
These studies can identify the differential expression of genes in AAA wall
compared with wall obtained from normal and occluded aorta.
Analysis using a limited gene microarray platform has  revealed only 44 of 1176
genes investigated (3.7%) to be differentially expressed in AAA wall compared
with wall from normal aorta135. Genes that were consistently upregulated with the
greatest-fold increase were: myeloid nuclear cell differentiation antigen,
cathepsin H, platelet-derived growth factor A, apolipoprotein E, MMP-9 and
interleukin-8. Genes that were consistently down regulated were myosin light
chain kinase and β1 integrin. This pattern of gene expression reflects chronic
inflammation, extracellular matrix degradation, atherosclerosis and smooth
muscle cell depletion.
A smaller microarray chip set analysis comparing gene expression in wall from
AAA, AOD and normal aorta has revealed a similar proportion of differentially
expressed genes between AAA and AOD (11 of 265, 4.1%)250. Three were down
regulated in AAA: collagen VI αI, glycoprotein IIIA and alpha2 macroglobulin and
three were upregulated in both AOD and AAA: MMP9, ICAM-1 and TNFβ
receptor. Three genes were down regulated in both AOD and AAA: integrin α5,
ephrin α5, and rho/rac guanine nucleotide exchange factor. Only MMP9 was
significantly upregulated in both AAA and AOD of the 16 MMPs evaluated.
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Evaluation of three of the TIMPs showed no significant expression for all tissue
types although TIMP-1 tended towards upregulation in AAA.
Comparison of gene expression in infra-renal AAA, with thoracic aneurysms and
normal aorta  again using a limited microarray of 1185 genes95 found that of 8
gene products that were significantly differentially expressed between AAA and
thoracic aneurysms only 4 were directionally concordant (MMP 9, v-yes-1
oncogene, mitogen-activated protein kinase 9, and intercellular adhesion
molecule 1/CD54). MMP-9, CD86/B7-2 antigen, bystin-like, apolipoprotein E,
integrins β2 and β8, non-receptor tyrosine kinase 1, Janus Kinase 3, IL-8 and
PKC-σ were differentially expressed when comparing AAA with normal aortic
wall.
Comparison of normal aorta with AAA in two studies using different microarray
platforms95;135 that interrogated a variable number of transcripts (1176 and 1185
respectively) has revealed a similar differential expression profile of genes.
These included Cathepsin H, ApoE, MMP-9, IL-8, CXCR4, Decorin, RANTES,
MLCK and ICAM-1. Of these, MMP-9, ApoE and ICAM-1 were, however,  found
to be equally upregulated in AOD and AAA compared with normal aorta,
confirming the mRNA expression studies250, which suggest these factors  are
mediators of atherosclerosis rather than aneurysmal disease development123.
The differential expression of cathepsin H at the protein and activity level (in AAA
versus AOD) has been recently confirmed133.
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Of the genes located on chromosome 19q13, only GRLF1 (a factor regulating
endothelial vascular permeability) was found to be upregulated in AAA compared
with normal wall251.
These findings need to be confirmed using a whole transcriptome approach that
compares AAA, AOD and normal aortic wall. This may help to elucidate novel
genes that are specifically up or down regulated in the aneurysmal wall and are
not associated with atherosclerosis.
1.15 Hypothesis and Aims
1.15.1 Hypothesis
AAA is a polygenic disorder. To date, only focused gene expression studies have
been carried out to identify genes that might be important in AAA development.
The only genomewide array has looked at differential gene expression in  AAA
rupture compared with the wall of normal aorta145.  These studies are limited and
have not screened for genes that are located on chromosome 19q13 that has
been identified as a susceptible locus240. A comprehensive genomewide analysis
will provide the full profile of differentially expressed genes that could reveal
novel genes that are important in AAA development.
80
1.15.2 Aims
1. To characterise the gene expression signature in AAA, AOD and NA using a
genomewide scan.
2. To identify the genes that are differentially expressed on the two chromosomal
loci (19q13 and 4q31)240 that have been the most strongly linked to AAA. These
are the only two linkage studies published at the time this experiment was carried
out.
3. To confirm the differential expression of consistently expressed genes at the
transcription level (using quantitative real-time polymerase chain reaction, qRT-
PCR) on a larger sample size.
4. To carry out bioinformatics analysis in order to identify molecular pathways
that may be involved in AAA.
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Chapter 2




2.1.1 RNA and its extraction
Ribonucleic acid (RNA) is composed of nucleic acids that are found in the nuclei
of plants and animals. Nucleic acids consist of high molecular weight
macromolecules that are made up of smaller single units called nucleotides. RNA
represents the genetic traits of an organism and determines phenotypes through
translation into protein.
Each nucleotide molecule consists of a sugar group, a phosphate group and an
amino group. There are only four bases that make up RNA: adenine, cytosine,
guanine and uracil (A, C, G and U respectively). Structurally, the backbone
consists of alternating sugar and phosphate parts, while the amino groups
protrude like branches from the backbone (Figure 2.1) 252.
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Figure 2.1 Structure of RNA253.
Successful RNA extraction and purification involve 3 steps252:
i) effective disruption of cells or tissue;
ii) denaturation of nucleoprotein complexes;
iii) inactivation of nucleases that is capable of degrading the RNA.
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RNA is an unstable molecule, having a very short half-life once extracted. There
are two methods of RNA extraction: conventional method and solid phase
extraction.
2.1.1.1 Liquid phase extraction. The guanidinium-thiocyanate-phenol-
chloroform extraction method is a single step technique first described by
Chomczynski and Sacchi254. RNA is separated from DNA and protein using a
solvent/aqueous phase separation.
2.1.1.2 Solid phase RNA extraction. This method of RNA extraction is used by
most commercial extraction kits. It allows quick and efficient purification
compared with conventional methods. Glass particles, silica matrices and anion-
exchange carriers can be used as solid or selective adsorption surface. The
sample is first digested using a lysis buffer and the digest applied to a spin
column which has been conditioned for adsorption using a buffer at a particular
pH. RNA will adsorb to the column with the aid of the high pH and salt
concentration of the binding solution. Other contaminants which may bond to the
column surface are then removed using a washing buffer containing a
competitive agent. RNAse free water is then used to elute the RNA from the
column in the purified state255.
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2.1.2 RNA QUALITY CONTROL
Traditionally, RNA integrity has been determined using agrose gel
electrophoresis stained with ethidium bromide. This typically shows 2 bands
comprising of the 28S and 18S ribosomal RNA (rRNA) species and other bands
where smaller RNA species are located. RNA is considered of high quality when
the ratio of 28S:18S is about 2.0 256. This approach has two disadvantages:
(i) it requires a relatively large volume (5µl) of potentially precious sample;
(ii) it is subjective, in that the gel images rely on human interpretation making
comparisons from one laboratory with another difficult.
2.1.2.1 Bioanalyser 2100 (Agilent).
The bioanalyser uses the same principle as gel electrophoresis. Each RNA chip
contains an interconnected set of microchannels that is used for separation of
nucleic acid fragments. Tiny amounts of RNA samples (10µl) are separated in
the channels according to their molecular weight and subsequently detected via
laser-induced fluorescence detection. The results are visualised as an
electropherogram (Figure 2.3) where the amount of measured fluorescence
correlates with the amount of RNA of a given size.
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Figure 2.2 Bioanalyzer 2100 (Agilent technologies).
Figure 2.3 Electrophoregram from the bioanalyser. The segment preceding
the lower marker is designated the pre-region. The 5S region covers the
small rRNA fragments. The 18S and 28S represent the main RNA ribosomal
peaks256.
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The quality of the RNA is assessed by the 28S:18S ribosomal ratio and the RNA
integrity number (RIN). The RIN number is generated by the software using
methods to rank features according to their informative content and using a
Bayesian approach to select and train a prediction model on the basis of artificial
neural networks256. RIN value is assigned a number from 1 (totally degraded
RNA) to 10 (pure RNA) (Figure 2.4). The following features are taken into
account when assigning a RIN value256:
i) The total RNA ratio. This is the fraction of the area in the region of the 18S and
28S compared with the total area under the curve. This reflects the proportion of
large molecules compared with smaller ones. The higher the ratio is the smaller
is the RIN number.
ii) The height of the 28S peak. The 28S band disappears faster during RNA
degradation than the 18S band and therefore it allows detection of a beginning of
degradation.
iii) The fast area ratio. This reflects the degree of RNA degradation.
iv) The marker height. The value will be higher for degraded RNA compared with
pure RNA.
Based on the following features, the value generated by the RIN number has
been shown to be a more consistent and reproducible method of assessing RNA
quality between laboratories.
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Figure 2.4 Electrophoregrams of RNA at different stages of degradation
ranging from 10 (pure RNA) to 1 (totally degraded RNA) 256.
Time (s)
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Figure 2.5 Correlation between RIN and 28S:18S ratio against average
expressions of housekeeping genes256.
Figure 2.5 shows a number of RNA samples with varying RIN values and
ribosomal ratios and their average expressions of 4 housekeeping genes
(GAPDH, KYNF, NEFL, β2M) in an RT-PCR experiment. RNA samples of high
quality will show high expression of housekeeping genes. A RIN value > 5.5 is
more sensitive and specific than a ribosomal ratio of 2.0 or higher as determined
by gel electrophoresis at identifying RNA of high quality256.
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2.1.2.2 Nanodrop
The Nanodrop ND-1000 is a full spectrum (220-750 nm, Figure 2.6)
spectrophotometer that uses sample retention technology that employs surface
tension alone to hold the sample in place. It accurately measures RNA
concentration and purity257. It has the following advantages over the conventional
spectrophotometer with cuvette:
i) it uses only 1µl of the sample as opposed to 5µl;
ii) it is less cumbersome and time consuming to set up;
iii) it can measure samples with high concentration accurately without dilution.
Figure 2.6 Nanodrop ND-1000
RNA extract is placed on one end of a fibre optic cable. A second fibre optic
cable is then brought into contact with the liquid sample bridging the gap
between the fibre optic ends. A pulsed xenon flash lamp provides the light
source. The light  passing through the sample is analysed using a
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spectrometer utilising a CCD array257. The concentration of the nucleic acid
and the absorbance at 260 and 280nm are displayed. The ratio of the
absorbance at 260 and 280nm is used to assess the purity of the RNA. A
ratio of approximately 2.0 indicates pure RNA. If the ratio is appreciably lower,
it indicates the presence of proteins, phenol or other contaminants that
absorb strongly at 280nm257 ( Figure 2.7).
Figure 2.7 Example of spectrum display for nucleic acids using the
Nanodrop, ND 1000.
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2.2 Material and Methods
2.2.1 Samples used
AAA and AOD cases were identified during their outpatient visits at St Thomas’s
Hospital. Informed consents for blood samples and aortic tissues were obtained
from all the patients by the research fellows during their inpatient stay prior to
their surgery. All samples were collected under the approval of the ethics
committee responsible for Guy’s and St Thomas NHS trust. All AAA cases were
confirmed either on ultrasound scan or computed tomography scan. AOD cases
were confirmed on peripheral angiograms. Relevant data including date of
collection, time between collection of tissues from theatre to being snap-frozen in
liquid nitrogen (only for samples collected by myself), patients’ demographics, co-
morbidities, smoking history and size of aneurysms were duly recorded in a
database.
Normal infra-renal aorta was obtained from the tissue bank at the UKHTB,
Leicester, UK. The tissues were obtained from cadaveric donors under the





Aortic walls were obtained from 27 patients with AAA (labelled AAA1-AAA27)
and 17 patients with AOD (labelled AOD1–AOD17). A 1×3 cm strip of wall was
taken from the middle anterior sac during aneurysm repair, and a small sample of
wall was taken from the arteriotomy site during AOD repair. A sample of normal
infra-renal aortic wall was also collected from 10 normal subjects (labelled NA1-
NA10) (obtained from the tissue bank at the UKHTB, Leicester, UK). The study
flow for samples used in each group (i.e. AAA, AOD and NA) in the microarray
and qRT-PCR studies is shown in Figure 2.8.


















The tissue was washed with sterile Dulbecco’s phosphate buffered saline (D-
PBS), ph 7.4, to remove clots and blood in order to prevent contamination from
blood components. The tissue was cut into 5mm squares, snap-frozen in liquid
nitrogen and stored at -80ºC to prevent RNA degradation.
2.3.2 Tissue homogenisation and RNA extraction
All RNA extractions and subsequent experiments for all the samples were done
by me. Polytetrafluoroethylene (PTFE) cups and stainless steel ball bearings
were autoclaved twice to reduce any RNAse activity and pre-cooled in liquid
nitrogen for about 20 minutes to minimise RNA degradation during
homogenisation. Tissue (~100mg) was homogenised using the Micro-
Dismembrator S (Sartorius) at 3000rpm for 1 minute. This ‘ball-milling’ method
breaks up the frozen tissue into powder. Trizol reagent 1ml, (GIBCO, BRL, UK)
was added to the frozen powder and the mixture further homogenised for 30
seconds, at 3000rpm on the Micro-dismembrator. The homogenate was allowed
to stand for 10 minutes at room temperature, before being transferred to a sterile
polypropylene, conical Eppendorf microtube. Chloroform (Molecular Biology
Grade, Sigma) was added to the mixture at a volume of 0.2ml per 1ml of Trizol
used. The tube was shaken vigourously by hand for 20 seconds and allowed to
stand on ice for 5 minutes. Following centrifugation at 3000rpm for 20 minutes at
4ºC, the colourless upper aqueous phase was then recovered taking care not to
contaminate it with the white DNA interphase.
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2.3.3 RNA purification
Two methods of RNA purification were compared.
2.3.3.1 Precipitation with isopropanol The aqueous phase containing the RNA
was mixed with 0.5ml of isopropanol (Molecular Biology Grade, Sigma) per ml of
Trizol used for the isolation. This was mixed by inversion and allowed to stand for
10 minutes. Precipitation of the pellet containing the RNA was obtained after
centrifugation at 3000rpm. The pellet was washed with 70% ethanol (Molecular
Biology Grade, Sigma) air dried for about 10 minutes, reconstituted with 20µl of
RNAse free water (Qiagen, UK) and snap frozen and stored at -80ºC.
2.3.3.2 Purification with RNEasy kit (Qiagen) The aqueous phase was mixed
with an equal volume of 70% ethanol and mixed by pipetting. The sample was
applied to an RNA Midi Column (Qiagen) and passed through the column by
centrifuging for 5 minutes at 1500rpm and room temperature (Figure 2.9). The
column was washed with buffer RW1 from the Midi Column kit. DNAse digestion
was carried out by pipetting 160µl of DNAse I mix (Qiagen) directly on the
RNeasy column and allowed to incubate at 20-30ºC on the bench top for 15
minutes. This optional step was added in order to decrease possible
contamination with genomic DNA, which could affect the specificity and
sensitivity of both the micro-array and subsequent qRT-PCR analysis. The
column was given a further wash using buffer RW1, followed by two successive
washes with buffer RPE from the same kit. The RNA was eluted from the column
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by addition of 150µl of RNAse free water (Qiagen, UK). The RNA was snap-
frozen and stored at −80ºC.
Figure 2.9 Schematic representation of RNA extraction and purification










2.4 RNA quantification and quality
The quality and total concentration of total RNA in the sample was determined
using the Bioanalyser 2100 and Nanodrop systems.
2.5 RESULTS
2.5.1 Comparison of two methods of RNA isolation
The purity and the integrity of the RNA were affected by both the age of the
material (Figure 2.10A) and the method of RNA isolation (Figures 2.10B and C).
When isoproponol was used to precipitate the RNA the purity was compromised
by the presence of genomic DNA and ethanol contamination (arrow Fig 2.10B).
These were absent following isolation using the Qiagen midicolumn. Archived
RNA which had gone through a process of recurrent thawing and freezing
underwent degradation as shown by the peak in the fast region in Figure 2.10A
(arrow). None of the archived RNA samples were used in this study. All RNA
samples used in this study were extracted by me using Trizol and precipitated
and purified using the RNA midi column kit (Qiagen, UK) to minimise
contamination with genomic DNA and organic solvents (Section 2.3.3.2).
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Figure 2.10 Bioanalyser traces from the same sample. (A) RNA extracted
and archived for 1 year. (B) RNA extracted using Trizol and isopropanolol.
(C) RNA extracted using Trizol followed by Qiagen midicolumn. The arrows

















































































2.5.2 Quality of all RNA samples extracted
Tables 2.1-2.3 summarise the processing time for each sample (i.e. from time of
collection of the tissue sample to the extraction of RNA) and the quality of the
RNA yielded. Quality of RNA extracted is inversely correlated with the
processing time. Only RNA with RIN > 5.5 were used in the microarray and qRT-
PCR experiments.
Table 2.1 Quality of RNA extracted in AAA group.
AAA samples Processing time RIN
AAA1 5 days 8.5
AAA2 10 days 7.5
AAA3 10 days 7.6
AAA4 2 months 7.3
AAA5 3 months 7.5
AAA6 3 months 7.5
AAA7 4 months 6.2
AAA8 4 months 7.1
AAA9 6 months 6.6
AAA10 3 months 6.4
AAA11 8 months 7.0
AAA12 8 months 7.1
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AAA13 6 months 7.2
AAA14 9 months 6.1
AAA15 9 months 6.2
AAA17 12 months 5.3
AAA18 12 months 5.2
AAA19 12 months 6.1
AAA20 16 months 4.2
AAA21 16 months 4.5
AAA22 18 months 6.3
AAA23 16 months 4.5
AAA24 18 months 6.1
AAA25 16 months 5.1
AAA26 18 months 4.2
AAA27 18 months 5.3
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Table 2.2 Quality of RNA extracted in AOD group
AOD Sample Processing time RIN
AOD1 4 months 6.7
AOD2 6 months 7.2
AOD3 6 months 6.8
AOD4 8 months 6.9
AOD5 6 months 6.1
AOD6 12 months 6.1
AOD7 13 months 6.2
AOD8 8 months 6.2
AOD9 12 months 5.7
AOD10 15 months 6.2
AOD11 18 months 5.3
A0D12 20 months 5.2
AOD13 22 months 5.1
AOD14 18 months 4.8
AOD15 24 months 4.8
AOD16 18 months 5.0
AOD17 22 months 5.2
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Table 2.3 Quality of RNA extracted in NA group
NA samples Processing time RIN
NA1 6 months 6.7
NA2 8 months 7.0
NA3 6 months 6.2
NA4 8 months 6.5
NA5 8 months 6.3
NA6 9 months 6.5
NA7 12 months 6.2
NA8 13 months 6.0
NA9 12 months 4.3
NA10 14 months 3.2
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2.5.3 Patient demographics for microarray study
Patient demographics for the samples used in the microarray experiment are
shown in Table 2.4. Patients were age and sex matched.
Table 2.4 Demographics of patients used in microarray experiment
Demographics AAA (n=5) AOD (n=5) NA (n=5)
Mean age 70 (63-77) 62 (53-73) 56 (50-62)
Sex ( M/F) 5 / 0 5 / 0 5 / 0
Aortic diameter 6.6 (5.5-8.0) - -
Smoking 3 3 2
Hypertension 3 2 2
IHD 3 3 0
Diabetes 2 3 0
The sample size in each group was five. Though patients in the AOD group
tended to be younger than in the AAA group, there was no difference in their co-
morbidities. Patients from the NA cohort were younger and had significantly less
co-morbidity than those in the AAA or AOD cohorts, as expected.
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2.5.4 RNA profiles of aortic tissues used in the microarray
experiment
Only RNAs with the highest RIN in each group were used in the microarray
study. Bioanalyser traces for the RNA are shown in figures 2.11-2.13 and the
RIN values are summarised in Table 2.5.
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Table 2.5 Summary of RNA (RIN and A260/280) ratio for all samples



















RNA was extracted from aortic tissue using Trizol reagent however the RNEasy
midi kit protocol (Qiagen) was preferred to the isopropanol technique for RNA
purification. The RNEasy midi kit protocol involves a DNAse digestion step to
decrease contamination with genomic DNA and the highly adsorbent column
decreases the risk of contamination with organic solvent. The superiority of this
technique was shown by the decreased noise in the fast region of the
bioanalyser traces (Figures 10B and 10C).
RIN numbers for AAA samples were higher than those from either AOD or
normal aortic wall. This could be explained by the fact that the AAA samples
were stored for a shorter time prior to RNA extraction compared with AOD and
NA samples. The AOD samples, available for this study, although quickly snap-
frozen following collection, had been archived at -80ºC up to months before
extraction. Unfortunately, open surgery for aorto-iliac bypass is rare with the
advent of less invasive endovascular techniques and therefore limited the pool of
AOD samples available. The results on RNA quality from AOD also confirm our
experience of RNA extraction from other occluded arteries (carotid), where
quality was likewise a problem even though samples were freshly extracted258.
Normal aortic wall samples were obtained from UKHTB and according to their
records had much longer processing times. This affects the quality of the RNA
and is reflected by the increased noise in the fast regions and inter-regions of the
bioanalyser traces. Picochips were used to analyse the RNA from normal aortic
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wall samples (explaining the difference in scaling on the x-axis of the
electrophoregrams between AAA and normal aortic wall or AOD and normal
aortic wall) as the yield of RNA from these samples were smaller and the
picochips allowed for a much smaller volume to be used for RIN analysis on the
bioanalyser.
RNA quality and yield are also dependent on the disease processes affecting the
tissues. This probably reflects disease-specific physiological stresses on the
tissues. For example lower RIN value and yield are characteristic of some tissues
such as liver or lung independent of the sources259. None of the microarray
experiments carried out on human aortic tissues95;135;250 have reported on the
quality of the RNA used. When degraded RNA is used in a gene expression
experiment, genes with high levels of expression can still be characterised with
respect to relative expression levels. However, degradation compromises the
ability to detect differences in expression of genes expressed at low levels260.
All the RNA used for the micro-array experiment showed high level of expression
of housekeeping genes on the microarray test chips (Affymetrix) (Section 3.4.6).
This allowed us to proceed with downstream experiments with confidence in the






3.1.1 Principle of DNA microarray technology
DNA microarray technology is based on the principle of hybridisation between
two DNA strands. Hybridisation is the property of complementary nucleic acid
sequences to specifically pair with each other by forming hydrogen bonds
between complementary nucleotide base pairs. Two DNA strands will hybridise if
they are complementary to each other according to the Watson-Crick rule. The
strands of DNA can be replaced by RNA and hybridisation will still occur as long
as there is complementarity261.
In a DNA microarray experiment, many genes-specific ‘probes’ are immobilised
on a solid support (usually glass) and the array is exposed to labelled cDNA
‘targets’ derived from a biological sample. Both specific and non-specific bonding
sequences occur due to the high number of complementary base pairs in a
nucleotide sequence. The array is cleared of non-specific bonding sequences
through a washing process. The labelled cDNA targets that remain bound to a
probe sequence on the array generates a signal that depends on the strength of
the hybridisation. The strength of the signal at a particular spot on the array
depends on the amount of labelled cDNA targets that binds to a gene-specific
probe present at that particular spot262.
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Microarray technology has been used mainly for gene expression analysis or for
point mutation/SNP analysis. Gene expression analysis has helped in elaborating
the pathogenesis of different cancers, namely hepatocellular carcinoma263;264,
Hodgkin’s lymphoma265, breast cancer266 and colorectal cancer267. Gene
expression analysis has also played an important role in drug discovery,
metabolism and toxicity268;269, microbiological and infectious disease270;271,
genotyping272;273 and disease diagnostics274;275.
3.1.2 Fabrication of DNA microarray
DNA microarrays are generally fabricated on glass, silicon or plastic substrates.
Different probes are attached within micrometers of each other so that a DNA
microarray may have up to 106 test sites in a 1-2 cm2  area. The probes can
include synthetic oligonucleotides or larger DNA/RNA fragments. A variety of
techniques are used to spot the probes onto the test sites276. These are
discussed below.
3.1.2.1 Photolithographic process (Affymetrix).
Affymetrix microarrays are manufactured using a combination of DNA synthesis
chemistry and photolithography techniques. A glass array is first coated with a
chemical linker containing photolabile protecting groups. A mask is applied
exposing selected portions of the probe array to ultraviolet light. Illumination
removes the photolabile protecting groups enabling selective nucleoside
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phosphoramidite addition only at previously exposed sites. A different mask is
then applied and the cycle of illumination and chemical coupling is performed
again. By repeating this cycle, a specific set of oligonucleotide probes is
synthesized with each probe type in a known location. The completed probe
arrays are then packaged into cartridges (Figure 3.1)276.
Figure 3.1 Photolithography and combinatorial chemistry technology for
manufacturing Affymetrix Gene Chip276.
3.1.2.2 Spotted arrays
A robot spotter is used to move small quantities of probe in solution from a
microtitre plate to the surface of a glass plate277. The probe consists of an
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oligonucleotide that is complementary to a unique gene. The glass slides are first
coated with a polylysine reagent, a highly positively charged compound that
improves adherence of oligonucleotides and a robot is used to spot probes onto
the glass slides. Subsequent preparation and hybridisation to the array is similar
to the Affymetrix protocol discussed below (Section 3.1.3)276.
The main advantage compared with the Affymetrix array is that any probe can be
designed for spotting onto the array. The disadvantages are that spotting will not
be as uniform as in situ synthesised Affymetrix chips and the cost of designing
the probes are high.
3.1.2.3 Digital Micromirror arrays (Geniom One, NimbleGen).
This technique uses a digital micromirror device in combination with a mercury
lamp to control light-directed synthesis of oligonucleotide arrays. The process
involves deprotection of photolabile groups and coupling with DNA building
blocks. Repeated cycles of photodeprotection and coupling result in
oligonucleotide chain elongation with a specific sequence for each spot278.
3.1.2.4 Inkjet arrays (Agilent).
Printing technology developed for inkjet printer is used. Pre-synthesized
oligonucleotides are printed directly onto the glass surface. These are known as
deposition arrays279.
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3.1.2.5 Bead arrays (Illumina).
Bead array technology is based on 3-micron silica beads that self assemble in
microwells on a substrate which is either fibre optic bundles or planar silica.
When randomly assembled on one of these two substrates, the beads have a
uniform spacing of about 5 microns. Each bead is then covered with hundreds of
thousands of copies of a specific oligonucleotide280.
3.1.3 General overview of target preparation and hybridisation
The primer consisting of a T7 oligo (dT) is added to the total RNA sample. The
primer binds mRNA only, as it has a polyA tail (selective binding of adenine on
mRNA and thymine on primer) and a reverse transcriptase starts synthesis of the
first strand of cDNA from the mRNA. An RNA degrading enzyme (RNAseH)
removes the primer and allows the binding of DNA polymerase I which starts the
synthesis of the second strand of cDNA. Ligase enzyme catalyses formation of
phosphodiester bonds between the strands of cDNA forming double stranded
DNA. The cDNA is then reverse transcribed to cRNA which is labelled with biotin.
The biotin-labelled cRNA is then fragmented into smaller oligonucleotides of
about 25 basepairs. The fragmented oligonucleotides are then hybridised with
the oligonucleotides on the genechip. The genechip is stained with streptavidin-
phycoerythrin which binds to biotin and fluoresces under the laser in the scanner.
The intensity of the fluorescence reflects the level of expression of the gene
(Figure 3.2)276.
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The one-cycle cDNA synthesis kit (Affymetrix) was used for steps (i) and (ii)
(Appendix A).
(i) First strand cDNA synthesis. Total RNA (5μg) from each sample was placed
in a 0.2mL RNAse free PCR tube (Eppendorf, UK). The volume of the sample
was reduced to less than 10μl using a Gyrovap vacuum system at 1500g and
20ºC. T7-Oligo (dT) primer (2μl of 50μM) was added and the solution made up to
12μl with RNase-free water. The contents of the tube were mixed by flicking and
the reaction mix incubated for 10 minutes at 70ºC. The sample was cooled to 4ºC
for at least 2 minutes.
A first strand master mix (FSMM) was prepared using 4μl of 5×concentration of
first strand reaction mix, 2μl of 0.1M dithiothreitol (DTT) and 1μl of 10mM of
deoxyribonucleotide triphosphate (dNTP). The FSMM (7μl) was added to each
RNA/T7-Oligo (dT) primer mix above to give a final volume of 19μl. The reaction
mix was incubated at 42ºC for 2 minutes. SuperScript II (reverse transcriptase)
(1μl) was added for a final volume of 20μl. The reaction was incubated at 42ºC
for 1 hour and cooled to 4ºC for at least 2 minutes.
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(ii) Second strand cDNA synthesis. Second strand mastermix (SSM) was
prepared using the following reagents in the proportion shown in Table 3.1.





5 × 2nd Strand Reaction Mix 30
dNTP , 10mM 3
E. coli DNA ligase 1
E. coli DNA polymerase I 4
RNase H 1
Total Volume 130
The SSM (130μL) was added to each first strand synthesis sample from step (i)
for a total volume of 150μL. The reaction was incubated for 2 hours at 16ºC. T4
DNA polymerase (2μL) was added to each sample and incubated at 16ºC for 5
minutes, after which 10μL of EDTA was added to stop the reaction.
(iii) Clean-up of the double-stranded cDNA. The sample clean up module kit
(Affymetrix) was used. cDNA binding buffer (600μL) was added to the double-
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stranded cDNA synthesis preparation from step (ii). The mixture was added to
the cDNA cleanup spin column and centrifuged for 1 minute at 3000rpm. The
non-adsorbed sample was discarded. cDNA wash buffer was pipetted onto the
spin column and centrifuged for 1 minute at 3000rpm. The column was dried by
centrifuging at 4000rpm for 5 minutes. cDNA elution buffer was pipetted directly
on the spin column and eluted by centrifuging at 4000rpm for 1 minute.
(iv) Synthesis of biotin-labelled cRNA. The GeneChip in vitro transcription
(IVT) labelleling kit (Affymetrix) was used. The template cDNA synthesized above
was added to the reagents in Table 3.2. The mixture was then incubated at 37ºC.
Table 3.2 Reagents for preparation of cDNA template.
Component Volume  (μL)
Template cDNA 12
RNase-free water 8
10 × IVT Labelling Buffer 4
IVT Labelling NTP Mix 12
IVT Labelling Enzyme Mix 4
Total Volume 40
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(v) Cleanup of biotin-labelled cRNA. The sample clean-up module kit
(Affymetrix) was used. RNase-free water (60μL) was added to the IVT reaction
and mixed. IVT cRNA binding buffer (350μL) was added to the sample and
mixed. This was followed by addition of 250μL of ethanol (96-100%, molecular
grade, Sigma). The sample was then applied to the IVT cRNA cleanup spin
column and centrifuged for 15 seconds at 3000rpm. IVT cRNA wash buffer
(500μL) was then pipetted onto the spin column and centrifuged at 3000rpm.
Ethanol (500μL of 80%) was added and the spin column centrifuged at 3000rpm.
The column was then dried by centrifuging it for 5 minutes at 4000rpm. The
biotin-labelled cRNA was eluted with 21μL of RNAse-free water.
(vi) Quantification of the cRNA. The amount of cRNA was quantified using both
the Nanodrop and Bioanalyser 2100 (Agilent). Figure 3.3 shows an example of a
typical electrophoregram of cRNA from the Bioanalyser 2100.  Successful cRNA
synthesis is shown by a broad hump.
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Figure 3.3 Electrophoregram of biotin-labelled cRNA. Successful cRNA
synthesis is shown by a broad hump (blue arrow).
(vii) cRNA fragmentation. The sample cleanup module kit (Affymetrix) was
used. The cRNA was fragmented by adding 8μL of a 5×concentrate of
fragmentation buffer to each sample and the volume made up to 40μL by adding
RNAse free water. The reaction was incubated at 94ºC for 5 minutes. Successful
fragmentation was checked by running each sample on the Bioanalyser 2100
(Figure 3.4).
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Figure 3.4 Example of an electrophoregram of fragmented cRNA. The peak
will show a shift towards the left.
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The Genechip hybridisation, wash and stain kit (Affymetrix) was used for steps
(viii) and (ix) (Appendix A).
(viii) Target Hybridisation. A hybridisation cocktail was prepared using the
reagents shown in Table 3.3. This cocktail (300μl) was added to 15μg of each
cRNA sample into a 0.2mL pcr tube (Eppendorf, UK). The mixture was then
heated at 99ºC for 5 minutes.
Table 3.3 Hybridisation cocktail.
Component Volume ( μL)
Control Oligonucleotide B2 ( 3nM) 5
20 × Eukaryotic Hybridisation controls 15
Herring Sperm DNA (10mg/mL) 3
BSA ( 50mg/mL) 3
2 × Hybridisation buffer 150
DMSO 30
RNAse free water Variable
Final Volume 300
The Human genome 133 Plus 2.0 genechip was used. The genechip contains
54,675 transcripts. The probe arrays (Figure 3.5) were equilibrated to room
temperature and filled with 250μL of 1×hybridisation buffer (Affymetrix). They
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were incubated for 10 minutes in the hybridisation oven (Figure 3.6) at 45ºC with
rotation. The hybridisation buffer was removed and the probe arrays filled with
200μL of the hybridisation cocktail before hybridisation for 16 hours at 45ºC with
rotation of 100rpm.
Figure 3.5 Human genome U133 Plus 2.0 probe array (Affymetrix).
Figure 3.6 Genechip hybridisation oven (Affymetrix).
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(ix) Probe array washing and staining. Immediately following hybridisation, the
probe arrays underwent an automated washing and staining protocol on the
fluidics station (Figure 3.7 Affymetrix). Staining and antibody mix were prepared
using reagents in Tables 3.4 and 3.5 respectively and loaded on the fluidics
station.
Figure 3.7 Fluidics station (Affymetrix) 276.
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2 × Stain Buffer 600
50mg/mL BSA 48
1mg/mL Streptavidin Phycoerythrin (SAPE) 12
DI water 540
Total Volume 1200
Table 3.5 Antibody solution mix.
Components Volume
( μL)
2 × Stain Buffer 300
50mg/mL BSA 24
10mg/mL Goat IgG Stock 6




The fluidics station was used to wash and stain the probe arrays. Once the
fluidics station protocol was complete, the probe arrays were then ready for
scanning.
(x) Probe Array Scan. The probe arrays were scanned on the Genechip
Scanner 3000 (Affymetrix). The Gene-Chip Command Console (GCOS) software
(Affymetrix) defined the probe cells and computes intensity for each cell.
3.3 Data output quality control.276
3.3.1 Probe array image inspection
The probe array image for each sample was visually inspected for artifacts
(spots, scratches or array defects) that would present as a distinct pattern of
abnormal intensities on the image.
3.3.2 B2 Oligo performance
B2 oligo is spiked into each sample and is used as a control for features around
the edge of the chip. After scanning of the chip, the software created a grid over
the image to demarcate each probe cell. Hybridisation of B2 oligo was used as a
control for proper alignment of the grid for further data analysis. In order to
ensure the array was working optimally, the presence of the following was
assessed:
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 An alternating pattern of intensities on the border (Figure 3.8).
 A checkerboard pattern at each corner (Figure 3.8).
 The array name located in the upper-left or upper-middle of each array
(Figure 3.9).
Figure 3.8 Alternating pattern of intensities at the border and checkerboard
appearance at corner secondary to B2 oligo hybridisation276.
Figure 3.9 Array name showing successful hybridisation of B2 oligo276.
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3.3.3 Average background
The background value is a measure of the signal intensity caused by auto-
fluorescence from the array surface as well as non-specific binding of target or
stain molecules (SAPE). The background value of each genechip should ideally
be between 20 and 100. The background value for each genechip is generated
automatically during scanning. Replicates should ideally have comparable
background values.
3.3.4 Noise
Noise is a measure of pixel-to-pixel variation on the genechip and is determined
by the electrical noise of the scanner and the quality of the sample being
scanned. Noise values should be comparable as the same scanner was used for
all the samples.
3.3.5 Hybridisation controls: bioB, bioC, bioD and Cre
BioB, bioC and bioD are genes in the biotin synthesis pathway of E.coli and Cre
is the recombinase gene from B1 bacteriophage. Oligonucleotide fragments are
provided in the Affymetrix kit as a mixture of biotin labelled cRNA transcripts in
staggered concentrations (1.5pM, 5pM, 25pM and 100pM final concentrations for
bioB, bioC, bioD and Cre respectively). 1ml of the mixture was spiked into each
sample before the hybridisation step to evaluate its efficiency (Table 3.3 – 20×
Eukaryotic hybridisation controls). BioB is at the level of assay sensitivity
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(1:100,000) and should be detected in at least 50% of the samples. BioC, bioD
and Cre should always be detected with increasing signal values reflecting the
staggering concentrations.
3.3.6 Internal control genes
Probes for the housekeeping genes, β-actin and GAPDH were used to assess
RNA and assay quality. Specifically, the signal values of the 3’ probe sets for β-
actin and GAPDH were compared to the signal values of the 5’ probe sets. The
ratio of the 3’ probe set to the 5’ probe set should be < 3. A higher ratio indicated
degraded RNA or inefficient transcription.
3.3.7 Percent present
The percentage of probes called ‘Present’ or expressed should be comparable
between replicates. The values depend on tissue type, biological variables, array
used and disease investigated.
3.3.8 Scaling factor
All arrays are scaled to a target intensity of 100 in order to correct for differences
in intensity between arrays. These differences are caused by pipetting error and
hybridisation, washing and staining efficiencies which are independent of
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transcript expression. The scaling factors between replicates should be within 3-




Adequate cRNAs were synthesized for all the samples as shown in the
bioanalyser traces in Figures 3.10A-C.























The cRNAs were then fragmented into smaller oligonucleotides of 25-200
basepairs, indicated by a left shift of the bioanalyser traces (Figures 3.11A-C).
This allowed for complementary hybridisation of the cRNA to the oligonucleotides
on the genechip.
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The background values for all the samples were within range (20-100 units) as
shown in Figures 3.12 A, B and C. There was little variation between samples.
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Figure 3.12 Background autofluorescence values for hybridisation of
samples for A) AAA, B) AOD and C) Normal artery.
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3.4.4 Noise
Noise values for all replicates within each group were between 2 and 3 units with















Figure 3.13 Noise values for A) AAA, B) AOD and C) Normal artery.
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3.4.5 Hybridisation controls: bioB, bioC, bioD and Cre
BioB was present in all 15 samples indicating a high sensitivity for all the assays.
Each sample showed increased signal intensities for bioB, bioC, bioD and Cre
respectively reflecting their staggering concentrations. This step confirmed that
hybridisation was successful in every sample (Figures 3.14 A, B and C).
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Figure 3.14 Hybridisation controls for A) AAA, B) AOD and C) Normal
artery.
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3.4.6 Internal control genes
3’/5’ ratios for both GAPDH and β-Actin were less than 3.0 in all the samples
used. This indicates that good quality RNA was used for all the samples which
would result in reduced non-specific hybridisation.
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Figure 3.15 3’/5’ ratios of housekeeping genes for A) AAA, B) AOD and C)
Normal artery.
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3.4.7 Percent probe present
The percentage of probes called ‘Present’ was about 50% in each sample with
minimal variation between samples.
149




The scaling factors for all the 15 samples were within 3-fold of each other making
them suitable for statistical comparison (Figures 3.17 A, B and C).
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Figure 3.17 Scaling factors for A) AAA, B) AOD and C) Normal artery.
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3.5 Discussion
The quality control step is crucial in ensuring that all the samples satisfy the
stringent criteria as set out by the chip manufacturer (Affymetrix). All the quality
control parameters investigated were within normal limits for all 15 samples
employed in this study. The variations in the RIN numbers of the RNA used for
the samples did not appear to affect the micro-array experiment as evidenced by
the 3’/5’ ratios of GAPDH and β-Actin which were <3 for all samples, indicating
minimal degradation. The quality of the scanned images was therefore







Microarray experiment generates a large volume of data. Different software
packages (GeneSpring, Genemaths XT, Genesifter, and Spotfire) are available
for data analysis to determine significant target genes. The principle of the
analysis is, however, the same and involves the following steps:
i) Normalisation: A normalised value represents a relative intensity resulting
from division of a raw value (signal intensity derived from microarray experiment)
by a control value. The control value is the value by which the raw intensities are
divided to normalise the data and centre them on 1. Types of normalisation
applied in this study are detailed in section 4.2.1.
ii) Principal component analysis (PCA): This is a decomposition technique that
reduces the multi-dimensionality of a data set to allow visual analysis. Dimension
is defined as the minimum number of coordinates needed to specify each point.
Since visual analysis is performed in three dimensions, in a coordinate system of
x, y and z, PCA allows reduction of a matrix of any dimensionality to only three
dimensions281.
iii) Clustering: This is the assignment of a set of observations into subsets
(called clusters) so that observations in the same cluster are similar in some
sense282. Clustering technique used in this study is detailed in Section 4.2.2.
iv) Statistical analysis: This is detailed in Section 4.2.4.
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v) Classification according to GO (Gene ontology) processes: The
GeneSpring software (version 7.3.1, Agilent technologies) was used to analyse
the microarray data in this study.
4.2 Methods
The microarray data from all the samples were imported into the GeneSpring
software (Agilent technologies). Two comparisons were carried out: AAA vs.
AOD and AAA vs. NA.  The data was analysed systematically using the following
steps as detailed out by GeneSpring.
4.2.1 Normalisation
The data was first normalised to ensure consistency in terms of biological and
non-biological variations between the samples. Normalisation was carried out in
the following order:
i) Data transformation. Measurements less than 0.01 were set to 0.01 as
GeneSpring uses log values for comparison.
ii) Per chip normalisation to 50%. This step controlled for variation in intensity
across the chips, caused by non-biological variations such as inconsistencies in
washing and staining of the chips on the fluidics station.
iii) Per gene normalisation to median. This accounted for differences in
detection efficiency between spots. The relative change in expression level was
compared using the formula:
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(Signal strength of gene A in sample / Median of expression of gene A in all the
samples)
4.2.2 Quality control
This step is used to determine whether variations within the data are due to
methodological differences rather than biological variations. This step is crucial
prior to statistical analysis.
i) Normalisations. After the normalisation steps described above, all the
samples and their distributions around 1 were analysed. Replicates for the same
condition should have similarly shaped normalisation curves around 1.
ii) Principal Component Analysis (PCA). The data from expression arrays are
of high dimensionality. In this experiment, 54000 transcripts were measured in 15
patients, generating a matrix of 15 × 54000. It is impossible to analyse for trends
in such a matrix by visual inspection. PCA is a decomposition technique that
reduces the dimensionality of the data into a new set of variables (principal
components) to summarise the essential features of the data. The first
component accounts for maximum variability between conditions. It gives a
general view of the variation between replicates281;283.
iii) Hierarchal clustering. This clustering technique shows how similar the
samples are based on their gene expression profiles. This is based on
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correlations between the samples. For true reflection of the correlation, the ‘per
gene normalisation step’ (Section 4.2.1) is removed prior to cluster analysis
otherwise samples will look artificially close. Pearson’s correlation which
assumes a normal distribution and equality of variances is most commonly used.
The variance assumption has, however, been shown to be a cofounder in
microarray analysis and thus a more conservative correlation measure that
makes use of ranked data namely the Spearman’s correlation was used282;284. A
distance measure corresponding to the Spearman ranked correlation is
computed as follows285:
d s = 1 – r s
d s - distance based on Spearman correlation
r s - Spearman rank correlation.
Samples that represent the same disease should cluster together. This technique
may fail if there are a large number of genes in the order of several thousands282.
4.2.3 Generating list of genes of interest
Once the samples had passed the quality control steps above, they were
analysed for biological variation. Genes that were consistently differentially
expressed by at least two-fold when comparing either AAA vs. AOD or AAA vs.
NA were identified using the filters described below.
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i) Genes that were called ‘Present’ or ‘Marginal’ in 4 out of 10 samples. This
filter allowed all genes that were ‘Present’ or ‘Marginal’ in 4 out of 10 samples in
the microarray data to be included for further analysis thus ensuring that only
genes that are consistently differentially expressed were included for further
analysis.
ii) Standard deviation (SD) filter. Only genes that varied by less than 1.5 SD
around their mean of expressions of the replicates were considered. Genes with
a high variance are likely to be less reliable.
iii) Fold change of 2. Only genes that were differentially expressed by at least 2-
fold were included95;135;145;258.
The purpose of applying these filters was to generate a set of reliable genes for
further analysis and to decrease the number of false positives that passed
through the filters following statistical analysis.
4.2.4 Statistical analysis
A one-way ANOVA with a parametric t-test was used to identify genes that were
differentially expressed (P < 0.05) after Benjamini-Hochberg correction test (false
discovery rate = 0.05) to decrease the false discovery rate in a large gene set. A
parametric t-test was used as all the data were normalised and showed normal
distribution curves prior to statistical analysis (sections 4.2.1 and 4.3.1).
159
4.2.5. Gene ontology
Differentially expressed genes were analysed in terms of their molecular
functions. Genes were grouped into the following categories: proteolysis, immune
response, apoptosis and angiogenesis.
4.2.6 Identifying genes on chromosomes 19q13 and 4q31
Genes on chromosomes 19q13 and 4q31 were identified. These chromosomes




Both normalisation curves comparing AAA vs. AOD, or AAA vs. NA showed
similar shapes for replicates. All the samples normalised around 1 as would be
expected (Figures 4.1 A and B respectively).
Figure 4.1A Normalisation of AAA vs. AOD samples.
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Figure 4.1B Normalisation of AAA vs. NA samples.
4.3.2 Principal component analysis
This helps to visually identify samples that are outliers for a given condition.
Comparison of AAA vs. AOD (Figure 4.2A) showed that all the AOD replicates
clustered together. Similarly with the exception of one sample the AAA replicates
clustered together. The matrix for the outlying sample lies in the XZ plane as the
other AAA replicates compared to the AOD replicates which lie in the XY plane
indicating closer similarity to the AAA samples. Comparison of AAA and NA
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samples (Figure 4.2B), there revealed 2 distinct group of matrices representing
each condition.
Figure 4.2A Principal components showing variances between AAA
replicates (yellow) and AOD replicates (red).
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Figure 4.2B Principal components showing variances between AAA
replicates (red) and NA replicates (yellow).
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4.3.3 Hierarchal clustering
Similarity of gene expression between replicates of AAA and AOD can be
visualised by hierarchal clustering using Spearman correlation. The data is
represented using a dendogram with a colour coded matrix for gene expression.
The colour intensity reflects gene expression level of a particular gene within a
sample. The samples are then clustered according to their similarities based on
Euclidian distance. One of the AAA replicates in Figure 4.3A clusters as a
separate branch. This can account for biological variation (family history of AAA
as opposed to spontaneous AAA) and this sample was included in the analysis
as it shows a closer similarity to AAA replicates rather than AOD replicates (d s =
0.792 compared with other AAA samples and d s = 0.501 compared with other
AOD samples, p=0.04). Figure 4.3B shows that AAA and NA replicates cluster
according to the conditions they represent.
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Figure 4.3A Hierarchal clustering of AAA and AOD replicates.
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Figure 4.3B Hierarchal clustering of AAA and NA replicates.
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4.3.4 Filtering for genes of interest
The genes of interest were generated using the steps described in section 4.2.3.
Each step eliminated genes that were potentially unreliable. As shown in Table 4.1
below, the number of transcripts that were entered in the statistical analysis was
significantly lower than the 54,675 originally present.
Table 4.1 Genes of interest identified when comparing gene expression of AAA
with AOD and NA.
Number of transcripts
Filters applied AAA vs. AOD AAA vs. NA
Total 54 675 54 675
Present or Marginal 4/10 29 141 31426
Standard deviation_ 1.5 28 630 31075
Fold change > 2 1 126 6855
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4.3.5 Statistical analysis
Statistical analysis was carried out as described in section 4.2.4. The numbers of
differentially expressed genes when comparing AAA with AOD or NA are shown in
Table 4.2. The top 30 genes with the greatest fold change are shown in Tables 4.3
and 4.4 (AAA vs. AOD) and Tables 4.5 and 4.6 (AAA vs. NA) respectively and
details of the remaining genes are given in Appendixes B-E.
Table 4.2 Number of differentially expressed genes when comparing AAA with
AOD and NA.










1 Polycystic kidney and hepatic disease 1(autosomal recessive)-like 1 PKHD1L1 32
2 Ig kappa chain precursor V region -human  (fragment) LOC391427 23
3 Stathmin-like 2 STMN2 22
4 Immunoglobulin heavy locus 18
5 Similar to Ig kappa chain LOC339562 15
6 Similar to omega protein LOC91353 14
7 Immunoglobulin lambda joining 3 IGLC2 14
8 Claudin 11 CLDN11 12
9 Hook homolog 1 (Drosophila) HOOK1 12
10 Immunoglobulin kappa variable 1D-13 IGKV1D-13 11
11 BCR downstream signaling 1 BRDG1 10
12 UDP-Gal:beta 1,3-galactosyltransferase,polypeptide 2 B3GALT2 9
13
Immunoglobulin J polypeptide, linker
protein for immunoglobulin alpha and
mu polypeptides
IGJ 8
14 Membrane-spanning 4-domains,subfamily A, member 1 MS4A1 7
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15 Bagpipe homeobox homolog 1(Drosophila) BAPX1 6
16 CD79A antigen (immunoglobulin-associated alpha) CD79A 6
17 Pre-B lymphocyte gene 3 VPREB3 6
18 Fc receptor-like 1 FCRL1 6
19 Fc receptor-like 2 FCRL2 6
20 Paired box gene 5 (B-cell lineagespecific activator) PAX5 5
21 Membrane-spanning 4-domains,subfamily A, member 1 MS4A1 5
22 Major histocompatibility complex, classII, DO beta HLA-DOB 5
23 Ral GEF with PH domain and SH3binding motif 2 RALGPS2
5
24 Homeo box D10 HOXD10 4
25 Signal peptide, CUB domain, EGF-like 2 SCUBE2 4
26 Spi-B transcription factor (Spi-1/PU.1related) SPIB 4
27 Papilin, proteoglycan-like sulfatedglycoprotein PAPLN 4
28 C1q and tumor necrosis factor relatedprotein 7 C1QTNF7 4
29 Complement component 3 C3 4
30 CD19 antigen CD19 4
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1 peroxidasin homolog-like (Drosophila) PXDNL 10
2 SPOC domain containing 1 SPOCD1 10
3 aortic preferentially expressed gene 1 APEG1 8
4 angiopoietin-like 4 ANGPTL4 7
5 heme oxygenase (decycling) 1 HMOX1 7
6 solute carrier family 16 (monocarboxylicacid transporters), member 10 SLC16A10 5
7 collagen, type V, alpha 3 COL5A3 5
8 PDZ and LIM domain 3 PDLIM3 4
9 Effector cell peptidase receptor 1 BIRC5 4
10 integrin, alpha 5 (fibronectin receptor,alpha polypeptide) ITGA5 4
11 Spermidine/spermine N1-acetyltransferase SAT 4
12 folate hydrolase (prostate-specificmembrane antigen) 1 FOLH1 4
13 collagen, type XVIII, alpha 1 COL18A1 4
14 PDZ binding kinase PBK 3
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15 Endothelin receptor type A EDNRA 3
16 endothelial differentiation, sphingolipidG-protein-coupled receptor, 3 EDG3 3
17 Sulfatase 1 SULF1 3
18 fibronectin 1 FN1 3
19 collagen, type V, alpha 3 COL5A3 3
20 Ribosomal protein S7 NSF 3
21 LIM and senescent cell antigen-likedomains 3 LIMS3 3
22 adipose differentiation-related protein ADFP 3
23 Protocadherin 17 PCDH17 3
24 solute carrier family 7, (cationic aminoacid transporter, y+ system) member 11 SLC7A11 3
25 SH3-domain GRB2-like (endophilin)interacting protein 1
DKFZp761D
221 3
26 tumor necrosis factor, alpha-inducedprotein 6 TNFAIP6 3
27 ATP-binding cassette, sub-family C(CFTR/MRP), member 3 ABCC3 3
28 collagen, type I, alpha 1 COL1A1 3
29 angiotensinogen (serpin peptidaseinhibitor, clade A, member 8) AGT 3
30 lysyl oxidase-like 2 LOXL2 3
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1 Dystrobrevin, beta DTNB 88
2 Immunoglobulin lambda joining 3 IGLC2 79
3 Similar to Ig kappa chain precursor Vregion LOC391427 62
4 Fc receptor-like and mucin-like 1 FCRLM1 58
5 Immunoglobulin kappa variable 1-5 IGKC 55
6 Immunoglobulin lambda variable 3-25 IGLV3-25 52
7 Similar to omega protein LOC91353 50
8 Immunoglobulin heavy constant mu IGHM 50
9 Immunoglobulin kappa constant IGKC 47
10 Coiled-coil domain containing 4 CCDC4 47
11 Immunoglobulin lambda variable 2-14 IGLV2-14 42
12 Fc receptor-like 1 FCRL1 39
13  Immunoglobulin heavy constant gamma1 (G1m marker) IGHG1 38
14 CD79A antigen (immunoglobulin-associated alpha) CD79A 36
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15 Similar to Ig kappa chain LOC339562 34
16 Immunoglobulin kappa variable 1D-13 IGKV1D-13 29
17 Protein kinase (cAMP-dependent,catalytic) inhibitor alpha PKIA 21
18 Polycystic kidney and hepatic disease 1(autosomal recessive)-like 1 PKHD1L1 21
19
Immunoglobulin J polypeptide, linker
protein for immunoglobulin alpha and
mu polypeptides
IGJ 20
20 SLAM family member 7 SLAMF7 19
21 BCR downstream signaling 1 BRDG1 17
22 Wingless-type MMTV integration sitefamily, member 16 WNT16 15
23 Suppression of tumorigenicity 18 (breastcarcinoma) (zinc finger protein) ST18 15
24 T-cell activation GTPase activatingprotein TAGAP 15
25 CD19 antigen CD19 15
26 Class-I MHC-restricted T cell associatedmolecule CRTAM 14
27 Fas apoptotic inhibitory molecule 3 ; Fasapoptotic inhibitory molecule 3 FAIM3 13
28 Regulator of G-protein signalling 13 RGS13 13
29 CD69 antigen (p60, early T-cellactivation antigen) CD69 12
30 Carbopeptidase Z CPZ 12
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1 aortic preferentially expressed gene 1 APEG1 56
2 chromosome 6 open reading frame 168 C6orf168 24
3 neuronal pentraxin II NPTX2 16
4 ATPase, Na+/K+ transporting, alpha 2(+) polypeptide ATP1A2 16
5 G protein-coupled receptor 37(endothelin receptor type B-like) GPR37 16
6 ADAM metallopeptidase withthrombospondin type 1 motif, 8 ADAMTS8 15
7 transient receptor potential cationchannel, subfamily C, member 4 TRPC4 14
8
protein tyrosine phosphatase, receptor
type, f polypeptide (PTPRF), interacting
protein (liprin), alpha 4
PPFIA4 14
9 chromosome 14 open reading frame 132 C14orf132 14
10 receptor-interacting serine-threoninekinase 4 RIPK4 13
11 microsomal triglyceride transfer protein(large polypeptide, 88kDa) MTP 13
12
thyroid hormone receptor, alpha
(erythroblastic leukemia viral (v-erb-a)
oncogene homolog, avian)
THRA 12
13 chromosome 8 open reading frame 46 C8orf46 12
14 E2a-Pbx1-associated protein EB-1 12
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15 Astrotactin 2 ASTN2 12
16 neurotrophic tyrosine kinase, receptor,type 3 NTRK3 12
17 metallophosphoesterase domaincontaining 2 MPPED2 12
18 ryanodine receptor 2 (cardiac) RYR2 12
19 attractin-like 1 ATRNL1 11
20 integrin, alpha 10 ITGA10 11
21 neurotrophic tyrosine kinase, receptor,type 3 NTRK3 11
22 copine IV CPNE4 11
23 calsequestrin 2 (cardiac muscle) CASQ2 10
24 purinergic receptor P2Y, G-proteincoupled, 2 P2RY2 10
25 betacellulin BTC 10
26 leucine-rich repeat-containing G protein-coupled receptor 6 LGR6 10
27 transient receptor potential cationchannel, subfamily C, member 4 TRPC4 9
28 caspase 12 pseudogene 1 CASP12P1 9
29 regulator of G-protein signalling 5 RGS5 9
30 leiomodin 1 (smooth muscle) LMOD1 9
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4.3.6 Gene ontology
Genes were classified according to their molecular functions in groups that reflected
processes known to be important in AAA development. These included: proteolysis,
inflammation, apoptosis and angiogenesis. Table 4.7 summarises the number of
genes that are differentially expressed in each group when comparing AAA vs. NA or
AAA vs. AOD. The differentially expressed genes between AAA and AOD and AAA
and NA are shown in Appendix F and J (Inflammatory genes), G and K (Proteolytic
genes), H and L (Apoptotic genes) and I and M (Angiogenic genes) respectively.
Table 4.7 Number of differentially expressed genes in pathological processes
known to be associated with aneurysmal disease.
AAA vs. NA AAA vs. AOD
Pathological process
Up Down Up Down
Inflammation 144 48 31 9
Proteolysis 110 253 10 20
Apoptosis 23 50 6 6
Angiogenesis 4 11 3 5
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The expressions of the following proteolytic genes, which have been previously
investigated at our laboratory: MMP-3, MMP-9 and Cathepsin H are shown in figures
4.4–4.6 respectively. Both MMP-3 and Cathepsin H were up-regulated in AAA
compared with AOD and NA. MMP-9 showed no significant change between AAA
and AOD but significantly higher expression in AAA compared with NA in this
microarray experiment.
Figure 4.4 Microarray analysis derived MMP-3 expression.
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Figure 4.5 Microarray analysis derived MMP-9 expression.
Figure 4.6 Microarray analysis derived Cathepsin H expression.
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4.3.7 Genes differentiated on chromosome 19q13
CD79A, Spi-B transcription factor (Figures 4.7–4.8) and ryanodine receptor 1
(RYR1) were upregulated in AAA compared with AOD. No gene was differentially
expressed on chromosome 4q31.
Figure 4.7 Microarray analysis derived CD79A expression.
Figure 4.8 Microarray analysis derived Spi-B transcription factor expression.
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4.4 Discussion
The quality control steps carried out in this Affymetrix whole genome gene chip
analysis of gene expression in AAA, AOD and NA walls have satisfied the
requirements for statistical analysis. When comparing AAA with NA, there were a
ten-fold greater number of genes that were differentially expressed than in the AAA
vs. AOD group. Atherosclerosis is a consistent finding in the walls of AAA153.
Comparison of gene expression in AAA wall with that in the wall of AOD is intuitively
more relevant as this removes genes associated with atherosclerosis from the
analysis123 and may highlight genes that are important in AAA development only.
The data from this whole genome analysis confirms that of previous studies in which
AAA was compared with AOD. Carrell et al123 showed that MMP-3 was differentially
expressed when comparing AAA with AOD and there was no difference for MMP-9
expression. Abisi et al95 showed higher expression and activity of Cathepsin H only
in AAA compared with AOD at the translational level. These results were reflected in
our data (Figures 4.4–4.6).
The importance of inflammation in AAA is highlighted by the large number of
inflammatory genes that were upregulated in both comparisons i.e. AAA vs. NA and
AAA vs. AOD in this study. Among the genes with the highest fold-change (i.e. first
20 genes in either comparison), there was a predominance of inflammatory genes
(55% in AAA vs. AOD and 75% in AAA vs. NA). A whole transcriptome analysis
comparing AAA with NA96 has also highlighted a predominance of overexpressed
inflammatory genes in the AAA group.
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The proteolytic genes represent the second largest group of differentially expressed
genes in AAA compared with AOD or NA. Extracellular matrix degradation and
remodelling is a component of both AAA and AOD147;286. Except for upregulation of
MMP-3 and downregulation of MMP-14 none of the other MMPs or protease
inhibitors was differentially expressed in our study. Similar results were shown by
Armstrong et al250 where they found no differential expression of MMPs or TIMPs in
AAA compared with AOD using a limited microarray platform. Although MMP-9 is
increased in both AAA and AOD compared with normal, its location in the aortic wall
in both pathological processes differs. In AAA, MMP-9 is localised to the adventitia
as compared with AOD where it is restricted to the media286. Interestingly, the
proteolytic genes are predominantly downregulated when comparing AAA with AOD
or NA. This may reflect the fact that the aneurysmal tissues used in this study were
from large aneurysms and genes expressed at that stage of the disease pertains
more to extracellular matrix remodelling rather than degradation. Also, the
upregulated proteases are possibly those that do the most damage to the vessel
wall.
Differential expression of genes present on chromosome 19q13 (a susceptible locus
for aneurysm development)240 was also found. Genes encoding CD79A (Figure 4.8)
and Spi-B transcription factor (Figure 4.9) showed the highest fold change when
comparing AAA against AOD or NA. CD79A is a B-cell surface receptor which has
been implicated in haematological malignancies287. Spi-B is a transcription factor
which is involved in determining haemopoetic lineage288. There were no differentially
expressed genes on the other susceptible locus for AAA, chromosome 4q31240.
183
Chapter 5




5.1.1 Overview of qRT-PCR
qRT-PCR has become widely established as a benchmark in the detection and
quantification of RNA targets289. The ability to amplify the target sequence allows for
greater sensitivity of detection than other RNA quantification techniques such as
Northern blotting. Its reproducibility together with its potential for high throughput has
seen it emerge as a key technology in identifying biomarkers, investigating molecular
pathways and putative therapeutic targets. qRT-PCR based diagnostic assays are
now available for a range of clinical conditions290-292.
The following steps are involved in qRT-PCR:
1. appropriate quantification strategy;
2. reverse transcription of RNA to cDNA using a reverse transcriptase;
3. suitable detection chemistry to report the presence of PCR products;
4. monitoring of amplification in real-time and appropriate software for quantitative
analysis.
5.1.2 Quantification strategies
There are two quantification methods: absolute (standard curve) and relative
quantification293. Each is suitable for different applications.
i) Absolute quantification is based on the generation of a standard curve using a
dilution series of an external standard. A linear plot of the log of the initial template
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quantity against the Ct (threshold cycle) values for the standards is generated. The
initial quantity of the unknown samples can then be determined by comparing their Ct
values to the standard curve plot293. A variety of sources can be used as standard
templates including plasmid containing a clone gene of interest, genomic DNA,
cDNA, synthetic oligos or total RNA291. This strategy is important when the exact
level of a template in the samples needs to be determined (e.g. the monitoring of
viral load).
ii) Relative quantification refers to the relative concentration of the gene of interest
in unknown samples compared to a calibrator or control sample. The calibrator is a
baseline for the expression of a given target gene. The calibrator can be a time point,
an untreated sample or a normal sample. Difference in the Ct (cycle threshold)
values between an unknown sample and calibrator is expressed as fold changes (i.e.
upregulated or downregulated) relative to the calibrator294. In order to control for
variability in RNA isolation and in the efficiency of the reverse transcription step, the
Ct value for each sample is normalised with a normalising reference gene(s) or
target(s). A normalising gene is one whose expression is constant in both the
experimental sample and the calibrator294.
5.1.3 Choice of housekeeping genes for relative quantification
The identification of a valid housekeeping gene for data normalisation remains a very
difficult and controversial problem. It is especially difficult when dealing with ‘in vivo’
samples and comparing gene expression patterns between different individuals293.
The differences in cell composition between different samples could be responsible
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for the observed fluctuations in overall gene abundance. Housekeeping genes that
are considered to remain stable in a particular cell type under different conditions
may be expressed at a different abundance level in a different cell type. Even if their
expression remains stable in each cell type, differences in cell composition would
reflect differences in the overall gene abundance.
Nine commonly used methods for normalising data, including a marker for 18s and
eight housekeeping genes were assessed at our laboratory to identify the markers
with the most stable expression levels across 35 different carotid plaque
segments258. The stability of the housekeeping genes were measured using an M
value as described by Vandesompele et al295. For every normalisation method, the
pairwise variation with all other control genes was determined as the standard
deviation of the logarithmically transformed expression ratios. The internal control
gene-stability measure M was subsequently calculated as the average pairwise
variation of a particular gene with all other control genes. Genes with the lowest M
values had the most stable expression. The gene with the highest M value was
excluded and M values were recalculated for all genes after each exclusion step.
Assuming that the control genes are not co-regulated, stepwise exclusion of the
gene with the highest M value resulted in a combination of three constitutively
expressed housekeeping genes that have the most stable expression in the tested
samples. GAPDH and β-actin were found to be the most stable housekeeping genes
in this particular type of tissue (Table 5.1)296.
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Table 5.1 Order of stability of the nine normalisation methods according to
their M values296.
Housekeeping genes M value
18s (ribosomal RNA) 2.19
HMBS (Hydroxymethyl-bilane synthase) 1.75
SHDA (Succinate dehydrogenase complex) 1.45
Cyclophilin 1.39
36B4 (human acidic ribosomal phosphoprotein) 1.20





One- step vs. two –step. qRT-PCR can be performed as either a one-step or two-
step procedure. A one-step experiment is a single tube reaction that converts RNA to
cDNA, followed by qPCR amplification using gene specific primers. A two-step
experiment involves the initial conversion of RNA to cDNA followed by a second
reaction for the qPCR amplification of the gene of interest. The one-step reaction is
more suited for high-throughput screening when sample availability is unlimited.  The
two- step format allows for the amplification of multiple genes when the quantity of
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RNA template available is limited, the capability for more extensive optimisation and
the ability to archive the 1st strand of cDNA for future analysis297.
5.1.4 Priming consideration
Primers are short DNA sequences complementary to the target region that
selectively amplifies the target region along with DNA polymerase. Priming strategies
for the reverse transcription reaction fall into the following categories: Oligo (dT),
random and gene-specific298.
i) Oligo (dT) priming Oligo (dT) primers are oligonucleotides comprised of thymine
bases. They are specific for mRNA as the latter has a polyA tail (adenine binds to
thymine). Oligo (dT) priming achieves an accurate cDNA representation of the
mRNA fraction. This method requires high quality RNA that is full-length. It is not a
good choice to prime for RNA that is likely to be fragmented291.
ii) Random priming Random primers are usually hexamers or nonamers with a
random combination of A, T, G and C bases. This method yields the largest amount
of cDNA as the primers can reverse transcribe the majority of the total RNA (i.e.
ribosomal RNA, messenger RNA and transfer RNA). It is the least satisfactory
method of synthesising cDNA as the RT reaction is not focused to the mRNA
fraction, which is the coding region of the gene291.
iii) Gene-specific priming Gene–specific primers are designed by the researcher to
specifically target the transcript of interest and thus provide the most sensitive
method of quantification. However, they require separate priming reaction for each
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target and therefore are not practical where the amounts of RNA available are
limited291.
5.1.5 qRT - PCR chemistry options
Two different methods are currently used to detect the amplification products of the
qRT-PCR experiment.299
1. A sequence specific probe which consists of an oligonucleotide labelled with a
fluorescent dye and a quencher (e.g. Taqman probes, Molecular Beacons and
Scorpions).
2. A non-specific DNA binding dye such as SYBR Green I that fluoresce when
bound to double-stranded DNA.
5.1.5.1 Probe-based chemistries
An internal probe is used to detect the qPCR product of interest and therefore
increases detection specificity. The probe is bound to a reporter dye and a quencher.
In the absence of a specific target, the probe remains quenched. Conversely, in the
presence of a specific target, the probe fluoresces. The level of fluorescence
correlates with the amount of amplified targets299;300.
i) Hydrolysis probes Linear or Taqman probes are oligonucleotides with a
fluorescent reporter dye, typically 6–carboxyfluorescin (FAM) attached at the 5’ end
of the probe and a quencher such as tetramethylrhodamine (TAMRA) attached at the
3’ end of the probe300. As long as the reporter and the quencher are within close
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proximity, no fluorescence is detected. The probe is designed to anneal to one
strand of the target sequence just slightly downstream of one of the primers. As the
polymerase extends that primer, it encounters the 5’ end of the probe. Taq DNA
polymerase has 5’-3’ nuclease activity so that it displaces and degrades the 5’ end,
releasing free reporter dye into the solution. Fluorescence can be detected following
separation of the reporter dye and the quencher. The different steps are illustrated in
Figure 5.1. The main advantages of hydrolysis probes are that they are specific and
can be multiplexed (simultaneously measures multiple analyses using a single
assay). They are however costly.
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Figure 5.1 Taqman probe chemistry mechanism.
ii) Hybridisation probes Molecular Beacons consist of a hairpin loop structure300.
The central loop sequence is complimentary to the target of interest and the stem
arms are complementary to each other. One end of the stems has a reporter
fluorophore while the other end carries a quencher. Since they are in close proximity,












the loop sequence to the target causes the separation of the fluorophore and the
quencher thus allowing detection of the reporter sequence. The different steps are
illustrated in Figure 5.2. Hybridisation probes are specific, can be multiplexed and
their reactions are reversible. They are however difficult to design.
Figure 5.2 Molecular beacon chemistry. When the target anneals to the
molecular beacon, a hybrid is formed with separation of the fluorophore and








5.1.5.2 DNA Binding Dyes
SYBR Green I displays relatively low fluorescence when free in solution, but in the
presence of double-stranded DNA, its fluorescence increases by 1000-fold and in
proportion to the DNA concentration of the sample (Figure 5.3). Detection of the
target is therefore amplified. The concentration of double stranded DNA can be
directly measured by the increase in fluorescence signal. The advantages of SYBR
Green I are its relatively low cost and the assays are relatively easy to design and
run. However, the main limitation is its non–specificity as SYBR Green will bind to
any double-stranded DNA. Non-specific binding can be avoided by designing
specific primers299;300.
Figure 5.3 SYBR Green I detection mechanism. In the bound state SYBR Green
is 1000-fold more fluorescent than in the unbound state.
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5.1.6 Real time amplification and analysis
Following the RT steps and choice of appropriate detection chemistry, a detection
system such as the ABI Prism 7000 Sequence Detection Systems (Applied
Biosystems) is used to report on the presence of PCR products. It monitors the
amplification in real-time and provides appropriate software for quantitative analysis.
In essence, qRT-PCR is characterised by the point in time during cycling when
amplification of a PCR product is first detected. Conventionally, traditional PCR
detects PCR products at the endpoint of the reaction. However; there is considerable
variability in the endpoints between replicates making these results unreliable291;300.
Figure 5.4 shows examples of the amplification plots for 3 samples. The Ct values
represent the cycle fractions where the instrument can first reliably detect
fluorescence derived from the amplification reaction. The higher the starting copy
number of the nucleic acids, the sooner a significant increase in fluorescence is
noted and the smaller the Ct value.
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A relative quantification method was used for the purpose of this experiment with
RNA from NA as the calibrator. RNA was extracted from AAA wall (n=13), AOD wall
(n=10) and NA wall (n=7) using the method described in section 2.2.
The number of genes that could be confirmed in this experiment were limited both by
the amount of RNA available and cost. Nine genes were thus chosen for
confirmation by qRT-PCR. MMP-3, MMP-9 and Cathepsin H were included as
positive controls for the experiment as these genes have been confirmed in previous
studies carried out at our laboratory67;123. The expressions of these genes have also
been inconsistent in different studies involving AAA. Novel genes were included
based on a literature review and their likelihood of affecting AAA development based
on what is already known regarding their biological functions. CD79A and Spi-B
transcription factor are located on chromosome 19q13, a susceptible locus for AAA.
CD19 is a marker of B-cells and the majority of the differentially expressed
inflammatory genes with the highest fold change in the microarray experiment were
related to B-cells.Thus, by confirming CD19, the top genes in the experiment will be
confirmed. SPEG and BMP-6 have not been studied in AAA development but as
explained in Chapter 7, they may influence AAA formation. ADAMTS-9 was also
included as a novel gene due to its ability to break down the extracellular matrix.
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A two-step RT reaction was carried out using Taqman probes and assays (designed
by Applied Biosystems). Only exon spanning probes (Table 5.2) were chosen as
they do not anneal with genomic DNA and therefore decrease the frequencies of
non-specific binding.





A disintegrin and metalloproteinase with
thrombospodin motif-9




Hs00233962_m1 Matrix metalloproteinase 3
Hs00957562_m1 Matrix metalloproteinase 9
Hs00162150_m1 Spi-B transcription factor
Hs00195347_m1 SPEG complex locus
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5.2.2 Reverse transcription (RT)
The Enhanced Avian RT First Strand Synthesis Kit (Sigma, USA) was used for the
RT reaction. Total RNA (1.5μg) was used as a starting template for the reaction. The
total RNA was mixed with 1μl of oligo (dT) 23 primer and 1μl of dNTP to a final volume
of 10μl in a PCR microcentrifuge tube (Eppendorf, UK) on ice. The tube was then
incubated for 10 minutes at 70°C in a thermal cycler. The following components were
then added as shown in the Table 5.3 below:




10 × buffer for eAMV-RT 2
Enhanced avian RT 1
RNase inhibitor 1
RNAse free water 6
Total volume 20




Target amplification was carried out using TaqMan Gene Expression Assays
(Applied Biosystems) according to their recommended protocol. The PCR reaction
was carried out in a 96–well plate (Applied Biosystems). Each reaction was carried
out in triplicate for both the gene of interest and the housekeeping genes, GAPDH
(Applied Biosystems) and β-actin (Applied Biosystems). Expressions of the
housekeeping genes have been shown to be constant in previous work carried out
on vascular tissue in our laboratory258 (Section 5.1.3). A standard which is a 1:100
dilution of all the samples in the experiment was used on each plate to correct for
variability in the efficiency of the PCR machine between plates. A ‘no template
control’ (i.e. RNAse free water) was also used on each plate to rule out cross-
contamination of reagents and surfaces. The reaction size in each well was 25μl and
consisted of reagents as shown in Table 5.4. Each plate was set up as in Figure 5.5.
Table 5.4 qPCR step reagents.
Component Volume
(μl)
Taqman Gene Expression Assay (20×) 1.25
cDNA template + RNAse free water 11.25
TaqMan Universal PCR Master Mix (2×) 12.5
Total Volume 25
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Figure 5.5 Plate set-up for each run on the ABI Prism 7000
Gene of interest GAPDH B-actin S- standard N – No template control
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The plate was covered with an optical adhesive cover and centrifuged for 1 minute to
collect the reaction at the bottom of each well.  Each plate was placed in the ABI
7000 Sequence Detection Systems (Applied Biosystems) using the recommended
thermal cycling conditions (Figure 5.6).
Figure 5.6 Thermal cycling profile.
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5.2.4 Statistical analysis of qRT-PCR data
Relative gene expression was analysed using the 2-ΔΔCt method 302 .The following
equation was used to calculate ΔΔCt :
ΔΔCt = (ΔCt sample - ΔCt housekeeping genes)
ΔCt sample = Average of ΔCt values for the triplicates used for each sample
ΔCt housekeeping genes = Mean of the ΔCt values for GAPDH and B-actin
Fold change is derived from 2-ΔΔCt. Statistical differences in gene expression
between AAA and AOD and AAA and NA were analysed by unpaired t test as the
data was normally distributed and sample size in each group is unequal.
203
5.3 Results
Patient demographics for the samples used in the qRT-PCR experiment are shown
in Table 5.5.
Table 5.5 Demographics of patients used in qRT-PCR experiment.
Demographics AAA (n=13) AOD (n=10) NA (n=7)
Mean age 70 (61-80) 66 (53-66) 59 (50-67)
Median AAA size 6.6 (5.3-9.0) ---- ----
Sex (M / F) 10 / 3 8 / 2 6 /1
Smoking 9 8 5
Hypertension 8 4 4
IHD 7 8 0
Diabetes 4 3 1
There was no significant difference between the AAA and AOD groups of patients in
terms of the demographic variables listed in Table 5.5. As expected, patients in the
NA group were younger and had a healthier profile in terms of their cardiovascular
risk factors.
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The RNA samples used were all of high qualities with RIN > 5.5 as shown in Table
5.6 A, B and C below.
Table 5.6A Quality of aneurysm samples used.















Table 5.6B Quality of AOD samples used.
Table 5.6C Quality of NA samples used.




















Patterns of mRNA expression for a selection of 9 genes were independently
examined using qRT-PCR. Raw data for each gene is shown in Appendix O. The
results for fold change and significance for each gene of interest are shown in Table
5.7(AAA vs. AOD) and Table 5.8(AAA vs. NA). The results for the qRT-PCR and the
microarray experiment are represented graphically for each gene (Figure 5.7).
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Table 5.7 Relative quantification of mRNA expression between AAA and AOD
using qRT-PCR. SPEG is downregulated.





ADAMTS9 6.382 ± 1.080 7.554 ± 1.188 2 0.025
BMP-6 6.589 ± 1.390 7.743 ± 1.708 2 0.042
CATH 4.697 ± 0.652 5.929 ± 1.321 2 0.009
CD19 6.619 ± 1.934 10.975 ± 4.342 20 0.002
CD79A 3.754 ± 1.667 6.835  ±  3.435 6 0.010
MMP-3 10.459 ± 2.217 14.872  ±  5.137 21 0.010
MMP-9 4.178 ± 3.521 3.990 ± 2.476 0.9 0.441
SPIB 7.415 ± 2.023 11.222 ± 4.601 14 0.015
SPEG 8.521 ± 1.169 7.185 ± 1.738 0.3 0.027
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Table 5.8 Relative quantification of mRNA expression between AAA and NA
using QRT-PCR. SPEG is downregulated.





ADAMTS9 6.382 ± 1.080 6.777 ±0.916 1.7 0.191
BMP-6 6.589 ± 1.390 8.734±0.735 4 <0.001
CATH 4.697 ± 0.652 6.527±1.713 4 0.010
CD19 6.619 ± 1.934 14.001±5.983 167 0.004
CD79A 3.754 ± 1.667 9.308±3.782 47 0.002
MMP-3 10.459 ± 2.217 15.750±3.561 39 0.002
MMP-9 4.178 ± 3.521 6.457±3.284 5 0.040
SPIB 7.415 ± 2.023 12.766±3.81 40 0.009





























































































Figure 5.7 Graphical representations of microarray and qRT-PCR data for each






The qRT-PCR experiment confirmed the microarray results on a larger sample size
for each of the genes probed except for ADAMTS-9 when comparing AAA with NA.
These results add to the robustness of the microarray data. The sequences used for
genes in the PCR experiment were different to that on the microarray platform and
this might account for the differing result for ADAMTS-9. This high confirmatory rate
(8 out of 9 genes confirmed) is similar to that reported by other microarray
studies95;258.
The sample sizes for AOD and NA were limited by availability of samples. Only a few
AOD samples were available as angioplasty has superseded aortic bypass surgery
in the treatment of aortic occlusive disease. It is not feasible to obtain tissue during
angioplasty. This also limited the total number of genes that could be confirmed as
only limited quantities of total RNA could be extracted from the available samples.
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Chapter 6




The identification of the most differentially expressed genes in any dataset is clearly
a valid approach. Pathway and network analysis can, however, also be used to
identify potentially smaller, but consistent changes in expression of a group of genes
with related functions. The aim of this analysis was to identify pathways and/or
networks that were significantly enriched and may therefore be involved in the
pathogenesis of AAA.
Enrichment analysis is used to determine the most populated pathways or networks
for a particular set of differentially expressed genes.
i) Pathway analysis. This analysis can be applied to maps which contain
information of the type that might be found in a text book or review article
(canonical). A pathway has a defined start and end, usually spanning from the
extracellular space, through ligands and receptors, to intracellular signalling via
enzymes and kinases to nuclear functions mediated by transcription factors.
ii) Network analysis. Unlike pathway maps (canonical), networks can be composed
of 1-step associations and may or may not be part of an established pathway. An
algorithm intended to find regulatory pathways that are activated under pathological
conditions can also be used. It defines a set of transcription factors that are directly
regulating genes of interest and a set of receptors whose ligands are in the list of
interest and then constructs series of networks. Each network contains all shortest
paths from a receptor to the selected transcriptional factors and their targets. This
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approach allows us to reveal the most important areas of regulatory machinery
affected under the investigated pathological condition.
Affected networks were identified using the Z score which is based on the number of
fragments of canonical pathways present and are sorted by enrichment p-value.
r – number of interactions the objects has with objects in the active experiment
R – total number of network objects that interact with the object
n – number of network objects in the active experiment
N – total number of network objects in the database.
6.2 Methods
Differentially expressed gene lists were generated as previously described in
(Sections 4.2.3 and 4.2.4) from the comparison of both AOD and AAA to normal
artery. Those genes which were more than two fold upregulated with a p value of
less than 0.05 were submitted for pathway analysis and network analysis. Legends
to pathways and networks are shown in Appendix N.
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All pathway and network analysis were conducted using MetaCore software Version
6.3 (GeneGo, Inc). A list of genes that was unique to AAA was generated.
Enrichment analysis was used to determine the most populated pathways or
networks for the set of differentially expressed genes which were unique to AAA. The
likelihood that differentially regulated genes in the experimental dataset participate in
a given pathway by chance was measured using the hypergeometric mean
calculation and a p value was assigned.
Transcription factors and receptors involved in the different networks were identified.
A transcription factor binds DNA and initiates a process of increased or decreased
gene transcription. Thus, it regulates a number of important cellular processes
including transcription regulation, differential enhancement of transcription, cell
differentiation and response to intercellular signals303. Receptors are transmembrane
or intra-cellular proteins to which ligands (such as pharmaceutical agents) bind




There was approximately the same number of genes that were unique to AAA or
AOD (Figure 6.1).
Figure 6.1 Venn diagram showing the number of unique genes for AAA and
AOD.
6.3.1 Pathway analysis
Top pathway maps suggest immune and inflammatory themes with involvement of
the complement pathway, CCR3 signalling and histamine signalling (Figure 6.2). The
top 2 maps are detailed below (Figures 6.3 and 6.4).
218
Figure 6.2 Main pathway maps involving differentially expressed genes
associated with AAA.
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Figure 6.3 Immune response: Classical complement pathway.
Red thermometers show a gene that is upregulated. Green arrows represent
positive, red negative and grey unspecified interactions. Boxes on the line represent
the type of regulation: B = binding, C= cleavage and CS= complex subunit (Protein is
a subunit of a protein complex).
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Figure 6.4 Immune response: lectin induced complement pathway.
Red thermometers show a gene that is upregulated. Green arrows represent
positive, red negative and grey unspecified interactions. Boxes on the line represent
the type of regulation: B = binding, C= cleavage and CS= complex subunit (Protein is
a subunit of a protein complex).
A large number of upregulated genes in AAA compared with AOD were involved in
both pathways. In the classical complement pathway, 17 out of 37 genes were
significantly upregulated in AAA compared with AOD. There was no downregulated
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gene. In the lectin induced complement pathway, 17 out of 41 genes were
significantly upregulated in AAA compared with AOD.
6.3.2 Network analysis
The top five networks selected on the basis of the number of fragments of canonical
pathways present and sorted by enrichment p-value (Table 6.1) are described below.
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Pathways P-value Z score g score
1
Organ development (73.5%), positive
regulation of transcription (51.0%), positive
regulation of gene expression (51.0%)
50 19 101 1.02e-17 15.71 141.96
2
Regulation of cell proliferation (72.9%),
response to organic substance (66.7%), positive
regulation of biological process (81.2%)
50 14 71 2.47e-11 11.27 100.02
3
Response to steroid hormone stimulus (28.6%),
response to hormone stimulus (32.7%),
response to organic substance (40.8%)
52 22 34 9.38e-22 18.17 60.67
4
Positive regulation of transcription (41.7%),
positive regulation of transcription,
DNA-dependent (39.6%), positive regulation of
macromolecule biosynthetic process (43.8%)
50 27 29 8.37e-30 22.81 59.06
5
Positive regulation of biological process
(66.0%), response to organic substance
(50.0%), positive regulation of cellular process
(62.0%)
50 25 23 1.42e-26 21.04 49.79
223
Figure 6.5 Network 1 from AAA unique gene list.
Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes
are marked with red circles; down-regulated with blue circles. The 'checkerboard'
colour indicates mixed expression for the gene between files or between multiple
tags for the same gene.
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Table 6.2 Receptors, transcription factors and protein involved in network 1.
Genes in red are those that are differentially expressed in the experiment.
Transcription factors Receptors Protein secreted















Figure 6.6 Network 2 from AAA unique gene list.
Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes
are marked with red circles; down-regulated genes with blue circles. The
'checkerboard' colour indicates mixed expression for the gene between files or
between multiple tags for the same gene.
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Table 6.3 Receptors, transcription factors and protein involved in network 2.
Genes in red are those that are differentially expressed in the experiment.
Transcription factors Receptors Protein secreted
Androgen receptor FCGRT CSH1
BTG2 GHR Endostatin











Figure 6.7 Network 3 from AAA unique gene list.
Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes
are marked with red circles; down-regulated genes with blue circles. The
'checkerboard' colour indicates mixed expression for the gene between files or
between multiple tags for the same gene.
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Table 6.4 Receptors, transcription factors and protein involved in network 3.
Genes in red are those that are differentially expressed in the experiment.
Transcription factors Receptors Protein secreted
C –Fos COLEC12 IGF – 2
ESR – 2 SR – B1 PDGF – A
SHP TNF - α
SP1 VEGF - A
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Figure 6.8 Network 4 from AAA unique gene list.
Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes
are marked with red circles; down-regulated genes with blue circles. The
'checkerboard' colour indicates mixed expression for the gene between files or
between multiple tags for the same gene.
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Table 6.5 Receptors, transcription factors and protein involved in network 4.
Genes in red are those that are differentially expressed in the experiment.
Transcription factors Receptors Protein secreted
AP-2A G alpha (i) specific EDG FGF-12















Figure 6.9 Network 5 from AAA unique gene list.
Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes
are marked with red circles; down-regulated with blue circles. The 'checkerboard'
colour indicates mixed expression for the gene between files or between multiple
tags for the same gene.
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Table 6.6 Receptors, transcription factors and protein involved in network 5.
Genes in red are those that are differentially expressed in the experiment.




ESR1 NKG2A NT – 3
p53 SDF – 1









Inflammation is an important feature of the remodelling process involved in human
AAA formation304. This was reflected by a predominance of inflammatory pathways
which were significantly enriched by differentially expressed genes which are unique
to AAA. All components of the complement system (alternative, classical and lectin)
featured strongly among the top pathway maps. The complement system plays an
important role in host innate humoral immunity. The basic functions of complement
are opsonisation, chemotaxis for macrophages and neutrophils, lysis of antigens,
debris removal and response to tissue injury305;306. Complement activation generates
the anaphylatoxins C3a and C5a, which are potent leukocyte chemoattractants307.
Involvement of the complement system in the pathophysiology of AAA has been
demonstrated in an elastase-induced mice model of AAA308. A deficiency in
complement activity (antibody depletion) protected mice against AAA compared with
controls. Activation of the complement pathway led to the recruitment of neutrophils
to the aortic wall with generation of neutrophil associated proteases (including potent
elastases) that are important in AAA development308. The presence of complement
fixing IgG subclasses along with increased C3 has been demonstrated using
immunocytochemistry in human AAA wall309. Further studies investigating
expression and activity of complement at different stages of AAA expansion are
needed to elucidate the direct involvement of complement in human AAA
development.
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IRE1 is an ER (endoplasmic reticulum) localised transmembrane protein that is
upregulated in this study. IRE1 increases the expression of stress response genes
through mRNA processing310 and attenuates the response of several genes by
cleavage of mRNA311. One of the cleavage targets is CD59 whose expression is
reduced in human cultured cells when IRE1 is overexpressed 312. CD59 is a
glycoprotein that regulates human complement–mediated cell lysis by inhibiting
assembly of the membrane attack complex (MAC)313. CD59 binds complement C8
and / or C9 during assembly of MAC, thereby inhibiting inclusion of multiple copies of
C9 into the complex, which is necessary for osmolytic pore formation313. Deficiency
of CD59 has been shown to accelerate AAA in angiotensin II induced ApoE null mice
(complement depleted) model of AAA. It is postulated that deficiency of CD59 results
in overexpression of MAC which induces upregulation of MMP-2 and MMP-9314.
These proteolytic enzymes are thought to play a role in AAA pathogenesis315. MAC
is also chemotatic for macrophages314 which are a source of  MMP-9316.
Nuclear factor of activated T-cells (NFATs) are calcium dependent transcription
factors, activated by stimulation of receptors coupled to calcium/calcineurin signals,
such as the antigen receptors on T-Cells and B-Cells317. NFAT signalling plays an
important role in cell-cell communication among different cells of the immune
system318. It is also critical in the expression of a number of immmunologically
important  genes, including a wide array of cytokines: interleukins ( IL-2 , IL-3, IL-4,
IL-5 IL-6, IL-10 and IL-13) , interferon-gamma (IFN -γ), tumour necrosis factor-alpha
(TNF-α),and granulocyte-macrophage colony-stimulating factor (GMCSF),as well as
several related membrane-bound proteins such as CD40 ligand (CD40L), fas ligand
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(Fas L) and cytotoxic T- lymphocyte-associated antigen-4 (CTLA4)318;319. A putative
role for interleukins in AAA has been confirmed in a number of studies. Serum levels
of IL-2 and IL-6 have been shown to be higher in AAA patients compared with
controls320.  TNF may be involved in AAA expansion through VSMC apoptosis321,
proteolytic breakdown of the extracellular matrix321 and induction of inflammatory and
immunological processes322;323. Serum levels of TNF are elevated in patients with
AAA compared with healthy individuals and correlate positively with aneurysm
size320. IFN-γ inhibits collagen production by VSMC in the aortic wall324. Its serum
concentrations have also been shown to correlate with AAA expansion325.  CD40L
has been shown to enhance mRNA and protein production of MMP-2 in cultured
AAA tissues326.  Trapidil, a CD40-CD40L pathway inhibitor, has a potential
therapeutic role in AAA326.  The NFAT signalling pathway is thus critical in immune
response and an understanding of its biochemistry will allow development of more
selective and efficient pharmaceuticals that suppress, modify, or augment immune
responses in AAA development.
6.4.2 Network analysis
6.4.2.1 Network 1
The top scoring network (Network 1) identified several transcription factors:
doublesex and mab-3 related transcription factor-1 (DMRT1), paired box gene-9
(PAX-9) and retinoic acid receptor - alpha (RAR-α) which were upregulated in AAA.
Bone morphogenic protein (BMP) genes feature prominently in this pathway.
Upregulation of BMP-6 has been confirmed on qRT-PCR in this experiment (Section
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6.3) and its possible role in the pathogenesis of AAA will be discussed in Section 7.1.
Other genes of interest are IL20RB and p21. IL20 and its receptors belong to the
IL10 family of cytokines and play a role in skin inflammation327 and development of
hematopoietic cells. IL20RB is expressed on human endothelial cells328 and binding
of IL20 to its receptors induces upregulation of VEGF and bFGF329 and angiogenesis
in human umbilical vein endothelial cells. Both of these angiogenic genes have been
implicated in the pathogenesis of AAA145. IL20 also increases the expression of
MMP-2329 , a proteolytic enzyme involved in degradation of elastin and AAA
expansion330. p21 is a potent cyclin-dependent kinase inhibitor  involved in apoptosis
following caspase activation331. Upregulation of p21 is a putative mechanism
involved in VSMC apoptosis in AAA formation332.
RAR-α is a drug target (Tamibarolene, Isotretinonin, Retinoic acid) for Network 1.
This gene has been implicated in a myriad of functions including apoptosis333,
differentiation333, granulopoeisis333 and transcription of clock genes334.  Retinoids are
increasingly being used for remission of cancer334 and are being tested to limit
neointimal proliferation in vascular disease such as atherosclerosis and
hypertension335;336. Retinoic acid has been shown to induce vascular remodelling in
rat aortic smooth muscle cells through modulation of vascular integrins337. VSMC
depletion is a feature of AAA formation and therefore maintenance of VSMC integrity
is important to prevent remodelling of the aortic wall.
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6.4.2.2 Network 2
A different set of pathways are involved in Network 2 with expression of a different
set of transcription factors. A possible role for IL-6 in AAA formation has been
demonstrated in previous studies338;339. Janus kinase (Jak) induced tyrosine
phosphorylation of the signal transducer and activator of transcription (STAT) is a
primary mediator of IL-6 induced signalling 340. The Jak-STAT pathway controls
genes that are important in macrophage activation and vascular remodelling340. The
IL-6 induced Jak-STAT signalling cascade has been shown to be activated in
angiotensinII infused rats which induces AAA formation341.  B-cell translocation gene
2 (BTG-2) has anti-proliferative properties, but its role in vascular disease has not
been elucidated yet342.  Brain – specific angiogenesis inhibitor -1 (BAI-1), which is
expressed downstream of the BTG -2 pathway, is known to regulate
angiogenesis343.
Insulin growth factor -1 (IGF-1) is a possible therapeutic target. IGF-1 has potent
collagen and proteoglycan stimulating activity344 and its concentration is decreased
in human aortic aneurysm wall compared with normal aorta at the protein level345.
IGF-1 has a role in the deregulation of collagen metabolism in AAA345. Simvastatin
downregulates IGF-1 receptor346 and can reduce AAA expansion rate347. Its other
activities such as inhibition of cathepsin and MMPs may also be involved.
238
6.4.2.3 Networks 3-5
The three remaining networks show an overlap of a number of genes and pathways.
The oestrogen receptor (ESR 1, ESR 2 and ESR3) are present in all three remaining
networks. Oestrogen receptors are known to have a major role in vascular
physiology348. In primates fed with atherogenic diets oestrogen supplementation
inhibited collagen accumulation and elastin loss in the abdominal aorta349. These
changes could predispose to AAA development. ESR-2 polymorphism has also been
put forward as a genetic determinant in AAA in human350.
Pathway analysis has revealed novel genes upstream or downstream of a specific
gene known to be involved in AAA formation. Novel pathways that may be involved
in AAA pathogenesis have also been identified.
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Chapter 7
Discussion, future work and
conclusions
Table 3. Relative quantification of mRNA expression between AAA and AOD by QRT-PCR
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7.1 General Discussion
This is the first whole transcriptome analysis investigating tripartite differential gene
expression in the wall of AAA, AOD and normal abdominal aorta. This study has
unravelled novel genes and pathways with potential roles in the pathogenesis of
AAA. By comparing AAA with AOD, the gene set has been reduced considerably
probably shifting the emphasis on genes that are more relevant in AAA formation.
The results from these experiments are robust as they have passed all the stringent
criteria for quality control of microarray analysis. A small number of these
differentially expressed genes were confirmed by qRT-PCR. The large numbers of
genes that are differentially expressed support the notion that AAA is a polygenic
disorder.
7.1.1 Comparison with other microarray studies
There have been two studies of gene expression profiling in AAA and NA using
limited arrays. Absi et al95 used an array of 1185 genes and showed differential
expression of 104 genes (65 increased and 39 decreased). A large number of these
differentially expressed genes were confirmed in our whole genome microarray
analysis. Tung et al135 used an array of 1176 genes. Four out of the six most
upregulated genes (MMP-9, Cathepsin H, myeloid cell nuclear differentiation antigen
and platelet derived growth factor A) and both of the most downregulated genes
(myosin light chain kinase and integrin β1) were also found to be differentially
expressed in this study.
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Armstrong et al250 evaluated differential gene expression in AAA, AOD and NA using
a 225 genes array. They found that there was no differential expression of the matrix
metalloproteinase or tissue inhibitors of metalloproteinase. This is in accordance with
the results of this study with the exception that we have shown MMP-3 to be
differentially expressed, confirming our previous work123. Increased expression of
laminin α4 and insulin receptor in AOD and decreased expression in COL6A1,
Glycoprotein IIIA and α2 – macroglobulin in AAA were also reflected in our study.
The high confirmatory rate and reproducibility between the current study and the
previous micro-array studies provides support for the robustness of our data.
7.1.2 Genes differentially expressed on chromosomes 4q31 and
19q13
Chromosomes 4q31 and 19q13 have been identified as susceptible loci for AAA240.
We found no differentially expressed genes between AAA and AOD located on
chromosome 4q31, while three genes (Spi-B transcription factor, CD79A and RYR1)
were differentially expressed on 19q13. Two of these, Spi-B transcription factor and
CD79A, were subsequently confirmed on both microarray and qRT-PCR although
RYR1 was not assessed by qRT-PCR.
CD79A is a B-lymphocyte antigen receptor351. It is expressed during both the early
stage of B lymphoblast and terminal stage of plasma cells. CD79a thus plays a key
role in B-cell development, stabilisation and function352;353.
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Figure 7.1 BCR – B cell receptor.
CD79A is associated with the BCR complex. When the BCR complex is activated by
binding of antigen it causes growth and proliferation of B-cells354. An increased
concentration of B-cell infiltrates has been shown in the adventitia of AAA wall109. B
cell is also an important source of immunoglobulins and this study has also
demonstrated a higher expression of genes expressing autoantibodies in the walls of
AAA. IGHA1 , also known as IGA, showed the highest differential expression in AAA
compared with AOD or NA and its presence has been previously demonstrated with
a trend towards a higher proportion of IgA with increasing thickness of the wall355.
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Spi-B is a member of a family of ETS transcription factors356. Spi-B is expressed in
plasmacytoid dendritic cell precursors and it modulates the development of T-cells,
B-cells and Natural Killer cells357;358. These cells are important inflammatory
mediators in AAA formation98;101. Their presence in AAA wall has been confirmed in
previous studies97;98;101 and they are responsible for the Th1/Th2 response that
leads to AAA formation in mouse models105.
RYR1 (Ryanodine receptor 1) is also located on chromosome 19q13. It increases
the expression of major histocompatibility complex II molecules on the surface of
dendritic cells and thus may play a role in inflammatory responses in AAA359.
7.1.3 Inflammation
The large number of inflammatory genes that were up-regulated in AAA vs. AOD and
AAA vs. NA in this study highlights the importance of inflammation in AAA. Among
the genes with the highest fold-change (i.e. first 20 genes in either AAA vs. AOD or
AAA vs. NA), there was a predominance of inflammatory genes (55% in AAA vs.
AOD and 75% in AAA vs. NA). This is in agreement with a previous whole
transcriptome analysis comparing AAA with NA96. When comparing AAA with AOD,
there was an increased incidence of genes that were related to B-cells. CD19, a B-
cell marker360, was upregulated in AAA wall on both micro array and RT-PCR
analysis in our study. There is ,however, evidence to suggest that AAA is a specific
antigen driven T-cell disease99-101.These studies have also confirmed the presence
of  B cells in AAA wall99;100 and one of the studies101 looked specifically at
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immunophenotypes of the intraluminal thrombus in  AAA rather than AAA wall. Cells
present in the thrombus vary from those present in the aortic wall361.  T-cells also
play an important role in atherosclerosis362;363. This could explain the lower incidence
of T-cells related genes in comparing AAA with AOD.  When comparing AAA vs. NA,
markers of T-cells e.g. CD69 and CD3 were highly differentially expressed (fold-
change of 12 and 9, respectively). CD3+ T cells account for approximately 50% of
hemopoetic cells that have been recovered from aortic tissues99-101. CD69+ T cells
are expressed at an early stage of AAA development108.
Other inflammatory genes of interest that we found differentially expressed were toll-
like receptor (TLR10) which has a fundamental role in pathogen recognition and
activation  of innate immunity364. TLRs recognise pathogens at the cell surface365.
Several microbial pathogens113 that have been proposed as culprits in AAA
formation including Salmonella, Chlamydia, CMV and treponoma are capable of
interacting with TLRs. The interaction between the TLR and the microbial component
triggers the activation of signalling cascades leading to induction of genes producing
pro-inflammatory cytokines and type I interferons366. Increased expression of TLR4
RNA and protein was found in cerebal aneurysm in humans367.
The chemokines CCL13 and CX3CR1 were upregulated in AAA compared with AOD
or NA. CCL13 plays a role in the accumulation of leukocytes during inflammation. It
may be involved in the recruitment of monocytes in the arterial wall368. CX3CR1,
fractalkine receptor, expressed on natural killer cells and T cells, has been shown to
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be present in AAA wall and through its interaction with CX3CL1 may contribute to
recruitment of inflammatory cells in AAA tissues369.
IL7370 and IL2RG371, which were overexpressed in AAA in our study,  are
interleukins whose role in AAA are yet to be determined but are known to be
important mediators of inflammation.IL-7372 and IL2RG373 are both important for B
and T- cell development.
7.1.4 Proteolysis
MMPs .The matrix metallopeptidases have been extensively studied in the
proteolytic breakdown of AAA wall122;193;374. Only MMP-3 was upregulated in AAA
when compared with either AOD or NA. MMP9 was highly expressed in both AAA
and AOD compared with NA. These results are in agreement with those of two other
studies of MMP expression at the transcriptional level123;250 suggesting that MMP-9 is
more a marker of atherosclerosis. The presence of the 5A allele in the promoter
region of the MMP-3 gene is associated with increased MMP-3 production and
increased risk of developing AAA191-194. MMP-3 activity might therefore be a useful
target for the treatment of AAA.
Cathepsins. These proteolytic enzymes have  potent collagenase and elastase
activities131. Cathepsins D, H and L degrade structural proteins and there is greater
activity of these enzymes in AAA wall and mural thrombus than in normal aortic
wall132;135;140;375. Cathepsin H was the only cysteine protease that was upregulated
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when comparing AAA with AOD67 although cathepsins D and K mRNA were higher
in AAA vs. NA in this study. Cathepsin L expression is downregulated in AAA and is
associated with atherosclerosis376.
ADAMTS. ADAMTS-6 and ADAMTS-9 form part of a family of metalloproteases that
play an important role in the turnover of extracellular matrix proteins in various
tissues and have been implicated in atherosclerosis377. Both genes were
downregulated in this study although downregulation of ADAMTS-9 was not
confirmed by qRT-PCR for putative reasons elaborated on in the previous chapter.
Surprisingly, few genes regulating proteolysis were upregulated with twice as many
downregulated when comparing AAA with AOD suggesting that remodelling of the
aortic wall in AAA and AOD might involve to some extent a common set of genes.
7.1.5 Apoptosis
VSMCs apoptosis plays an important role in AAA development147;148;378. This study
confirmed upregulation of genes that have been previously studied in AAA:
caspases, Fas, p53 and TIMP-3123;378;379. Activin A receptor type IC (ACVR1C)
showed the highest fold change in either group. It induces apoptosis through
activation of TGFβ pathways150 which have been implicated in AAA formation150.




The medial layer of the infra-renal abdominal aorta is devoid of vasa vasorum141.
Neovascularisation of the medial layer is however an established feature of AAA142.
These microvessels allow entry of inflammatory cells into the media leading to
extracellular matrix degradation144. Angiogenesis is thus important for AAA
development. In the angiogenic group, two HOX genes were upregulated when
comparing AAA with AOD. Both genes maintain endothelial cells in a non-angiogenic
differentiated stage381;382. VEGF and IL-8 were highly expressed in both AAA and
AOD.
7.1.7 Bone morphogenic protein 6
Bone morphogenic protein 6 (BMP-6) was one of the upregulated microarray genes
that was confirmed by RT-PCR. BMP-6 belongs to the TGF-β superfamily and has a
variety of roles in different cell types. BMP-6 has a role in immune response
pathways and inhibits cell growth in mature B cells383, which we know are present in
large numbers in AAA wall. Endogenous BMP-6 increases aldosterone production
through angiotensin II related pathways384. This may be crucial in AAA development
as increased aldosterone and angiotensin II are associated with hypertension that is
a major risk factor for AAA.
BMP-6 increases the level of osteopontin (OPN)384, a gene implicated in the
pathogenesis of AAA formation384.OPN is a phosphorylated acidic glycoprotein that
has been implicated  in vascular calcification. OPN is not found in normal arteries but
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is abundant at sites of calcification in human atherosclerotic plaques385. In mouse
models, OPN inhibits arterial calcification which is inversely correlated to the growth
rate of small AAAs385;386. Thus, increased level of OPN in aortic wall will predispose
to AAA formation. The ability of BMP-6 to influence the above pathways makes it an
interesting therapeutic target to limit AAA formation.
7.2 Limitations of this study
A major limitation of this study is that differential expression of genes in AAA was
investigated in the patients who were undergoing elective repair and therefore the
AAAs were always larger than 5 cm. The gene profile would therefore represent
expression during ‘late stage ‘disease, which may be considerably different from the
transcriptional profile at an earlier stage of AAA development. Obtaining tissues from
patients with small aneurysms is ethically not possible and animal models of AAA
development may not be totally representative of the processes that lead to AAA
development in man. Differentially expressed genes also need to be confirmed at the
protein level, as it is well recognised that RNA expression does not always lead to
protein production387 and many post translational processes such as glycosylation
and phosphorylation affect final protein activity and function.
Normal aortic tissues were obtained from organ donors who are relatively younger
than patients with AAA and AOD and therefore it was difficult to match these
accurately for demographic and vascular risk factors. Comparison between AAA and
AOD removes age and atherosclerosis as confounding variables. There are
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however, morphological differences in the aortic walls of AAA and AOD. AAA is
mainly a disease of the media while AOD is a diseae of the intima suggesting that
different molecular processes may be involved in the formation of the atherosclerotic
plaques.
The samples of AAA used were of high quality as they were harvested fresh from
theatre. AOD and normal aorta samples were archived specimens which showed
increased amount of degraded RNA. This selection bias may, to some extent, skew
the results obtained.
Despite, these limitations, this study provides an insight into the differential gene
expression patterns in large AAA compared with stenosing disease of the aorta
which has atherosclerosis as a common denominator, but results in different
pathology.
7.3 Future work and conclusions
The differential expression of a number of novel genes has been elucidated and the
next steps would be to confirm the expression of these genes at the translational and
activity level.
Factors that are confirmed to be differentially expressed at the protein and activity
level should also be investigated at different stages during AAA development in
mouse models of disease such as the ApoE mouse Angiotensin II infusion model388.
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Low concentrations of Angiotensin II infused gives rise to a slow AAA formation389
and this would allow sampling windows at early, mid and late stage development of
AAA. The importance of a factor that is shown to correlate strongly with AAA
development could then be studied by cross-breeding ApoE mice with mice that
have a total deficiency (knockout) or are conditional knockout or knockin (e.g. no or
overexpression in macrophages) for a particular factor. AngII–induced AAA
development could then be assessed in these transgenic mice.
Comparison of genetic and expression data could lead to the elucidation of novel
pathways that could be targeted for the medical management of AAA.
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APPENDIX A: Reagents and materials used.
Total RNA isolation
Dulbecco’s phosphate buffered saline (D-PBS) pH 7.4
TRIzol reagent, Invitrogen Life Technologies
Chloroform 99.5% (Molecular biology grade, Sigma)
Isopropanol 99% (Molecular biology grade, Sigma)
Ethanol 99% (Molecular biology grade, Sigma)
RNAse free- water (Qiagen)
RNeasy Midi Kit, Qiagen




APPENDIX A: Reagents and materials used (continued).
Micro-array target labelling
One-cycle cDNA synthesis kit (Affymetrix)
T7-Oligo (dT) Primer, 50μM




5× 2nd strand reaction mix
E Coli DNA ligase, 10U/μL
E Coli DNA polymerase , 10U/μL
RNAseH, 2U/μL
T4 DNA Polymerase , 5U/μL
EDTA, 0.5M
RNAse free-water
Sample cleanup module kit (Affymetrix)
cDNA binding buffer




APPENDIX A: Reagents and materials used (continued).
5×- Fragmentation buffer
2-mL collection tube
IVT labelling kit (Affymetrix)
10× - IVT labelling buffer
IVT labelling NTP mix
IVT labelling enzyme mix
Sample clean-up module (Affymetrix)
IVT binding buffer
IVT cRNA clean-up spin column
IVT cRNA wash buffer
Genechip hybridization, wash and stain kit (Affymetrix)
Control oligonucleotide B2 (3nM)
20 × eukaryotic hybridization controls
Herring sperm DNA (10mg/ml)
BSA (50mg/ml)
2 × hybridization buffer
DMSO
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APPENDIX A: Reagents and materials used (continued)
qRT-PCR reaction
RT step (Enhanced avian RT first strand synthesis kit, SIGMA)
Deoxynucleotide mix (10mM dATP, 10mM dCTP, 10mM dTTP, 10mM dGTP)
Random nanomers
Enhanced Avian Reverse Transcriptase (solution in 200mM KH2PO4, pH 7.2, 2mM
DTT, 0.2% Triton, 50% glycerol)
10 × buffer for eAMV Reverse Transcriptase , 500mM Tris-HCL, pH 8.3, 400mM
KCL, 80mM MgCl2 , 10mM DTT)
PCR step (TaqMan gene expression assays, Applied Biosystems)
TaqMan gene expression assays (20×)
TaqMan Universal PCR Master Mix (2×)
TaqMan Fast Universal PCR Master Mix (2×)
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Probe Gene Description Gene symbol EntrezGene ID Fold change
230673_at polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 PKHD1L1 93035 32
217378_x_at
similar to Ig kappa chain precursor V region (orphon V108) - human
(fragment) LOC391427 391427 23
203000_at stathmin-like 2 STMN2 11075 22
214916_x_at immunoglobulin heavy locus 283650 18
217480_x_at similar to Ig kappa chain LOC339562 339562 15
215946_x_at similar to omega protein LOC91353 91353 14
234884_x_at Immunoglobulin lambda joining 3 IGLC2 3538 14
228335_at claudin 11 (oligodendrocyte transmembrane protein) CLDN11 5010 12
225792_at Hook homolog 1 (Drosophila) HOOK1 51361 12
216207_x_at immunoglobulin kappa variable 1D-13 IGKV1D-13 28902 11
220059_at BCR downstream signaling 1 BRDG1 26228 10
210121_at UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 B3GALT2 8707 9
212592_at
Immunoglobulin J polypeptide, linker protein for immunoglobulin alpha
and mu polypeptides IGJ 3512 8
210356_x_at membrane-spanning 4-domains, subfamily A, member 1 MS4A1 931 7
207031_at bagpipe homeobox homolog 1 (Drosophila) BAPX1 579 6
1555779_a_at CD79A antigen (immunoglobulin-associated alpha) CD79A 973 6
220068_at pre-B lymphocyte gene 3 VPREB3 29802 6
235982_at Fc receptor-like 1 FCRL1 115350 6
235965_at DKFZP434B0335 protein DKFZP434B0335 25851 6
221239_s_at Fc receptor-like 2 ; Fc receptor-like 2 FCRL2 79368 6
221969_at Paired box gene 5 (B-cell lineage specific activator) PAX5 5079 5
219667_s_at B-cell scaffold protein with ankyrin repeats 1 BANK1 55024 5
228599_at membrane-spanning 4-domains, subfamily A, member 1 MS4A1 931 5
205671_s_at major histocompatibility complex, class II, DO beta HLA-DOB 3112 5
227224_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103
5
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Probe Gene Description
Gene symbol EntrezGene ID Fold change
229400_at homeo box D10 HOXD10 3236 4
219197_s_at signal peptide, CUB domain, EGF-like 2 SCUBE2 57758 4
232739_at Spi-B transcription factor (Spi-1/PU.1 related) SPIB 6689 4
226435_at papilin, proteoglycan-like sulfated glycoprotein PAPLN 89932 4
239349_at C1q and tumor necrosis factor related protein 7 C1QTNF7 114905 4
227533_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 4
217767_at complement component 3 C3 718 4
206398_s_at CD19 antigen CD19 930 4
205692_s_at CD38 antigen (p45) CD38 952 4
1563674_at Fc receptor-like 2 FCRL2 79368 4
213317_at Chloride intracellular channel 5 CLIC5 53405 4
1558881_at hypothetical protein LOC145820 LOC145820 145820 4
205898_at chemokine (C-X3-C motif) receptor 1 CX3CR1 1524 4
1552519_at activin A receptor, type IC ACVR1C 130399 4
223751_x_at toll-like receptor 10 TLR10 81793 4
228377_at kelch-like 14 (Drosophila) KLHL14 57565 4
206999_at interleukin 12 receptor, beta 2 IL12RB2 3595 3
204424_s_at LIM domain only 3 (rhombotin-like 2) LMO3 55885 3
213247_at sushi, von Willebrand factor type A, EGF and pentraxin domain
containing 1
SVEP1 79987 3
224009_x_at dehydrogenase/reductase (SDR family) member 9 DHRS9 10170 3
1553856_s_at purinergic receptor P2Y, G-protein coupled, 10 P2RY10 27334 3
225706_at glucocorticoid induced transcript 1 GLCCI1 113263 3
209220_at glypican 3 GPC3 2719 3
223952_x_at dehydrogenase/reductase (SDR family) member 9 DHRS9 10170 3
50965_at RAB26, member RAS oncogene family RAB26 25837 3
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236293_at Ras homolog gene family, member H RHOH 399 3
225571_at leukemia inhibitory factor receptor LIFR 3977 3
219552_at Sushi, von Willebrand factor type A, EGF and pentraxin domain
containing 1
C9orf13 79987 3
220169_at hypothetical protein FLJ23235 FLJ23235 80008 3
212311_at KIAA0746 protein KIAA0746 23231 3
224406_s_at Fc receptor-like 5 ; Fc receptor-like 5 FCRL5 83416 3
242458_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 3
235278_at chromosome 20 open reading frame 133 C20orf133 140733 3
242517_at G protein-coupled receptor 54 GPR54 84634 3
221586_s_at E2F transcription factor 5, p130-binding E2F5 1875 3
213094_at G protein-coupled receptor 126 GPR126 57211 3
235372_at Fc receptor-like and mucin-like 1 FCRLM1 84824 3
222915_s_at B-cell scaffold protein with ankyrin repeats 1 BANK1 55024 3
200670_at X-box binding protein 1 XBP1 7494 3
214971_s_at ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 3
210448_s_at purinergic receptor P2X, ligand-gated ion channel, 5 P2RX5 5026 3
228434_at butyrophilin-like 9 BTNL9 153579 3
209840_s_at leucine rich repeat neuronal 3 LRRN3 54674 3
222245_s_at fer-1-like 4 (C. elegans) FER1L4 80307 3
219799_s_at dehydrogenase/reductase (SDR family) member 9 DHRS9 10170 3
227525_at glucocorticoid induced transcript 1 GLCCI1 113263 3
206030_at aspartoacylase (Canavan disease) ASPA 443 3
205083_at aldehyde oxidase 1 AOX1 316 3
238439_at ankyrin repeat domain 22 ANKRD22 118932 3
209506_s_at nuclear receptor subfamily 2, group F, member 1 NR2F1 7025 3
Appendix B: Genes upregulated in AAA vs. AOD (continued).
292
Appendix B: Genes upregulated in AAA vs. AOD (continued)
Probe Gene Description Gene symbol EntrezGene ID Fold change
219429_at fatty acid 2-hydroxylase FA2H 79152 3
225575_at leukemia inhibitory factor receptor LIFR 3977 3
230075_at RAB39B, member RAS oncogene family RAB39B 116442 3
223299_at SEC11-like 3 (S. cerevisiae) SEC11L3 90701 3
206513_at absent in melanoma 2 AIM2 9447 3
225700_at glucocorticoid induced transcript 1 GLCCI1 113263 3
244033_at chromosome 14 open reading frame 145 C14orf145 145508 3
204777_s_at mal, T-cell differentiation protein MAL 4118 3
1554208_at similar to mouse meiosis defective 1 gene MGC40042 150365 3
206126_at Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C
motif) receptor 5)
BLR1 643 3
217369_at immunoglobulin heavy constant gamma 1 (G1m marker) IGHG1 3500 3
214203_s_at proline dehydrogenase (oxidase) 1 PRODH 5625 3
233500_x_at C-type lectin domain family 2, member D CLEC2D 29121 3
225912_at tumor protein p53 inducible nuclear protein 1 TP53INP1 94241 3
203961_at nebulette NEBL 10529 3
227198_at AF4/FMR2 family, member 3 AFF3 3899 3
205297_s_at CD79B antigen (immunoglobulin-associated beta) CD79B 974 3
230006_s_at hypothetical protein DKFZp313A2432 DKFZp313A2432 258010 3
242388_x_at T-cell activation GTPase activating protein TAGAP 117289 3
202062_s_at sel-1 suppressor of lin-12-like (C. elegans) SEL1L 6400 3
211077_s_at tousled-like kinase 1 ; tousled-like kinase 1 TLK1 9874 2
237484_at hypothetical gene supported by AK092637 LOC440087 440087 2
221601_s_at Fas apoptotic inhibitory molecule 3 ; Fas apoptotic inhibitory molecule
3
FAIM3 9214 2
215343_at KIAA1509 KIAA1509 440193 2
228368_at Rho GTPase activating protein 20 ARHGAP20 57569 2
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204951_at ras homolog gene family, member H RHOH 399 2
206176_at bone morphogenetic protein 6 BMP6 654 2
220432_s_at cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39A1 51302 2
219551_at ELL associated factor 2 EAF2 55840 2
215407_s_at astrotactin 2 ASTN2 23245 2
205485_at ryanodine receptor 1 (skeletal) RYR1 6261 2
205828_at Matrix metallopeptidase 3 MMP3 4314 2
227834_at taxilin beta TXLNB 167838 2
215243_s_at gap junction protein, beta 3, 31kDa (connexin 31) GJB3 2707 2
242541_at ATP-binding cassette, sub-family A (ABC1), member 9 ABCA9 10350 2
202747_s_at integral membrane protein 2A ITM2A 9452 2
202295_s_at Cathepsin H CTSH 1512 2
223569_at phosphatidic acid phosphatase type 2 domain containing 1B PPAPDC1B 84513 2
206407_s_at chemokine (C-C motif) ligand 13 CCL13 6357 2
1561820_at sodium channel, voltage gated, type VIII, alpha SCN8A 6334 2
213844_at homeo box A5 HOXA5 3202 2
226560_at Sphingosine-1-phosphate phosphotase 2 SGPP2 130367 2
201004_at signal sequence receptor, delta (translocon-associated protein delta) SSR4 6748 2
206896_s_at guanine nucleotide binding protein (G protein), gamma 7 GNG7 2788 2
230983_at B-cell novel protein 1 BCNP1 199786 2
230285_at hypothetical protein DKFZp313A2432 DKFZp313A2432 258010 2
213540_at hydroxysteroid (17-beta) dehydrogenase 8 HSD17B8 7923 2
236313_at cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) CDKN2B 1030 2
202746_at integral membrane protein 2A ITM2A 9452 2
1554462_a_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 4189 2
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Probe Gene Description Gene symbol EntrezGene ID
Fold
change
226145_s_at Fraser syndrome 1 FRAS1 80144 2
204116_at interleukin 2 receptor, gamma (severe combined
immunodeficiency)
IL2RG 3561 2
223036_at phenylalanine-tRNA synthetase-like, beta subunit FARSLB 10056 2
201998_at ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 2
203528_at sema domain, immunoglobulin domain (Ig) SEMA4D 10507 2
220338_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 2
223435_s_at protocadherin alpha 9 ; PCDHA9 56134 2
220941_s_at chromosome 21 open reading frame 91 C21orf91 54149 2
205752_s_at glutathione S-transferase M5 GSTM5 2949 2
209292_at Inhibitor of DNA binding 4, dominant negative helix-loop-helix
protein
ID4 3400 2
1561390_at family with sequence similarity 41, member A, Y-linked FAM41AY 340618 2
206693_at interleukin 7 IL7 3574 2
232635_at chromosome 14 open reading frame 145 C14orf145 145508 2
204949_at intercellular adhesion molecule 3 ICAM3 3385 2
203608_at aldehyde dehydrogenase 5 family, member A1 (succinate-
semialdehyde dehydrogenase)
ALDH5A1 7915 2
203962_s_at nebulette NEBL 10529 2
213954_at KIAA0888 protein KIAA0888 26049 2
242104_at Ankyrin repeat and KH domain containing 1 ANKHD1 54882 2
232011_s_at microtubule-associated protein 1 light chain 3 alpha MAP1LC3A 84557 2
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241942_at peroxidasin homolog-like (Drosophila) PXDNL 137902 10
235417_at SPOC domain containing 1 SPOCD1 90853 10
221009_s_at aortic preferentially expressed gene 1 APEG1 10290 8
203665_at angiopoietin-like 4 ANGPTL4 51129 7
222939_s_at heme oxygenase (decycling) 1 HMOX1 3162 7
235548_at solute carrier family 16 (monocarboxylic acid transporters),
member 10
SLC16A10 117247 5
218975_at hypothetical protein FLJ90166 FLJ90166 164284 5
223333_s_at collagen, type V, alpha 3 COL5A3 50509 5
1553449_at hypothetical protein FLJ36701 FLJ36701 283860 4
210170_at PDZ and LIM domain 3 PDLIM3 27295 4
1555826_at Effector cell peptidase receptor 1 BIRC5 332 4
201389_at integrin, alpha 5 (fibronectin receptor, alpha polypeptide) ITGA5 3678 4
230333_at Spermidine/spermine N1-acetyltransferase SAT 6303 4
205860_x_at folate hydrolase (prostate-specific membrane antigen) 1 FOLH1 2346 4
209081_s_at collagen, type XVIII, alpha 1 COL18A1 80781 4
219148_at PDZ binding kinase PBK 55872 3
243555_at Endothelin receptor type A EDNRA 1909 3
228176_at endothelial differentiation, sphingolipid G-protein-coupled
receptor, 3
EDG3 1903 3
241473_at Sulfatase 1 SULF1 23213 3
1558199_at fibronectin 1 FN1 2335 3
52255_s_at collagen, type V, alpha 3 COL5A3 50509 3
1566785_x_at Ribosomal protein S7 NSF 4905 3
229095_s_at LIM and senescent cell antigen-like domains 3 LIMS3 96626 3
209122_at adipose differentiation-related protein ADFP 123 3
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228863_at Protocadherin 17 PCDH17 27253 3
209921_at solute carrier family 7, (cationic amino acid transporter, y+ system) member
11
SLC7A11 23657 3
1569603_at SH3-domain GRB2-like (endophilin) interacting protein 1 DKFZp761D221 84251 3
206026_s_at tumor necrosis factor, alpha-induced protein 6 TNFAIP6 7130 3
208161_s_at ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ABCC3 8714 3
202311_s_at collagen, type I, alpha 1 COL1A1 1277 3
219915_s_at solute carrier family 16 (monocarboxylic acid transporters), member 10 SLC16A10 117247 3
202834_at angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT 183 3
202998_s_at lysyl oxidase-like 2 LOXL2 4017 3
221577_x_at growth differentiation factor 15 GDF15 9518 3
239443_at protocadherin beta 6 PCDHB6 56130 3
202087_s_at cathepsin L CTSL 1514 3
210305_at phosphodiesterase 4D interacting protein (myomegalin) PDE4DIP 9659 3
241872_at SH3-domain GRB2-like (endophilin) interacting protein 1 DKFZp761D221 84251 3
209960_at hepatocyte growth factor (hepapoietin A; scatter factor) HGF 3082 3
229139_at junctophilin 1 JPH1 56704 3
236121_at olfactory receptor, family 51, subfamily E, member 2 OR51E2 81285 3
208475_at FERM domain containing 4A FRMD4A 55691 3
217678_at solute carrier family 7, (cationic amino acid transporter, y+ system) member
11
SLC7A11 23657 3
224324_at maestro ; maestro MRO 83876 3
224657_at ERBB receptor feedback inhibitor 1 ERRFI1 54206 3
205450_at phosphorylase kinase, alpha 1 (muscle) PHKA1 5255 3
205567_at carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 CHST1 8534 3
229876_at Phosphorylase kinase, alpha 1 (muscle) PHKA1 5255 3
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238289_at Retinitis pigmentosa GTPase regulator RPGR 6103 3
232530_at phospholipase D1, phophatidylcholine-specific PLD1 5337 3
1566129_at LIM and senescent cell antigen-like domains 1 LIMS1 3987 3
202208_s_at ADP-ribosylation factor-like 7 ARL7 10123 3
203823_at regulator of G-protein signalling 3 RGS3 5998 3
210755_at hepatocyte growth factor (hepapoietin A; scatter factor) HGF 3082 3
201468_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1728 3
215761_at Dmx-like 2 DMXL2 23312 3
209882_at Ras-like without CAAX 1 RIT1 6016 3
202856_s_at solute carrier family 16 (monocarboxylic acid transporters), member 3 SLC16A3 9123 3
230748_at solute carrier family 16 (monocarboxylic acid transporters), member 6 SLC16A6 440459 3
204163_at elastin microfibril interfacer 1 EMILIN1 11117 3
203382_s_at apolipoprotein E APOE 348 3
200648_s_at glutamate-ammonia ligase (glutamine synthetase) GLUL 2752 2
207224_s_at sialic acid binding Ig-like lectin 7 SIGLEC7 27036 2
235629_at Fibronectin 1 FN1 2335 2
217430_x_at collagen, type I, alpha 1 COL1A1 1277 2
160020_at matrix metallopeptidase 14 (membrane-inserted) MMP14 4323 2
226814_at ADAM metallopeptidase with thrombospondin type 1 motif, 9 ADAMTS9 56999 2
233167_at selenoprotein O SELO 83642 2
212013_at peroxidasin homolog (Drosophila) PXDN 7837 2
207837_at RNA binding protein with multiple splicing RBPMS 11030 2
223567_at sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6B
SEMA6B 10501 2
1558460_at ATP-binding cassette, sub-family C (CFTR/MRP), member 5 ABCC5 10057 2
237624_at Collagen, type IV, alpha 2 COL4A2 1284 2
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218113_at transmembrane protein 2 TMEM2 23670 2
35666_at sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3F
SEMA3F 6405 2
210612_s_at synaptojanin 2 SYNJ2 8871 2
213592_at angiotensin II receptor-like 1 AGTRL1 187 2
1569157_s_at hypothetical protein LOC162993 LOC162993 162993 2
201261_x_at biglycan BGN 633 2
203325_s_at collagen, type V, alpha 1 COL5A1 1289 2
213506_at coagulation factor II (thrombin) receptor-like 1 F2RL1 2150 2
223683_at zinc finger, MYND-type containing 15 ZMYND15 84225 2
202627_s_at serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor
type 1), member 1
SERPINE1 5054 2
236910_at Mitochondrial ribosomal protein L39 MRPL39 54148 2
220750_s_at leucine proline-enriched proteoglycan (leprecan) 1 LEPRE1 64175 2
223251_s_at ankyrin repeat domain 10 ANKRD10 55608 2
221730_at collagen, type V, alpha 2 COL5A2 1290 2
202974_at membrane protein, palmitoylated 1, 55kDa MPP1 4354 2
205936_s_at hexokinase 3 (white cell) HK3 3101 2
205180_s_at ADAM metallopeptidase domain 8 ; ADAM metallopeptidase domain 8 ADAM8 101 2
227289_at hypothetical protein LOC144997 LOC144997 144997 2
219394_at phosphatidylglycerophosphate synthase PGS1 9489 2
212828_at synaptojanin 2 SYNJ2 8871 2
236545_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform
(calcineurin A alpha)
PPP3CA 5530 2
209135_at aspartate beta-hydroxylase ASPH 444 2
218451_at CUB domain containing protein 1 CDCP1 64866 2
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212488_at collagen, type V, alpha 1 COL5A1 1289 2
209365_s_at extracellular matrix protein 1 ECM1 1893 2
228816_at hypothetical protein LOC92270 LOC92270 92270 2
212658_at lipoma HMGIC fusion partner-like 2 LHFPL2 10184 2
241384_x_at hypothetical protein MGC40579 MGC40579 256356 2
238542_at UL16 binding protein 2 ULBP2 80328 2
229218_at Collagen, type I, alpha 2 COL1A2 1278 2
222446_s_at beta-site APP-cleaving enzyme 2 BACE2 25825 2
224773_at neuron navigator 1 NAV1 89796 2
212012_at peroxidasin homolog (Drosophila) PXDN 7837 2
61734_at reticulocalbin 3, EF-hand calcium binding domain RCN3 57333 2
202862_at fumarylacetoacetate hydrolase (fumarylacetoacetase) FAH 2184 2
227314_at Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 3673 2
205099_s_at chemokine (C-C motif) receptor 1 CCR1 1230 2
1568765_at serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor
type 1), member 1
SERPINE1 5054 2
207135_at 5-hydroxytryptamine (serotonin) receptor 2A HTR2A 3356 2
219815_at galactose-3-O-sulfotransferase 4 GAL3ST4 79690 2
205574_x_at bone morphogenetic protein 1 BMP1 649 2
202855_s_at solute carrier family 16 (monocarboxylic acid transporters), member 3 SLC16A3 9123 2
236153_at Suppressor of hairy wing homolog 4 (Drosophila) SUHW4 54816 2
219957_at RUN and FYVE domain containing 2 RUFY2 55680 2
232685_at Ets variant gene 6 (TEL oncogene) ETV6 2120 2
203417_at microfibrillar-associated protein 2 MFAP2 4237 2
237411_at ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 11174 2
206298_at Rho GTPase activating protein 22 ARHGAP22 58504 2
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218585_s_at denticleless homolog (Drosophila) DTL 51514 2
207714_s_at serpin peptidase inhibitor, clade H (heat shock protein 47), member 1,
(collagen binding protein 1)
SERPINH1 871 2
226722_at family with sequence similarity 20, member C FAM20C 56975 2
205572_at angiopoietin 2 ANGPT2 285 2
214702_at fibronectin 1 FN1 2335 2
203282_at glucan (1,4-alpha-), branching enzyme 1 GBE1 2632 2
209053_s_at Wolf-Hirschhorn syndrome candidate 1 WHSC1 7468 2




1559814_at Chondroitin sulfate synthase 3 CSS3 337876 2
1556151_at T-cell immunomodulatory protein CDA08 81533 2
200827_at procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 PLOD1 5351 2
221143_at replication protein A4, 34kDa RPA4 29935 2
1558078_at DNA directed RNA polymerase II polypeptide J-related gene POLR2J2 246721 2
210422_x_at solute carrier family 11 (proton-coupled divalent metal ion transporters),
member 1
SLC11A1 6556 2
228054_at transmembrane protein 44 TMEM44 93109 2
219102_at reticulocalbin 3, EF-hand calcium binding domain RCN3 57333 2
201505_at laminin, beta 1 LAMB1 3912 2
233090_at Glypican 6 GPC6 10082 2
217518_at fer-1-like 3, myoferlin (C. elegans) FER1L3 26509 2
219457_s_at Ras and Rab interactor 3 RIN3 79890 2
200840_at lysyl-tRNA synthetase KARS 3735 2
208928_at P450 (cytochrome) oxidoreductase POR 5447 2










204150_at stabilin 1 STAB1 23166 2
205525_at caldesmon 1 CALD1 800 2
210119_at potassium inwardly-rectifying channel, subfamily J, member 15 KCNJ15 3772 2
213943_at twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen syndrome)
(Drosophila)
TWIST1 7291 2
201655_s_at heparan sulfate proteoglycan 2 (perlecan) HSPG2 3339 2
218749_s_at solute carrier family 24 (sodium/potassium/calcium exchanger), member
6
SLC24A6 80024 2
236249_at IKK interacting protein IKIP 121457 2
202733_at procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide II
P4HA2 8974 2
208613_s_at filamin B, beta (actin binding protein 278) FLNB 2317 2
213001_at angiopoietin-like 2 ANGPTL2 23452 2
205676_at cytochrome P450, family 27, subfamily B, polypeptide 1 CYP27B1 1594 2
231823_s_at KIAA1295 KIAA1295 285590 2
236475_at Microtubule associated monoxygenase, calponin and LIM domain
containing 2
MICAL2 9645 2
209397_at malic enzyme 2, NAD(+)-dependent, mitochondrial ME2 4200 2
220668_s_at DNA (cytosine-5-)-methyltransferase 3 beta DNMT3B 1789 2
1562416_at Filamin B, beta (actin binding protein 278) FLNB 2317 2
206028_s_at c-mer proto-oncogene tyrosine kinase MERTK 10461 2
228845_at hypothetical protein LOC196463 LOC196463 196463 2
210868_s_at ELOVL family member 6, elongation of long chain fatty acids
(FEN1/Elo2, SUR4/Elo3-like, yeast)
ELOVL6 79071 2
203925_at glutamate-cysteine ligase, modifier subunit GCLM 2730 2
229899_s_at similar to RPE-spondin HSUP1 441951 2










214435_x_at v-ral simian leukemia viral oncogene homolog A (ras related) RALA 5898 2
209172_s_at centromere protein F, 350/400ka (mitosin) ; centromere protein F,
350/400ka (mitosin)
CENPF 1063 2
209803_s_at pleckstrin homology-like domain, family A, member 2 PHLDA2 7262 2
218502_s_at trichorhinophalangeal syndrome I TRPS1 7227 2
221729_at collagen, type V, alpha 2 COL5A2 1290 2
202202_s_at laminin, alpha 4 LAMA4 3910 2
228520_s_at Amyloid beta (A4) precursor-like protein 2 APLP2 334 2
208002_s_at acyl-CoA thioesterase 7 ACOT7 11332 2
215198_s_at caldesmon 1 CALD1 800 2
226216_at Insulin receptor INSR 3643 2
232080_at HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 57520 2
210184_at integrin, alpha X (antigen CD11C (p150), alpha polypeptide) ITGAX 3687 2
213700_s_at Pyruvate kinase, muscle PKM2 5315 2
239719_at CD109 antigen (Gov platelet alloantigens) CD109 135228 2
243305_at Kelch domain containing 5 KIAA1340 57542 2
213905_x_at biglycan ; serologically defined colon cancer antigen 33 BGN 10194 2
218815_s_at transmembrane protein 51 TMEM51 55092 2
204114_at nidogen 2 (osteonidogen) NID2 22795 2
219952_s_at mucolipin 1 MCOLN1 57192 2
214052_x_at BAT2 domain containing 1 XTP2 23215 2
222680_s_at denticleless homolog (Drosophila) DTL 51514 2
203903_s_at hephaestin HEPH 9843 2
207828_s_at centromere protein F, 350/400ka (mitosin) CENPF 1063 2
226498_at (vascular endothelial growth factor/vascular permeability factor receptor) FLT1 2321 2
234372_at Family with sequence similarity 70, member B MGC20579 348013 2
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215565_at dystrobrevin, beta DTNB 1838 88
216984_x_at Immunoglobulin lambda joining 3 IGLC2 3538 79
217378_x_at similar to Ig kappa chain precursor V region (orphon V108) - human  (fragment) LOC391427 391427 62
235401_s_at Fc receptor-like and mucin-like 1 FCRLM1 84824 58
211643_x_at Immunoglobulin kappa variable 1-5 IGKC 3514 55
234884_x_at Immunoglobulin lambda joining 3 IGLC2 3538 53
215214_at immunoglobulin lambda variable 3-25 IGLV3-25 28793 52
215946_x_at similar to omega protein LOC91353 91353 50
215949_x_at immunoglobulin heavy constant mu IGHM 3507 50
211644_x_at immunoglobulin kappa constant IGKC 3514 47
230896_at coiled-coil domain containing 4 CCDC4 389206 47
217148_x_at immunoglobulin lambda variable 2-14 IGLV2-14 28815 42
235982_at Fc receptor-like 1 FCRL1 115350 39
228518_at  immunoglobulin heavy constant gamma 1 (G1m marker)  IGHG1 3500 38
205049_s_at CD79A antigen (immunoglobulin-associated alpha) CD79A 973 36
217480_x_at similar to Ig kappa chain LOC339562 339562 34
216207_x_at immunoglobulin kappa variable 1D-13 IGKV1D-13 28902 29
1563217_at Protein kinase (cAMP-dependent, catalytic) inhibitor alpha PKIA 5569 21
230673_at polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 PKHD1L1 93035 21
212592_at
Immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu
polypeptides IGJ 3512 20
234306_s_at SLAM family member 7 SLAMF7 57823 19
220059_at BCR downstream signaling 1 BRDG1 26228 17
216542_x_at




224022_x_at wingless-type MMTV integration site family, member 16 WNT16 51384 15
206135_at suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein) ST18 9705 15
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227300_at hypothetical protein LOC338773 LOC338773 338773 15
242388_x_at T-cell activation GTPase activating protein TAGAP 117289 15
206398_s_at CD19 antigen CD19 930 15
206914_at class-I MHC-restricted T cell associated molecule CRTAM 56253 14
221602_s_at Fas apoptotic inhibitory molecule 3 ; Fas apoptotic inhibitory molecule 3 FAIM3 9214 13
244887_at Regulator of G-protein signalling 13 RGS13 6003 13
237009_at CD69 antigen (p60, early T-cell activation antigen) CD69 969 12
211062_s_at Carbopeptidase Z CPZ 8532 12
220338_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 12
235965_at DKFZP434B0335 protein DKFZP434 25851 12
219667_s_at B-cell scaffold protein with ankyrin repeats 1 BANK1 55024 11
229723_at T-cell activation GTPase activating protein TAGAP 117289 11
223484_at normal mucosa of esophagus specific 1 NMES1 84419 11
234050_at T-cell activation GTPase activating protein TAGAP 117289 11
206150_at tumor necrosis factor receptor superfamily, member 7 TNFRSF7 939 11
236293_at Ras homolog gene family, member H RHOH 399 11
224406_s_at Fc receptor-like 5 ; Fc receptor-like 5 FCRL5 83416 11
221969_at Paired box gene 5 (B-cell lineage specific activator) PAX5 5079 11
1563674_at Fc receptor-like 2 FCRL2 79368 10
209606_at pleckstrin homology, Sec7 and coiled-coil domains, binding protein PSCDBP 9595 10
236341_at cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 10
244357_at Stromal membrane-associated protein 1-like LOC64744 64744 10
221601_s_at Fas apoptotic inhibitory molecule 3 ; Fas apoptotic inhibitory molecule 3 FAIM3 9214 10
1554474_a_at monooxygenase, DBH-like 1 MOXD1 26002 10
205692_s_at CD38 antigen (p45) CD38 952 10
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222106_at prion protein 2 (dublet) PRND 23627 10
1569225_a_at sex comb on midleg-like 4 (Drosophila) SCML4 256380 10
202988_s_at regulator of G-protein signalling 1 RGS1 5996 9
227224_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 9
239237_at Amphiphysin (Stiff-Man syndrome with breast cancer 128kDa autoantigen) AMPH 273 9
228658_at hypothetical protein LOC150271 LOC150271 150271 9
203798_s_at visinin-like 1 VSNL1 7447 9
206804_at CD3G antigen, gamma polypeptide (TiT3 complex) CD3G 917 9
205990_s_at wingless-type MMTV integration site family, member 5A WNT5A 7474 9
207734_at lymphocyte transmembrane adaptor 1 LAX1 54900 9
1552542_s_at T-cell activation GTPase activating protein TAGAP 117289 9
1559170_at Similar to ankyrin repeat domain 20A ; Hypothetical gene supported by
NM_032250
388466 9
227361_at heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 HS3ST3B1 9953 9
205671_s_at major histocompatibility complex, class II, DO beta HLA-DOB 3112 9
228964_at PR domain containing 1, with ZNF domain PRDM1 639 9
34210_at CD52 antigen (CAMPATH-1 antigen) CD52 1043 9
224009_x_at dehydrogenase/reductase (SDR family) member 9 DHRS9 10170 9
1558662_s_at B-cell scaffold protein with ankyrin repeats 1 BANK1 55024 9
220068_at pre-B lymphocyte gene 3 VPREB3 29802 9
1552343_s_at phosphodiesterase 7A PDE7A 5150 8
224402_s_at Fc receptor-like 4 FCRL4 83417 8
206337_at chemokine (C-C motif) receptor 7 CCR7 1236 8
219463_at chromosome 20 open reading frame 103 C20orf103 24141 8
204052_s_at secreted frizzled-related protein 4 SFRP4 6424 8
222895_s_at B-cell CLL/lymphoma 11B (zinc finger protein) BCL11B 64919 8
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217028_at chemokine (C-X-C motif) receptor 4 CXCR4 7852 8
210164_at granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) GZMB 3002 8
211919_s_at chemokine (C-X-C motif) receptor 4 CXCR4 7852 8
1558972_s_at chromosome 6 open reading frame 190 C6orf190 387357 8
203936_s_at matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV
collagenase)
MMP9 4318 8
204661_at CD52 antigen (CAMPATH-1 antigen) ; CD52 antigen (CAMPATH-1 antigen) CD52 1043 8
242104_at Ankyrin repeat and KH domain containing 1 ANKHD1 54882 8
204951_at ras homolog gene family, member H RHOH 399 8
1553856_s_at purinergic receptor P2Y, G-protein coupled, 10 P2RY10 27334 8
1557285_at Amphiregulin (schwannoma-derived growth factor) AREG 374 8
222915_s_at B-cell scaffold protein with ankyrin repeats 1 BANK1 55024 8
244261_at interleukin 28 receptor, alpha (interferon, lambda receptor) IL28RA 163702 8
1559263_s_at zinc finger CCCH-type containing 12D ZC3H12D 340152 8
209596_at matrix-remodelling associated 5 MXRA5 25878 8
223750_s_at toll-like receptor 10 TLR10 81793 8
206834_at hemoglobin, delta ; hemoglobin, delta HBD 3045 8
226218_at Interleukin 7 receptor IL7R 3575 8
227566_at neurotrimin HNT 50863 7
215967_s_at lymphocyte antigen 9 LY9 4063 7
241891_at Dedicator of cytokinesis 8 DOCK8 81704 7
205114_s_at chemokine (C-C motif) ligand 3 CCL3 414062 7
1405_i_at chemokine (C-C motif) ligand 5 CCL5 6352 7
204286_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 5366 7
242947_at DnaJ (Hsp40) homolog, subfamily C, member 16 KIAA0962 23341 7
212311_at KIAA0746 protein KIAA0746 23231 7
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242458_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 7
216834_at regulator of G-protein signalling 1 RGS1 5996 7
202901_x_at cathepsin S CTSS 1520 7
205590_at RAS guanyl releasing protein 1 (calcium and DAG-regulated) RASGRP1 10125 7
209670_at T cell receptor alpha constant ; T cell receptor alpha constant TRAC 28755 7
230983_at B-cell novel protein 1 BCNP1 199786 7
209708_at monooxygenase, DBH-like 1 MOXD1 26002 7
213425_at wingless-type MMTV integration site family, member 5A WNT5A 7474 7
1568604_a_at Ca2+-dependent secretion activator CADPS 8618 7
209201_x_at chemokine (C-X-C motif) receptor 4 CXCR4 7852 7
221266_s_at transmembrane 7 superfamily member 4 ; transmembrane 7 superfamily
member 4
TM7SF4 81501 7
228377_at kelch-like 14 (Drosophila) KLHL14 57565 7
235372_at Fc receptor-like and mucin-like 1 FCRLM1 84824 7
237496_at 3'-phosphoadenosine 5'-phosphosulfate synthase 2 PAPSS2 9060 7
207031_at bagpipe homeobox homolog 1 (Drosophila) BAPX1 579 7
227533_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 7
235353_at KIAA0746 protein KIAA0746 23231 6
228167_at kelch-like 6 (Drosophila) KLHL6 89857 6
209138_x_at Immunoglobulin lambda joining 3 IGLC2 3538 6
226811_at family with sequence similarity 46, member C FAM46C 54855 6
220169_at hypothetical protein FLJ23235 FLJ23235 80008 6
202643_s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 6
209671_x_at T cell receptor alpha locus TRA@ 28755 6
205484_at signaling threshold regulating transmembrane adaptor 1 SIT1 27240 6
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226435_at papilin, proteoglycan-like sulfated glycoprotein PAPLN 89932 6
1554343_a_at BCR downstream signaling 1 BRDG1 26228 6
205249_at early growth response 2 (Krox-20 homolog, Drosophila) EGR2 1959 6
210354_at interferon, gamma IFNG 3458 6
219734_at SID1 transmembrane family, member 1 SIDT1 54847 6
206513_at absent in melanoma 2 AIM2 9447 6
219799_s_at dehydrogenase/reductase (SDR family) member 9 DHRS9 10170 6
227189_at copine V CPNE5 57699 6
228258_at TBC1 domain family, member 10C TBC1D10C 374403 6
225792_at Hook homolog 1 (Drosophila) HOOK1 51361 6
211796_s_at T cell receptor beta variable 21-1 TRBV21-1 28566 6
214615_at purinergic receptor P2Y, G-protein coupled, 10 P2RY10 27334 6
221558_s_at lymphoid enhancer-binding factor 1 LEF1 51176 6
205419_at Epstein-Barr virus induced gene 2 (lymphocyte-specific G protein-coupled
receptor)
EBI2 1880 6
211597_s_at homeodomain-only protein ; homeodomain-only protein HOP 84525 6
211902_x_at T cell receptor alpha locus TRA@ 6955 6
212314_at KIAA0746 protein KIAA0746 23231 6
235885_at purinergic receptor P2Y, G-protein coupled, 12 P2RY12 64805 6
207777_s_at SP140 nuclear body protein SP140 11262 6
214405_at CUG triplet repeat, RNA binding protein 2 CUGBP2 10659 6
233302_at B-cell CLL/lymphoma 11B (zinc finger protein) BCL11B 64919 5
219454_at EGF-like-domain, multiple 6 EGFL6 25975 5
227134_at synaptotagmin-like 1 SYTL1 84958 5
205828_at matrix metallopeptidase 3 MMP3 4314 5
230753_at similar to RIKEN cDNA 4930424G05 LOC197135 197135 5
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209829_at chromosome 6 open reading frame 32 C6orf32 9750 5
210915_x_at T cell receptor beta variable 19 ; T cell receptor beta constant 1 TRBV19 28568 5
207979_s_at CD8 antigen, beta polypeptide 1 (p37) CD8B1 926 5
218858_at DEP domain containing 6 DEPDC6 64798 5
205648_at wingless-type MMTV integration site family member 2 WNT2 7472 5
219985_at heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 HS3ST3A1 9955 5
39318_at T-cell leukemia/lymphoma 1A TCL1A 8115 5
204103_at chemokine (C-C motif) ligand 4 CCL4 6351 5
232112_at Ral GEF with PH domain and SH3 binding motif 2 RALGPS2 55103 5
230233_at RasGEF domain family, member 1B RASGEF1B 153020 5
232739_at Spi-B transcription factor (Spi-1/PU.1 related) SPIB 6689 5
241871_at calcium/calmodulin-dependent protein kinase IV CAMK4 814 5
221331_x_at cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 5
1570585_at hypothetical protein LOC196264 LOC196264 196264 5
220577_at GTPase, very large interferon inducible 1 GVIN1 387751 5
1555613_a_at zeta-chain (TCR) associated protein kinase 70kDa ZAP70 7535 5
232277_at Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 SLC28A3 64078 5
208268_at ADAM metallopeptidase domain 28 ADAM28 10863 5
205831_at CD2 antigen (p50), sheep red blood cell receptor ; CD2 antigen (p50), sheep red
blood cell receptor
CD2 914 5
1560999_a_at Interleukin 12 receptor, beta 2 IL12RB2 3595 5
204007_at Fc fragment of IgG, low affinity IIIb, receptor (CD16b) FCGR3B 2215 5
1553155_x_at ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d isoform 2 ATP6V0D2 245972 5
230011_at similar to mouse meiosis defective 1 gene MGC40042 150365 5
210279_at G protein-coupled receptor 18 GPR18 2841 5
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1560396_at Kelch-like 6 (Drosophila) KLHL6 89857 5
211742_s_at ecotropic viral integration site 2B ; ecotropic viral integration site 2B EVI2B 2124 5
242946_at CD53 antigen CD53 963 5
204563_at selectin L (lymphocyte adhesion molecule 1) SELL 6402 5
220005_at purinergic receptor P2Y, G-protein coupled, 13 P2RY13 53829 5
204116_at interleukin 2 receptor, gamma (severe combined immunodeficiency) IL2RG 3561 5
236539_at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 26191 5
229695_at Chromosome 10 open reading frame 45 C10orf45 83641 5
1560416_at dynein, axonemal, heavy polypeptide 11 DNAH11 8701 5
243981_at serine/threonine kinase 4 STK4 6789 5
205666_at flavin containing monooxygenase 1 FMO1 2326 5
204891_s_at lymphocyte-specific protein tyrosine kinase LCK 3932 5
213958_at CD6 antigen ; CD6 antigen CD6 923 5
219117_s_at FK506 binding protein 11, 19 kDa FKBP11 51303 5
219528_s_at B-cell CLL/lymphoma 11B (zinc finger protein) BCL11B 64919 5
206404_at fibroblast growth factor 9 (glia-activating factor) FGF9 2254 5
202902_s_at cathepsin S CTSS 1520 5
223729_at cat eye syndrome chromosome region, candidate 2 CECR2 27443 5
204051_s_at secreted frizzled-related protein 4 SFRP4 6424 5
219874_at solute carrier family 12 (potassium/chloride transporters), member 8 SLC12A8 84561 5
206773_at lymphocyte antigen 6 complex, locus H LY6H 4062 5
239529_at chromosome 5 open reading frame 20 C5orf20 140947 5
213502_x_at similar to bK246H3.1 (immunoglobulin lambda-like polypeptide 1, pre-B-cell
specific)
LOC91316 91316 5
202644_s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 5
1563473_at Protein phosphatase 1, regulatory (inhibitor) subunit 16B PPP1R16B 26051 5
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1554208_at similar to mouse meiosis defective 1 gene MGC40042 150365 5
222859_s_at dual adaptor of phosphotyrosine and 3-phosphoinositides DAPP1 27071 5
219648_at dilute suppressor DSU 55686 5
232824_at ATPase, Class II, type 9B ATP9B 374868 5
229686_at purinergic receptor P2Y, G-protein coupled, 8 P2RY8 286530 5
230261_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 ST8SIA4 7903 5
1552899_at hypothetical protein MGC34034 MGC34034 154089 5
213539_at CD3D antigen, delta polypeptide (TiT3 complex) CD3D 915 5
220035_at nucleoporin 210kDa NUP210 23225 4
216748_at pyrin and HIN domain family, member 1 PYHIN1 149628 4
205997_at ADAM metallopeptidase domain 28 ADAM28 10863 4
214084_x_at neutrophil cytosolic factor 1 (47kDa, chronic granulomatous disease, autosomal
1)
NCF1 4687 4
203917_at coxsackie virus and adenovirus receptor CXADR 1525 4
219812_at hypothetical protein MGC2463 MGC2463 79037 4
1552480_s_at protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
241860_at Serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 4
232383_at transcription factor EC TFEC 22797 4
211339_s_at IL2-inducible T-cell kinase ITK 3702 4
222020_s_at neurotrimin HNT 50863 4
230493_at transmembrane protein 46 TMEM46 387914 4
214470_at killer cell lectin-like receptor subfamily B, member 1 KLRB1 3820 4
210116_at SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) SH2D1A 4068 4
211771_s_at POU domain, class 2, transcription factor 2 ; POU domain, class 2, transcription
factor 2
POU2F2 5452 4
231377_at similar to Ab2-183 LOC158830 158830 4
207651_at G protein-coupled receptor 171 GPR171 29909 4
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206100_at carboxypeptidase M CPM 1368 4
1554676_at proteoglycan 1, secretory granule PRG1 5552 4
228636_at basic helix-loop-helix domain containing, class B, 5 BHLHB5 27319 4
209763_at chordin-like 1 CHRDL1 91851 4
243109_at Multiple C2-domains with two transmembrane regions 2 MCTP2 55784 4
1554240_a_at integrin, alpha L (antigen CD11A (p180) ITGAL 3683 4
211478_s_at dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 4
232311_at Beta-2-microglobulin B2M 567 4
236738_at Similar to LOC166075 LOC401097 401097 4
201341_at ectodermal-neural cortex (with BTB-like domain) ENC1 8507 4
236295_s_at NOD3 protein NOD3 197358 4
210347_s_at B-cell CLL/lymphoma 11A (zinc finger protein) BCL11A 53335 4
1555372_at BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 4
232843_s_at dedicator of cytokinesis 8 DOCK8 81704 4
215468_at DEAH (Asp-Glu-Ala-His) box polypeptide 9 DHX9 1660 4
213764_s_at microfibrillar associated protein 5 MFAP5 8076 4
233514_x_at testis expressed sequence 11 TEX11 56159 4




3039 ; 3040 4
211696_x_at hemoglobin, beta ; hemoglobin, beta HBB 3043 4
225912_at tumor protein p53 inducible nuclear protein 1 TP53INP1 94241 4
207001_x_at TSC22 domain family, member 3 TSC22D3 1831 4
212588_at protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
35974_at lymphoid-restricted membrane protein LRMP 4033 4
214203_s_at proline dehydrogenase (oxidase) 1 PRODH 5625 4
244813_at RAD51-like 1 (S. cerevisiae) RAD51L1 5890 4
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243006_at FYN oncogene related to SRC, FGR, YES FYN 2534 4
1559078_at B-cell CLL/lymphoma 11A (zinc finger protein) BCL11A 53335 4
203413_at NEL-like 2 (chicken) ; NEL-like 2 (chicken) NELL2 4753 4
228335_at claudin 11 (oligodendrocyte transmembrane protein) CLDN11 5010 4




236471_at nuclear factor (erythroid-derived 2)-like 3 NFE2L3 9603 4
232231_at runt-related transcription factor 2 RUNX2 860 4
214012_at type 1 tumor necrosis factor receptor shedding aminopeptidase regulator ARTS-1 51752 4
236995_x_at transcription factor EC TFEC 22797 4
223746_at serine/threonine kinase 4 STK4 6789 4
243683_at Mortality factor 4 like 2 MORF4L2 9643 4
222717_at serum deprivation response (phosphatidylserine binding protein) SDPR 8436 4
210258_at regulator of G-protein signalling 13 RGS13 6003 4
207339_s_at lymphotoxin beta (TNF superfamily, member 3) LTB 4050 4
205943_at tryptophan 2,3-dioxygenase TDO2 6999 4
214070_s_at ATPase, Class V, type 10B ATP10B 23120 4
227210_at Scm-like with four mbt domains 2 SFMBT2 57713 4
1566887_x_at KIAA0284 KIAA0284 283638 4
242109_at T-complex-associated-testis-expressed 1-like 1 TCTEL1 6993 4
207655_s_at B-cell linker BLNK 29760 4
204205_at apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G APOBEC3G 60489 4
209827_s_at interleukin 16 (lymphocyte chemoattractant factor) IL16 3603 4
1552386_at hypothetical protein FLJ33641 FLJ33641 202309 4
212587_s_at protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
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223423_at G protein-coupled receptor 160 GPR160 26996 4
228343_at POU domain, class 2, transcription factor 2 POU2F2 5452 4
1552398_a_at C-type lectin domain family 12, member A CLEC12A 160364 4
237361_at Doublecortin and CaM kinase-like 1 DCAMKL1 9201 4
232617_at cathepsin S CTSS 1520 4
206060_s_at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 26191 4
219551_at ELL associated factor 2 EAF2 55840 4
203932_at major histocompatibility complex, class II, DM beta HLA-DMB 3109 4
211795_s_at FYN binding protein (FYB-120/130) FYB 2533 4
40665_at flavin containing monooxygenase 3 FMO3 2328 4
220918_at chromosome 21 open reading frame 96 C21orf96 80215 4
207238_s_at protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
1552626_a_at hypothetical protein DKFZp566N034 DKFZP 81615 4
204118_at CD48 antigen (B-cell membrane protein) ; CD48 antigen (B-cell membrane
protein)
CD48 962 4
206171_at adenosine A3 receptor ADORA3 140 4
220252_x_at chromosome X open reading frame 21 CXorf21 80231 4
204674_at lymphoid-restricted membrane protein LRMP 4033 4
225502_at dedicator of cytokinesis 8 DOCK8 81704 4
204823_at neuron navigator 3 NAV3 89795 4
212671_s_at major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1 3117 4
239233_at KIAA1212 KIAA1212 55704 4
227817_at Protein kinase C, beta 1 PRKCB1 5579 4
208010_s_at protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 26191 4
242517_at G protein-coupled receptor 54 GPR54 84634 4
1557718_at protein phosphatase 2, regulatory subunit B (B56), gamma isoform PPP2R5C 5527 4
315





1553237_x_at protocadherin alpha subfamily C, 1 PCDHAC1 56135 4
230245_s_at hypothetical protein LOC283663 LOC283663 283663 4
230014_at Yippee-like 5 (Drosophila) YPEL5 51646 4
204363_at coagulation factor III (thromboplastin, tissue factor) F3 2152 4
225282_at stromal membrane-associated protein 1-like SMAP1L 64744 4
227346_at Zinc finger protein, subfamily 1A, 1 (Ikaros) ZNFN1A1 10320 4
219290_x_at dual adaptor of phosphotyrosine and 3-phosphoinositides DAPP1 27071 4
213888_s_at TRAF3 interacting protein 3 TRAF3IP3 80342 4
205214_at serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 4
1562528_at RAR-related orphan receptor A RORA 6095 4
225706_at glucocorticoid induced transcript 1 GLCCI1 113263 4
238581_at Guanylate binding protein 5 GBP5 115362 4
234260_at CDC42 small effector 2 CDC42SE2 56990 4
222326_at Phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog,
Drosophila)
PDE4B 5142 4
222858_s_at dual adaptor of phosphotyrosine and 3-phosphoinositides DAPP1 27071 4
201340_s_at ectodermal-neural cortex (with BTB-like domain) ENC1 8507 4
218723_s_at response gene to complement 32 RGC32 28984 4
237104_at Cathepsin S CTSS 1520 4
222378_at Hypothetical protein FLJ43663 FLJ43663 378805 4
212998_x_at major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 3119 4
200670_at X-box binding protein 1 XBP1 7494 3
203178_at glycine amidinotransferase (L-arginine:glycine amidinotransferase) GATM 2628 3
1557459_at SNF1-like kinase 2 SNF1LK2 23235 3
238063_at hypothetical protein FLJ32028 FLJ32028 201799 3
211734_s_at Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide FCER1A 2205 3
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204890_s_at lymphocyte-specific protein tyrosine kinase LCK 3932 3
217452_s_at UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 B3GALT2 8707 3
232213_at Pellino homolog 1 (Drosophila) PELI1 57162 3
205269_at lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of
76kDa)
LCP2 3937 3
227266_s_at FYN binding protein (FYB-120/130) FYB 2533 3
227228_s_at KIAA1509 KIAA1509 440193 3
204702_s_at nuclear factor (erythroid-derived 2)-like 3 NFE2L3 9603 3
244023_at Spleen tyrosine kinase SYK 6850 3
213537_at major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 3113 3
233690_at Chromosome 21 open reading frame 96 C21orf96 80215 3
204949_at intercellular adhesion molecule 3 ICAM3 3385 3
241849_at CD74 antigen (invariant polypeptide of major histocompatibility complex, class II
antigen-associated)
CD74 972 3
235086_at Thrombospondin 1 THBS1 7057 3
206206_at CD180 antigen CD180 4064 3
210031_at CD3Z antigen, zeta polypeptide (TiT3 complex) CD3Z 919 3
240232_at Chromosome 3 open reading frame 1 C3orf1 51300 3
205101_at class II, major histocompatibility complex, transactivator CIITA 4261 3
213416_at integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) ITGA4 3676 3
244172_at B-cell linker BLNK 29760 3
226930_at fibronectin type III domain containing 1 FNDC1 84624 3
201688_s_at tumor protein D52 TPD52 7163 3
220356_at corin, serine peptidase CORIN 10699 3
204057_at interferon regulatory factor 8 ; interferon regulatory factor 8 IRF8 3394 3
206295_at interleukin 18 (interferon-gamma-inducing factor) IL18 3606 3
213765_at microfibrillar associated protein 5 MFAP5 8076 3
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212613_at butyrophilin, subfamily 3, member A2 BTN3A2 11118 3
1555275_a_at kelch-like 6 (Drosophila) KLHL6 89857 3
1564164_at hypothetical protein FLJ20054 FLJ20054 54530 3
219259_at sema domain, immunoglobulin domain (Ig) SEMA4A 64218 3
230970_at Slingshot homolog 2 (Drosophila) SSH2 85464 3
204613_at phospholipase C, gamma 2 (phosphatidylinositol-specific) PLCG2 5336 3
229014_at hypothetical gene supported by AK124699 FLJ42709 441094 3
204204_at solute carrier family 31 (copper transporters), member 2 SLC31A2 1318 3
201689_s_at tumor protein D52 TPD52 7163 3
209030_s_at immunoglobulin superfamily, member 4 IGSF4 23705 3
209758_s_at microfibrillar associated protein 5 MFAP5 8076 3
209685_s_at protein kinase C, beta 1 PRKCB1 5579 3
220988_s_at C1q and tumor necrosis factor related protein 3 C1QTNF3 114899 3
1552584_at interleukin 12 receptor, beta 1 IL12RB1 3594 3
209627_s_at oxysterol binding protein-like 3 OSBPL3 26031 3
244599_at Ceramide kinase-like CERKL 375298 3
213975_s_at leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),
member 1
 LILRB1 4069 3
1554050_at sphingomyelin phosphodiesterase, acid-like 3B SMPDL3B 27293 3
223620_at G protein-coupled receptor 34 GPR34 2857 3
232181_at hypothetical protein LOC153346 LOC153346 153346 3
1565544_at ring finger protein 141 RNF141 50862 3
244251_at Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of
76kDa)
LCP2 3937 3
205456_at CD3E antigen, epsilon polypeptide (TiT3 complex) CD3E 916 3
201008_s_at thioredoxin interacting protein TXNIP 10628 3
1552703_s_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 114769 3
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222245_s_at fer-1-like 4 (C. elegans) FER1L4 80307 3
240231_at Antizyme inhibitor 1 OAZIN 51582 3
201739_at serum/glucocorticoid regulated kinase SGK 6446 3
233500_x_at C-type lectin domain family 2, member D CLEC2D 29121 3
203717_at dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 3
210340_s_at colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) CSF2RA 1438 3
215894_at prostaglandin D2 receptor (DP) PTGDR 5729 3
242642_at NudE nuclear distribution gene E homolog like 1 (A. nidulans) NDEL1 81565 3
242482_at protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific
extinguisher 1)
PRKAR1A 5573 3
205255_x_at transcription factor 7 (T-cell specific, HMG-box) TCF7 6932 3
205884_at integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) ITGA4 3676 3
206707_x_at chromosome 6 open reading frame 32 C6orf32 9750 3
235735_at Tumor necrosis factor (ligand) superfamily, member 8 TNFSF8 944 3
204044_at quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase
(carboxylating))
QPRT 23475 3
226560_at Sphingosine-1-phosphate phosphotase 2 SGPP2 130367 3
244773_at ATPase, aminophospholipid transporter (APLT), Class I, type 8A, member 1 ATP8A1 10396 3
214157_at GNAS complex locus GNAS 2778 3
1552953_a_at neurogenic differentiation 2 NEUROD2 4761 3
204529_s_at thymus high mobility group box protein TOX TOX 9760 3
231794_at cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 3
1558143_a_at BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 3
215796_at T cell receptor alpha variable 20 TRAV20 28663 3
206805_at sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3A
SEMA3A 10371 3
235522_at C-type lectin domain family 2, member D OCIL 29121 3
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212951_at G protein-coupled receptor 116 GPR116 221395 3
207075_at cold autoinflammatory syndrome 1 CIAS1 114548 3
243819_at Guanine nucleotide binding protein (G protein), gamma 2 GNG2 54331 3
1554455_at lines homolog 1 (Drosophila) LINS1 55180 3
209301_at carbonic anhydrase II CA2 760 3
201656_at integrin, alpha 6 ITGA6 3655 3
242814_at serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 5272 3
206176_at bone morphogenetic protein 6 BMP6 654 3
1556698_a_at hypothetical protein LOC285513 LOC285513 285513 3
1552658_a_at neuron navigator 3 NAV3 89795 3
1555691_a_at killer cell lectin-like receptor subfamily C, member 4 KLRC4 22914 3
226525_at Serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 3
233109_at Collagen, type XII, alpha 1 COL12A1 1303 3
223862_at ghrelin precursor GHRL 51738 3
242268_at CUG triplet repeat, RNA binding protein 2 CUGBP2 10659 3
235801_at Tumor suppressor candidate 3 TUSC3 7991 3
236199_at Arachidonate 5-lipoxygenase ALOX5 240 3
230110_at mucolipin 2 MCOLN2 255231 3
239901_at Hypothetical protein FLJ43663 FLJ43663 378805 3
204197_s_at runt-related transcription factor 3 RUNX3 864 3
205821_at killer cell lectin-like receptor subfamily K, member 1 KLRK1 22914 3
208130_s_at thromboxane A synthase 1 (platelet, cytochrome P450, family 5,
subfamily A)
TBXAS1 6916 3
41577_at protein phosphatase 1, regulatory (inhibitor) subunit 16B PPP1R16B 26051 3
1559425_at Protein kinase C, eta PRKCH 5583 3
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239835_at kelch repeat and BTB (POZ) domain containing 8 KBTBD8 84541 3
206674_at fms-related tyrosine kinase 3 FLT3 2322 3
235385_at Membrane-associated ring finger (C3HC4) 1 MARCH-I 55016 3
236782_at sterile alpha motif domain containing 3 SAMD3 154075 3
232635_at chromosome 14 open reading frame 145 C14orf145 145508 3
238488_at synleurin SLRN 353281 3
241435_at V-ets erythroblastosis virus E26 oncogene homolog 1 (avian) ETS1 2113 3
212316_at nucleoporin 210kDa NUP210 23225 3
217192_s_at PR domain containing 1, with ZNF domain PRDM1 639 3
211654_x_at major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 3119 3
203854_at I factor (complement) IF 3426 3
215392_at Ubiquitin specific peptidase 3 USP3 9960 3
209823_x_at major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 3119 3
217394_at T cell receptor alpha locus TRA@ 6955 3
206637_at purinergic receptor P2Y, G-protein coupled, 14 P2RY14 9934 3
228055_at napsin B aspartic peptidase pseudogene NAPSB 256236 3
236921_at Embigin homolog (mouse) EMB 133418 3
205467_at caspase 10, apoptosis-related cysteine peptidase CASP10 843 3
210040_at solute carrier family 12, (potassium-chloride transporter) member 5 SLC12A5 57468 3
1560486_at syntaxin binding protein 3 STXBP3 6814 3
204995_at cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1 8851 3
226878_at major histocompatibility complex, class II, DO alpha HLA-DOA 3111 3
206370_at phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 5294 3
215930_s_at CTAGE family, member 5 CTAGE5 4253 3
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1560754_at chemokine-like factor superfamily 7 CKLFSF7 112616 3
204623_at trefoil factor 3 (intestinal) TFF3 7033 3
236422_at Hypothetical protein FLJ22662 FLJ22662 79887 3
239260_at corin, serine peptidase CORIN 10699 3
242210_at Zinc finger protein 24 (KOX 17) ZNF24 7572 3
205504_at Bruton agammaglobulinemia tyrosine kinase BTK 695 3
221698_s_at C-type lectin domain family 7, member A ; C-type lectin domain family
7, member A
CLEC7A 64581 3
210184_at integrin, alpha X (antigen CD11C (p150), alpha polypeptide) ITGAX 3687 3
238452_at Fc receptor-like and mucin-like 2 FCRLM2 127943 3
203416_at CD53 antigen CD53 963 3
217478_s_at major histocompatibility complex, class II, DM alpha HLA-DMA 3108 3
227344_at Zinc finger protein, subfamily 1A, 1 (Ikaros) ZNFN1A1 10320 3
220560_at chromosome 11 open reading frame 21 C11orf21 29125 3
209846_s_at butyrophilin, subfamily 3, member A2 BTN3A2 11118 3
212950_at G protein-coupled receptor 116 GPR116 221395 3
229383_at Membrane-associated ring finger (C3HC4) 1 MARCH-I 55016 3
206608_s_at retinitis pigmentosa GTPase regulator interacting protein 1 RPGRIP1 57096 3
209696_at fructose-1,6-bisphosphatase 1 FBP1 2203 3
229802_at WNT1 inducible signaling pathway protein 1 WISP1 8840 3
208763_s_at TSC22 domain family, member 3 TSC22D3 1831 3
230550_at membrane-spanning 4-domains, subfamily A, member 6A MS4A6A 64231 3
227014_at similar to aspartate beta hydroxylase (ASPH) LOC57168 57168 3
1558783_at Wilms tumor 1 associated protein WTAP 9589 3
213915_at natural killer cell group 7 sequence NKG7 4818 3
209626_s_at oxysterol binding protein-like 3 OSBPL3 26031 3
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38521_at myelin associated glycoprotein MAG 4099 3
210038_at protein kinase C, theta PRKCQ 5588 3
228113_at RAB37, member RAS oncogene family RAB37 326624 3
202524_s_at sparc/osteonectin, cwcv and kazal-like domains proteoglycan
(testican) 2
SPOCK2 9806 3
223358_s_at Phosphodiesterase 7A PDE7A 5150 3
205987_at CD1C antigen, c polypeptide CD1C 911 3
239893_at Multiple C2-domains with two transmembrane regions 2 MCTP2 55784 3
AFFX-
M27830
SRY (sex determining region Y)-box 18 SOX18 54345 3
1554786_at chromosome 20 open reading frame 32 C20orf32 57091 3
213036_x_at ATPase, Ca++ transporting, ubiquitous ATP2A3 489 3
212543_at absent in melanoma 1 AIM1 202 3
232687_at Hypothetical protein LOC285513 LOC285513 285513 3
215243_s_at gap junction protein, beta 3, 31kDa (connexin 31) GJB3 2707 3
226150_at Phosphatidic acid phosphatase type 2 domain containing 1B HTPAP 84513 3
238790_at CLR pseudogene LOC374443 374443 3
204852_s_at protein tyrosine phosphatase, non-receptor type 7 PTPN7 5778 3
206278_at platelet-activating factor receptor PTAFR 5724 3
215483_at A kinase (PRKA) anchor protein (yotiao) 9 AKAP9 10142 3
1554545_at chromosome 1 open reading frame 169 C1orf169 403314 3
239162_at Death-associated protein kinase 1 DAPK1 1612 3
205698_s_at mitogen-activated protein kinase kinase 6 MAP2K6 5608 3
225700_at glucocorticoid induced transcript 1 GLCCI1 113263 3
202295_s_at cathepsin H CTSH 1512 3
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243403_x_at carboxypeptidase M CPM 1368 3
219313_at hypothetical protein DKFZp434C0328 DKF 54762 3
220646_s_at killer cell lectin-like receptor subfamily F, member 1 KLRF1 51348 3
243465_at Hypothetical protein FLJ11000 FLJ11000 55281 3
219690_at U2(RNU2) small nuclear RNA auxiliary factor 1-like 4 U2AF1L4 79713 3
243993_at PCTAIRE protein kinase 2 PCTK2 5128 3
205297_s_at CD79B antigen (immunoglobulin-associated beta) CD79B 974 3
207794_at chemokine (C-C motif) receptor 2 ; chemokine (C-C motif) receptor 2 CCR2 1231 3
1568830_at RNA binding motif, single stranded interacting protein 1 IRAK3 11213 3
228869_at Selectin ligand interactor cytoplasmic-1 SLIC1 124460 3
1558120_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X 1654 3
241765_at carboxypeptidase M CPM 1368 3
229958_at chromosome 8 open reading frame 61 C8orf61 619435 3
239586_at family with sequence similarity 83, member A FAM83A 84985 3
225606_at BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 3
234996_at Calcitonin receptor-like CALCRL 10203 3
232304_at Pellino homolog 1 (Drosophila) PELI1 57162 3
217302_at olfactory receptor, family 2, subfamily F, member 2 OR2F2 135948 3
204959_at myeloid cell nuclear differentiation antigen ; myeloid cell nuclear
differentiation antigen
MNDA 4332 3
1559654_s_at Growth hormone regulated TBC protein 1 GRTP1 79774 3
212699_at secretory carrier membrane protein 5 SCAMP5 192683 3
212732_at maternally expressed 3 MEG3 55384 3
233867_at Zinc finger, SWIM-type containing 6 MGC40405 257415 3
1557558_s_at Matrilin 1, cartilage matrix protein MATN1 4146 3









1564077_at Hypothetical protein LOC285513 LOC285513 285513 3
223851_s_at tumor necrosis factor receptor superfamily, member 18 TNFRSF18 8784 3
226517_at branched chain aminotransferase 1, cytosolic BCAT1 586 3
207735_at ring finger protein 125 RNF125 54941 3
207957_s_at Protein kinase C, beta 1 PRKCB1 5579 3
206118_at signal transducer and activator of transcription 4 STAT4 6775 3
201690_s_at tumor protein D52 TPD52 7163 3
210039_s_at protein kinase C, theta PRKCQ 5588 3
226659_at differentially expressed in FDCP 6 homolog (mouse) DEF6 50619 3
223218_s_at nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, zeta
NFKBIZ 64332 3
243765_at SEC31-like 1 (S. cerevisiae) SEC31L1 22872 3
1554519_at CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) CD80 941 3
204265_s_at G-protein signalling modulator 3 (AGS3-like, C. elegans) GPSM3 63940 3
228071_at GTPase, IMAP family member 7 GIMAP7 168537 3
231310_at Transcribed locus 3
226991_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFATC2 4773 3
235970_at transcription factor MLR1 MLR1 254251 3
204820_s_at butyrophilin, subfamily 3, member A3 BTN3A3 10384 3
237461_at NACHT, leucine rich repeat and PYD containing 7 NALP7 199713 3
234167_at Hypothetical protein LOC254128 MKI67IP 84365 3
1559848_at NOL1/NOP2/Sun domain family, member 4 NSUN4 387338 3
201009_s_at thioredoxin interacting protein TXNIP 10628 3
238593_at hypothetical protein FLJ22531 FLJ22531 79703 3
243764_at V-set and immunoglobulin domain containing 1 VSIG1 340547 3
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209032_s_at immunoglobulin superfamily, member 4 IGSF4 23705 3
235706_at carboxypeptidase M CPM 1368 3
224046_s_at phosphodiesterase 7A PDE7A 5150 3
240260_at Protein tyrosine phosphatase, non-receptor type 1 PTPN1 5770 3
219947_at C-type lectin domain family 4, member A CLEC4A 50856 3
1562529_s_at RAR-related orphan receptor A RORA 6095 3
207426_s_at tumor necrosis factor (ligand) superfamily, member 4 TNFSF4 7292 3
235574_at guanylate binding protein 4 GBP4 115361 3
214181_x_at leukocyte specific transcript 1 LST1 7940 3
236528_at Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1 51465 2
238062_at high density lipoprotein-binding protein LOC338328 338328 2
239957_at Hypothetical protein FLJ10707 FLJ10707 55209 2
1569369_at Zinc finger, FYVE domain containing 28 ZFYVE28 57732 2
233252_s_at spermatid perinuclear RNA binding protein STRBP 55342 2
205801_s_at RAS guanyl releasing protein 3 (calcium and DAG-regulated) RASGRP3 25780 2
209496_at retinoic acid receptor responder (tazarotene induced) 2 RARRES2 5919 2
208109_s_at chromosome 15 open reading frame 5 ; chromosome 15 open reading
frame 5
C15orf5 81698 2
202450_s_at cathepsin K (pycnodysostosis) CTSK 1513 2
228754_at solute carrier family 6 (neurotransmitter transporter, taurine), member
6
SLC6A6 6533 2
229513_at Spermatid perinuclear RNA binding protein STRBP 55342 2
204897_at prostaglandin E receptor 4 (subtype EP4) PTGER4 5734 2
244033_at chromosome 14 open reading frame 145 C14orf145 145508 2
229070_at chromosome 6 open reading frame 105 C6orf105 84830 2
38149_at Rho GTPase activating protein 25 ARHGAP25 9938 2
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204101_at myotubularin 1 MTM1 4534 2
201236_s_at BTG family, member 2 BTG2 7832 2
205027_s_at mitogen-activated protein kinase kinase kinase 8 MAP3K8 1326 2
243395_at Decay accelerating factor for complement (CD55, Cromer blood group
system)
DAF 1604 2
1553096_s_at BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 2
1553271_at KIAA1463 protein KIAA1463 57609 2
39402_at interleukin 1, beta IL1B 3553 2
223217_s_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
zeta
NFKBIZ 64332 2
228793_at jumonji domain containing 1C JMJD1C 221037 2
217984_at ribonuclease T2 RNASET2 8635 2
235380_at Arachidonate 5-lipoxygenase ALOX5 240 2
1552634_a_at zinc finger protein 101 ZNF101 94039 2
243066_at N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) NPL 80896 2
205651_x_at Rap guanine nucleotide exchange factor (GEF) 4 RAPGEF4 11069 2
205920_at solute carrier family 6 (neurotransmitter transporter, taurine), member 6 SLC6A6 6533 2
232835_at Jumonji, AT rich interactive domain 2 JARID2 3720 2
214518_at pyruvate dehydrogenase (lipoamide) alpha 2 PDHA2 5161 2
226677_at zinc finger protein 521 ZNF521 25925 2
201669_s_at myristoylated alanine-rich protein kinase C substrate MARCKS 4082 2
207686_s_at caspase 8, apoptosis-related cysteine peptidase CASP8 841 2
232455_x_at hypothetical protein LOC340085 LOC340085 340085 2
1554202_x_at calcium binding protein 4 CABP4 57010 2
206765_at potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 3759 2










218035_s_at RNA-binding protein FLJ20273 54502 2
222307_at hypothetical protein LOC282997 LOC282997 282997 2
219700_at plexin domain containing 1 PLXDC1 57125 2
205789_at CD1D antigen, d polypeptide ; CD1D antigen, d polypeptide CD1D 912 2
205988_at CD84 antigen (leukocyte antigen) CD84 8832 2
244388_at Wingless-type MMTV integration site family, member 5A WNT5A 7474 2
221648_s_at chromosome 1 open reading frame 121 C1orf121 51029 2
215633_x_at leukocyte specific transcript 1 LST1 7940 2
215775_at Thrombospondin 1 THBS1 7057 2
230590_at Slingshot homolog 2 (Drosophila) SSH2 85464 2
1557145_at Serine/threonine kinase 38 STK38 11329 2







221080_s_at DENN/MADD domain containing 1C DENND1C 79958 2
238332_at ankyrin repeat domain 29 ANKRD29 147463 2
227354_at phosphoprotein associated with glycosphingolipid microdomains 1 PAG1 55824 2
1552519_at activin A receptor, type IC ACVR1C 130399 2
213506_at coagulation factor II (thrombin) receptor-like 1 F2RL1 2150 2
233011_at Annexin A1 ANXA1 301 2
222062_at interleukin 27 receptor, alpha IL27RA 9466 2
206896_s_at guanine nucleotide binding protein (G protein), gamma 7 GNG7 2788 2
1559249_at Ataxin 1 ATXN1 6310 2
237051_at Solute carrier family 30 (zinc transporter), member 9 SLC30A9 10463 2
219694_at hypothetical protein FLJ11127 FLJ11127 54491 2
226039_at Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isoenzyme A
MGAT4A 11320 2
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237001_at NIK and IKK binding protein T1 83696 2
1561390_at family with sequence similarity 41, member A, Y-linked FAM41AY 340618 2
203028_s_at cytochrome b-245, alpha polypeptide CYBA 1535 2
205898_at chemokine (C-X3-C motif) receptor 1 CX3CR1 1524 2
213475_s_at integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated
antigen 1; alpha polypeptide)
ITGAL 3683 2
242672_at Raft-linking protein RAFTLIN 23180 2
205038_at Zinc finger protein, subfamily 1A, 1 (Ikaros) ZNFN1A1 10320 2
209281_s_at ATPase, Ca++ transporting, plasma membrane 1 ATP2B1 490 2
219602_s_at family with sequence similarity 38, member B FAM38B 63895 2
224797_at arrestin domain containing 3 ARRDC3 57561 2
214574_x_at leukocyte specific transcript 1 LST1 7940 2
232793_at Immunoglobulin superfamily, member 4 IGSF4 23705 2
1552541_at T-cell activation GTPase activating protein TAGAP 117289 2
44790_s_at chromosome 13 open reading frame 18 C13orf18 80183 2
205288_at CDC14 cell division cycle 14 homolog A (S. cerevisiae) CDC14A 8556 2
219501_at hypothetical protein FLJ10094 FLJ10094 55068 2
214148_at Forkhead box M1 FOXM1 2305 2
238439_at ankyrin repeat domain 22 ANKRD22 118932 2
218322_s_at acyl-CoA synthetase long-chain family member 5 ACSL5 51703 2
239938_x_at MADS box transcription enhancer factor 2, polypeptide C (myocyte
enhancer factor 2C)
MEF2C 4208 2
208056_s_at core-binding factor, runt domain, alpha subunit 2; translocated to, 3 CBFA2T3 863 2
206316_s_at kinetochore associated 1 KNTC1 9735 2
1554462_a_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 4189 2
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221586_s_at E2F transcription factor 5, p130-binding E2F5 1875 2
205471_s_at dachshund homolog 1 (Drosophila) DACH1 1602 2
218746_at TAP binding protein-like TAPBPL 55080 2
205685_at CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) CD86 942 2
241027_at optic atrophy 1 (autosomal dominant) OPA1 4976 2
223322_at Ras association (RalGDS/AF-6) domain family 5 RASSF5 83593 2
217168_s_at homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-
like domain member 1
HERPUD1 9709 2
217120_s_at cofactor required for Sp1 transcriptional activation, subunit 2, 150kDa CRSP2 9282 2
203317_at pleckstrin and Sec7 domain containing 4 PSD4 23550 2
210176_at toll-like receptor 1 TLR1 7096 2
213373_s_at caspase 8, apoptosis-related cysteine peptidase CASP8 841 2
236067_at Muscleblind-like 2 (Drosophila) MBNL2 10150 2
234562_x_at Chemokine-like factor superfamily 8 CKLFSF8 152189 2
211286_x_at colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage)
CSF2RA 1438 2
232565_at RAB6 interacting protein 2 RAB6IP2 23085 2
208981_at platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 5175 2
236345_at Thromboxane A synthase 1 (platelet, cytochrome P450, family 5,
subfamily A)
TBXAS1 6916 2
207038_at solute carrier family 16 (monocarboxylic acid transporters), member 6 SLC16A6 9120 2
232034_at hypothetical protein LOC203274 LOC203274 203274 2
241843_at Eukaryotic translation initiation factor 5 EIF5 1983 2
229750_at POU domain, class 2, transcription factor 2 POU2F2 5452 2
220684_at T-box 21 TBX21 30009 2
213317_at Chloride intracellular channel 5 CLIC5 53405 2
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1565598_at RNA-binding protein FLJ20273 54502 2
205551_at synaptic vesicle glycoprotein 2B SV2B 9899 2
201324_at epithelial membrane protein 1 EMP1 2012 2
232744_x_at Ataxin 1 ATXN1 6310 2
211582_x_at leukocyte specific transcript 1 LST1 7940 2
205554_s_at deoxyribonuclease I-like 3 DNASE1L3 1776 2
207890_s_at matrix metallopeptidase 25 MMP25 64386 2
239336_at Thrombospondin 1 THBS1 7057 2
239167_at AF4/FMR2 family, member 1 MLLT2 4299 2
227558_at chromobox homolog 4 (Pc class homolog, Drosophila) CBX4 8535 2
213017_at abhydrolase domain containing 3 ABHD3 171586 2
239122_at Interleukin 24 IL24 11009 2
205945_at interleukin 6 receptor ; interleukin 6 receptor IL6R 3570 2
1560625_s_at Hypothetical gene supported by BC052750 MGC50811 375307 2
1564333_a_at Sortilin-related VPS10 domain containing receptor 2 SORCS2 57537 2
207522_s_at ATPase, Ca++ transporting, ubiquitous ATP2A3 489 2
209993_at ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABCB1 5243 2
236808_at FGFR1 oncogene partner 2 FGFR1OP2 26127 2
227867_at hypothetical protein LOC129293 LOC129293 129293 2
213496_at plasticity related gene 1 LPPR4 9890 2
228442_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2
NFATC2 4773 2
1556001_at hypothetical protein LOC284939 LOC284939 284939 2
220603_s_at multiple C2-domains with two transmembrane regions 2 MCTP2 55784 2
244341_at Mak3 homolog (S. cerevisiae) MAK3 80218 2
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223717_s_at acrosin binding protein ACRBP 84519 2
215051_x_at allograft inflammatory factor 1 AIF1 199 2
201110_s_at thrombospondin 1 THBS1 7057 2
217983_s_at ribonuclease T2 RNASET2 8635 2
230792_at hypothetical protein FLJ31204 FLJ31204 158584 2
230789_at suppressor of hairy wing homolog 2 (Drosophila) SUHW2 140883 2
242558_at Catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1 1499 2
241837_at AT rich interactive domain 5B (MRF1-like) ARID5B 84159 2
201149_s_at TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
TIMP3 7078 2
1556643_at Hypothetical protein BC011840 LOC93343 93343 2
223709_s_at wingless-type MMTV integration site family, member 10A WNT10A 80326 2
223922_x_at membrane-spanning 4-domains, subfamily A, member 6A MS4A6A 64231 2
244650_at Hypothetical protein FLJ11127 FLJ11127 54491 2
1559413_at T-complex 11 (mouse) like 2 MGC40368 255394 2
234900_at similar to dJ612B18.1 (similar to 40S ribosomal protein) LOC391137 391137 2
239096_at Chromosome 14 open reading frame 32 C14orf32 93487 2
238886_at Transmembrane emp24-like trafficking protein 10 (yeast) TMP21 10972 2
205865_at AT rich interactive domain 3A (BRIGHT- like) ARID3A 1820 2
224480_s_at hypothetical protein MGC11324 ; hypothetical protein MGC11324 MGC11324 84803 2
238428_at potassium inwardly-rectifying channel, subfamily J, member 15 KCNJ15 3772 2
1569600_at BCMS upstream neighbor-like BCMSUNL 79469 2
209770_at butyrophilin, subfamily 3, member A1 BTN3A1 11119 2
208982_at Platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 5175 2
240094_at Thioredoxin domain containing 13 DJ971N18.2 56255 2
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207414_s_at proprotein convertase subtilisin/kexin type 6 PCSK6 5046 2
236436_at hypothetical protein LOC283130 LOC283130 283130 2
226333_at interleukin 6 receptor IL6R 3570 2
201108_s_at thrombospondin 1 THBS1 7057 2
228575_at fibronectin type III domain containing 6 FNDC6 152028 2
218751_s_at F-box and WD-40 domain protein 7 (archipelago homolog,
Drosophila)
FBXW7 55294 2
243362_s_at lymphoid enhancer-binding factor 1 LEF1 51176 2
208119_s_at zinc finger protein 505 ; zinc finger protein 505 ZNF505 81931 2
210538_s_at baculoviral IAP repeat-containing 3 BIRC3 330 2
204061_at protein kinase, X-linked PRKX 5613 2
214590_s_at ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) UBE2D1 7321 2
242239_at NOL1/NOP2/Sun domain family, member 6 NSUN6 221078 2
214772_at chromosome 11 open reading frame 41 C11orf41 25758 2
244377_at Solute carrier family 1 (glutamate/neutral amino acid transporter),
member 4
SLC1A4 6509 2
238812_at Zinc finger, A20 domain containing 3 ZA20D3 54469 2
239579_at abhydrolase domain containing 7 ABHD7 253152 2
236313_at cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) CDKN2B 1030 2
210982_s_at major histocompatibility complex, class II, DR alpha HLA-DRA 3122 2
230438_at T-box 15 TBX15 6913 2
226474_at nucleotide-binding oligomerization domains 27 NOD27 84166 2
229214_at Syntaxin 7 STX7 8417 2
217825_s_at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1 51465 2
206036_s_at v-rel reticuloendotheliosis viral oncogene homolog (avian) REL 5966 2
229819_at alpha-1-B glycoprotein A1BG 1 2









59644_at BMP2 inducible kinase BMP2K 55589 2
238423_at synaptotagmin-like 3 SYTL3 94120 2
201733_at chloride channel 3 CLCN3 1182 2
209946_at vascular endothelial growth factor C VEGFC 7424 2
227761_at myosin VA (heavy polypeptide 12, myoxin) MYO5A 4644 2
1565754_x_at FYVE, RhoGEF and PH domain containing 2 FGD2 221472 2
208368_s_at breast cancer 2, early onset BRCA2 675 2
219577_s_at ATP-binding cassette, sub-family A (ABC1), member 7 ABCA7 10347 2
1556931_at Cell division cycle 42 (GTP binding protein, 25kDa) CDC42 998 2
201148_s_at TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
TIMP3 7078 2
233816_at Solute carrier family 8 (sodium/calcium exchanger), member 1 SLC8A1 6546 2
214735_at phosphoinositide-binding protein PIP3-E PIP3-E 26034 2
236285_at Kelch domain containing 7B MGC16635 113730 2
1563357_at Serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 5272 2
232797_at Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) ITGAV 3685 2
1565913_at Zinc finger CCCH-type, antiviral 1 ZC3HAV1 56829 2
206995_x_at scavenger receptor class F, member 1 SCARF1 8578 2
213142_x_at hypothetical protein LOC54103 LOC54103 54103 2
211129_x_at ectodysplasin A EDA 1896 2
204602_at dickkopf homolog 1 (Xenopus laevis) DKK1 22943 2
235780_at protein kinase, cAMP-dependent, catalytic, beta PRKACB 5567 2
206508_at tumor necrosis factor (ligand) superfamily, member 7 TNFSF7 970 2
239489_at Ubiquitin-like domain containing CTD phosphatase 1 MGC10067 134510 2
242384_at Cytoplasmic polyadenylation element binding protein 4 CPEB4 80315 2
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1566446_at Kruppel-like factor 12 KLF12 11278 2
235486_at hypothetical protein MGC34830 MGC34830 120196 2
244020_at Hypothetical protein MGC13204 MGC13204 83695 2
206377_at forkhead box F2 FOXF2 2295 2
236395_at MADS box transcription enhancer factor 2, polypeptide C (myocyte
enhancer factor 2C)
MEF2C 4208 2
211799_x_at major histocompatibility complex, class I, C HLA-C 3107 2
227372_s_at BAI1-associated protein 2-like 1 BAIAP2L1 55971 2
217715_x_at Zinc finger protein 354A ZNF354A 6940 2
227686_at hypothetical protein BC008322 MGC15763 92106 2
230609_at enthoprotin ENTH 9685 2
201109_s_at thrombospondin 1 THBS1 7057 2
214567_s_at chemokine (C motif) ligand 1 ; chemokine (C motif) ligand 2 XCL1 ;
XCL2
6375 ; 6846 2
203988_s_at fucosyltransferase 8 (alpha (1,6) fucosyltransferase) FUT8 2530 2
224388_s_at collagen, type XXV, alpha 1 ; collagen, type XXV, alpha 1 COL25A1 84570 2
1554616_at serpin peptidase inhibitor, clade B (ovalbumin), member 8 SERPINB8 5271 2
240363_at ankyrin 1, erythrocytic ANK1 286 2
201147_s_at TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
TIMP3 7078 2
1552322_at hypothetical protein BC017868 RP3-
473B4.1
159091 2
205080_at retinoic acid receptor, beta RARB 5915 2
211842_s_at solute carrier family 24 (sodium/potassium/calcium exchanger),
member 1
SLC24A1 9187 2
229765_at Transcribed locus 2
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205265_s_at aortic preferentially expressed gene 1 APEG1 10290 56
232067_at chromosome 6 open reading frame 168 C6orf168 84553 24
213479_at neuronal pentraxin II NPTX2 4885 16
203295_s_at ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide ATP1A2 477 16
214586_at G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 2861 16
220677_s_at ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAMTS8 11095 15
224219_s_at transient receptor potential cation channel, subfamily C, member 4 TRPC4 7223 14
214978_s_at protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF),
interacting protein (liprin), alpha 4
PPFIA4 8497 14
231859_at chromosome 14 open reading frame 132 C14orf132 56967 14
221215_s_at receptor-interacting serine-threonine kinase 4 RIPK4 54101 13
205675_at microsomal triglyceride transfer protein (large polypeptide, 88kDa) MTP 4547 13
204100_at thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a)
oncogene homolog, avian)
THRA 7067 12
228695_at chromosome 8 open reading frame 46 C8orf46 254778 12
227441_s_at E2a-Pbx1-associated protein EB-1 56899 12
1557315_a_at Astrotactin 2 ASTN2 23245 12
1557795_s_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 12
205413_at metallophosphoesterase domain containing 2 MPPED2 744 12
207557_s_at ryanodine receptor 2 (cardiac) RYR2 6262 12
213745_at attractin-like 1 ATRNL1 26033 11
228449_at Hypothetical protein FLJ35801 FLJ35801 150291 11
206766_at integrin, alpha 10 ITGA10 8515 11
215025_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 11
228796_at copine IV CPNE4 131034 11
207317_s_at calsequestrin 2 (cardiac muscle) CASQ2 845 10
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206277_at purinergic receptor P2Y, G-protein coupled, 2 P2RY2 5029 10
241412_at betacellulin BTC 685 10
227819_at leucine-rich repeat-containing G protein-coupled receptor 6 LGR6 59352 10
224457_at hypothetical protein MGC12982 ; hypothetical protein MGC12982 MGC12982 84793 9
224220_x_at transient receptor potential cation channel, subfamily C, member
4
TRPC4 7223 9
1564736_a_at caspase 12 pseudogene 1 CASP12P1 120329 9
1555725_a_at regulator of G-protein signalling 5 RGS5 8490 9
226415_at KIAA1576 protein KIAA1576 57687 9
203296_s_at ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide ATP1A2 477 9
203766_s_at leiomodin 1 (smooth muscle) LMOD1 25802 9
230463_at Synapsin II SYN2 6854 9
1554702_at voltage gated channel like 1 VGCNL1 259232 9
205893_at neuroligin 1 NLGN1 22871 9
204953_at synaptosomal-associated protein, 91kDa homolog (mouse) SNAP91 9892 9
233059_at Potassium inwardly-rectifying channel, subfamily J, member 3 KCNJ3 3760 9
226523_at Proprotein convertase subtilisin/kexin type 7 PCSK7 9159 9
206462_s_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 9
201496_x_at myosin, heavy polypeptide 11, smooth muscle MYH11 4629 9
219295_s_at procollagen C-endopeptidase enhancer 2 PCOLCE2 26577 9
214966_at glutamate receptor, ionotropic, kainate 5 GRIK5 2901 9
204284_at protein phosphatase 1, regulatory (inhibitor) subunit 3C PPP1R3C 5507 9
218864_at tensin 1 TNS1 7145 9
201481_s_at phosphorylase, glycogen; brain PYGB 5834 8
221319_at protocadherin beta 8 PCDHB8 56128 8
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205475_at scrapie responsive protein 1 SCRG1 11341 8
209441_at Rho-related BTB domain containing 2 RHOBTB2 23221 8
225548_at shroom SHRM 57619 8
230311_s_at PR domain containing 6 PRDM6 93166 8
221747_at Tensin 1 ; Tensin 1 TNS 7145 8
219167_at RAS-like, family 12 RASL12 51285 8
228716_at thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a)
oncogene homolog 2, avian)
THRB 7068 8
228849_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 8
214044_at ryanodine receptor 2 (cardiac) RYR2 6262 8
206389_s_at phosphodiesterase 3A, cGMP-inhibited PDE3A 5139 8
219743_at hairy/enhancer-of-split related with YRPW motif 2 HEY2 23493 8
228182_at adenylate cyclase 5 ADCY5 111 8
1555819_s_at hypothetical protein LOC201191 LOC201191 201191 8
244058_at chromosome 10 open reading frame 72 C10orf72 196740 8
234971_x_at phospholipase C, delta 3 PLCD3 113026 7
226325_at adenylosuccinate synthase like 1 ADSSL1 122622 7
209621_s_at PDZ and LIM domain 3 PDLIM3 27295 7
233442_at PDZ domain containing RING finger 3 PDZRN3 23024 7
222771_s_at myelin expression factor 2 MYEF2 50804 7
1558828_s_at hypothetical gene supported by BX640700 LOC401212 401212 7
209081_s_at collagen, type XVIII, alpha 1 COL18A1 80781 7
207961_x_at myosin, heavy polypeptide 11, smooth muscle MYH11 4629 7
210869_s_at melanoma cell adhesion molecule MCAM 4162 7
217377_x_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 7
229657_at thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a)
oncogene homolog 2, avian)
THRB 7068 7
Appendix E: Genes downregulated in AAA vs. NA (continued).
338
Probe Gene description Genesymbol
Entrez
Gene ID Fold change
217033_x_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 7
227088_at phosphodiesterase 5A, cGMP-specific PDE5A 8654 7
230104_s_at brain-specific protein p25 alpha TPPP 11076 7
203756_at Rho guanine nucleotide exchange factor (GEF) 17 ARHGEF17 9828 7
206757_at phosphodiesterase 5A, cGMP-specific PDE5A 8654 7
215115_x_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 7
223843_at scavenger receptor class A, member 3 SCARA3 51435 7
204846_at ceruloplasmin (ferroxidase) CP 1356 7
221280_s_at par-3 partitioning defective 3 homolog (C. elegans) PARD3 56288 7
205957_at plexin B3 PLXNB3 5365 7
240045_at PR domain containing 16 PRDM16 63976 7
218087_s_at sorbin and SH3 domain containing 1 SORBS1 10580 7
209087_x_at melanoma cell adhesion molecule MCAM 4162 6
227440_at E2a-Pbx1-associated protein EB-1 56899 6
211094_s_at
neurofibromin 1 (neurofibromatosis, von Recklinghausen disease,
Watson disease) NF1 4763 6
203951_at calponin 1, basic, smooth muscle CNN1 1264 6
205331_s_at chromosome 5 open reading frame 19 C5orf19 51308 6
219829_at integrin beta 1 binding protein (melusin) 2 ITGB1BP2 26548 6
220117_at zinc finger protein 659 ZNF659 79750 6
235050_at solute carrier family 2 (facilitated glucose transporter), member 12 SLC2A12 154091 6
222570_at frequenin homolog (Drosophila) FREQ 23413 6
203698_s_at frizzled-related protein FRZB 2487 6
212730_at desmuslin DMN 23336 6
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203088_at fibulin 5 FBLN5 10516 6
242269_at FLJ42875 protein FLJ42875 440556 6
222043_at clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein
2,
CLU 1191 6
238751_at Sorbin and SH3 domain containing 2 ARGBP2 8470 6
235129_at protein phosphatase 1, regulatory (inhibitor) subunit 1A PPP1R1A 5502 6
211892_s_at prostaglandin I2 (prostacyclin) synthase ; prostaglandin I2
(prostacyclin) synthase
PTGIS 5740 6
219728_at myotilin MYOT 9499 6
229484_at protein phosphatase 1J (PP2C domain containing) PPM1J 333926 6
206187_at prostaglandin I2 (prostacyclin) receptor (IP) PTGIR 5739 6
234970_at membrane targeting (tandem) C2 domain containing 1 MTAC2D1 123036 6
211160_x_at actinin, alpha 1 ACTN1 87 6
235209_at RPE-spondin RPESP 157869 6
202796_at synaptopodin SYNPO 11346 6
209488_s_at RNA binding protein with multiple splicing RBPMS 11030 6
1553613_s_at forkhead box C1 FOXC1 2296 6
232017_at tight junction protein 2 (zona occludens 2) TJP2 9414 6
202274_at actin, gamma 2, smooth muscle, enteric ACTG2 72 6
229799_s_at neural cell adhesion molecule 1 NCAM1 4684 6
223612_s_at ligand of numb-protein X LNX 84708 6
204627_s_at integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 3690 6
202566_s_at supervillin SVIL 6840 6
214121_x_at PDZ and LIM domain 7 (enigma) PDLIM7 9260 6
244419_at Frizzled-related protein FRZB 2487 6
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233546_at Hypothetical protein LOC283075 LOC283075 283075 6
203238_s_at Notch homolog 3 (Drosophila) NOTCH3 4854 6
209244_s_at kinesin family member 1C KIF1C 10749 6
227427_at RAC/CDC42 exchange factor GEFT 115557 6
209070_s_at regulator of G-protein signalling 5 RGS5 8490 6
206498_at oculocutaneous albinism II (pink-eye dilution homolog, mouse) OCA2 4948 6
227202_at Contactin 1 CNTN1 1272 6
212848_s_at chromosome 9 open reading frame 3 C9orf3 84909 6
212823_s_at pleckstrin homology domain containing, family G (with RhoGef
domain) member 3
PLEKHG3 26030 6
242736_at Sorbin and SH3 domain containing 1 SORBS1 10580 6
213746_s_at filamin A, alpha (actin binding protein 280) FLNA 2316 6
206832_s_at sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3F
SEMA3F 6405 6
213714_at calcium channel, voltage-dependent, beta 2 subunit CACNB2 783 6
207326_at betacellulin BTC 685 6
218892_at dachsous 1 (Drosophila) DCHS1 8642 6
204151_x_at aldo-keto reductase family 1, member C1 AKR1C1 1645 6
214053_at V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 2066 6
223842_s_at scavenger receptor class A, member 3 SCARA3 51435 6
224049_at potassium channel, subfamily K, member 17 KCNK17 89822 6
235874_at protease, serine, 35 PRSS35 167681 5
229405_at kinesin family member 7 KIF7 374654 5
214752_x_at filamin A, alpha (actin binding protein 280) FLNA 2316 5
235210_s_at RPE-spondin RPESP 157869 5
210605_s_at milk fat globule-EGF factor 8 protein MFGE8 4240 5
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241834_at Small nuclear ribonucleoprotein polypeptide N SNRPN 6638 5
227400_at nuclear factor I/X (CCAAT-binding transcription factor) NFIX 4784 5
201674_s_at A kinase (PRKA) anchor protein 1 AKAP1 8165 5
208637_x_at actinin, alpha 1 ACTN1 87 5
218266_s_at frequenin homolog (Drosophila) FREQ 23413 5
238165_at PDZ domain containing RING finger 3 PDZRN3 23024 5
233974_s_at chromosome 9 open reading frame 88 C9orf88 64855 5
206243_at TIMP metallopeptidase inhibitor 4 TIMP4 7079 5
213744_at attractin-like 1 ATRNL1 26033 5
231851_at hypothetical protein FLJ10770 RAVER2 55225 5
209082_s_at collagen, type XVIII, alpha 1 COL18A1 80781 5
204306_s_at CD151 antigen CD151 977 5
201262_s_at biglycan BGN 633 5
211141_s_at CCR4-NOT transcription complex, subunit 3 CNOT3 4849 5
225258_at filamin binding LIM protein 1 FBLIM1 54751 5
222772_at myelin expression factor 2 MYEF2 50804 5
1557380_at KIAA1975 protein similar to MRIP2 KIAA1975 119385 5
221845_s_at ClpB caseinolytic peptidase B homolog (E. coli) CLPB 81570 5
202565_s_at supervillin SVIL 6840 5
214520_at forkhead box C2 (MFH-1, mesenchyme forkhead 1) FOXC2 2303 5
1552455_at chromosome 9 open reading frame 65 C9orf65 158471 5
212554_at CAP, adenylate cyclase-associated protein, 2 (yeast) CAP2 10486 5
1552649_a_at ring finger and FYVE-like domain containing 1 RFFL 117584 5
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227827_at Sorbin and SH3 domain containing 2 ARGBP2 8470 5
1553175_s_at phosphodiesterase 5A, cGMP-specific PDE5A 8654 5
227826_s_at Sorbin and SH3 domain containing 2 ARGBP2 8470 5
220334_at regulator of G-protein signalling 17 RGS17 26575 5
225381_at hypothetical gene supported by BX647608 LOC399959 399959 5
205236_x_at superoxide dismutase 3, extracellular SOD3 6649 5
40524_at protein tyrosine phosphatase, non-receptor type 21 PTPN21 11099 5
1569290_s_at glutamate receptor, ionotrophic, AMPA 3 GRIA3 2892 5
1568760_at myosin, heavy polypeptide 11, smooth muscle MYH11 4629 5
205384_at FXYD domain containing ion transport regulator 1
(phospholemman)
FXYD1 5348 5
204337_at regulator of G-protein signalling 4 RGS4 5999 5
219685_at transmembrane protein 35 TMEM35 59353 5
204163_at elastin microfibril interfacer 1 EMILIN1 11117 5
211380_s_at protein kinase, cGMP-dependent, type I PRKG1 5592 5
206320_s_at SMAD, mothers against DPP homolog 9 (Drosophila) SMAD9 4093 5
221214_s_at nasal embryonic LHRH factor NELF 26012 5
236300_at Phosphodiesterase 3A, cGMP-inhibited PDE3A 5139 5
220676_at ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAMTS8 11095 5
215913_s_at GULP, engulfment adaptor PTB domain containing 1 GULP1 51454 5
205208_at aldehyde dehydrogenase 1 family, member L1 ALDH1L1 10840 5
226303_at phosphoglucomutase 5 PGM5 5239 5
206078_at kalirin, RhoGEF kinase KALRN 8997 5
239764_at hypothetical LOC401048 LOC401048 401048 5
239443_at protocadherin beta 6 PCDHB6 56130 5
211382_s_at transforming, acidic coiled-coil containing protein 2 TACC2 10579 5
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226552_at immediate early response 5-like IER5L 389792 5
212713_at microfibrillar-associated protein 4 MFAP4 4239 5
207542_s_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 358 5
209160_at aldo-keto reductase family 1, member C3 (3-alpha
hydroxysteroid dehydrogenase, type II)
AKR1C3 8644 5
228816_at hypothetical protein LOC92270 LOC92270 92270 5
231361_at Neuroligin 1 NLGN1 22871 5
238983_at hypothetical protein FLJ14001 FLJ14001 79730 5
91703_at EH domain binding protein 1-like 1 EHBP1L1 254102 5
207836_s_at RNA binding protein with multiple splicing RBPMS 11030 5
210702_s_at prostaglandin I2 (prostacyclin) synthase PTGIS 5740 5
214162_at hypothetical protein LOC284244 LOC284244 284244 5
208491_s_at phosphoglucomutase 5 PGM5 5239 5
212757_s_at calcium/calmodulin-dependent protein kinase (CaM kinase) II
gamma
CAMK2G 818 5
227253_at Hermansky-Pudlak syndrome 3 ; Ceruloplasmin (ferroxidase) HPS3 ; CP 1356 ;
84343
5
204505_s_at erythrocyte membrane protein band 4.9 (dematin) EPB49 2039 5
205002_at AT hook, DNA binding motif, containing 1 AHDC1 27245 5
228507_at Phosphodiesterase 3A, cGMP-inhibited PDE3A 5139 5
204288_s_at sorbin and SH3 domain containing 2 SORBS2 8470 5
202729_s_at latent transforming growth factor beta binding protein 1 LTBP1 4052 5
204041_at monoamine oxidase B MAOB 4129 5
218935_at EH-domain containing 3 EHD3 30845 5
203662_s_at tropomodulin 1 TMOD1 7111 5
212944_at Mitochondrial ribosomal protein S6 MRPS6 64968 5
218820_at chromosome 14 open reading frame 132 C14orf132 56967 5
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232734_at tetratricopeptide repeat domain 23 TTC23 64927 5
202613_at CTP synthase CTPS 1503 5
210299_s_at four and a half LIM domains 1 FHL1 2273 5
232676_x_at myelin expression factor 2 MYEF2 50804 5
203571_s_at chromosome 10 open reading frame 116 C10orf116 10974 5
238323_at TEA domain family member 2 TEAD2 8463 5
235737_at thymic stromal lymphopoietin TSLP 85480 5
208791_at clusterin (complement lysis inhibitor) CLU 1191 5
226966_at Huntingtin interacting protein C HYPC 25766 5
227662_at synaptopodin 2 SYNPO2 171024 5
218730_s_at osteoglycin (osteoinductive factor, mimecan) OGN 4969 5
222921_s_at hairy/enhancer-of-split related with YRPW motif 2 HEY2 23493 5
216080_s_at fatty acid desaturase 3 FADS3 3995 5
203986_at genethonin 1 GENX-3414 8987 5
207876_s_at filamin C, gamma (actin binding protein 280) FLNC 2318 5
242935_at SET binding factor 2 SBF2 81846 5
200859_x_at filamin A, alpha (actin binding protein 280) FLNA 2316 5
223629_at protocadherin beta 5 PCDHB5 26167 5
207554_x_at thromboxane A2 receptor TBXA2R 6915 5
204428_s_at lecithin-cholesterol acyltransferase LCAT 3931 5
232570_s_at ADAM metallopeptidase domain 33 ADAM33 80332 5
223321_s_at fibroblast growth factor receptor-like 1 FGFRL1 53834 5
228388_at nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, beta
NFKBIB 4793 5
61297_at CASK interacting protein 2 CASKIN2 57513 5
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223475_at cysteine-rich secretory protein LCCL domain containing 1 CRISPLD1 83690 5
218418_s_at ankyrin repeat domain 25 ANKRD25 25959 5
203516_at syntrophin, alpha 1 (dystrophin-associated protein A1, 59kDa, acidic
component)
SNTA1 6640 5
233882_s_at sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6D
SEMA6D 80031 5
212062_at ATPase, Class II, type 9A ATP9A 10079 5
223749_at C1q and tumor necrosis factor related protein 2 C1QTNF2 114898 5
212336_at erythrocyte membrane protein band 4.1-like 1 EPB41L1 2036 5
211340_s_at melanoma cell adhesion molecule MCAM 4162 4
228310_at enabled homolog (Drosophila) ENAH 55740 4
204773_at interleukin 11 receptor, alpha IL11RA 3590 4
1555483_x_at filamin binding LIM protein 1 FBLIM1 54751 4
213381_at Chromosome 10 open reading frame 72 C10orf72 196740 4
823_at chemokine (C-X3-C motif) ligand 1 CX3CL1 6376 4
1559840_s_at T-box 18 TBX18 9096 4
201058_s_at myosin, light polypeptide 9, regulatory MYL9 10398 4
209832_s_at DNA replication factor CDT1 81620 4
201234_at integrin-linked kinase ILK 3611 4
227439_at E2a-Pbx1-associated protein EB-1 56899 4
236372_at Pannexin 1 PANX1 24145 4
202821_s_at LIM domain containing preferred translocation partner in lipoma LPP 4026 4
217025_s_at drebrin 1 DBN1 1627 4
213205_s_at KIAA0809 protein SRISNF2L 23132 4
217966_s_at chromosome 1 open reading frame 24 C1orf24 116496 4
230933_at Destrin (actin depolymerizing factor) DSTN 11034 4
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206813_at cardiotrophin 1 CTF1 1489 4
205577_at phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage
disease type V)
PYGM 5837 4
209928_s_at musculin (activated B-cell factor-1) MSC 9242 4
228890_at atonal homolog 8 (Drosophila) ATOH8 84913 4
219882_at tubulin tyrosine ligase-like family, member 7 TTLL7 79739 4
240088_at phosphodiesterase 5A, cGMP-specific PDE5A 8654 4
221583_s_at potassium large conductance calcium-activated channel, subfamily M,
alpha member 1
KCNMA1 3778 4
218062_x_at CDC42 effector protein (Rho GTPase binding) 4 CDC42EP4 23580 4
1555270_a_at Wolfram syndrome 1 (wolframin) WFS1 7466 4
234980_at Transmembrane protein 56 FLJ31842 148534 4
212669_at calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma CAMK2G 818 4
201841_s_at heat shock 27kDa protein 1 HSPB1 3315 4
213547_at cullin-associated and neddylation-dissociated 2 (putative) CAND2 23066 4
206012_at left-right determination factor 2 LEFTY2 7044 4
221870_at EH-domain containing 2 EHD2 30846 4
218353_at regulator of G-protein signalling 5 RGS5 8490 4
229975_at Bone morphogenetic protein receptor, type IB BMPR1B 658 4
239480_at Glutamate receptor, metabotropic 3 GRM3 2913 4
203498_at Down syndrome critical region gene 1-like 1 DSCR1L1 10231 4
221748_s_at tensin 1 ; tensin 1 TNS1 7145 4
205117_at fibroblast growth factor 1 (acidic) FGF1 2246 4
204083_s_at tropomyosin 2 (beta) TPM2 7169 4
1552760_at histone deacetylase 9 HDAC9 9734 4
218824_at hypothetical protein FLJ10781 FLJ10781 55228 4
230146_s_at frequenin homolog (Drosophila) FREQ 23413 4
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1556096_s_at unc-13 homolog C (C. elegans) UNC13C 440279 4
226018_at hypothetical protein Ells1 Ells1 222166 4
224919_at mitochondrial ribosomal protein S6 MRPS6 64968 4
1553132_a_at membrane targeting (tandem) C2 domain containing 1 MTAC2D1 123036 4
212091_s_at collagen, type VI, alpha 1 COL6A1 1291 4
243209_at potassium voltage-gated channel, KQT-like subfamily, member 4 KCNQ4 9132 4
212518_at phosphatidylinositol-4-phosphate 5-kinase, type I, gamma PIP5K1C 23396 4
214212_x_at pleckstrin homology domain containing, family C (with FERM
domain) member 1
PLEKHC1 10979 4
226207_at hypothetical protein FLJ39378 FLJ39378 353116 4
211126_s_at cysteine and glycine-rich protein 2 CSRP2 1466 4
235128_at synaptopodin SYNPO 11346 4
226360_at zinc and ring finger 3 ZNRF3 84133 4
221974_at Small nuclear ribonucleoprotein polypeptide N SNRPN 6638 4
210941_at BH-protocadherin (brain-heart) PCDH7 5099 4
40489_at atrophin 1 ATN1 1822 4
1558034_s_at ceruloplasmin (ferroxidase) CP 1356 4
205295_at creatine kinase, mitochondrial 2 (sarcomeric) CKMT2 1160 4
207030_s_at cysteine and glycine-rich protein 2 CSRP2 1466 4
205952_at potassium channel, subfamily K, member 3 KCNK3 3777 4
227236_at tetraspanin 2 TSPAN2 10100 4
210935_s_at WD repeat domain 1 WDR1 9948 4
219093_at hypothetical protein FLJ20701 ; hypothetical protein FLJ20701 FLJ20701 55022 4
229464_at myelin expression factor 2 MYEF2 50804 4
226408_at TEA domain family member 2 TEAD2 8463 4
1553194_at neuronal growth regulator 1 NEGR1 257194 4
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222722_at osteoglycin (osteoinductive factor, mimecan) OGN 4969 4
202222_s_at desmin DES 1674 4
220595_at PDZ domain containing RING finger 4 PDZRN4 29951 4
211323_s_at inositol 1,4,5-triphosphate receptor, type 1 ITPR1 3708 4
236584_at chromosome 1 open reading frame 86 C1orf86 199990 4
212567_s_at microtubule-associated protein 4 MAP4 4134 4
217728_at S100 calcium binding protein A6 (calcyclin) S100A6 6277 4
207837_at RNA binding protein with multiple splicing RBPMS 11030 4
227248_at hypothetical protein FLJ21019 FLJ21019 79990 4
233487_s_at leucine rich repeat containing 8 family, member A LRRC8A 56262 4
209071_s_at regulator of G-protein signalling 5 RGS5 8490 4
238583_at methionine sulfoxide reductase B3 MSRB3 253827 4
209262_s_at nuclear receptor subfamily 2, group F, member 6 NR2F6 2063 4
219327_s_at G protein-coupled receptor, family C, group 5, member C GPRC5C 55890 4
202289_s_at transforming, acidic coiled-coil containing protein 2 TACC2 10579 4
225728_at Importin 9 IPO9 55705 4
231386_at FLJ30851 protein FLJ30851 375190 4
204749_at nucleosome assembly protein 1-like 3 NAP1L3 4675 4
221755_at EH domain binding protein 1-like 1 EHBP1L1 254102 4
1557223_at RNA binding protein with multiple splicing RBPMS 11030 4
228277_at F-box and leucine-rich repeat protein 19 FBXL19 54620 4
218675_at solute carrier family 22 (organic cation transporter), member 17 SLC22A17 51310 4
201868_s_at transducin (beta)-like 1X-linked TBL1X 6907 4
204693_at CDC42 effector protein (Rho GTPase binding) 1 CDC42EP1 11135 4
224663_s_at cofilin 2 (muscle) CFL2 1073 4
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200879_s_at endothelial PAS domain protein 1 EPAS1 2034 4
229890_at proline-rich transmembrane protein 1 PRRT1 80863 4
237515_at Transmembrane protein 56 FLJ31842 148534 4
207159_x_at mucoepidermoid carcinoma translocated 1 MECT1 23373 4
208937_s_at inhibitor of DNA binding 1, dominant negative helix-loop-helix protein ID1 3397 4
204669_s_at ring finger protein 24 RNF24 11237 4
209651_at transforming growth factor beta 1 induced transcript 1 TGFB1I1 7041 4
224976_at nuclear factor I/A NFIA 4774 4
211573_x_at transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase)
TGM2 7052 4
213974_at ADAMTS-like 3 ADAMTSL3 57188 4
225342_at adenylate kinase 3-like 1 AK3L1 205 4
201675_at A kinase (PRKA) anchor protein 1 AKAP1 8165 4
208889_s_at nuclear receptor co-repressor 2 NCOR2 9612 4
201801_s_at solute carrier family 29 (nucleoside transporters), member 1 SLC29A1 2030 4
204348_s_at adenylate kinase 3-like 1 AK3L1 205 4
215506_s_at DIRAS family, GTP-binding RAS-like 3 DIRAS3 9077 4
207336_at SRY (sex determining region Y)-box 5 SOX5 6660 4
201604_s_at protein phosphatase 1, regulatory (inhibitor) subunit 12A PPP1R12A 4659 4
227945_at TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 TBC1D1 23216 4
206117_at tropomyosin 1 (alpha) TPM1 7168 4
228988_at zinc finger protein 6 (CMPX1) ZNF6 7552 4
204944_at protein tyrosine phosphatase, receptor type, G PTPRG 5793 4
213497_at ankyrin repeat and BTB (POZ) domain containing 2 ABTB2 25841 4
204235_s_at GULP, engulfment adaptor PTB domain containing 1 GULP1 51454 4
219377_at family with sequence similarity 59, member A FAM59A 64762 4
215692_s_at metallophosphoesterase domain containing 2 MPPED2 744 4
Appendix E: Genes downregulated in AAA vs. NA (continued).
350





227272_at FLJ43339 protein FLJ43339 388115 4
209209_s_at pleckstrin homology domain containing, family C (with FERM domain)
member 1
PLEKHC1 10979 4
242734_x_at galactose-1-phosphate uridylyltransferase GALT 2592 4
219609_at WD repeat domain 25 WDR25 79446 4
1555269_a_at transmembrane protein 16A TMEM16A 55107 4
205534_at BH-protocadherin (brain-heart) PCDH7 5099 4
234068_s_at adaptor-related protein complex 2, alpha 1 subunit AP2A1 160 4
1554126_at methionine sulfoxide reductase B3 MSRB3 253827 4
239744_at Regulator of G-protein signalling 3 RGS3 5998 4
231131_at hypothetical protein FLJ37659 RP1-32F7.2 286499 4
208430_s_at dystrobrevin, alpha DTNA 1837 4
209243_s_at paternally expressed 3 PEG3 5178 4
223853_at blood vessel epicardial substance BVES 11149 4
218974_at hypothetical protein FLJ10159 FLJ10159 55084 4
211347_at CDC14 cell division cycle 14 homolog B (S. cerevisiae) CDC14B 8555 4
204894_s_at amine oxidase, copper containing 3 (vascular adhesion protein 1) AOC3 8639 4
230360_at gliomedin GLDN 342035 4
227702_at cytochrome P450, family 4, subfamily X, polypeptide 1 CYP4X1 260293 4
214875_x_at amyloid beta (A4) precursor-like protein 2 APLP2 334 4
219369_s_at OTU domain, ubiquitin aldehyde binding 2 OTUB2 78990 4
212338_at myosin ID MYO1D 4642 4
222664_at potassium channel tetramerisation domain containing 15 KCTD15 79047 4
216352_x_at protocadherin gamma subfamily A, 3 PCDHGA3 56112 4
209487_at RNA binding protein with multiple splicing RBPMS 11030 4
212328_at KIAA1102 protein KIAA1102 22998 4
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205579_at histamine receptor H1 HRH1 3269 4
203661_s_at tropomodulin 1 TMOD1 7111 4
206973_at protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF) PPFIA2 8499 4
1554640_at paralemmin 2 PALM2 114299 4
228967_at Eukaryotic translation initiation factor 1 SUI1 10209 4
220975_s_at C1q and tumor necrosis factor related protein 1 ; C1q and tumor
necrosis factor related protein 1
C1QTNF1 114897 4
237329_at hypothetical LOC389100 LOC389100 389100 4
232806_s_at hypothetical protein MGC21688 MGC21688 131408 4
213924_at Metallophosphoesterase 1 MPPE1 65258 4
228213_at H2A histone family, member J H2AFJ 55766 4
204657_s_at Src homology 2 domain containing adaptor protein B SHB 6461 4
202709_at fibromodulin FMOD 2331 4
204321_at neogenin homolog 1 (chicken) NEO1 4756 4
202908_at Wolfram syndrome 1 (wolframin) WFS1 7466 4
233167_at selenoprotein O SELO 83642 4
209951_s_at mitogen-activated protein kinase kinase 7 MAP2K7 5609 4
209098_s_at jagged 1 (Alagille syndrome) JAG1 182 4





222101_s_at dachsous 1 (Drosophila) DCHS1 8642 4
238514_at transmembrane protein 25 TMEM25 84866 4
33850_at microtubule-associated protein 4 MAP4 4134 4
204939_s_at phospholamban PLN 5350 4
202401_s_at serum response factor (c-fos serum response element-binding
transcription factor)
SRF 6722 4
205120_s_at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB 6443 4
39549_at neuronal PAS domain protein 2 NPAS2 4862 4
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202822_at LIM domain containing preferred translocation partner in lipoma LPP 4026 4
221088_s_at protein phosphatase 1, regulatory (inhibitor) subunit 9A PPP1R9A 55607 4
225270_at neogenin homolog 1 (chicken) NEO1 4756 4
227297_at Integrin, alpha 9 ITGA9 3680 4
226814_at ADAM metallopeptidase with thrombospondin type 1 motif, 9 ADAMTS9 56999 4
229034_at hypothetical protein FLJ10159 FLJ10159 55084 4
212361_s_at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP2A2 488 4
202054_s_at aldehyde dehydrogenase 3 family, member A2 ALDH3A2 224 4
243_g_at microtubule-associated protein 4 MAP4 4134 4
212473_s_at microtubule associated monoxygenase, calponin and LIM domain
containing 2
MICAL2 9645 4
219218_at KIAA1447 protein KIAA1447 57597 4
201681_s_at discs, large homolog 5 (Drosophila) DLG5 9231 4
209293_x_at inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 3400 4
214322_at calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma CAMK2G 818 4
214721_x_at CDC42 effector protein (Rho GTPase binding) 4 CDC42EP4 23580 4
213164_at solute carrier family 5 (inositol transporters), member 3 SLC5A3 6526 4
221884_at ecotropic viral integration site 1 EVI1 2122 4
226926_at dermokine ZD52F10 93099 4
227506_at solute carrier family 16 (monocarboxylic acid transporters), member 9 SLC16A9 220963 4
212325_at KIAA1102 protein KIAA1102 22998 4
228143_at ceruloplasmin (ferroxidase) CP 1356 4
49051_g_at deltex 3 homolog (Drosophila) DTX3 196403 4
212573_at KIAA0830 protein KIAA0830 23052 4
218843_at fibronectin type III domain containing 4 FNDC4 64838 4
213010_at protein kinase C, delta binding protein PRKCDBP 112464 4
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222433_at enabled homolog (Drosophila) ENAH 55740 4
213447_at imprinted in Prader-Willi syndrome IPW 3653 4
207069_s_at SMAD, mothers against DPP homolog 6 (Drosophila) SMAD6 4091 4
208874_x_at protein phosphatase 2A, regulatory subunit B' (PR 53) PPP2R4 5524 4
225078_at epithelial membrane protein 2 EMP2 2013 4
205076_s_at myotubularin related protein 11 MTMR11 10903 4
227644_at regulating synaptic membrane exocytosis 4 RIMS4 140730 4
216867_s_at platelet-derived growth factor alpha polypeptide PDGFA 5154 4
219733_s_at solute carrier family 27 (fatty acid transporter), member 5 SLC27A5 10998 4
226884_at leucine rich repeat neuronal 1 LRRN1 57633 4
224970_at nuclear factor I/A NFIA 4774 4
218045_x_at parathymosin PTMS 5763 4
219509_at myozenin 1 MYOZ1 58529 4
204237_at GULP, engulfment adaptor PTB domain containing 1 GULP1 51454 4
223495_at coiled-coil domain containing 8 CCDC8 83987 4
229063_s_at hypothetical protein MGC31967 MGC31967 203260 4
227392_at nischarin NISCH 11188 4
210706_s_at ring finger protein 24 RNF24 11237 4
220825_s_at kin of IRRE like (Drosophila) KIRREL 55243 4
222434_at enabled homolog (Drosophila) ENAH 55740 4
204570_at cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) COX7A1 1346 4
205397_x_at SMAD, mothers against DPP homolog 3 (Drosophila) SMAD3 4088 4
204257_at fatty acid desaturase 3 FADS3 3995 4
226518_at potassium channel tetramerisation domain containing 10 KCTD10 83892 4
227084_at dystrobrevin, alpha DTNA 1837 4
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202555_s_at myosin, light polypeptide kinase ; myosin, light polypeptide
kinase
MYLK 4638 4
227699_at chromosome 14 open reading frame 149 C14orf149 112849 4
217967_s_at chromosome 1 open reading frame 24 C1orf24 116496 4
213541_s_at v-ets erythroblastosis virus E26 oncogene like (avian) ERG 2078 4
227328_at Calmodulin binding transcription activator 1 CAMTA1 23261 4
216272_x_at synapse defective 1, Rho GTPase, homolog 1 (C. elegans) SYDE1 85360 4
203441_s_at cadherin 2, type 1, N-cadherin (neuronal) CDH2 1000 4
201559_s_at chloride intracellular channel 4 CLIC4 25932 4
225020_at DAB2 interacting protein DAB2IP 153090 4
237116_at Profilin 2 PFN2 5217 4
227848_at phosphatidylethanolamine-binding protein 4 PEBP4 157310 4
206306_at ryanodine receptor 3 RYR3 6263 4
235108_at Potassium channel, subfamily K, member 3 KCNK3 3777 4
210625_s_at A kinase (PRKA) anchor protein 1 AKAP1 8165 4
202834_at angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT 183 4
211538_s_at heat shock 70kDa protein 2 HSPA2 3306 4
212937_s_at collagen, type VI, alpha 1 COL6A1 1291 4
233498_at V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 2066 4
228984_at KIAA1394 protein KIAA1394 57571 4
1553672_at enabled homolog (Drosophila) ENAH 55740 4
201173_x_at nuclear distribution gene C homolog (A. nidulans) NUDC 10726 4
40850_at FK506 binding protein 8, 38kDa FKBP8 23770 4
233496_s_at cofilin 2 (muscle) CFL2 1073 4
204004_at PRKC, apoptosis, WT1, regulator PAWR 5074 4
224057_s_at THAP domain containing 4 THAP4 51078 4
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213283_s_at sal-like 2 (Drosophila) SALL2 6297 4
202928_s_at PHD finger protein 1 PHF1 5252 4
212564_at potassium channel tetramerisation domain containing 2 KCTD2 23510 4
200621_at cysteine and glycine-rich protein 1 CSRP1 1465 4
235497_at Hypothetical protein LOC284591 LOC284591 284591 4
211110_s_at androgen receptor AR 367 4
242545_at tubulin tyrosine ligase-like family, member 11 TTLL11 158135 4
205717_x_at protocadherin gamma subfamily C, 3 PCDHGC3 26025 4
229774_at CXXC finger 4 CXXC4 80319 4
1554574_a_at cytochrome b5 reductase 3 CYB5R3 1727 4
221656_s_at Rho guanine nucleotide exchange factor (GEF) 10-like ARHGEF10L 55160 4
208682_s_at melanoma antigen family D, 2 MAGED2 10916 4
201497_x_at myosin, heavy polypeptide 11, smooth muscle MYH11 4629 4
204992_s_at profilin 2 PFN2 5217 4
232235_at chromosome 18 open reading frame 4 C18orf4 92126 4
209633_at protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha PPP2R3A 5523 4
220617_s_at zinc finger protein 532 ZNF532 55205 4
223496_s_at coiled-coil domain containing 8 CCDC8 83987 4
209896_s_at protein tyrosine phosphatase, non-receptor type 11 (Noonan
syndrome 1)
PTPN11 5781 4
225380_at hypothetical protein BC007901 LOC91461 91461 4
1554784_at contactin 1 CNTN1 1272 4
204036_at endothelial differentiation, lysophosphatidic acid G-protein-coupled
receptor, 2
EDG2 1902 4
226856_at musculoskeletal, embryonic nuclear protein 1 MUSTN1 389125 4
205934_at phospholipase C-like 1 PLCL1 5334 3
232406_at Jagged 1 (Alagille syndrome) JAG1 182 3
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221408_x_at protocadherin beta 12 PCDHB12 56124 3
215306_at Luteinizing hormone/choriogonadotropin receptor LHCGR 3973 3
201869_s_at transducin (beta)-like 1X-linked TBL1X 6907 3
208760_at Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) UBE2I 7329 3
222406_s_at proline-rich nuclear receptor coactivator 2 PNRC2 55629 3
235721_at deltex 3 homolog (Drosophila) DTX3 196403 3
212372_at myosin, heavy polypeptide 10, non-muscle MYH10 4628 3
203550_s_at chromosome 1 open reading frame 2 C1orf2 10712 3
205231_s_at epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) EPM2A 7957 3
220936_s_at H2A histone family, member J H2AFJ 55766 3
209656_s_at transmembrane protein 47 TMEM47 83604 3
231721_at junctional adhesion molecule 3 JAM3 83700 3
224352_s_at cofilin 2 (muscle) ; cofilin 2 (muscle) CFL2 1073 3
226388_at transcription elongation factor A (SII), 3 TCEA3 6920 3
201554_x_at glycogenin GYG 2992 3
201467_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1728 3
212003_at chromosome 1 open reading frame 144 C1orf144 26099 3
242064_at sidekick homolog 2 (chicken) SDK2 54549 3
214282_at Ceruloplasmin (ferroxidase) CP 1356 3
204099_at SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily d, member 3
SMARCD3 6604 3
221628_s_at cytokine-like nuclear factor n-pac N-PAC 84656 3
203425_s_at insulin-like growth factor binding protein 5 IGFBP5 3488 3
207968_s_at MADS box transcription enhancer factor 2, polypeptide C (myocyte
enhancer factor 2C)
MEF2C 4208 3
229504_at RAB23, member RAS oncogene family RAB23 51715 3
1570515_a_at filamin A interacting protein 1 FILIP1 27145 3
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224798_s_at chromosome 15 open reading frame 17 C15orf17 57184 3
227083_at beta 3-glycosyltransferase-like B3GTL 145173 3
204485_s_at target of myb1-like 1 (chicken) TOM1L1 10040 3
1560407_at MAP/microtubule affinity-regulating kinase 1 MARK1 4139 3
202815_s_at hexamethylene bis-acetamide inducible 1 HEXIM1 10614 3
242447_at hypothetical gene supported by AK091454 LOC285382 285382 3
204422_s_at fibroblast growth factor 2 (basic) FGF2 2247 3
209195_s_at adenylate cyclase 6 ADCY6 112 3
201616_s_at caldesmon 1 CALD1 800 3
210317_s_at tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation
protein, epsilon polypeptide
YWHAE 7531 3
202085_at tight junction protein 2 (zona occludens 2) TJP2 9414 3
227326_at matrix-remodelling associated 7 MXRA7 439921 3
239763_at PR domain containing 11 PRDM11 56981 3
231336_at copine IV CPNE4 131034 3
203881_s_at dystrophin (muscular dystrophy, Duchenne and Becker types) DMD 1756 3
228625_at Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal
domain, 4
CITED4 163732 3
212437_at centromere protein B, 80kDa CENPB 1059 3
208704_x_at amyloid beta (A4) precursor-like protein 2 APLP2 334 3
219922_s_at latent transforming growth factor beta binding protein 3 LTBP3 4054 3
213627_at melanoma antigen family D, 2 MAGED2 10916 3
204037_at endothelial differentiation, lysophosphatidic acid G-protein-coupled
receptor, 2
EDG2 1902 3
1569149_at PDZ and LIM domain 7 (enigma) PDLIM7 9260 3
204396_s_at G protein-coupled receptor kinase 5 GRK5 2869 3
205429_s_at membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) MPP6 51678 3
215294_s_at SWI/SNF related, matrix associated, actin dependent regulator subfamily SMARCA1 6594 3
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209454_s_at TEA domain family member 3 TEAD3 7005 3
213906_at v-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 4603 3
45297_at EH-domain containing 2 EHD2 30846 3
218780_at hook homolog 2 (Drosophila) HOOK2 29911 3
224458_at chromosome 9 open reading frame 125 ; chromosome 9 open
reading frame 125
C9orf125 84302 3
210976_s_at phosphofructokinase, muscle PFKM 5213 3
205348_s_at dynein, cytoplasmic, intermediate polypeptide 1 DNCI1 1780 3
224773_at neuron navigator 1 NAV1 89796 3
201749_at Endothelin converting enzyme 1 ECE1 1889 3
208871_at atrophin 1 ATN1 1822 3
212803_at NGFI-A binding protein 2 (EGR1 binding protein 2) NAB2 4665 3
209015_s_at DnaJ (Hsp40) homolog, subfamily B, member 6 DNAJB6 10049 3
215324_at sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3D
SEMA3D 223117 3
203733_at dexamethasone-induced transcript DEXI 28955 3
205111_s_at phospholipase C, epsilon 1 PLCE1 51196 3
229095_s_at LIM and senescent cell antigen-like domains 3 LIMS3 96626 3
203464_s_at epsin 2 EPN2 22905 3
215505_s_at striatin, calmodulin binding protein 3 STRN3 29966 3
221584_s_at potassium large conductance calcium-activated channel, subfamily
M, alpha member 1
KCNMA1 3778 3
227120_at forkhead box P4 FOXP4 116113 3
216234_s_at protein kinase, cAMP-dependent, catalytic, alpha PRKACA 5566 3
224995_at spire homolog 1 (Drosophila) SPIRE1 56907 3
212680_x_at protein phosphatase 1, regulatory (inhibitor) subunit 14B PPP1R14B 26472 3
209789_at coronin, actin binding protein, 2B CORO2B 10391 3
207781_s_at zinc finger protein 6 (CMPX1) ZNF6 7552 3
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205224_at surfeit 2 SURF2 6835 3
226223_at PRKC, apoptosis, WT1, regulator PAWR 5074 3
228737_at chromosome 20 open reading frame 100 C20orf100 84969 3
212005_at chromosome 1 open reading frame 144 C1orf144 26099 3
226305_at Ly6/neurotoxin 1 LYNX1 66004 3
229004_at ADAM metallopeptidase with thrombospondin type 1 motif, 15 ADAMTS15 170689 3
226188_at HSPC159 protein HSPC159 29094 3
218678_at nestin NES 10763 3
219451_at methionine sulfoxide reductase B2 MSRB2 22921 3
213324_at v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
(avian)
SRC 6714 3
219965_s_at PDZ domain containing, X chromosome FLJ21687 79917 3
227099_s_at hypothetical LOC387763 LOC387763 387763 3
204310_s_at natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic
peptide receptor B)
NPR2 4882 3
219929_s_at zinc finger, FYVE domain containing 21 ZFYVE21 79038 3
227875_at kelch-like 13 (Drosophila) KLHL13 90293 3
213138_at AT rich interactive domain 5A (MRF1-like) ARID5A 10865 3
228306_at Cornichon homolog 4 (Drosophila) HSPC163 29097 3
217818_s_at actin related protein 2/3 complex, subunit 4, 20kDa ARPC4 10093 3
239657_x_at forkhead box protein O6 FOXO6 343552 3
211031_s_at cytoplasmic linker 2 ; cytoplasmic linker 2 CYLN2 7461 3
207012_at matrix metallopeptidase 16 (membrane-inserted) MMP16 4325 3
211621_at androgen receptor (dihydrotestosterone receptor; testicular
feminization;
AR 367 3
210967_x_at calcium channel, voltage-dependent, beta 1 subunit CACNB1 782 3
1557382_x_at KIAA1975 protein similar to MRIP2 KIAA1975 119385 3
228162_at Esterase D/formylglutathione hydrolase ESD 2098 3
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205993_s_at T-box 2 TBX2 6909 3
212705_x_at patatin-like phospholipase domain containing 2 PNPLA2 57104 3
211569_s_at L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain HADHSC 3033 3
205450_at phosphorylase kinase, alpha 1 (muscle) PHKA1 5255 3
203612_at bystin-like BYSL 705 3
202617_s_at methyl CpG binding protein 2 (Rett syndrome) MECP2 4204 3
209837_at adaptor-related protein complex 4, mu 1 subunit AP4M1 9179 3
210544_s_at aldehyde dehydrogenase 3 family, member A2 ALDH3A2 224 3
202328_s_at polycystic kidney disease 1 (autosomal dominant) PKD1 5310 3
209632_at protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha PPP2R3A 5523 3
228933_at Nance-Horan syndrome (congenital cataracts and dental
anomalies)
NHS 4810 3
219179_at dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) DACT1 51339 3
230161_at CD99 antigen CD99 4267 3
221104_s_at nipsnap homolog 3B (C. elegans) NIPSNAP3B 55335 3
238021_s_at hypothetical gene supported by AF275804 LOC388279 388279 3
204135_at downregulated in ovarian cancer 1 DOC1 11259 3
205279_s_at glycine receptor, beta GLRB 2743 3
218204_s_at FYVE and coiled-coil domain containing 1 FYCO1 79443 3
201468_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1728 3
200808_s_at zyxin ZYX 7791 3
226500_at zinc finger protein 651 ZNF651 92999 3
208790_s_at polymerase I and transcript release factor PTRF 284119 3
223614_at hypothetical protein DKFZp761D112 DKFZp761D112 84257 3
244623_at Transcribed locus 3
1554710_at potassium large conductance calcium-activated channel,
subfamily M, beta member 1
KCNMB1 3779 3
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225855_at erythrocyte membrane protein band 4.1 like 5 EPB41L5 57669 3
232309_at hypothetical protein LOC202181 LOC202181 202181 3
200931_s_at vinculin VCL 7414 3
235759_at EF-hand calcium binding protein 1 EFCBP1 64168 3
236330_at CDNA FLJ42688 fis, clone BRAMY3002120 3
218359_at chromosome 20 open reading frame 98 C20orf98 80023 3
1552521_a_at transmembrane protein 74 TMEM74 157753 3
219902_at betaine-homocysteine methyltransferase 2 BHMT2 23743 3
226492_at sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6D
SEMA6D 80031 3
226542_at Full-length cDNA clone CS0DJ002YF02 of T cells (Jurkat cell line) 3
217509_x_at glutamate receptor, ionotropic, kainate 5 GRIK5 2901 3
226411_at ecotropic viral integration site 5-like EVI5L 115704 3
204628_s_at integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 3690 3
229335_at immunoglobulin superfamily, member 4C IGSF4C 199731 3
209402_s_at solute carrier family 12 (potassium/chloride transporters), member 4 SLC12A4 6560 3
224894_at Yes-associated protein 1, 65kDa YAP1 10413 3
217223_s_at breakpoint cluster region BCR 613 3
215247_at hypothetical protein LOC339692 LOC339692 339692 3
208255_s_at FK506 binding protein 8, 38kDa FKBP8 23770 3
1556194_a_at CDNA clone IMAGE:5285801 3
40093_at Lutheran blood group (Auberger b antigen included) LU 4059 3
211404_s_at amyloid beta (A4) precursor-like protein 2 APLP2 334 3
32094_at carbohydrate (chondroitin 6) sulfotransferase 3 CHST3 9469 3
204793_at G protein-coupled receptor associated sorting protein 1 GPRASP1 9737 3
224811_at CDNA clone IMAGE:5286019 3
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238805_at similar to RIKEN cDNA 2310030G06 gene MGC14839 91894 3
209878_s_at v-rel reticuloendotheliosis viral oncogene homolog A, RELA 5970 3
225935_at CDNA clone IMAGE:4769453 3
204472_at GTP binding protein overexpressed in skeletal muscle GEM 2669 3
1556129_at Hypothetical protein FLJ12986 FLJ12986 197319 3
205442_at microfibrillar-associated protein 3-like MFAP3L 9848 3
1560537_at Fibroblast growth factor 13 FGF13 2258 3
225459_at angiomotin like 1 AMOTL1 154810 3
227034_at chromosome 2 open reading frame 26 C2orf26 65124 3
222956_at fidgetin FIGN 55137 3
226051_at selenoprotein M SELM 140606 3
1558152_at Hypothetical protein MGC3234 MGC3234 66005 3
1558487_a_at transmembrane emp24 protein transport domain containing 4 TMED4 222068 3
1554783_s_at rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2 9181 3
220482_s_at deafness locus associated putative guanine nucleotide exchange
factor
DELGEF 26297 3
201332_s_at signal transducer and activator of transcription 6, interleukin-4
induced
STAT6 6778 3
202336_s_at peptidylglycine alpha-amidating monooxygenase PAM 5066 3
1559839_at T-box 18 TBX18 9096 3
202982_s_at acyl-CoA thioesterase 2 ACOT2 10965 3
210150_s_at laminin, alpha 5 LAMA5 3911 3
202032_s_at mannosidase, alpha, class 2A, member 2 MAN2A2 4122 3
1555240_s_at guanine nucleotide binding protein (G protein), gamma 12 GNG12 55970 3
225096_at hypothetical protein, clone 2746033 HSA272196 55352 3
213103_at START domain containing 13 STARD13 90627 3
203710_at inositol 1,4,5-triphosphate receptor, type 1 ITPR1 3708 3
Appendix E: Genes downregulated in AAA vs. NA (continued).
363





208096_s_at collagen, type XXI, alpha 1 ; collagen, type XXI, alpha 1 COL21A1 81578 3
1557375_at Ellis van Creveld syndrome EVC 2121 3
219511_s_at synuclein, alpha interacting protein (synphilin) SNCAIP 9627 3
219053_s_at vacuolar protein sorting 37C (yeast) VPS37C 55048 3
215515_at Kin of IRRE like (Drosophila) KIRREL 55243 3
223681_s_at InaD-like (Drosophila) INADL 10207 3
208131_s_at prostaglandin I2 (prostacyclin) synthase ; prostaglandin I2
(prostacyclin) synthase
PTGIS 5740 3
564_at guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 3
221566_s_at nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3 8996 3
210473_s_at G protein-coupled receptor 125 GPR125 166647 3
222918_at RAB9B, member RAS oncogene family RAB9B 51209 3
201983_s_at epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-
b) oncogene homolog, avian)
EGFR 1956 3
217294_s_at enolase 1, (alpha) ENO1 2023 3
218364_at leucine rich repeat (in FLII) interacting protein 2 LRRFIP2 9209 3
204975_at epithelial membrane protein 2 EMP2 2013 3
213710_s_at Calmodulin 1 (phosphorylase kinase, delta) CALM1 801 3
203722_at aldehyde dehydrogenase 4 family, member A1 ALDH4A1 8659 3
213181_s_at molybdenum cofactor synthesis 1 MOCS1 4337 3
211343_s_at collagen, type XIII, alpha 1 COL13A1 1305 3
1558214_s_at catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 1495 3
212327_at KIAA1102 protein KIAA1102 22998 3
213217_at adenylate cyclase 2 (brain) ADCY2 108 3
201120_s_at progesterone receptor membrane component 1 PGRMC1 10857 3
231118_at ankyrin repeat domain 35 ANKRD35 148741 3
227679_at Histone deacetylase 11 HDAC11 79885 3
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215706_x_at zyxin ZYX 7791 3
212655_at zinc finger, CCHC domain containing 14 ZCCHC14 23174 3
219670_at chromosome 1 open reading frame 165 C1orf165 79656 3
200623_s_at calmodulin 3 (phosphorylase kinase, delta) CALM3 808 3
226420_at ecotropic viral integration site 1 EVI1 2122 3
221487_s_at endosulfine alpha ENSA 2029 3
212701_at Talin 2 TLN2 83660 3
210792_x_at CD27-binding (Siva) protein SIVA 10572 3
218416_s_at hypothetical protein FLJ20489 FLJ20489 55652 3
203792_x_at polycomb group ring finger 2 PCGF2 7703 3
1558295_a_at protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), PPFIA2 8499 3
1557910_at heat shock 90kDa protein 1, beta HSPCB 3326 3
219011_at pleckstrin homology domain containing, family A (phosphoinositide
binding specific) member 4
PLEKHA4 57664 3
226591_at Small nuclear ribonucleoprotein polypeptide N SNRPN 6638 3
208977_x_at tubulin, beta, 2 TUBB2 10383 3
226763_at SEC14 and spectrin domains 1 SESTD1 91404 3
216268_s_at jagged 1 (Alagille syndrome) JAG1 182 3
234312_s_at acyl-CoA synthetase short-chain family member 2 ACSS2 55902 3
226071_at thrombospondin repeat containing 1 TSRC1 54507 3
1554179_s_at Ly6/neurotoxin 1 LYNX1 66004 3
200836_s_at microtubule-associated protein 4 MAP4 4134 3
221846_s_at CASK interacting protein 2 CASKIN2 57513 3
202464_s_at 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 PFKFB3 5209 3
1554127_s_at methionine sulfoxide reductase B3 MSRB3 253827 3
223482_at transmembrane protein induced by tumor necrosis factor alpha TMPIT 83862 3
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219368_at nucleosome assembly protein 1-like 2 NAP1L2 4674 3
212253_x_at dystonin DST 667 3
230433_at hypothetical gene supported by AK094796 LOC400764 400764 3
225978_at family with sequence similarity 80, member B FAM80B 57494 3
35846_at thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-
a) oncogene homolog, avian)
THRA 7067 3
201809_s_at endoglin (Osler-Rendu-Weber syndrome 1) ENG 2022 3
238592_at PDZ and LIM domain 3 PDLIM3 27295 3
228115_at Transcribed locus 3
220233_at F-box protein 17 FBXO17 115290 3
213386_at Chromosome 9 open reading frame 125 C9orf125 84302 3
216944_s_at inositol 1,4,5-triphosphate receptor, type 1 ITPR1 3708 3
205439_at glutathione S-transferase theta 2 GSTT2 2953 3
203796_s_at B-cell CLL/lymphoma 7A BCL7A 605 3
210688_s_at carnitine palmitoyltransferase 1A (liver) CPT1A 1374 3
223208_at potassium channel tetramerisation domain containing 10 KCTD10 83892 3
237664_at Protein tyrosine phosphatase-like (proline instead of catalytic
arginine), member a
PTPLA 9200 3
226744_at hypothetical protein MGC3329 MGC3329 79066 3
226313_at chromosome 10 open reading frame 35 C10orf35 219738 3
228523_at nanos homolog 1 (Drosophila) NANOS1 340719 3
229876_at Phosphorylase kinase, alpha 1 (muscle) PHKA1 5255 3
242519_at Selenoprotein P, plasma, 1 SEPP1 6414 3
214433_s_at selenium binding protein 1 ; selenium binding protein 1 SELENBP1 8991 3
223237_x_at adaptor-related protein complex 2, alpha 1 subunit AP2A1 160 3
222834_s_at guanine nucleotide binding protein (G protein), gamma 12 GNG12 55970 3
203019_x_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 117178 3
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225044_at hypothetical protein MGC20781 MGC20781 115024 3
209047_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 358 3
225868_at tripartite motif-containing 47 TRIM47 91107 3
226168_at zinc finger, AN1-type domain 2B ZFAND2B 130617 3
213992_at collagen, type IV, alpha 6 COL4A6 1288 3
205110_s_at fibroblast growth factor 13 FGF13 2258 3
204395_s_at G protein-coupled receptor kinase 5 GRK5 2869 3
223539_s_at small EDRK-rich factor 1A (telomeric) ; SERF1A 56617 3
225979_at pleckstrin homology domain containing, family G (with RhoGef
domain) member 2
PLEKHG2 64857 3
228584_at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB 6443 3
218094_s_at chromosome 20 open reading frame 35 C20orf35 55861 3
204497_at adenylate cyclase 9 ADCY9 115 3
227308_x_at latent transforming growth factor beta binding protein 3 LTBP3 4054 3
228728_at hypothetical protein FLJ21986 FLJ21986 79974 3
235083_at hypothetical protein FLJ38359 FLJ38359 151009 3
205381_at leucine rich repeat containing 17 LRRC17 10234 3
212728_at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3 1741 3
221708_s_at smooth muscle cell associated protein-1 ; smooth muscle cell
associated protein-1
SMAP-1 55898 3
201867_s_at transducin (beta)-like 1X-linked TBL1X 6907 3
208827_at proteasome (prosome, macropain) subunit, beta type, 6 PSMB6 5694 3
203919_at transcription elongation factor A (SII), 2 TCEA2 6919 3
210790_s_at SAR1 gene homolog A (S. cerevisiae) SAR1A 56681 3
203033_x_at fumarate hydratase FH 2271 3
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230287_at RUN and TBC1 domain containing 2 RUTBC2 129049 3
201261_x_at biglycan BGN 633 3
225021_at zinc finger protein 532 ZNF532 55205 3
241873_at Unc-5 homolog C (C. elegans) UNC5C 8633 3
202364_at MAX interactor 1 ; MAX interactor 1 MXI1 4601 3
209885_at ras homolog gene family, member D RHOD 29984 3
212197_x_at myosin phosphatase-Rho interacting protein M-RIP 23164 3
203410_at adaptor-related protein complex 3, mu 2 subunit AP3M2 10947 3
214318_s_at hypothetical protein CG003 13CDNA73 10129 3
212647_at related RAS viral (r-ras) oncogene homolog RRAS 6237 3
224624_at leucine rich repeat containing 8 family, member A LRRC8A 56262 3
212566_at microtubule-associated protein 4 MAP4 4134 3
1558348_at De-etiolated homolog 1 (Arabidopsis) DET1 55070 3
221527_s_at par-3 partitioning defective 3 homolog (C. elegans) PARD3 56288 3
210519_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 1728 3
209292_at Inhibitor of DNA binding 4, dominant negative helix-loop-helix
protein
ID4 3400 3
238204_at Leiomodin 1 (smooth muscle) LMOD1 25802 3
1569150_x_at PDZ and LIM domain 7 (enigma) PDLIM7 9260 3
244370_at KIAA2022 protein KIAA2022 340533 3
228278_at nuclear factor I/X (CCAAT-binding transcription factor) NFIX 4784 3
227166_at DnaJ (Hsp40) homolog, subfamily C, member 18 DNAJC18 202052 3
207839_s_at chromosome 9 open reading frame 127 C9orf127 51754 3
1552520_at transmembrane protein 74 TMEM74 157753 3
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209191_at tubulin, beta 6 TUBB6 84617 3
238477_at Kinesin family member 1C KIF1C 10749 3
219468_s_at CUE domain containing 1 CUEDC1 404093 3
204248_at guanine nucleotide binding protein (G protein), alpha 11 (Gq
class)
GNA11 2767 3
206511_s_at sine oculis homeobox homolog 2 (Drosophila) SIX2 10736 3
1556325_at filamin A interacting protein 1 FILIP1 27145 3
227705_at transcription elongation factor A (SII)-like 7 TCEAL7 56849 3
1557458_s_at Src homology 2 domain containing adaptor protein B SHB 6461 3
1555390_at chromosome 14 open reading frame 21 C14orf21 161424 3
1554614_a_at polypyrimidine tract binding protein 2 PTBP2 58155 3
227545_at BRCA1 associated RING domain 1 BARD1 580 3
233540_s_at CDK5 regulatory subunit associated protein 2 CDK5RAP2 55755 3
232027_at spectrin repeat containing, nuclear envelope 1 SYNE1 23345 3
212599_at autism susceptibility candidate 2 AUTS2 26053 3
205398_s_at SMAD, mothers against DPP homolog 3 (Drosophila) SMAD3 4088 3
230630_at Adenylate kinase 3-like 1 AK3 205 3
212494_at tensin like C1 domain containing phosphatase (tensin 2) TENC1 23371 3
211564_s_at PDZ and LIM domain 4 PDLIM4 8572 3
211003_x_at transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase)
TGM2 7052 3
236234_at phosphodiesterase 1A, calmodulin-dependent PDE1A 5136 3
203263_s_at Cdc42 guanine nucleotide exchange factor (GEF) 9 ARHGEF9 23229 3
225693_s_at calmodulin binding transcription activator 1 CAMTA1 23261 3
204984_at glypican 4 GPC4 2239 3
213467_at Rho family GTPase 2 RND2 8153 3
224710_at RAB34, member RAS oncogene family RAB34 83871 3
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212895_s_at active BCR-related gene ABR 29 3
224720_at mindbomb homolog 1 (Drosophila) MIB1 57534 3
213578_at bone morphogenetic protein receptor, type IA BMPR1A 657 3
208848_at alcohol dehydrogenase 5 (class III), chi polypeptide ADH5 128 3
207747_s_at docking protein 4 DOK4 55715 3
212673_at methionyl aminopeptidase 1 METAP1 23173 3
220935_s_at CDK5 regulatory subunit associated protein 2 CDK5RAP2 55755 3
228292_at Glucosidase, beta (bile acid) 2 GBA2 57704 3
1564002_a_at chromosome 6 open reading frame 199 C6orf199 221264 3
204686_at insulin receptor substrate 1 IRS1 3667 3
218180_s_at EPS8-like 2 EPS8L2 64787 3
221207_s_at neurobeachin NBEA 26960 3
202089_s_at solute carrier family 39 (zinc transporter), member 6 SLC39A6 25800 3
205543_at heat shock 70kDa protein 4-like HSPA4L 22824 3
201267_s_at proteasome (prosome, macropain) 26S subunit, ATPase, 3 PSMC3 5702 3
1556047_s_at melanoma antigen family E, 1 MAGEE1 57692 3
204281_at TEA domain family member 4 TEAD4 7004 3
213400_s_at transducin (beta)-like 1X-linked TBL1X 6907 3
201161_s_at cold shock domain protein A CSDA 8531 3
201042_at transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase)
TGM2 7052 3
212983_at v-Ha-ras Harvey rat sarcoma viral oncogene homolog HRAS 3265 3
219610_at Rho-guanine nucleotide exchange factor RGNEF 64283 3
203264_s_at Cdc42 guanine nucleotide exchange factor (GEF) 9 ARHGEF9 23229 3
225104_at zinc finger protein 598 ZNF598 90850 3
40562_at guanine nucleotide binding protein (G protein), alpha 11 (Gq
class)
GNA11 2767 3
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209210_s_at pleckstrin homology domain containing, family C (with FERM
domain) member 1
PLEKHC1 10979 3
213476_x_at tubulin, beta 3 TUBB3 10381 3
225677_at B-cell receptor-associated protein 29 BCAP29 55973 3
1559388_a_at Ly6/neurotoxin 1 LYNX1 66004 3
212439_at inositol hexaphosphate kinase 1 IHPK1 9807 3
210870_s_at epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) EPM2A 7957 3
228233_at FRAS1 related extracellular matrix 1 FREM1 158326 3
202218_s_at fatty acid desaturase 2 FADS2 9415 3
226869_at EGF-like-domain, multiple 3 EGFL3 1953 3
224445_s_at zinc finger, FYVE domain containing 21 ; zinc finger, FYVE domain
containing 21
ZFYVE21 79038 3
1569796_s_at attractin-like 1 ATRNL1 26033 3
225915_at calcium binding protein 39-like CAB39L 81617 3
223019_at chromosome 9 open reading frame 88 C9orf88 64855 3
202694_at serine/threonine kinase 17a (apoptosis-inducing) STK17A 9263 3
225665_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 3
225105_at hypothetical protein LOC387882 387882 3
239342_at diacylglycerol kinase, zeta 104kDa DGKZ 8525 3
223316_at coiled-coil domain containing 3 CCDC3 83643 3
215537_x_at dimethylarginine dimethylaminohydrolase 2 DDAH2 23564 3
1569208_a_at KIAA1102 protein KIAA1102 22998 3
236634_at chromosome 8 open reading frame 48 C8orf48 157773 3
217657_at B-cell receptor-associated protein 29 BCAP29 55973 3
223593_at aminoadipate aminotransferase AADAT 51166 3
212828_at synaptojanin 2 SYNJ2 8871 3
225662_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 3
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227862_at hypothetical LOC388610 LOC388610 388610 3
208677_s_at basigin (OK blood group) BSG 682 3
218612_s_at tumor suppressing subtransferable candidate 4 TSSC4 10078 3
201714_at tubulin, gamma 1 TUBG1 7283 3
203627_at Insulin-like growth factor 1 receptor IGF1R 3480 3
227846_at putative G protein coupled receptor GPR 11245 3
201802_at solute carrier family 29 (nucleoside transporters), member 1 SLC29A1 2030 3
222559_s_at hypothetical protein FLJ10656 P15RS 55197 3
1555630_a_at RAB34, member RAS oncogene family RAB34 83871 3
202111_at solute carrier family 4, anion exchanger, member 2 (erythrocyte
membrane protein band 3-like 1)
SLC4A2 6522 3
204347_at adenylate kinase 3-like 1 ; adenylate kinase 3-like 2 AK3L1 205 ; 387851 3
228355_s_at Myc-induced mitochondria protein mimitin 91942 3
226933_s_at Inhibitor of DNA binding 4, dominant negative helix-loop-helix
protein
ID4 3400 3
227944_at protein tyrosine phosphatase, non-receptor type 3 PTPN3 5774 3
213079_at hypothetical protein DT1P1A10 RP1-
112K5.2
90121 3
224984_at nuclear factor of activated T-cells 5, tonicity-responsive NFAT5 10725 3
222998_at MAF1 homolog (S. cerevisiae) MAF1 84232 3
225288_at Collagen, type XXVII, alpha 1 COL27A1 85301 3
219304_s_at platelet derived growth factor D PDGFD 80310 3
200840_at lysyl-tRNA synthetase KARS 3735 3
212703_at talin 2 TLN2 83660 3
202344_at heat shock transcription factor 1 HSF1 3297 3
214823_at zinc finger protein 204 ZNF204 7754 3
209311_at BCL2-like 2 BCL2L2 599 3
214073_at cortactin CTTN 2017 3
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212736_at chromosome 16 open reading frame 45 C16orf45 89927 3
204688_at sarcoglycan, epsilon SGCE 8910 3
218651_s_at La ribonucleoprotein domain family, member 6 LARP6 55323 3
228548_at RAP1A, member of RAS oncogene family RAP1A 5906 3
230309_at Betaine-homocysteine methyltransferase 2 BHMT2 23743 3
205740_s_at hypothetical protein MGC10433 MGC10433 79171 3
1554004_a_at Rho-guanine nucleotide exchange factor RGNEF 64283 3
212525_s_at H2A histone family, member X H2AFX 3014 3
218634_at pleckstrin homology-like domain, family A, member 3 PHLDA3 23612 3
226705_at Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2,
Pfeiffer syndrome)
FGFR1 2260 3
227543_at HIV-1 Tat interacting protein, 60kDa HTATIP 10524 3
218823_s_at potassium channel tetramerisation domain containing 9 KCTD9 54793 3
225806_at jub, ajuba homolog (Xenopus laevis) JUB 84962 3
229286_at melanoma antigen family E, 1 MAGEE1 57692 3
211043_s_at clathrin, light polypeptide (Lcb) ; clathrin, light polypeptide (Lcb) CLTB 1212 3
244246_at mirror-image polydactyly 1 MIPOL1 145282 3
224397_s_at ARG99 protein ; ARG99 protein ARG99 83857 3
206037_at cysteine conjugate-beta lyase; cytoplasmic (glutamine
transaminase K, kyneurenine aminotransferase)
CCBL1 883 3
212914_at chromobox homolog 7 CBX7 23492 3
213726_x_at tubulin, beta, 2 TUBB2 10383 3
212510_at glycerol-3-phosphate dehydrogenase 1-like GPD1L 23171 3
222582_at protein kinase, AMP-activated, gamma 2 non-catalytic subunit PRKAG2 51422 3
203835_at leucine rich repeat containing 32 LRRC32 2615 3
213977_s_at CDKN1A interacting zinc finger protein 1 CIZ1 25792 3
217359_s_at neural cell adhesion molecule 1 NCAM1 4684 3
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226710_at similar to RIKEN cDNA C030006K11 gene MGC70857 414919 3
225308_s_at TPR domain, ankyrin-repeat and coiled-coil-containing TANC 85461 3
201231_s_at enolase 1, (alpha) ENO1 2023 3
1554008_at oncostatin M receptor OSMR 9180 3
224365_s_at tigger transposable element derived 7 ; tigger transposable
element derived 7
TIGD7 91151 3
202755_s_at glypican 1 GPC1 2817 3
203450_at PKD2 interactor, golgi and endoplasmic reticulum associated 1 PGEA1 25776 3
221016_s_at transcription factor 7-like 1 (T-cell specific, HMG-box) TCF7L1 83439 3
215735_s_at tuberous sclerosis 2 TSC2 7249 3
243502_at Gap junction protein, alpha 7, 45kDa (connexin 45) GJA7 10052 3
221216_s_at sex comb on midleg homolog 1 (Drosophila) SCMH1 22955 3
209156_s_at collagen, type VI, alpha 2 COL6A2 1292 3
222778_s_at Wolf-Hirschhorn syndrome candidate 1 WHSC1 7468 3
227572_at Ubiquitin specific peptidase 30 USP30 84749 3
216836_s_at v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 ERBB2 2064 3
223576_at chromosome 6 open reading frame 203 C6orf203 51250 3
213424_at KIAA0895 protein KIAA0895 23366 3
241963_at zinc finger protein 704 ZNF704 619279 3
201027_s_at eukaryotic translation initiation factor 5B EIF5B 9669 3
228104_at plexin A4, A PLXNA4A 57671 3
212135_s_at ATPase, Ca++ transporting, plasma membrane 4 ATP2B4 493 3
1553764_a_at jub, ajuba homolog (Xenopus laevis) JUB 84962 3
220032_at hypothetical protein FLJ21986 FLJ21986 79974 3
200659_s_at prohibitin PHB 5245 3
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202616_s_at methyl CpG binding protein 2 (Rett syndrome) MECP2 4204 3
218373_at fused toes homolog (mouse) FTS 64400 3
201373_at plectin 1, intermediate filament binding protein 500kDa PLEC1 5339 3
218762_at zinc finger protein 574 ZNF574 64763 3
223805_at oxysterol binding protein-like 6 OSBPL6 114880 3
232051_at hypothetical protein LOC92922 MGC10992 92922 3
234734_s_at trinucleotide repeat containing 6A TNRC6A 27327 3
242590_at RNA (guanine-9-) methyltransferase domain containing 3 RG9MTD3 158234 3
204904_at gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2701 3
225450_at angiomotin like 1 AMOTL1 154810 3
205824_at heat shock 27kDa protein 2 HSPB2 3316 3
44702_at synapse defective 1, Rho GTPase, homolog 1 (C. elegans) SYDE1 85360 3
224999_at Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b)
oncogene homolog, avian)
EGFR 1956 3
229507_at similar to RIKEN cDNA 6530418L21 LOC389119 389119 3
222668_at potassium channel tetramerisation domain containing 15 KCTD15 79047 3
201430_s_at dihydropyrimidinase-like 3 DPYSL3 1809 3
222760_at zinc finger protein 703 ZNF703 80139 3
201035_s_at L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain HADHSC 3033 3
232983_s_at deafness locus associated putative guanine nucleotide exchange factor DELGEF 26297 3
205712_at protein tyrosine phosphatase, receptor type, D PTPRD 5789 3
227219_x_at microtubule-associated protein 1 light chain 3 alpha MAP1LC3A 84557 3
244057_s_at chromosome 10 open reading frame 72 C10orf72 196740 3
232282_at WNK lysine deficient protein kinase 3 WNK3 65267 3
213066_at RUN and SH3 domain containing 2 RUSC2 9853 3
206698_at Kell blood group precursor (McLeod phenotype) XK 7504 3
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210751_s_at regucalcin (senescence marker protein-30) RGN 9104 3
229257_at KIAA1856 protein KIAA1856 84629 3
222489_s_at Werner helicase interacting protein 1 WRNIP1 56897 3
209432_s_at cAMP responsive element binding protein 3 CREB3 10488 3
212081_x_at HLA-B associated transcript 2 BAT2 7916 3
228370_at Small nuclear ribonucleoprotein polypeptide N SNRPN 6638 3
235109_at Zinc finger, BED-type containing 3 ZBED3 84327 3
202468_s_at catenin (cadherin-associated protein), alpha-like 1 CTNNAL1 8727 3
202316_x_at ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 10277 3
213887_s_at polymerase (RNA) II (DNA directed) polypeptide E, 25kDa POLR2E 5434 3
212045_at golgi apparatus protein 1 GLG1 2734 3
212776_s_at obscurin-like 1 OBSL1 23363 3
225923_at VAMP (vesicle-associated membrane protein)-associated protein B
and C
VAPB 9217 3
207842_s_at cancer susceptibility candidate 3 CASC3 22794 3
242828_at Fidgetin FIGN 55137 3
200764_s_at catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 1495 3
205726_at diaphanous homolog 2 (Drosophila) DIAPH2 1730 3
205158_at ribonuclease, RNase A family, 4 RNASE4 6038 3







233825_s_at CD99 antigen-like 2 CD99L2 83692 3
41037_at TEA domain family member 4 TEAD4 7004 3
240063_at hypothetical LOC 441046 LOC441046 441046 3
217607_x_at eukaryotic translation initiation factor 4 gamma, 2 EIF4G2 1982 3
202801_at protein kinase, cAMP-dependent, catalytic, alpha PRKACA 5566 3
212343_at Yip1 domain family, member 6 YIPF6 286451 3
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201039_s_at RAD23 homolog A (S. cerevisiae) RAD23A 5886 3
225018_at spire homolog 1 (Drosophila) SPIRE1 56907 3
218686_s_at rhomboid family 1 (Drosophila) RHBDF1 64285 3
213905_x_at biglycan ; serologically defined colon cancer antigen 33 BGN 10194 ;
633
3
203896_s_at phospholipase C, beta 4 PLCB4 5332 3
207808_s_at protein S (alpha) PROS1 5627 3
219104_at ring finger protein 141 RNF141 50862 3
225871_at six transmembrane epithelial antigen of the prostate 2 STEAP2 261729 3
211737_x_at pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1)
PTN 5764 3
220200_s_at PR/SET domain containing protein 8 SET8 387893 3
241897_at RNA binding protein with multiple splicing RBPMS 11030 3
219298_at enoyl Coenzyme A hydratase domain containing 3 ECHDC3 79746 3
226581_at zinc finger, FYVE domain containing 20 ZFYVE20 64145 3
236657_at Full length insert cDNA YI37C01 3
203895_at phospholipase C, beta 4 PLCB4 5332 3
222240_s_at myo-inositol 1-phosphate synthase A1 ISYNA1 51477 3
209099_x_at jagged 1 (Alagille syndrome) JAG1 182 3
235467_s_at potassium voltage-gated channel, Shaw-related subfamily, member 4 KCNC4 3749 3
228224_at proline/arginine-rich end leucine-rich repeat protein PRELP 5549 3
208831_x_at suppressor of Ty 6 homolog (S. cerevisiae) SUPT6H 6830 3
217918_at dynein, cytoplasmic, light polypeptide 2A DNCL2A 83658 3
215407_s_at astrotactin 2 ASTN2 23245 3
225745_at low density lipoprotein receptor-related protein 6 LRP6 4040 3
212484_at family with sequence similarity 89, member B FAM89B 23625 3
212350_at TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 TBC1D1 23216 3
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209291_at inhibitor of DNA binding 4, dominant negative helix-loop-helix
protein
ID4 3400 3
205932_s_at msh homeo box homolog 1 (Drosophila) MSX1 4487 3
223353_at HCCA2 protein HCCA2 81532 3
213343_s_at glycerophosphodiester phosphodiesterase domain containing 5 GDPD5 81544 3
212958_x_at peptidylglycine alpha-amidating monooxygenase PAM 5066 3
226638_at Rho GTPase activating protein 23 ARHGAP23 57636 3
236565_s_at La ribonucleoprotein domain family, member 6 LARP6 55323 3
221567_at nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3 8996 3
228930_at Hypothetical protein LOC123722 LOC123722 123722 3
235977_at MRNA; cDNA DKFZp686N1345 (from clone DKFZp686N1345) 3
236656_s_at Full length insert cDNA YI37C01 3
201194_at selenoprotein W, 1 SEPW1 6415 3
238322_s_at TEA domain family member 2 TEAD2 8463 3
204447_at ProSAPiP1 protein ProSAPiP1 9762 3
218425_at TRIAD3 protein TRIAD3 54476 3
209197_at synaptotagmin XI SYT11 23208 3
218110_at XPA binding protein 2 XAB2 56949 3
1569512_at Supervillin SVIL 6840 3
200697_at hexokinase 1 HK1 3098 3
202154_x_at tubulin, beta 3 TUBB3 10381 3
238426_at hypothetical protein DKFZp761L1417 DKFZp761L1417 222865 3
205280_at glycine receptor, beta GLRB 2743 3
1555724_s_at transgelin TAGLN 6876 3
232224_at mannan-binding lectin serine peptidase 1 (C4/C2 activating
component of Ra-reactive factor)
MASP1 5648 3
200765_x_at catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 1495 3
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214771_x_at myosin phosphatase-Rho interacting protein M-RIP 23164 3
212243_at glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A ;
GRINL1A combined protein
GRINL1A 145781 3
215230_x_at eukaryotic translation initiation factor 3, subunit 8, 110kDa EIF3S8 8663 3
214656_x_at myosin IC MYO1C 4641 3
212503_s_at KIAA0934 KIAA0934 22982 3
216215_s_at RNA binding motif protein 9 RBM9 23543 3
226683_at Sorting nexin associated golgi protein 1 SNAG1 112574 3
232322_x_at START domain containing 10 STARD10 10809 3
212727_at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3 1741 3
228563_at gap junction protein, alpha 7, 45kDa (connexin 45) GJA7 10052 3
220748_s_at zinc finger protein 580 ZNF580 51157 3
202245_at lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) LSS 4047 3
213942_at EGF-like-domain, multiple 3 EGFL3 1953 3
205121_at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB 6443 3
1554597_at hypothetical gene supported by AK092922; AL831912 LOC440426 440426 3
219251_s_at WD repeat domain 60 WDR60 55112 3
222217_s_at solute carrier family 27 (fatty acid transporter), member 3 SLC27A3 11000 3
201328_at v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 2114 3
203068_at kelch-like 21 (Drosophila) KLHL21 9903 3
211275_s_at glycogenin GYG 2992 3
228639_at FYVE, RhoGEF and PH domain containing 1 (faciogenital
dysplasia)
FGD1 2245 3
1552670_a_at hypothetical protein LOC286044 LOC286044 286044 3
201115_at polymerase (DNA directed), delta 2, regulatory subunit 50kDa POLD2 5425 3
219431_at Rho GTPase activating protein 10 ARHGAP10 79658 3
214724_at DIX domain containing 1 DIXDC1 85458 3
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209394_at acetylserotonin O-methyltransferase-like ASMTL 8623 3
228027_at G protein-coupled receptor associated sorting
protein 2
GPRASP2 114928 3
215329_s_at cell division cycle 2-like 1 (PITSLRE proteins) CDC2L1 984 3
201313_at enolase 2 (gamma, neuronal) ENO2 2026 3
226647_at transmembrane protein 25 TMEM25 84866 3
231430_at hypothetical protein MGC33846 MGC33846 220382 3
225080_at Myosin IC MYO1C 4641 3
225704_at KIAA1545 protein KIAA1545 57666 3
218695_at exosome component 4 EXOSC4 54512 3
242731_x_at Transcribed locus 3
200619_at splicing factor 3b, subunit 2, 145kDa SF3B2 10992 3
225674_at B-cell receptor-associated protein 29 BCAP29 55973 3
223005_s_at chromosome 9 open reading frame 5 C9orf5 23731 3
216028_at DKFZP564C152 protein DKFZP564C152 26120 3
217561_at calcitonin/calcitonin-related polypeptide, alpha CALCA 796 3
235541_at LAS1-like (S. cerevisiae) LAS1L 81887 3
210987_x_at tropomyosin 1 (alpha) TPM1 7168 3
228456_s_at hypothetical protein LOC149832 LOC149832 149832 3
219039_at block of proliferation 1 BOP1 23246 3
228461_at SH3 multiple domains 4 SH3MD4 344558 3
243111_at Weakly similar to zinc finger protein 195 FLJ34077 404033 3
219379_x_at zinc finger protein 358 ZNF358 140467 3
212807_s_at sortilin 1 SORT1 6272 3
230750_at RAB23, member RAS oncogene family RAB23 51715 3
217943_s_at arginine/proline rich coiled-coil 1 RPRC1 55700 3
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219863_at hect domain and RLD 5 HERC5 51191 3
233919_s_at hyaluronan binding protein 4 HABP4 22927 3
207163_s_at v-akt murine thymoma viral oncogene homolog 1 AKT1 207 3
214078_at P21 (CDKN1A)-activated kinase 3 PAK3 5063 3
227882_at fukutin related protein FKRP 79147 3
219087_at asporin (LRR class 1) ASPN 54829 3
225016_at adenomatosis polyposis coli down-regulated 1 APCDD1 147495 3
207169_x_at discoidin domain receptor family, member 1 DDR1 780 3
1552735_at protocadherin gamma subfamily A, 4 PCDHGA4 56111 3
209213_at carbonyl reductase 1 CBR1 873 3
202455_at histone deacetylase 5 HDAC5 10014 3
218175_at limkain beta 2 FLJ22471 80212 3
225303_at kin of IRRE like (Drosophila) KIRREL 55243 3
201036_s_at L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain HADHSC 3033 3
204223_at proline/arginine-rich end leucine-rich repeat protein PRELP 5549 3
217196_s_at calmodulin regulated spectrin-associated protein 1-like 1 CAMSAP1L1 23271 3
223007_s_at chromosome 9 open reading frame 5 C9orf5 23731 3
238636_at hypothetical protein LOC283439 LOC283439 283439 3
226895_at Nuclear factor I/C (CCAAT-binding transcription factor) NFIC 4782 3
217911_s_at BCL2-associated athanogene 3 BAG3 9531 3
1560359_at Pelota homolog (Drosophila) PELO 53918 3
222221_x_at EH-domain containing 1 EHD1 10938 3
212747_at ankyrin repeat and sterile alpha motif domain containing 1 ANKS1 23294 3
204001_at small nuclear RNA activating complex, polypeptide 3,
50kDa
SNAPC3 6619 3
217427_s_at HIR histone cell cycle regulation defective homolog A (S.
cerevisiae)
HIRA 7290 3
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201830_s_at neuroepithelial cell transforming gene 1 NET1 10276 3
225963_at kelch domain containing 5 KLHDC5 57542 3
201537_s_at dual specificity phosphatase 3 (vaccinia virus phosphatase
VH1-related)
DUSP3 1845 3
226655_at Syntaxin 17 STX17 55014 3
233563_s_at cleavage and polyadenylation specific factor 3-like CPSF3L 54973 3
227029_at chromosome 14 open reading frame 24 C14orf24 283635 3
1553646_at chromosome X open reading frame 43 CXorf43 139324 3
209693_at astrotactin 2 ASTN2 23245 3
212741_at monoamine oxidase A MAOA 4128 3
211714_x_at tubulin, beta polypeptide ; tubulin, beta polypeptide TUBB 203068 3
216271_x_at synapse defective 1, Rho GTPase, homolog 1 (C. elegans) SYDE1 85360 3
204716_at coiled-coil domain containing 6 CCDC6 8030 3
204993_at guanine nucleotide binding protein (G protein), alpha z
polypeptide
GNAZ 2781 3
203894_at tubulin, gamma 2 TUBG2 27175 3
1560648_s_at TSPY-like 1 TSPYL1 7259 3
219440_at retinoic acid induced 2 RAI2 10742 3
226846_at phytanoyl-CoA dioxygenase domain containing 1 PHYHD1 254295 3
226938_at WD repeat domain 21A WDR21A 26094 3
214671_s_at active BCR-related gene ABR 29 3
226231_at PRKC, apoptosis, WT1, regulator PAWR 5074 3
226718_at adhesion molecule with Ig-like domain 1 AMIGO1 57463 3
210882_s_at trophinin TRO 7216 3
214743_at cut-like 1, CCAAT displacement protein (Drosophila) CUTL1 1523 3
208703_s_at amyloid beta (A4) precursor-like protein 2 APLP2 334 3
225315_at mitochondrial ribosomal protein L21 MRPL21 219927 3
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212813_at junctional adhesion molecule 3 JAM3 83700 3
201829_at neuroepithelial cell transforming gene 1 NET1 10276 3
238613_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 3
208636_at Actinin, alpha 1 ACTN1 87 3
224281_s_at neugrin, neurite outgrowth associated NGRN 51335 3
222558_at hypothetical protein FLJ10656 P15RS 55197 3
208723_at ubiquitin specific peptidase 11 USP11 8237 3
209361_s_at poly(rC) binding protein 4 PCBP4 57060 3
204834_at fibrinogen-like 2 FGL2 10875 3
204005_s_at PRKC, apoptosis, WT1, regulator PAWR 5074 3
227688_at leucine-rich repeats and calponin homology (CH) domain containing 2 LRCH2 57631 3
225650_at sterile alpha motif domain containing 1 SAMD1 90378 3
214909_s_at dimethylarginine dimethylaminohydrolase 2 DDAH2 23564 3
204682_at latent transforming growth factor beta binding protein 2 LTBP2 4053 3
229884_s_at mitochondrial ribosomal protein L2 MRPL2 51069 3
218813_s_at SH3-domain GRB2-like endophilin B2 SH3GLB2 56904 3
235295_at Pannexin 1 PANX1 24145 3
208789_at polymerase I and transcript release factor PTRF 284119 3
241442_at Dishevelled associated activator of morphogenesis 2 DAAM2 23500 3
210871_x_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 117178 3
228255_at amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 ALS2CR4 65062 3
226451_at similar to RIKEN cDNA B230118G17 gene MGC19604 112812 3
204344_s_at Sec23 homolog A (S. cerevisiae) SEC23A 10484 3
228520_s_at Amyloid beta (A4) precursor-like protein 2 APLP2 334 3
213298_at nuclear factor I/C (CCAAT-binding transcription factor) NFIC 4782 3
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218029_at family with sequence similarity 65, member A FAM65A 79567 3
231137_at Acyl-CoA synthetase bubblegum family member 1 BG1 23205 3
1553204_at hypothetical protein FLJ30313 FLJ30313 253868 3
202196_s_at dickkopf homolog 3 (Xenopus laevis) DKK3 27122 3
213336_at Bromodomain adjacent to zinc finger domain, 1B BAZ1B 9031 3
212294_at guanine nucleotide binding protein (G protein), gamma 12 GNG12 55970 3
223116_at breast cancer anti-estrogen resistance 1 BCAR1 9564 3
205657_at 3-hydroxyanthranilate 3,4-dioxygenase HAAO 23498 3
203686_at N-methylpurine-DNA glycosylase MPG 4350 3
1552708_a_at dual specificity phosphatase 19 DUSP19 142679 3
222469_s_at toll interacting protein TOLLIP 54472 3
242137_at RNA binding motif, single stranded interacting protein RBMS3 27303 3
222463_s_at beta-site APP-cleaving enzyme 1 BACE1 23621 3
209242_at paternally expressed 3 PEG3 5178 3
37462_i_at splicing factor 3a, subunit 2, 66kDa SF3A2 8175 3
209614_at alcohol dehydrogenase 1A (class I), alpha polypeptide ADH1A 124 3
202249_s_at WD repeat domain 42A WDR42A 50717 3
229991_s_at Synaptotagmin-like 4 (granuphilin-a) SYTL4 94121 3
205273_s_at pitrilysin metallopeptidase 1 PITRM1 10531 3
204106_at testis-specific kinase 1 TESK1 7016 3
217286_s_at NDRG family member 3 NDRG3 57446 3
226587_at Small nuclear ribonucleoprotein polypeptide N SNRPN 6638 3
209198_s_at synaptotagmin XI SYT11 23208 3
218590_at progressive external ophthalmoplegia 1 PEO1 56652 3
202440_s_at suppression of tumorigenicity 5 ST5 6764 3
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230369_at G protein-coupled receptor 161 GPR161 23432 3
212851_at DCN1, defective in cullin neddylation 1, domain containing 4 (S.
cerevisiae)
DCUN1D4 23142 3
205354_at guanidinoacetate N-methyltransferase GAMT 2593 3
1560296_at Dystonin DST 667 3
202762_at Rho-associated, coiled-coil containing protein kinase 2 ROCK2 9475 3
223152_at protein phosphatase 1, regulatory (inhibitor) subunit 12C PPP1R12C 54776 3
219180_s_at peroxisome biogenesis factor 26 PEX26 55670 3
212674_s_at DEAH (Asp-Glu-Ala-His) box polypeptide 30 DHX30 22907 3
222887_s_at hypothetical protein FLJ20507 FLJ20507 55654 3
242738_s_at AT-binding transcription factor 1 ATBF1 463 3
231157_at tubulin tyrosine ligase-like family, member 11 TTLL11 158135 3
208740_at sin3-associated polypeptide, 18kDa SAP18 10284 3
202275_at glucose-6-phosphate dehydrogenase G6PD 2539 3
41657_at serine/threonine kinase 11 (Peutz-Jeghers syndrome) STK11 6794 3
217773_s_at NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa NDUFA4 4697 3
201961_s_at ring finger protein 41 RNF41 10193 3
219027_s_at myosin IXA MYO9A 4649 3
223764_x_at nipsnap homolog 3B (C. elegans) NIPSNAP3B 55335 3
201082_s_at dynactin 1 (p150, glued homolog, Drosophila) DCTN1 1639 3
229106_at dynein light chain 2 Dlc2 140735 3
235570_at RNA binding motif, single stranded interacting protein RBMS3 27303 3
223672_at SH3-domain GRB2-like (endophilin) interacting protein 1 SGIP1 84251 3
217925_s_at chromosome 6 open reading frame 106 C6orf106 64771 3
227325_at hypothetical protein LOC255783 LOC255783 255783 3
212259_s_at pre-B-cell leukemia transcription factor interacting protein 1 PBXIP1 57326 3
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201655_s_at heparan sulfate proteoglycan 2 (perlecan) HSPG2 3339 3
203906_at IQ motif and Sec7 domain 1 IQSEC1 9922 3
214890_s_at DKFZP564J102 protein DKFZP564J102 25854 3
231001_at similar to RIKEN cDNA 1110018M03 LOC387758 387758 3
224975_at nuclear factor I/A NFIA 4774 3
204983_s_at glypican 4 GPC4 2239 3
1555140_a_at BCL2-like 2 BCL2L2 599 3
217730_at transmembrane BAX inhibitor motif containing 1 TMBIM1 64114 3
204656_at Src homology 2 domain containing adaptor protein B SHB 6461 3
212115_at chromosome 16 open reading frame 34 C16orf34 90861 3
209691_s_at docking protein 4 DOK4 55715 3
227138_at cartilage associated protein CRTAP 10491 3
235471_at Chromosome 10 open reading frame 72 C10orf72 196740 3
205426_s_at huntingtin interacting protein 1 HIP1 3092 3
223468_s_at RGM domain family, member A RGMA 56963 3
233720_at Sorbin and SH3 domain containing 2 ARGBP2 8470 3
203212_s_at myotubularin related protein 2 MTMR2 8898 3
232506_s_at hypothetical protein HH114 HH114 84529 3
224280_s_at family with sequence similarity 54, member B FAM54B 56181 3
202652_at amyloid beta (A4) precursor protein-binding, family B, member
1 (Fe65)
APBB1 322 3
63305_at PBX/knotted 1 homeobox 2 PKNOX2 63876 3
222494_at checkpoint suppressor 1 CHES1 1112 3
209026_x_at tubulin, beta polypeptide TUBB 203068 3
214940_s_at chromosome 17 open reading frame 31 C17orf31 23293 3
226260_x_at zinc finger protein 358 ZNF358 140467 3
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227896_at BRCA2 and CDKN1A interacting protein BCCIP 56647 3
1553530_a_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)
ITGB1 3688 3
206042_x_at small nuclear ribonucleoprotein polypeptide N ; SNRPN upstream
reading frame
SNRPN 6638 3
210125_s_at barrier to autointegration factor 1 BANF1 8815 3
213290_at collagen, type VI, alpha 2 COL6A2 1292 3
219278_at mitogen-activated protein kinase kinase kinase 6 MAP3K6 9064 3
224962_at hypothetical gene supported by AK023162 LOC90120 90120 3
222016_s_at zinc finger protein 323 ZNF323 64288 3
210958_s_at microtubule associated serine/threonine kinase family member 4 MAST4 23227 3
212254_s_at dystonin DST 667 3
213488_at sushi, nidogen and EGF-like domains 1 SNED1 25992 3
235746_s_at phospholipase A2 receptor 1, 180kDa PLA2R1 22925 3
204854_at leprecan-like 2 LEPREL2 10536 3
221643_s_at arginine-glutamic acid dipeptide (RE) repeats RERE 473 3
211658_at peroxiredoxin 2 ; peroxiredoxin 2 PRDX2 7001 3
217796_s_at nuclear protein localization 4 NPL4 55666 3
209653_at karyopherin alpha 4 (importin alpha 3) KPNA4 3840 3
214915_at FLJ25476 protein FLJ25476 149076 3
229198_at ubiquitin specific peptidase 35 USP35 57558 3
218818_at four and a half LIM domains 3 FHL3 2275 3
221873_at zinc finger protein 143 (clone pHZ-1) ZNF143 7702 3
201799_s_at oxysterol binding protein OSBP 5007 3
234563_at Phosphodiesterase 3A, cGMP-inhibited PDE3A 5139 3
208776_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 PSMD11 5717 3
33736_at stomatin (EPB72)-like 1 STOML1 9399 3
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212948_at calmodulin binding transcription activator 2 CAMTA2 23125 3
221783_at widely-interspaced zinc finger motifs WIZ 58525 3
201136_at proteolipid protein 2 (colonic epithelium-enriched) PLP2 5355 3
218529_at CD320 antigen CD320 51293 3
205116_at laminin, alpha 2 (merosin, congenital muscular dystrophy) LAMA2 3908 3
205112_at Phospholipase C, epsilon 1 PLCE1 51196 3
204384_at golgi autoantigen, golgin subfamily a, 2 GOLGA2 2801 3
214649_s_at myotubularin related protein 2 MTMR2 8898 3
209139_s_at protein kinase, interferon-inducible double stranded RNA dependent
activator
PRKRA 8575 3
223142_s_at uridine-cytidine kinase 1 UCK1 83549 3
213758_at cytochrome c oxidase subunit IV isoform 1 COX4I1 1327 3
235004_at RNA binding motif protein 24 RBM24 221662 3
209781_s_at KH domain containing, RNA binding, signal transduction associated
3
KHDRBS3 10656 3
225998_at GRB2-associated binding protein 1 GAB1 2549 3
204241_at acyl-Coenzyme A oxidase 3, pristanoyl ACOX3 8310 3
226052_at Bromodomain containing 4 BRD4 23476 3
215030_at G-rich RNA sequence binding factor 1 GRSF1 2926 3
200895_s_at FK506 binding protein 4, 59kDa FKBP4 2288 3
203557_s_at 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of
hepatocyte nuclear factor 1 alpha (TCF1)
PCBD1 5092 3
226196_s_at MGC16028 similar to RIKEN cDNA 1700019E19 gene MGC16028 112752 3
214097_at ribosomal protein S21 RPS21 6227 3
224689_at mannosidase, beta A, lysosomal-like MANBAL 63905 3
203456_at PRA1 domain family, member 2 PRAF2 11230 3
1557553_at Protein phosphatase 1, regulatory (inhibitor) subunit 12B PPP1R12B 4660 3
211450_s_at mutS homolog 6 (E. coli) MSH6 2956 3
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201459_at RuvB-like 2 (E. coli) RUVBL2 10856 3
224078_at hippocampus abundant gene transcript-like 2 HIATL2 84278 3
1565717_s_at fusion (involved in t(12;16) in malignant liposarcoma) FUS 2521 3
229377_at Growth hormone regulated TBC protein 1 GRTP1 79774 3
202137_s_at zinc finger, MYND domain containing 11 ZMYND11 10771 3
227388_at tumor suppressor candidate 1 TUSC1 286319 3
213587_s_at ATPase, H+ transporting V0 subunit E isoform 2-like (rat) ATP6V0E2L 155066 3
215016_x_at dystonin DST 667 3
224671_at mitochondrial ribosomal protein L10 MRPL10 124995 3
200820_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 PSMD8 5714 3
209129_at thyroid hormone receptor interactor 6 TRIP6 7205 3
201679_at arsenate resistance protein ARS2 ARS2 51593 3
205775_at family with sequence similarity 50, member B FAM50B 26240 3
217753_s_at ribosomal protein S26 ; 40S ribosomal protein S26-like ; similar to
40S ribosomal protein S26
RPS26 400156 3
225782_at methionine sulfoxide reductase B3 MSRB3 253827 3
223852_s_at serine/threonine kinase 40 STK40 83931 3
200646_s_at nucleobindin 1 NUCB1 4924 3
224719_s_at likely ortholog of mouse gene rich cluster, C10 gene GRCC10 113246 3
235014_at hypothetical protein LOC147727 LOC147727 147727 3
218553_s_at potassium channel tetramerisation domain containing 15 KCTD15 79047 3
206972_s_at G protein-coupled receptor 161 GPR161 23432 3
207415_at phospholipase A2 receptor 1, 180kDa PLA2R1 22925 3
205125_at phospholipase C, delta 1 PLCD1 5333 3
222524_s_at ankyrin repeat and SOCS box-containing 6 ASB6 140459 3
227426_at Son of sevenless homolog 1 (Drosophila) SOS1 6654 3
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210640_s_at G protein-coupled receptor 30 GPR30 2852 3
232780_s_at zinc finger protein 691 ZNF691 51058 3
231183_s_at Jagged 1 (Alagille syndrome) JAG1 182 3
228776_at gap junction protein, alpha 7, 45kDa (connexin 45) GJA7 10052 3
204400_at embryonal Fyn-associated substrate EFS 10278 3
207622_s_at ATP-binding cassette, sub-family F (GCN20), member 2 ABCF2 10061 3
205084_at B-cell receptor-associated protein 29 BCAP29 55973 3
222860_s_at platelet derived growth factor D PDGFD 80310 3
226615_at Xenotropic and polytropic retrovirus receptor XPR1 9213 3
225480_at chromosome 1 open reading frame 122 C1orf122 127687 3
214002_at myosin, light polypeptide 6, alkali, smooth muscle and non-muscle MYL6 4637 3
211954_s_at RAN binding protein 5 RANBP5 3843 3
200611_s_at WD repeat domain 1 WDR1 9948 3
230656_s_at cirrhosis, autosomal recessive 1A (cirhin) CIRH1A 84916 3
211759_x_at cytoskeleton associated protein 1 ; cytoskeleton associated protein 1 CKAP1 1155 3
204905_s_at eukaryotic translation elongation factor 1 epsilon 1 EEF1E1 9521 3
213490_s_at mitogen-activated protein kinase kinase 2 MAP2K2 5605 3
217795_s_at transmembrane protein 43 TMEM43 79188 3
231961_at RNA binding protein with multiple splicing RBPMS 11030 3
202916_s_at family with sequence similarity 20, member B FAM20B 9917 3
217820_s_at enabled homolog (Drosophila) ENAH 55740 3
207749_s_at protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha PPP2R3A 5523 3
206356_s_at guanine nucleotide binding protein (G protein), alpha activating activity
polypeptide, olfactory type
GNAL 2774 3
204042_at WAS protein family, member 3 WASF3 10810 3
209355_s_at phosphatidic acid phosphatase type 2B PPAP2B 8613 3
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200956_s_at structure specific recognition protein 1 SSRP1 6749 3
212891_s_at growth arrest and DNA-damage-inducible, gamma interacting protein 1 GADD45GIP1 90480 3
202550_s_at VAMP (vesicle-associated membrane protein)-associated protein B
and C
VAPB 9217 3
227992_s_at hypothetical protein LOC147650 LOC147650 147650 3
201538_s_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-
related)
DUSP3 1845 3
202571_s_at discs, large (Drosophila) homolog-associated protein 4 DLGAP4 22839 3
220964_s_at RAB1B, member RAS oncogene family ; RAB1B, member RAS
oncogene family
RAB1B 81876 3
217923_at penta-EF-hand domain containing 1 PEF1 553115 3
209522_s_at carnitine acetyltransferase CRAT 1384 3
204790_at SMAD, mothers against DPP homolog 7 (Drosophila) SMAD7 4092 3
211598_x_at vasoactive intestinal peptide receptor 2 ; vasoactive intestinal peptide
receptor 2
VIPR2 7434 3
212729_at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3 1741 3
234192_s_at G kinase anchoring protein 1 GKAP1 80318 3
214177_s_at pre-B-cell leukemia transcription factor interacting protein 1 PBXIP1 57326 3
222318_at FLJ45850 protein FLJ45850 388569 3
212765_at calmodulin regulated spectrin-associated protein 1-like 1 CAMSAP1L1 23271 3
202587_s_at adenylate kinase 1 AK1 203 3
202069_s_at isocitrate dehydrogenase 3 (NAD+) alpha IDH3A 3419 3
209406_at BCL2-associated athanogene 2 BAG2 9532 3
212875_s_at chromosome 21 open reading frame 25 C21orf25 25966 3
212755_at KIAA1040 protein KIAA1040 23041 3
230790_x_at checkpoint suppressor 1 CHES1 1112 3
208456_s_at related RAS viral (r-ras) oncogene homolog 2 RRAS2 22800 3
225533_at PHD finger protein 19 PHF19 26147 3
212739_s_at non-metastatic cells 4, protein expressed in NME4 4833 3
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227064_at ankyrin repeat domain 40 ANKRD40 91369 3
212504_at KIAA0934 KIAA0934 22982 3
222165_x_at chromosome 9 open reading frame 16 C9orf16 79095 3
208702_x_at amyloid beta (A4) precursor-like protein 2 APLP2 334 3
225860_at hypothetical LOC400843 LOC400843 400843 3
233130_at Thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a)
oncogene homolog 2, avian)
THRB 7068 3
204424_s_at LIM domain only 3 (rhombotin-like 2) LMO3 55885 3
224844_at KIAA1458 protein KIAA1458 57606 3
202123_s_at v-abl Abelson murine leukemia viral oncogene homolog 1 ABL1 25 3
1556136_at hypothetical protein LOC340156 LOC340156 340156 3
201667_at gap junction protein, alpha 1, 43kDa (connexin 43) GJA1 2697 3
203404_at armadillo repeat containing, X-linked 2 ARMCX2 9823 3
223894_s_at fused toes homolog (mouse) FTS 64400 3
232950_s_at phosphatidylinositol transfer protein, membrane-associated 2 PITPNM2 57605 3
202570_s_at discs, large (Drosophila) homolog-associated protein 4 DLGAP4 22839 3
218641_at hypothetical protein MGC3032 MGC3032 65998 3
226653_at MAP/microtubule affinity-regulating kinase 1 MARK1 4139 3
219090_at solute carrier family 24 (sodium/potassium/calcium exchanger), member
3
SLC24A3 57419 3
223129_x_at myosin regulatory light chain interacting protein MYLIP 29116 3
208951_at aldehyde dehydrogenase 7 family, member A1 ALDH7A1 501 3
213696_s_at mediator of RNA polymerase II transcription, subunit 8 homolog (yeast) MED8 112950 3
229793_at Apobec-1 complementation factor ACF 29974 3
222482_at single stranded DNA binding protein 3 SSBP3 23648 3
201270_x_at NudC domain containing 3 NUDCD3 23386 3
201903_at ubiquinol-cytochrome c reductase core protein I UQCRC1 7384 3
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218942_at phosphatidylinositol-4-phosphate 5-kinase, type II, gamma PIP5K2C 79837 3
213262_at spastic ataxia of Charlevoix-Saguenay (sacsin) SACS 26278 3
243555_at Endothelin receptor type A EDNRA 1909 3
203711_s_at 3-hydroxyisobutyryl-Coenzyme A hydrolase HIBCH 26275 3
202124_s_at amyotrophic lateral sclerosis 2 (juvenile) chromosome region,
candidate 3
ALS2CR3 66008 3
241926_s_at v-ets erythroblastosis virus E26 oncogene like (avian) ERG 2078 3
201418_s_at SRY (sex determining region Y)-box 4 SOX4 6659 3
220770_s_at transposon-derived Buster3 transposase-like LOC63920 63920 3
211571_s_at chondroitin sulfate proteoglycan 2 (versican) CSPG2 1462 3
212686_at protein phosphatase 1H (PP2C domain containing) PPM1H 57460 3
228948_at EPH receptor A4 EPHA4 2043 3
1569104_a_at Protein tyrosine phosphatase, non-receptor type 23 PTPN23 25930 3
221486_at endosulfine alpha ENSA 2029 3
1566785_x_at Ribosomal protein S7 NSF 4905 3
227386_s_at cDNA DKFZp434C184 gene TTMB 399474 3
202734_at thyroid hormone receptor interactor 10 TRIP10 9322 3
204843_s_at protein kinase, cAMP-dependent, regulatory, type II, alpha PRKAR2A 5576 3
208963_x_at fatty acid desaturase 1 FADS1 3992 3
213325_at poliovirus receptor-related 3 PVRL3 25945 3
202522_at phosphatidylinositol transfer protein, beta PITPNB 23760 3
225094_at PR/SET domain containing protein 8 SET8 387893 3
227107_at Pannexin 1 PANX1 24145 3
202893_at unc-13 homolog B (C. elegans) UNC13B 10497 3
203411_s_at lamin A/C LMNA 4000 3
226484_at zinc finger protein 651 ZNF651 92999 3
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228455_at Solute carrier family 16 (monocarboxylic acid transporters),
member 4
SLC16A4 9122 3
209379_s_at KIAA1128 KIAA1128 54462 3
209482_at processing of precursor 7, ribonuclease P subunit (S. cerevisiae) POP7 10248 3
201431_s_at dihydropyrimidinase-like 3 DPYSL3 1809 3
223008_s_at chromosome 9 open reading frame 5 C9orf5 23731 3
225275_at EGF-like repeats and discoidin I-like domains 3 EDIL3 10085 3
214564_s_at protocadherin gamma subfamily C, 3 PCDHGC3 5098 3
222571_at ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3) ST6GALNAC6 30815 3
236118_at hypothetical LOC201484 LOC201484 201484 3




244680_at glycine receptor, beta GLRB 2743 3
210022_at polycomb group ring finger 1 PCGF1 84759 3
210372_s_at tumor protein D52-like 1 TPD52L1 7164 3
205357_s_at angiotensin II receptor, type 1 AGTR1 185 3
204718_at EPH receptor B6 EPHB6 2051 3
210991_s_at regulating synaptic membrane exocytosis 3 RIMS3 9783 3
1559360_at Nuclear RNA-binding protein, putative EFNA5 1946 3
221762_s_at chromosome 20 open reading frame 67 C20orf67 63935 3
212480_at KIAA0376 protein KIAA0376 23384 3
226033_at ubiquitin specific peptidase 31 USP31 57478 3
216210_x_at TRIO and F-actin binding protein TRIOBP 11078 3
205991_s_at paired related homeobox 1 PRRX1 5396 3
230121_at SERTA domain containing 4 SERTAD4 56256 3
233005_at Chromosome 1 open reading frame 181 FLJ20729 54680 3
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209834_at carbohydrate (chondroitin 6) sulfotransferase 3 CHST3 9469 3
224792_at tankyrase 1 binding protein 1, 182kDa TNKS1BP1 85456 3
206742_at c-fos induced growth factor (vascular endothelial growth factor D) FIGF 2277 3
226722_at family with sequence similarity 20, member C FAM20C 56975 3
1553678_a_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29
includes MDF2, MSK12)
ITGB1 3688 3
1554791_a_at hypothetical protein FLJ23861 FLJ23861 151050 3
225119_at chromatin modifying protein 4B CHMP4B 128866 3
235631_at Discoidin domain receptor family, member 2 DDR2 4921 3
224162_s_at F-box protein 31 FBXO31 79791 3
229590_at Ribosomal protein L13 RPL13 6137 3
212358_at CLIP-170-related protein CLIPR-59 25999 3
213435_at SATB family member 2 SATB2 23314 3
212775_at obscurin-like 1 OBSL1 23363 3
202927_at protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 PIN1 5300 3
1556787_s_at Phosphodiesterase 5A, cGMP-specific PDE5A 8654 3
201828_x_at CAAX box 1 CXX1 8933 3
202135_s_at ARP1 actin-related protein 1 homolog B, centractin beta (yeast) ACTR1B 10120 3
205172_x_at clathrin, light polypeptide (Lcb) CLTB 1212 3
217903_at striatin, calmodulin binding protein 4 STRN4 29888 3
207738_s_at NCK-associated protein 1 NCKAP1 10787 3
206929_s_at nuclear factor I/C (CCAAT-binding transcription factor) NFIC 4782 3
209612_s_at alcohol dehydrogenase IB (class I), beta polypeptide ADH1B 125 3
226656_at cartilage associated protein CRTAP 10491 3
225874_at LOC124402 LOC124402 124402 3
226198_at target of myb1-like 2 (chicken) TOM1L2 146691 3
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222065_s_at flightless I homolog (Drosophila) FLII 2314 3
225025_at immunoglobulin superfamily, member 8 IGSF8 93185 3
218518_at chromosome 5 open reading frame 5 C5orf5 51306 3
203160_s_at ring finger protein 8 RNF8 9025 3
213622_at collagen, type IX, alpha 2 COL9A2 1298 3
228845_at hypothetical protein LOC196463 LOC196463 196463 3
201397_at phosphoglycerate dehydrogenase PHGDH 26227 3
227096_at hypothetical transmembrane protein SBBI54 SBBI54 126119 3
234193_at Hypothetical protein FLJ10770 KIAA1579 55225 3
224804_s_at chromosome 15 open reading frame 17 C15orf17 57184 3
235550_at ASAP FLJ21159 79884 3
212853_at DCN1, defective in cullin neddylation 1, domain containing 4 (S.
cerevisiae)
DCUN1D4 23142 3
208248_x_at amyloid beta (A4) precursor-like protein 2 APLP2 334 3
1558522_at Membrane protein, palmitoylated 6 (MAGUK p55 subfamily
member 6)
MPP6 51678 3
214717_at hypothetical protein DKFZp434H1419 DKFZp434H1419 150967 3
210829_s_at single-stranded DNA binding protein 2 SSBP2 23635 3
1553113_s_at Cyclin-dependent kinase 8 CDK8 1024 3
212548_s_at KIAA0826 KIAA0826 23045 3
211208_s_at calcium/calmodulin-dependent serine protein kinase (MAGUK
family)
CASK 8573 3
223421_at cysteine/histidine-rich 1 CYHR1 50626 3
203823_at regulator of G-protein signalling 3 RGS3 5998 3
1564331_at hypothetical protein LOC162993 LOC162993 162993 2
208699_x_at transketolase (Wernicke-Korsakoff syndrome) TKT 7086 2
227153_at IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae) IMMP2L 83943 2
208016_s_at angiotensin II receptor, type 1 AGTR1 185 2
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211622_s_at ADP-ribosylation factor 3 ; ADP-ribosylation factor 3 ARF3 377 2
206414_s_at development and differentiation enhancing factor 2 DDEF2 8853 2
201764_at hypothetical protein MGC5576 MGC5576 79022 2
243618_s_at Hypothetical protein LOC152485 LOC152485 152485 2
200795_at SPARC-like 1 (mast9, hevin) SPARCL1 8404 2
211602_s_at transient receptor potential cation channel, subfamily C, member
1
TRPC1 7220 2
214011_s_at hypothetical protein HSPC111 HSPC111 51491 2
213901_x_at RNA binding motif protein 9 RBM9 23543 2
202133_at WW domain containing transcription regulator 1 WWTR1 25937 2
202804_at ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 4363 2
226795_at Leucine-rich repeats and calponin homology (CH) domain
containing 1
LRCH1 23143 2
205166_at calpain 5 CAPN5 726 2
202353_s_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 PSMD12 5718 2
1558027_s_at protein kinase, AMP-activated, beta 2 non-catalytic subunit PRKAB2 5565 2
203045_at ninjurin 1 NINJ1 4814 2
204242_s_at acyl-Coenzyme A oxidase 3, pristanoyl ACOX3 8310 2
202309_at methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 MTHFD1 4522 2
1553101_a_at hypothetical protein FLJ20308 FLJ20308 54890 2
211979_at G protein-coupled receptor 107 GPR107 57720 2
200940_s_at arginine-glutamic acid dipeptide (RE) repeats RERE 473 2
219496_at chromosome 2 open reading frame 26 C2orf26 65124 2
218679_s_at vacuolar protein sorting 28 (yeast) VPS28 51160 2
200878_at endothelial PAS domain protein 1 EPAS1 2034 2
202756_s_at glypican 1 GPC1 2817 2
232129_s_at leucine zipper, putative tumor suppressor 2 LZTS2 84445 2
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228046_at Hypothetical protein LOC152485 LOC152485 152485 2
226554_at zinc finger and BTB domain containing 7A ZBTB7A 51341 2
226428_at transportin 2 (importin 3, karyopherin beta 2b) TNPO2 30000 2
208847_s_at alcohol dehydrogenase 5 (class III), chi polypeptide ADH5 128 2
212610_at protein tyrosine phosphatase, non-receptor type 11 (Noonan
syndrome 1)
PTPN11 5781 2
239762_at hypothetical protein LOC286437 LOC286437 286437 2
208132_x_at HLA-B associated transcript 2 BAT2 7916 2
201984_s_at epidermal growth factor receptor (erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian)
EGFR 1956 2
203259_s_at HD domain containing 2 HDDC2 51020 2
232994_s_at Rho-guanine nucleotide exchange factor RGNEF 64283 2
203551_s_at COX11 homolog, cytochrome c oxidase assembly protein (yeast) COX11 1353 2
214894_x_at microtubule-actin crosslinking factor 1 MACF1 23499 2
205417_s_at dystroglycan 1 (dystrophin-associated glycoprotein 1) DAG1 1605 2
223033_s_at SCY1-like 1 (S. cerevisiae) SCYL1 57410 2
238568_s_at Chromosome 18 open reading frame 8 C18orf8 29919 2
210276_s_at TRIO and F-actin binding protein TRIOBP 11078 2
229412_at Taube nuss homolog (mouse) TBN 129685 2
223112_s_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa NDUFB10 4716 2
244753_at Actinin, alpha 4 ACTN4 81 2
203958_s_at zinc finger and BTB domain containing 40 ZBTB40 9923 2
225498_at chromatin modifying protein 4B CHMP4B 128866 2
201908_at dishevelled, dsh homolog 3 (Drosophila) DVL3 1857 2
241809_at chromosome 1 open reading frame 183 C1orf183 55924 2
1552660_a_at hypothetical protein FLJ11193 FLJ11193 55322 2
200812_at chaperonin containing TCP1, subunit 7 (eta) CCT7 10574 2
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200771_at laminin, gamma 1 (formerly LAMB2) LAMC1 3915 2
201804_x_at cytoskeleton associated protein 1 CKAP1 1155 2
230291_s_at Nuclear factor I/B NFIB 4781 2
227197_at Src homology 3 domain-containing guanine nucleotide exchange
factor
SGEF 26084 2
228882_at tubby homolog (mouse) TUB 7275 2
219855_at nudix (nucleoside diphosphate linked moiety X)-type motif 11 NUDT11 55190 2
223141_at uridine-cytidine kinase 1 UCK1 83549 2
227657_at ring finger protein 150 RNF150 57484 2
209044_x_at splicing factor 3b, subunit 4, 49kDa SF3B4 10262 2
231750_at protocadherin beta 4 PCDHB4 56131 2
221047_s_at MAP/microtubule affinity-regulating kinase 1 MARK1 4139 2
217511_at Kazal-type serine peptidase inhibitor domain 1 KAZALD1 81621 2
235857_at potassium channel tetramerisation domain containing 11 KCTD11 147040 2
213701_at hypothetical protein DKFZp434N2030 DKFZp434N2030 91298 2
230364_at choline phosphotransferase 1 CHPT1 56994 2
213242_x_at KIAA0284 KIAA0284 283638 2
212865_s_at collagen, type XIV, alpha 1 (undulin) COL14A1 7373 2
223879_s_at oxidation resistance 1 OXR1 55074 2
202290_at PDGFA associated protein 1 PDAP1 11333 2
223854_at protocadherin beta 10 PCDHB10 56126 2
212032_s_at prostate tumor overexpressed gene 1 PTOV1 53635 2
201770_at small nuclear ribonucleoprotein polypeptide A SNRPA 6626 2
233536_at KIAA1713 KIAA1713 80816 2
1558604_a_at MRNA; clone CD 43T7 2
214201_x_at HLA-B associated transcript 2 BAT2 7916 2
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220319_s_at myosin regulatory light chain interacting protein MYLIP 29116 2
212004_at chromosome 1 open reading frame 144 C1orf144 26099 2
224931_at solute carrier family 41, member 3 SLC41A3 54946 2
204398_s_at echinoderm microtubule associated protein like 2 EML2 24139 2
212698_s_at septin 10 Sep-10 151011 2
238753_at Frequenin homolog (Drosophila) FREQ 23413 2
232270_at Chromosome 9 open reading frame 3 C9orf3 84909 2
203874_s_at SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 1
SMARCA1 6594 2
238006_at SIN3 homolog A, transcription regulator (yeast) SIN3A 25942 2
209356_x_at EGF-containing fibulin-like extracellular matrix protein 2 EFEMP2 30008 2
217937_s_at histone deacetylase 7A HDAC7A 51564 2
218903_s_at hypothetical protein MGC2731 MGC2731 79035 2
217782_s_at G protein pathway suppressor 1 GPS1 2873 2
238458_at EF-hand domain family, member A2 EFHA2 286097 2
225245_x_at H2A histone family, member J H2AFJ 55766 2
200049_at MYST histone acetyltransferase 2 ; MYST histone acetyltransferase
2
MYST2 11143 2
223089_at transmembrane protein vezatin VEZATIN 55591 2
225975_at protocadherin 18 PCDH18 54510 2
244476_at Tight junction protein 1 (zona occludens 1) TJP1 7082 2
1554747_a_at septin 2 Sep-02 4735 2
222986_s_at scotin SCOTIN 51246 2
201603_at protein phosphatase 1, regulatory (inhibitor) subunit 12A PPP1R12A 4659 2
214247_s_at dickkopf homolog 3 (Xenopus laevis) DKK3 27122 2
200950_at actin related protein 2/3 complex, subunit 1A, 41kDa ARPC1A 10552 2
201897_s_at CDC28 protein kinase regulatory subunit 1B CKS1B 1163 2
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1555851_s_at selenoprotein W, 1 SEPW1 6415 2
1555500_s_at SLC2A4 regulator SLC2A4RG 56731 2
206284_x_at clathrin, light polypeptide (Lcb) CLTB 1212 2
1554159_a_at zinc finger, MYND domain containing 11 ZMYND11 10771 2
203303_at t-complex-associated-testis-expressed 1-like TCTE1L 6990 2
209200_at MADS box transcription enhancer factor 2, polypeptide C
(myocyte enhancer factor 2C)
MEF2C 4208 2
201968_s_at phosphoglucomutase 1 PGM1 5236 2
213470_s_at heterogeneous nuclear ribonucleoprotein H1 (H) HNRPH1 3187 2
211926_s_at myosin, heavy polypeptide 9, non-muscle MYH9 4627 2
201403_s_at microsomal glutathione S-transferase 3 MGST3 4259 2
203109_at ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) UBE2M 9040 2
208700_s_at transketolase (Wernicke-Korsakoff syndrome) TKT 7086 2
215222_x_at microtubule-actin crosslinking factor 1 MACF1 23499 2
223471_at RAB3A interacting protein (rabin3) RAB3IP 117177 2
39548_at neuronal PAS domain protein 2 NPAS2 4862 2
35666_at sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3F
SEMA3F 6405 2
209586_s_at prune homolog (Drosophila) PRUNE 58497 2
201022_s_at destrin (actin depolymerizing factor) DSTN 11034 2
244070_at spectrin repeat containing, nuclear envelope 1 SYNE1 23345 2
224318_s_at hypothetical protein FLJ10081 FLJ10081 55683 2
225005_at PHD finger protein 13 PHF13 148479 2
209381_x_at splicing factor 3a, subunit 2, 66kDa SF3A2 8175 2
210010_s_at solute carrier family 25 (mitochondrial carrier; citrate transporter),
member 1
SLC25A1 6576 2
40837_at transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila) TLE2 7089 2
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225471_s_at v-akt murine thymoma viral oncogene homolog 2 AKT2 208 2
212110_at solute carrier family 39 (zinc transporter), member 14 SLC39A14 23516 2
200988_s_at proteasome (prosome, macropain) activator subunit 3 (PA28
gamma; Ki)
PSME3 10197 2
241395_at Death effector domain containing DEDD 9191 2
212034_s_at exocyst complex component 7 EXOC7 23265 2
225260_s_at mitochondrial ribosomal protein L32 MRPL32 64983 2
206814_at nerve growth factor, beta polypeptide NGFB 4803 2
212244_at glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A ;
GRINL1A combined protein
GRINL1A 145781 2
224941_at pregnancy-associated plasma protein A, pappalysin 1 PAPPA 5069 2
217831_s_at NSFL1 (p97) cofactor (p47) NSFL1C 55968 2
219268_at ethanolamine kinase 2 ETNK2 55224 2
223690_at latent transforming growth factor beta binding protein 2 LTBP2 4053 2
222064_s_at hypothetical protein MGC2744 MGC2744 80755 2
225464_at FERM domain containing 6 FRMD6 122786 2
222400_s_at membrane-type 1 matrix metalloproteinase cytoplasmic tail
binding protein-1
MTCBP-1 55256 2
1562863_at Exostoses (multiple) 1 EXT1 2131 2
238454_at zinc finger protein 540 ZNF540 163255 2
220597_s_at ADP-ribosylation-like factor 6 interacting protein 4 ARL6IP4 51329 2
36554_at acetylserotonin O-methyltransferase-like ASMTL 8623 2
202806_at drebrin 1 DBN1 1627 2
219394_at phosphatidylglycerophosphate synthase PGS1 9489 2
205527_s_at gem (nuclear organelle) associated protein 4 GEMIN4 50628 2
202590_s_at pyruvate dehydrogenase kinase, isoenzyme 2 PDK2 5164 2
207722_s_at BTB (POZ) domain containing 2 BTBD2 55643 2
219520_s_at KIAA1280 protein KIAA1280 55841 2
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205079_s_at multiple PDZ domain protein MPDZ 8777 2
228093_at Zinc finger protein 599 ZNF599 148103 2
224982_at AKT1 substrate 1 (proline-rich) AKT1S1 84335 2
242985_x_at ring finger protein 180 RNF180 285671 2
225536_at transmembrane protein 54 TMEM54 113452 2
218284_at SMAD, mothers against DPP homolog 3 (Drosophila) SMAD3 4088 2
213244_at secretory carrier membrane protein 4 SCAMP4 113178 2
242697_at zinc finger protein 540 ZNF540 163255 2
200990_at tripartite motif-containing 28 TRIM28 10155 2
225751_at RNA binding motif protein 17 RBM17 84991 2
208670_s_at CREBBP/EP300 inhibitor 1 CRI1 23741 2
209337_at PC4 and SFRS1 interacting protein 1 PSIP1 11168 2
200980_s_at pyruvate dehydrogenase (lipoamide) alpha 1 PDHA1 5160 2
201436_at eukaryotic translation initiation factor 4E EIF4E 1977 2
208611_s_at spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) SPTAN1 6709 2
225298_at myofibrillogenesis regulator 1 MR-1 25953 2
201125_s_at integrin, beta 5 ITGB5 3693 2
212367_at fem-1 homolog b (C. elegans) FEM1B 10116 2
224774_s_at neuron navigator 1 NAV1 89796 2
212216_at prolyl endopeptidase-like PREPL 9581 2
209252_at histidyl-tRNA synthetase-like HARSL 23438 2
217722_s_at neugrin, neurite outgrowth associated NGRN 51335 2
224876_at hypothetical protein FLJ37562 FLJ37562 134553 2
221542_s_at SPFH domain family, member 2 SPFH2 11160 2
202117_at Rho GTPase activating protein 1 ARHGAP1 392 2
Appendix E: Genes downregulated in AAA vs. NA (continued).
403
Probe Gene description Gene symbol EntrezGene ID
Fold
change
202624_s_at calcineurin binding protein 1 CABIN1 23523 2
207623_at ATP-binding cassette, sub-family F (GCN20), member 2 ABCF2 10061 2
225623_at KIAA1737 KIAA1737 85457 2
226809_at similar to hypothetical protein A230046P18; cDNA sequence
BC055759
FLJ30428 150519 2
205794_s_at neuro-oncological ventral antigen 1 NOVA1 4857 2
210844_x_at catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 1495 2
207838_x_at pre-B-cell leukemia transcription factor interacting protein 1 PBXIP1 57326 2
201335_s_at Rho guanine nucleotide exchange factor (GEF) 12 ARHGEF12 23365 2
220134_x_at chromosome 1 open reading frame 78 C1orf78 55194 2
204811_s_at calcium channel, voltage-dependent, alpha 2/delta subunit 2 CACNA2D2 9254 2
221867_at Nedd4 binding protein 1 N4BP1 9683 2
207469_s_at pirin (iron-binding nuclear protein) PIR 8544 2
201507_at prefoldin 1 PFDN1 5201 2
238009_at SRY (sex determining region Y)-box 5 SOX5 6660 2
232073_at protein tyrosine phosphatase, receptor type, f polypeptide
(PTPRF), interacting protein (liprin), alpha 2
PPFIA2 8499 2
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 11010 2
201271_s_at RNA binding protein, autoantigenic (hnRNP-associated with
lethal yellow homolog (mouse))
RALY 22913 2
224697_at WD repeat domain 22 WDR22 8816 2
212015_x_at polypyrimidine tract binding protein 1 PTBP1 5725 2
204964_s_at sarcospan (Kras oncogene-associated gene) SSPN 8082 2
212186_at acetyl-Coenzyme A carboxylase alpha ACACA 31 2
226731_at Pelota homolog (Drosophila) PELO 53918 2
203105_s_at dynamin 1-like DNM1L 10059 2
219491_at leucine rich repeat and fibronectin type III domain containing 4 LRFN4 78999 2
217854_s_at polymerase (RNA) II (DNA directed) polypeptide E, 25kDa POLR2E 5434 2
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201932_at leucine rich repeat containing 41 LRRC41 10489 2
234942_s_at deoxynucleotidyltransferase, terminal, interacting protein 1 DNTTIP1 116092 2
224506_s_at phosphatidic acid phosphatase type 2 domain containing 3 PPAPDC3 84814 2
225905_s_at ST3 beta-galactoside alpha-2,3-sialyltransferase 3 ST3GAL3 6487 2
213944_x_at guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2
213455_at hypothetical LOC283677 LOC283677 283677 2
205345_at BRCA1 associated RING domain 1 BARD1 580 2
201334_s_at Rho guanine nucleotide exchange factor (GEF) 12 ARHGEF12 23365 2
218694_at armadillo repeat containing, X-linked 1 ARMCX1 51309 2
218861_at ring finger protein 25 RNF25 64320 2
211932_at heterogeneous nuclear ribonucleoprotein A3 HNRPA3 220988 2
203430_at heme binding protein 2 HEBP2 23593 2
243894_at solute carrier family 41, member 2 SLC41A2 84102 2
243305_at Kelch domain containing 5 KIAA1340 57542 2
223287_s_at forkhead box P1 FOXP1 27086 2
212932_at RAB3 GTPase activating protein subunit 1 (catalytic) RAB3GAP1 22930 2
226977_at similar to bovine IgA regulatory protein LOC492311 492311 2
203794_at CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA 8476 2
218477_at transmembrane protein 14A TMEM14A 28978 2
214726_x_at adducin 1 (alpha) ADD1 118 2
210428_s_at hepatocyte growth factor-regulated tyrosine kinase substrate HGS 9146 2
205282_at low density lipoprotein receptor-related protein 8, apolipoprotein e
receptor
LRP8 7804 2
227019_at hypothetical gene supported by AK125122 LOC400793 400793 2
224913_s_at translocase of inner mitochondrial membrane 50 homolog (yeast) TIMM50 92609 2
228378_at hypothetical protein DKFZp434N2030 DKFZp434N2030 91298 2
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201158_at N-myristoyltransferase 1 NMT1 4836 2
212126_at Chromobox homolog 5 (HP1 alpha homolog, Drosophila) CBX5 23468 2
229488_at Zinc finger, A20 domain containing 1 ZA20D1 56957 2
210115_at ribosomal protein L39-like RPL39L 116832 2
213489_at Microtubule-associated protein, RP/EB family, member 2 MAPRE2 10982 2
212009_s_at stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing
protein)
STIP1 10963 2
230757_at FLJ44796 protein FLJ44796 401209 2
200784_s_at low density lipoprotein-related protein 1 (alpha-2-macroglobulin
receptor)
LRP1 4035 2
224698_at family with sequence similarity 62 (C2 domain containing) member
B
FAM62B 57488 2
204875_s_at GDP-mannose 4,6-dehydratase GMDS 2762 2
227286_at hypothetical protein FLJ90652 FLJ90652 283899 2
228857_at hypothetical protein LOC285831 LOC285831 285831 2
202959_at methylmalonyl Coenzyme A mutase MUT 4594 2
203085_s_at transforming growth factor, beta 1 (Camurati-Engelmann disease) TGFB1 7040 2
204389_at monoamine oxidase A MAOA 4128 2
201540_at four and a half LIM domains 1 FHL1 2273 2
201241_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 DDX1 1653 2
220917_s_at WD repeat domain 19 WDR19 57728 2
217784_at SNARE protein Ykt6 YKT6 10652 2
201330_at arginyl-tRNA synthetase RARS 5917 2
225930_at NFKB inhibitor interacting Ras-like 1 NKIRAS1 28512 2
1555233_at ras homolog gene family, member J RHOJ 57381 2
203221_at transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) TLE1 7088 2
201066_at cytochrome c-1 CYC1 1537 2
219020_at HS1-binding protein 3 HS1BP3 64342 2
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226322_at ARG99 protein ARG99 83857 2
215493_x_at butyrophilin, subfamily 2, member A1 BTN2A1 11120 2
225999_at family with sequence similarity 80, member B FAM80B 57494 2
226749_at mitochondrial ribosomal protein S9 MRPS9 64965 2
200759_x_at nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
225958_at polyhomeotic-like 1 (Drosophila) PHC1 1911 2
201215_at plastin 3 (T isoform) PLS3 5358 2
228438_at Musculin (activated B-cell factor-1) MSC 8989 2




224772_at neuron navigator 1 NAV1 89796 2
223294_at chromosome X open reading frame 26 CXorf26 51260 2
228393_s_at zinc finger protein 302 ZNF302 55900 2
206721_at chromosome 1 open reading frame 114 C1orf114 57821 2
1554089_s_at Shwachman-Bodian-Diamond syndrome ; Shwachman-Bodian-
Diamond syndrome pseudogene
SBDS 155370 2
203965_at ubiquitin specific peptidase 20 USP20 10868 2
227078_at Musculoskeletal, embryonic nuclear protein 1 MGC52022 375346 2
206491_s_at N-ethylmaleimide-sensitive factor attachment protein, alpha NAPA 8775 2
1552283_s_at zinc finger, DHHC-type containing 11 ZDHHC11 79844 2
205961_s_at PC4 and SFRS1 interacting protein 1 PSIP1 11168 2
200948_at myeloid leukemia factor 2 MLF2 8079 2
211358_s_at CDKN1A interacting zinc finger protein 1 CIZ1 25792 2
202986_at aryl-hydrocarbon receptor nuclear translocator 2 ARNT2 9915 2
201320_at SWI/SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily c, member 2
SMARCC2 6601 2
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238058_at hypothetical protein LOC150381 LOC150381 150381 2
224301_x_at H2A histone family, member J H2AFJ 55766 2
226665_at AHA1, activator of heat shock 90kDa protein ATPase homolog 2
(yeast)
AHSA2 130872 2
226839_at TR4 orphan receptor associated protein TRA16 TRA16 126382 2
218502_s_at trichorhinophalangeal syndrome I TRPS1 7227 2
218326_s_at leucine-rich repeat-containing G protein-coupled receptor 4 LGR4 55366 2
204432_at SRY (sex determining region Y)-box 12 SOX12 6666 2
214043_at Protein tyrosine phosphatase, receptor type, D PTPRD 5789 2
212104_s_at RNA binding motif protein 9 RBM9 23543 2
225019_at calcium/calmodulin-dependent protein kinase (CaM kinase) II
delta
CAMK2D 817 2
213107_at TRAF2 and NCK interacting kinase TNIK 23043 2
212878_s_at kinesin 2 KNS2 3831 2
213493_at sushi, nidogen and EGF-like domains 1 SNED1 25992 2
225191_at cold inducible RNA binding protein CIRBP 1153 2
218307_at radical S-adenosyl methionine domain containing 1 RSAD1 55316 2
202417_at kelch-like ECH-associated protein 1 KEAP1 9817 2
208748_s_at flotillin 1 FLOT1 10211 2
204028_s_at RAB GTPase activating protein 1 RABGAP1 23637 2
213012_at neural precursor cell expressed, developmentally down-regulated
4
NEDD4 4734 2
1560060_s_at vacuolar protein sorting 37C (yeast) VPS37C 55048 2
217432_s_at iduronate 2-sulfatase (Hunter syndrome) IDS 3423 2
202939_at zinc metallopeptidase (STE24 homolog, yeast) ZMPSTE24 10269 2
225293_at collagen, type XXVII, alpha 1 COL27A1 85301 2
1556059_s_at spen homolog, transcriptional regulator (Drosophila) SPEN 23013 2
204388_s_at monoamine oxidase A MAOA 4128 2
Appendix E: Genes downregulated in AAA vs. NA (continued).
408





235562_at hypothetical gene supported by AK091454 LOC285382 285382 2
233899_x_at Zinc finger and BTB domain containing 10 ZBTB10 65986 2
219314_s_at zinc finger protein 219 ZNF219 51222 2
208690_s_at PDZ and LIM domain 1 (elfin) PDLIM1 9124 2
208625_s_at eukaryotic translation initiation factor 4 gamma, 1 EIF4G1 1981 2
1553994_at 5'-nucleotidase, ecto (CD73) NT5E 4907 2
208814_at Heat shock 70kDa protein 4 HSPA4 3308 2
214602_at collagen, type IV, alpha 4 COL4A4 1286 2
1555789_s_at PHD finger protein 23 PHF23 79142 2
228063_s_at nucleosome assembly protein 1-like 5 NAP1L5 266812 2
216194_s_at cytoskeleton associated protein 1 CKAP1 1155 2
222487_s_at ribosomal protein S27-like RPS27L 51065 2
209221_s_at oxysterol binding protein-like 2 OSBPL2 9885 2
226288_s_at neuroligin 2 NLGN2 57555 2
217890_s_at parvin, alpha PARVA 55742 2
226470_at gamma-glutamyltransferase-like 3 GGTL3 2686 2
203956_at MORC family CW-type zinc finger 2 MORC2 22880 2
223438_s_at peroxisome proliferative activated receptor, alpha PPARA 5465 2
227983_at hypothetical protein MGC7036 MGC7036 196383 2
204270_at v-ski sarcoma viral oncogene homolog (avian) SKI 6497 2
205841_at Janus kinase 2 (a protein tyrosine kinase) JAK2 3717 2
200896_x_at hepatoma-derived growth factor (high-mobility group protein 1-
like)
HDGF 3068 2
214794_at proliferation-associated 2G4, 38kDa PA2G4 5036 2
212863_x_at C-terminal binding protein 1 CTBP1 1487 2
203633_at carnitine palmitoyltransferase 1A (liver) CPT1A 1374 2
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218215_s_at nuclear receptor subfamily 1, group H, member 2 NR1H2 7376 2
203280_at scaffold attachment factor B2 SAFB2 9667 2
213362_at Protein tyrosine phosphatase, receptor type, D PTPRD 5789 2
228725_x_at HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) HRMT1L1 3275 2
201602_s_at protein phosphatase 1, regulatory (inhibitor) subunit 12A PPP1R12A 4659 2
203836_s_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 2
218504_at fumarylacetoacetate hydrolase domain containing 2A FAHD2A 51011 2
230027_s_at mitochondrial ribosomal protein L43 MRPL43 84545 2
227155_at LIM domain only 4 LMO4 8543 2
219046_s_at PBX/knotted 1 homeobox 2 PKNOX2 63876 2
226075_at splA/ryanodine receptor domain and SOCS box containing 1 SPSB1 80176 2
213278_at myotubularin related protein 9 MTMR9 66036 2
204141_at tubulin, beta 2 TUBB2 7280 2
203575_at casein kinase 2, alpha prime polypeptide CSNK2A2 1459 2
224743_at inositol monophosphatase domain containing 1 IMPAD1 54928 2
211626_x_at v-ets erythroblastosis virus E26 oncogene like (avian) ERG 2078 2
202793_at putative protein similar to nessy (Drosophila) C3F 10162 2
203392_s_at C-terminal binding protein 1 CTBP1 1487 2
203489_at CD27-binding (Siva) protein SIVA 10572 2
224661_at phosphatidylinositol glycan class Y PIG-Y 84992 2
225494_at Dynein light chain 2 Dlc2 140735 2
225273_at KIAA1280 protein KIAA1280 55841 2
215707_s_at prion protein (p27-30) PRNP 5621 2
221256_s_at haloacid dehalogenase-like hydrolase domain containing 3 HDHD3 81932 2
240983_s_at cysteinyl-tRNA synthetase CARS 833 2
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216384_x_at similar to prothymosin alpha LOC440085 440085 2
216565_x_at similar to Interferon-induced transmembrane protein 3 (Interferon-
inducible protein 1-8U)
LOC391020 391020 2
202794_at inositol polyphosphate-1-phosphatase INPP1 3628 2
210465_s_at small nuclear RNA activating complex, polypeptide 3, 50kDa SNAPC3 6619 2
228855_at similar to coenzyme A diphosphatase LOC440388 440388 2
201661_s_at acyl-CoA synthetase long-chain family member 3 ACSL3 2181 2
203909_at solute carrier family 9 (sodium/hydrogen exchanger), member 6 SLC9A6 10479 2
208779_x_at discoidin domain receptor family, member 1 DDR1 780 2
231726_at protocadherin beta 14 PCDHB14 56122 2
209378_s_at KIAA1128 KIAA1128 54462 2
201526_at ADP-ribosylation factor 5 ARF5 381 2
1552426_a_at TM2 domain containing 3 TM2D3 80213 2
202326_at euchromatic histone-lysine N-methyltransferase 2 EHMT2 10919 2
224927_at KIAA1949 KIAA1949 170954 2
239033_at KIAA1958 KIAA1958 158405 2
221526_x_at par-3 partitioning defective 3 homolog (C. elegans) PARD3 56288 2
201482_at quiescin Q6 QSCN6 5768 2
201491_at AHA1, activator of heat shock 90kDa protein ATPase homolog 1
(yeast)
AHSA1 10598 2
218336_at prefoldin 2 PFDN2 5202 2
218149_s_at zinc finger protein 395 ZNF395 55893 2
242272_at hypothetical protein FLJ32130 FLJ32130 146540 2
201021_s_at destrin (actin depolymerizing factor) DSTN 11034 2
216264_s_at laminin, beta 2 (laminin S) LAMB2 3913 2
223665_at actin related protein M1 ARPM1 84517 2
210687_at carnitine palmitoyltransferase 1A (liver) CPT1A 1374 2
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201375_s_at protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform PPP2CB 5516 2
204021_s_at purine-rich element binding protein A PURA 5813 2
219114_at chromosome 3 open reading frame 18 C3orf18 51161 2
230528_s_at hypothetical protein MGC2752 MGC2752 65996 2
218994_s_at stromal antigen 3-like FLJ13195 64940 2
227265_at MRNA; cDNA DKFZp686N07104 (from clone DKFZp686N07104) 2
217891_at hypothetical protein FLJ13868 FLJ13868 64755 2
200932_s_at dynactin 2 (p50) DCTN2 10540 2
214071_at Metallophosphoesterase 1 MPPE1 65258 2
220346_at methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like MTHFD2L 441024 2
1558924_s_at restin (Reed-Steinberg cell-expressed intermediate filament-
associated protein)
RSN 6249 2
201628_s_at Ras-related GTP binding A RRAGA 10670 2
211605_s_at retinoic acid receptor, alpha ; retinoic acid receptor, alpha RARA 5914 2
202022_at aldolase C, fructose-bisphosphate ALDOC 230 2
37022_at proline/arginine-rich end leucine-rich repeat protein PRELP 5549 2
206453_s_at NDRG family member 2 NDRG2 57447 2
207124_s_at guanine nucleotide binding protein (G protein), beta 5 GNB5 10681 2
212630_at SEC6-like 1 (S. cerevisiae) SEC6L1 11336 2
223519_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 2
214679_x_at guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2
207178_s_at fyn-related kinase FRK 2444 2
204032_at breast cancer anti-estrogen resistance 3 BCAR3 8412 2
211793_s_at abl interactor 2 ABI2 10152 2
228146_at hypothetical protein LOC339263 LOC339263 339263 2
243017_at Hypothetical protein LOC158572 LOC158572 158572 2
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212791_at hypothetical protein FLJ38984 FLJ38984 127703 2
201904_s_at CTD (carboxy-terminal domain, RNA polymerase II, polypeptide
A) small phosphatase-like
CTDSPL 10217 2
234300_s_at zinc finger protein 28 homolog (mouse) ZFP28 140612 2
200852_x_at guanine nucleotide binding protein (G protein), beta polypeptide 2 GNB2 2783 2
201651_s_at protein kinase C and casein kinase substrate in neurons 2 PACSIN2 11252 2
218312_s_at zinc finger protein 447 ZNF447 65982 2
223118_s_at ubiquitin specific peptidase 47 USP47 55031 2
200622_x_at calmodulin 3 (phosphorylase kinase, delta) CALM3 808 2
201417_at SRY (sex determining region Y)-box 4 SOX4 6659 2
230900_at KM-HN-1 protein KM-HN-1 256309 2
220864_s_at NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 NDUFA13 51079 2
218601_at up-regulated gene 4 URG4 55665 2
203120_at tumor protein p53 binding protein, 2 TP53BP2 7159 2
235897_at coatomer protein complex, subunit zeta 2 COPZ2 51226 2
236606_at Salvador homolog 1 (Drosophila) SAV1 60485 2
225404_at hypothetical protein BC011880 LOC113444 113444 2
233955_x_at CXXC finger 5 CXXC5 51523 2
200862_at 24-dehydrocholesterol reductase DHCR24 1718 2
225442_at Discoidin domain receptor family, member 2 DDR2 4921 2
224369_s_at F-box protein 38 ; F-box protein 38 FBXO38 81545 2
227169_at DnaJ (Hsp40) homolog, subfamily C, member 18 DNAJC18 202052 2
226996_at lysocardiolipin acyltransferase LYCAT 253558 2
219645_at calsequestrin 1 (fast-twitch, skeletal muscle) CASQ1 844 2
41160_at methyl-CpG binding domain protein 3 MBD3 53615 2
236077_at glucosidase, alpha; neutral C GANC 2595 2
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203035_s_at protein inhibitor of activated STAT, 3 PIAS3 10401 2
201277_s_at heterogeneous nuclear ribonucleoprotein A/B HNRPAB 3182 2
201685_s_at chromosome 14 open reading frame 92 C14orf92 9878 2
217981_s_at fracture callus 1 homolog (rat) FXC1 26515 2
201885_s_at cytochrome b5 reductase 3 CYB5R3 1727 2
201469_s_at SHC (Src homology 2 domain containing) transforming protein 1 SHC1 6464 2
213480_at vesicle-associated membrane protein 4 VAMP4 8674 2
201282_at oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) OGDH 4967 2
214107_x_at hypothetical protein FLJ11822 LOC440434 440434 2
211009_s_at zinc finger protein 271 ZNF271 10778 2
200721_s_at ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) ACTR1A 10121 2
222493_s_at testis expressed sequence 27 TEX27 60685 2
210102_at loss of heterozygosity, 11, chromosomal region 2, gene A LOH11CR2A 4013 2
218449_at hypothetical protein FLJ11200 FLJ11200 55325 2
201790_s_at 7-dehydrocholesterol reductase DHCR7 1717 2
206809_s_at heterogeneous nuclear ribonucleoprotein A3 HNRPA3 220988 2
205139_s_at uronyl-2-sulfotransferase UST 10090 2
64899_at lipid phosphate phosphatase-related protein type 2 LPPR2 64748 2
225086_at Hypothetical protein FLJ38426 FLJ38426 283742 2
227481_at CNKSR family member 3 CNKSR3 154043 2
213029_at Nuclear factor I/B NFIB 4781 2
221675_s_at choline phosphotransferase 1 CHPT1 56994 2
1553961_s_at chromosome 20 open reading frame 161 C20orf161 90203 2
218417_s_at hypothetical protein FLJ20489 FLJ20489 55652 2
221506_s_at transportin 2 (importin 3, karyopherin beta 2b) TNPO2 30000 2
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209041_s_at ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) UBE2G2 7327 2
200719_at S-phase kinase-associated protein 1A (p19A) SKP1A 6500 2
225914_s_at calcium binding protein 39-like CAB39L 81617 2
224516_s_at CXXC finger 5 ; CXXC finger 5 CXXC5 51523 2
203150_at Rab9 effector protein with kelch motifs RABEPK 10244 2
31799_at Coatomer protein complex, subunit beta 2 (beta prime) COPB2 9276 2
239481_at hypothetical protein FLJ37659 RP1-32F7.2 286499 2
203944_x_at butyrophilin, subfamily 2, member A1 BTN2A1 11120 2
207076_s_at argininosuccinate synthetase ASS 445 2
210892_s_at general transcription factor II, i GTF2I 2969 2
32032_at DiGeorge syndrome critical region gene 14 DGCR14 8220 2
242394_at CNKSR family member 3 CNKSR3 154043 2
200609_s_at WD repeat domain 1 WDR1 9948 2
222138_s_at WD repeat domain 13 WDR13 64743 2
226604_at SMILE protein SMILE 160418 2
224634_at G patch domain containing 4 GPATC4 54865 2
200634_at profilin 1 PFN1 5216 2
202053_s_at aldehyde dehydrogenase 3 family, member A2 ALDH3A2 224 2
203222_s_at transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) TLE1 7088 2
204038_s_at endothelial differentiation, lysophosphatidic acid G-protein-coupled
receptor, 2
EDG2 1902 2
225134_at hypothetical protein FLJ14800 FLJ14800 84926 2
229873_at hypothetical protein LOC283219 LOC283219 283219 2
219165_at PDZ and LIM domain 2 (mystique) PDLIM2 64236 2
215533_s_at ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 10277 2
209820_s_at transducin (beta)-like 3 TBL3 10607 2
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203467_at phosphomannomutase 1 PMM1 5372 2
204012_s_at leucine carboxyl methyltransferase 2 LCMT2 9836 2
236144_at carboxypeptidase X (M14 family), member 2 CPXM2 119587 2
207480_s_at Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) MEIS2 4212 2
203244_at peroxisomal biogenesis factor 5 PEX5 5830 2
229840_at IQ motif and Sec7 domain 2 IQSEC2 23096 2
221710_x_at chromosome 1 open reading frame 78 ; chromosome 1 open
reading frame 78
C1orf78 55194 2
208735_s_at CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A)
small phosphatase 2
CTDSP2 10106 2
223174_at BTB (POZ) domain containing 10 BTBD10 84280 2
1552548_at Bartter syndrome, infantile, with sensorineural deafness (Barttin) BSND 7809 2
235289_at eukaryotic translation initiation factor 5A2 EIF5A2 56648 2
241813_at methyl-CpG binding domain protein 1 MBD1 4152 2
209899_s_at fuse-binding protein-interacting repressor SIAHBP1 22827 2
226439_s_at neurobeachin NBEA 26960 2
209002_s_at calcium binding and coiled-coil domain 1 CALCOCO1 57658 2
210460_s_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 PSMD4 5710 2
200824_at glutathione S-transferase pi GSTP1 2950 2
225766_s_at Transportin 1 TNPO1 3842 2
212855_at DCN1, defective in cullin neddylation 1, domain containing 4 (S.
cerevisiae)
DCUN1D4 23142 2
232079_s_at poliovirus receptor-related 2 (herpesvirus entry mediator B) PVRL2 5819 2
218251_at MID1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) MID1IP1 58526 2
211985_s_at calmodulin 1 (phosphorylase kinase, delta) CALM1 801 2
227249_at Myosin, heavy polypeptide 11, smooth muscle MYH11 4629 2
219401_at xylosyltransferase II XYLT2 64132 2
238813_at Aminolevulinate, delta-, synthase 2 ALAS2 212 2
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223908_at histone deacetylase 8 HDAC8 55869 2
209268_at vacuolar protein sorting 45A (yeast) VPS45A 11311 2
220014_at mesenchymal stem cell protein DSC54 LOC51334 51334 2
203903_s_at hephaestin HEPH 9843 2
201168_x_at Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA 396 2
202282_at hydroxyacyl-Coenzyme A dehydrogenase, type II HADH2 3028 2
212333_at DKFZP564F0522 protein DKFZP564F0522 25940 2
208928_at P450 (cytochrome) oxidoreductase POR 5447 2
223819_x_at COMM domain containing 5 COMMD5 28991 2
211984_at calmodulin 1 (phosphorylase kinase, delta) CALM1 801 2
203781_at mitochondrial ribosomal protein L33 MRPL33 9553 2
225454_at hypothetical protein BC013949 LOC115098 115098 2
206649_s_at transcription factor binding to IGHM enhancer 3 TFE3 7030 2
202439_s_at iduronate 2-sulfatase (Hunter syndrome) IDS 3423 2
235431_s_at pellino homolog 3 (Drosophila) PELI3 246330 2
1562059_at Supervillin SVIL 6840 2
210740_s_at inositol 1,3,4-triphosphate 5/6 kinase ITPK1 3705 2
219488_at alpha 1,4-galactosyltransferase (globotriaosylceramide synthase) A4GALT 53947 2
203373_at suppressor of cytokine signaling 2 SOCS2 8835 2
234982_at zinc finger protein 650 ZNF650 130507 2
226644_at mindbomb homolog 2 (Drosophila) MIB2 142678 2
228931_at coenzyme Q4 homolog (yeast) COQ4 51117 2
226195_at MGC16028 similar to RIKEN cDNA 1700019E19 gene MGC16028 112752 2
228433_at hypothetical protein FLJ11236 FLJ11236 56008 2
204550_x_at glutathione S-transferase M1 GSTM1 2944 2
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202047_s_at chromobox homolog 6 CBX6 23466 2
215171_s_at translocase of inner mitochondrial membrane 17 homolog A
(yeast)
TIMM17A 10440 2
227965_at Adenomatosis polyposis coli 2 APC2 10297 2
214703_s_at mannosidase, alpha, class 2B, member 2 MAN2B2 23324 2
221483_s_at cyclic AMP phosphoprotein, 19 kD ARPP-19 10776 2
218187_s_at chromosome 8 open reading frame 33 C8orf33 65265 2
201557_at vesicle-associated membrane protein 2 (synaptobrevin 2) VAMP2 6844 2
202471_s_at isocitrate dehydrogenase 3 (NAD+) gamma IDH3G 3421 2
32811_at myosin IC MYO1C 4641 2
221519_at F-box and WD-40 domain protein 4 FBXW4 6468 2
225278_at protein kinase, AMP-activated, beta 2 non-catalytic subunit PRKAB2 5565 2
242033_at ring finger protein 180 RNF180 285671 2
227415_at hypothetical protein LOC283508 LOC283508 283508 2
223743_s_at mitochondrial ribosomal protein L4 MRPL4 51073 2
1559756_at hypothetical protein DKFZp667F0711 DKFZp667F0711 399716 2
1553107_s_at hypothetical protein FLJ37562 FLJ37562 134553 2
226102_at Zinc finger protein 192 ZNF192 7745 2
200857_s_at nuclear receptor co-repressor 1 NCOR1 9611 2
217770_at phosphatidylinositol glycan, class T PIGT 51604 2
223766_at Clone FLB4246 PRO1102 2
238569_at Gamma-aminobutyric acid (GABA) B receptor, 1 GABBR1 2550 2
59625_at nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3 8996 2
213330_s_at stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing
protein)
STIP1 10963 2
218773_s_at methionine sulfoxide reductase B2 MSRB2 22921 2
217815_at suppressor of Ty 16 homolog (S. cerevisiae) SUPT16H 11198 2










227327_at HBV pre-s2 binding protein 1 SBP1 90198 2
228402_at zinc finger, BED-type containing 3 ZBED3 84327 2
209537_at exostoses (multiple)-like 2 EXTL2 2135 2
229841_at Eukaryotic translation initiation factor 2C, 2 EIF2C2 27161 2
218216_x_at ADP-ribosylation-like factor 6 interacting protein 4 ARL6IP4 51329 2
203190_at NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa
(NADH-coenzyme Q reductase)
NDUFS8 4728 2
224662_at kinesin family member 5B KIF5B 3799 2
227170_at Hypothetical protein DKFZp547K054 DKFZp547K054 56974 2
213383_at SAPS domain family, member 2 KIAA0685 9701 2
225010_at coiled-coil domain containing 6 CCDC6 8030 2
209513_s_at hydroxysteroid dehydrogenase like 2 HSDL2 84263 2
223253_at ependymin related protein 1 (zebrafish) EPDR1 54749 2
208420_x_at suppressor of Ty 6 homolog (S. cerevisiae) SUPT6H 6830 2
223463_at RAB23, member RAS oncogene family RAB23 51715 2
226375_at Lemur tyrosine kinase 2 LMTK2 22853 2
213310_at Eukaryotic translation initiation factor 2C, 2 EIF2C2 27161 2
201121_s_at progesterone receptor membrane component 1 PGRMC1 10857 2
205966_at TAF13 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 18kDa
TAF13 6884 2
202378_s_at leptin receptor overlapping transcript LEPROT 54741 2
200649_at nucleobindin 1 NUCB1 4924 2
212641_at human immunodeficiency virus type I enhancer binding protein
2
HIVEP2 3097 2
225274_at prenylcysteine oxidase 1 PCYOX1 51449 2
218367_x_at ubiquitin specific peptidase 21 USP21 27005 2
227847_at EPM2A (laforin) interacting protein 1 EPM2AIP1 9852 2










223604_at GTPase activating Rap/RanGAP domain-like 3 GARNL3 84253 2
210612_s_at synaptojanin 2 SYNJ2 8871 2
218262_at hypothetical protein FLJ22318 FLJ22318 64777 2
214104_at G protein-coupled receptor 161 GPR161 23432 2
235956_at KIAA1377 protein KIAA1377 57562 2
213684_s_at PDZ and LIM domain 5 PDLIM5 10611 2
228778_at Microcephaly, primary autosomal recessive 1 MCPH1 79648 2
218285_s_at dehydrogenase/reductase (SDR family) member 6 DHRS6 56898 2
219940_s_at hypothetical protein FLJ11305 FLJ11305 55795 2
201611_s_at isoprenylcysteine carboxyl methyltransferase ICMT 23463 2
200696_s_at gelsolin (amyloidosis, Finnish type) GSN 2934 2
209000_s_at septin 8 Sep-08 23176 2
200613_at adaptor-related protein complex 2, mu 1 subunit AP2M1 1173 2
211928_at dynein, cytoplasmic, heavy polypeptide 1 DNCH1 1778 2
202480_s_at death effector domain containing DEDD 9191 2
201544_x_at poly(A) binding protein, nuclear 1 PABPN1 8106 2
227131_at mitogen-activated protein kinase kinase kinase 3 MAP3K3 4215 2
236475_at Microtubule associated monoxygenase, calponin and LIM domain
containing 2
MICAL2 9645 2
219933_at glutaredoxin 2 GLRX2 51022 2
227722_at ribosomal protein S23 RPS23 6228 2
231738_at protocadherin beta 7 PCDHB7 56129 2
208921_s_at sorcin SRI 6717 2
221434_s_at chromosome 14 open reading frame 156 ; chromosome 14 open
reading frame 156
C14orf156 81892 2
203771_s_at biliverdin reductase A BLVRA 644 2
200066_at IK cytokine, down-regulator of HLA II ; IK cytokine, down-
regulator of HLA II
IK 3550 2
Appendix E: Genes downregulated in AAA vs. NA (continued).
420





201906_s_at CTD (carboxy-terminal domain, RNA polymerase II, polypeptide
A) small phosphatase-like
CTDSPL 10217 2
227522_at similar to mouse 2310016A09Rik gene LOC134147 134147 2
201660_at Acyl-CoA synthetase long-chain family member 3 ACSL3 2181 2
223119_s_at ubiquitin specific peptidase 47 USP47 55031 2
1555360_a_at DnaJ (Hsp40) homolog, subfamily C, member 11 DNAJC11 55735 2
229537_at LIM domain only 4 LMO4 8543 2
203773_x_at biliverdin reductase A BLVRA 644 2
227181_at hypothetical protein LOC348801 LOC348801 348801 2
201326_at chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A 908 2
222093_s_at zinc finger, HIT type 4 ZNHIT4 83444 2
208996_s_at polymerase (RNA) II (DNA directed) polypeptide C, 33kDa POLR2C 5432 2
200885_at ras homolog gene family, member C RHOC 389 2
209581_at HRAS-like suppressor 3 HRASLS3 11145 2
222431_at spindlin SPIN 10927 2
212100_s_at polymerase (DNA-directed), delta interacting protein 3 POLDIP3 84271 2
233881_s_at toll interacting protein TOLLIP 54472 2
1554429_a_at dystrophia myotonica-containing WD repeat motif DMWD 1762 2
1554147_s_at chromosome 3 open reading frame 15 C3orf15 89876 2
207805_s_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 PSMD9 5715 2
209230_s_at p8 protein (candidate of metastasis 1) P8 26471 2
211271_x_at polypyrimidine tract binding protein 1 PTBP1 5725 2
229176_at Ankylosis, progressive homolog (mouse) ANKH 56172 2
222011_s_at t-complex 1 TCP1 6950 2
223006_s_at chromosome 9 open reading frame 5 C9orf5 23731 2
202043_s_at spermine synthase SMS 6611 2
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227127_at Musculoskeletal, embryonic nuclear protein 1 MGC52022 375346 2
201536_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-
related)
DUSP3 1845 2
214913_at ADAM metallopeptidase with thrombospondin type 1 motif, 3 ADAMTS3 9508 2
237231_at Chromosome 9 open reading frame 42 C9orf42 116224 2
227436_at Zinc finger, A20 domain containing 1 ZA20D1 56957 2
200720_s_at ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) ACTR1A 10121 2
201518_at chromobox homolog 1 (HP1 beta homolog Drosophila ) CBX1 10951 2
233803_s_at MYB binding protein (P160) 1a MYBBP1A 10514 2
227959_at Ankyrin repeat domain 9 ANKRD9 122416 2
224903_at cirrhosis, autosomal recessive 1A (cirhin) CIRH1A 84916 2
234001_s_at ADP-ribosylation factor GTPase activating protein 1 ARFGAP1 55738 2
203258_at DR1-associated protein 1 (negative cofactor 2 alpha) DRAP1 10589 2
227477_at zinc finger, MYND-type containing 19 ZMYND19 116225 2
209053_s_at Wolf-Hirschhorn syndrome candidate 1 WHSC1 7468 2
210949_s_at eukaryotic translation initiation factor 3, subunit 8, 110kDa EIF3S8 8663 2
225531_at Cdk5 and Abl enzyme substrate 1 CABLES1 91768 2
209972_s_at JTV1 gene JTV1 7965 2
218984_at hypothetical protein FLJ20485 FLJ20485 54517 2
1563776_at Hypothetical protein FLJ23342 FLJ23342 79684 2
203776_at G patch domain and KOW motifs GPKOW 27238 2
200642_at superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1
(adult))
SOD1 6647 2
205353_s_at prostatic binding protein PBP 5037 2
234338_s_at zinc finger protein 651 ZNF651 92999 2
201412_at low density lipoprotein receptor-related protein 10 LRP10 26020 2
225753_at zinc finger protein 513 ZNF513 130557 2
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201608_s_at PWP1 homolog (S. cerevisiae) PWP1 11137 2
201184_s_at chromodomain helicase DNA binding protein 4 CHD4 1108 2
202058_s_at karyopherin alpha 1 (importin alpha 5) KPNA1 3836 2
214035_x_at LOC399491 protein LOC399491 399491 2
203186_s_at S100 calcium binding protein A4 (calcium protein, calvasculin,
metastasin, murine placental homolog)
S100A4 6275 2
226852_at metastasis associated 1 family, member 3 MTA3 57504 2
213478_at kazrin KIAA1026 23254 2
212886_at DKFZP434C171 protein DKFZP434C171 26112 2
221489_s_at sprouty homolog 4 (Drosophila) SPRY4 81848 2
207721_x_at histidine triad nucleotide binding protein 1 HINT1 3094 2
226776_at enhancer of yellow 2 homolog (Drosophila) ENY2 56943 2
222216_s_at mitochondrial ribosomal protein L17 MRPL17 63875 2
211501_s_at eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa EIF3S9 8662 2
212231_at F-box protein 21 FBXO21 23014 2
212793_at dishevelled associated activator of morphogenesis 2 DAAM2 23500 2
212206_s_at H2A histone family, member V H2AFV 94239 2
213660_s_at topoisomerase (DNA) III beta TOP3B 8940 2
1555881_s_at leucine zipper, putative tumor suppressor 2 LZTS2 84445 2
226897_s_at zinc finger CCCH-type containing 7A ZC3H7A 29066 2
228019_s_at mitochondrial ribosomal protein S18C MRPS18C 51023 2
224636_at zinc finger protein 91 homolog (mouse) ZFP91 80829 2
210631_at neurofibromin 1 (neurofibromatosis, von Recklinghausen
disease, Watson disease)
NF1 4763 2
212017_at hypothetical protein LOC130074 LOC130074 130074 2
209733_at hypothetical protein LOC286440 LOC286440 286440 2
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204464_s_at endothelin receptor type A EDNRA 1909 2
217914_at two pore segment channel 1 TPCN1 53373 2
210002_at GATA binding protein 6 GATA6 2627 2
200919_at polyhomeotic-like 2 (Drosophila) PHC2 1912 2
1561394_s_at KIAA1755 protein KIAA1755 85449 2
201405_s_at COP9 constitutive photomorphogenic homolog subunit 6
(Arabidopsis)
COPS6 10980 2
213374_x_at 3-hydroxyisobutyryl-Coenzyme A hydrolase HIBCH 26275 2
221598_s_at cofactor required for Sp1 transcriptional activation, subunit 8,
34kDa
CRSP8 9442 2
208289_s_at etoposide induced 2.4 mRNA EI24 9538 2
1562228_s_at phosphodiesterase 5A, cGMP-specific PDE5A 8654 2
206274_s_at ciliary rootlet coiled-coil, rootletin CROCC 9696 2
231876_at tripartite motif-containing 56 TRIM56 81844 2
212711_at calmodulin regulated spectrin-associated protein 1 CAMSAP1 157922 2
226692_at Small EDRK-rich factor 2 SERF2 10169 2
213473_at BRCA1 associated protein BRAP 8315 2
225376_at chromosome 20 open reading frame 11 C20orf11 54994 2
1552705_at dual specificity phosphatase 19 DUSP19 142679 2
218472_s_at pelota homolog (Drosophila) PELO 53918 2
201864_at GDP dissociation inhibitor 1 GDI1 2664 2
227256_at ubiquitin specific peptidase 31 USP31 57478 2
203636_at midline 1 (Opitz/BBB syndrome) MID1 4281 2
635_s_at protein phosphatase 2, regulatory subunit B (B56), beta isoform PPP2R5B 5526 2
219637_at armadillo repeat containing 9 ARMC9 80210 2
209882_at Ras-like without CAAX 1 RIT1 6016 2
218488_at eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa EIF2B3 8891 2
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209667_at carboxylesterase 2 (intestine, liver) CES2 8824 2
201142_at eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa EIF2S1 1965 2
223446_s_at dystrobrevin binding protein 1 DTNBP1 84062 2
241866_at solute carrier family 16 (monocarboxylic acid transporters), member 7 SLC16A7 9194 2
201226_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa NDUFB8 4714 2
224522_s_at hypothetical protein FLJ22955 ; hypothetical protein FLJ22955 FLJ22955 79877 2
1552295_a_at solute carrier family 39 (zinc transporter), member 13 SLC39A13 91252 2
202116_at D4, zinc and double PHD fingers family 2 DPF2 5977 2
213269_at zinc finger protein 248 ZNF248 57209 2
212509_s_at matrix-remodelling associated 7 MXRA7 439921 2
203208_s_at mitochondrial fission regulator 1 MTFR1 9650 2
202839_s_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa NDUFB7 4713 2
228950_s_at chromosome 1 open reading frame 139 C1orf139 79971 2
223130_s_at myosin regulatory light chain interacting protein MYLIP 29116 2
226246_at potassium channel tetramerisation domain containing 1 KCTD1 284252 2
225953_at hypothetical protein FLJ10656 P15RS 55197 2
224013_s_at SRY (sex determining region Y)-box 7 SOX7 83595 2
224632_at G patch domain containing 4 GPATC4 54865 2
221693_s_at mitochondrial ribosomal protein S18A ; mitochondrial ribosomal
protein S18A
MRPS18A 55168 2
229838_at nucleobindin 2 NUCB2 4925 2
210880_s_at embryonal Fyn-associated substrate EFS 10278 2
216863_s_at MORC family CW-type zinc finger 2 MORC2 22880 2
217830_s_at NSFL1 (p97) cofactor (p47) NSFL1C 55968 2
201851_at SH3-domain GRB2-like 1 SH3GL1 6455 2
218183_at chromosome 16 open reading frame 5 C16orf5 29965 2
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212662_at poliovirus receptor PVR 5817 2
214306_at optic atrophy 1 (autosomal dominant) OPA1 4976 2
223110_at KIAA1429 KIAA1429 25962 2
226784_at TWIST neighbor TWISTNB 221830 2
226015_at zinc finger protein 12 ZNF12 7559 2
40016_g_at microtubule associated serine/threonine kinase family member 4 MAST4 23227 2
236273_at hypothetical protein FLJ20719 FLJ20719 55672 2
200683_s_at ubiquitin-conjugating enzyme E2L 3 UBE2L3 7332 2
200785_s_at low density lipoprotein-related protein 1 (alpha-2-macroglobulin
receptor)
LRP1 4035 2
201276_at RAB5B, member RAS oncogene family RAB5B 5869 2
212955_s_at polymerase (RNA) II (DNA directed) polypeptide I, 14.5kDa POLR2I 5438 2
209178_at DEAH (Asp-Glu-Ala-His) box polypeptide 38 DHX38 9785 2
218664_at mitochondrial trans-2-enoyl-CoA reductase MECR 51102 2
204928_s_at solute carrier family 10 (sodium/bile acid cotransporter family),
member 3
SLC10A3 8273 2
228977_at Interleukin 17D IL17D 53342 2
224823_at myosin, light polypeptide kinase MYLK 4638 2
201350_at flotillin 2 FLOT2 2319 2
225481_at FERM domain containing 6 FRMD6 122786 2
205545_x_at DnaJ (Hsp40) homolog, subfamily C, member 8 DNAJC8 22826 2
221480_at heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA
binding protein 1, 37kDa)
HNRPD 3184 2
212055_at chromosome 18 open reading frame 10 C18orf10 25941 2
228630_at Zinc finger protein 84 (HPF2) ZNF84 7637 2
209352_s_at SIN3 homolog B, transcription regulator (yeast) SIN3B 23309 2
229394_s_at Glucocorticoid receptor DNA binding factor 1 GRLF1 2909 2
216620_s_at Rho guanine nucleotide exchange factor (GEF) 10 ARHGEF10 9639 2
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212148_at Pre-B-cell leukemia transcription factor 1 PBX1 5087 2
230657_at Clock homolog (mouse) CLOCK 9575 2
1557578_at Pleckstrin homology-like domain, family B, member 2 PHLDB2 90102 2
1553960_at chromosome 20 open reading frame 161 C20orf161 90203 2
227976_at alpha-2-macroglobulin A2M 2 2
228155_at chromosome 10 open reading frame 58 C10orf58 84293 2
213122_at TSPY-like 5 TSPYL5 85453 2
217841_s_at protein phosphatase methylesterase-1 PME-1 51400 2
209009_at esterase D/formylglutathione hydrolase ESD 2098 2
219203_at chromosome 14 open reading frame 122 C14orf122 51016 2
201043_s_at acidic (leucine-rich) nuclear phosphoprotein 32 family, member A ANP32A 8125 2
221771_s_at M-phase phosphoprotein, mpp8 HSMPP8 54737 2
202172_at zinc finger protein 161 ZNF161 7716 2
212453_at KIAA1279 KIAA1279 26128 2
212217_at prolyl endopeptidase-like PREPL 9581 2
213318_s_at HLA-B associated transcript 3 BAT3 7917 2
204355_at DEAH (Asp-Glu-Ala-His) box polypeptide 30 DHX30 22907 2
203271_s_at unc-119 homolog (C. elegans) UNC119 9094 2
201946_s_at chaperonin containing TCP1, subunit 2 (beta) CCT2 10576 2
228073_at haloacid dehalogenase-like hydrolase domain containing 4 HDHD4 140838 2
229344_x_at family with sequence similarity 80, member B FAM80B 57494 2
226331_at Bobby sox homolog (Drosophila) BBX 56987 2
201831_s_at vesicle docking protein p115 VDP 8615 2
235405_at glutathione S-transferase A4 GSTA4 2941 2
225900_at SEC15-like 2 (S. cerevisiae) SEC15L2 23233 2
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219142_at RAS-like, family 11, member B RASL11B 65997 2
227188_at chromosome 21 open reading frame 63 C21orf63 59271 2
228098_s_at myosin regulatory light chain interacting protein MYLIP 29116 2
202773_s_at splicing factor, arginine/serine-rich 8 (suppressor-of-white-apricot
homolog, Drosophila)
SFRS8 6433 2
231213_at phosphodiesterase 1A, calmodulin-dependent PDE1A 5136 2
224576_at endoplasmic reticulum-golgi intermediate compartment 32 kDa
protein
KIAA1181 57222 2
239415_at ASAP FLJ21159 79884 2
223081_at PHD finger protein 23 PHF23 79142 2
238556_at Calcium/calmodulin-dependent protein kinase (CaM kinase) II
gamma
CAMK2G 818 2
214359_s_at heat shock 90kDa protein 1, beta HSPCB 3326 2
201980_s_at Ras suppressor protein 1 RSU1 6251 2
223132_s_at tripartite motif-containing 8 TRIM8 81603 2
226081_at Leucine zipper and CTNNBIP1 domain containing LZIC 84328 2
201673_s_at glycogen synthase 1 (muscle) GYS1 2997 2
219346_at leucine rich repeat and fibronectin type III domain containing 3 LRFN3 79414 2
1554480_a_at SVH protein SVH 83787 2
206818_s_at cyclin M2 CNNM2 54805 2
234284_at guanine nucleotide binding protein (G protein), gamma 8 GNG8 94235 2
226701_at gap junction protein, alpha 5, 40kDa (connexin 40) GJA5 2702 2
212508_at modulator of apoptosis 1 MOAP1 64112 2
200770_s_at laminin, gamma 1 (formerly LAMB2) LAMC1 3915 2
201259_s_at synaptophysin-like 1 SYPL1 6856 2
223093_at ankylosis, progressive homolog (mouse) ANKH 56172 2
201871_s_at unknown protein LOC51035 LOC51035 51035 2
202104_s_at spastic paraplegia 7, paraplegin (pure and complicated autosomal
recessive)
SPG7 6687 2
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227557_at scavenger receptor class F, member 2 SCARF2 91179 2
31874_at growth arrest-specific 2 like 1 GAS2L1 10634 2
206200_s_at annexin A11 ANXA11 311 2
221939_at Yip1 domain family, member 2 YIPF2 78992 2
207428_x_at cell division cycle 2-like 1 (PITSLRE proteins) ; cell division cycle
2-like 2 (PITSLRE proteins)
CDC2L1 ;
CDC2L2
984 ; 985 2
221942_s_at guanylate cyclase 1, soluble, alpha 3 GUCY1A3 2982 2
228006_at Phosphatase and tensin homolog (mutated in multiple advanced
cancers 1)
PTEN 5728 2
230353_at hypothetical protein LOC284112 LOC284112 284112 2
203267_s_at developmentally regulated GTP binding protein 2 DRG2 1819 2
1566257_at Hypothetical protein LOC144874 LOC144874 144874 2
209019_s_at PTEN induced putative kinase 1 PINK1 65018 2
203885_at RAB21, member RAS oncogene family RAB21 23011 2
226010_at solute carrier family 25 (mitochondrial carrier; phosphate carrier),
member 23
SLC25A23 79085 2
204090_at serine/threonine kinase 19 STK19 8859 2
203822_s_at E74-like factor 2 (ets domain transcription factor) ELF2 1998 2
231945_at filamin A interacting protein 1 FILIP1 27145 2
209511_at polymerase (RNA) II (DNA directed) polypeptide F POLR2F 5435 2
218034_at tetratricopeptide repeat domain 11 TTC11 51024 2
40687_at gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2701 2
202019_s_at LanC lantibiotic synthetase component C-like 1 (bacterial) LANCL1 10314 2
213617_s_at chromosome 18 open reading frame 10 C18orf10 25941 2
203562_at fasciculation and elongation protein zeta 1 (zygin I) FEZ1 9638 2
212979_s_at KIAA0738 gene product KIAA0738 9747 2
226241_s_at mitochondrial ribosomal protein L52 MRPL52 122704 2
201425_at aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 217 2
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1570511_at Rho guanine nucleotide exchange factor (GEF) 10-like ARHGEF10L 55160 2
202759_s_at PALM2-AKAP2 protein PALM2-
AKAP2
445815 2
221641_s_at acyl-CoA thioesterase 9 ACOT9 23597 2
205168_at discoidin domain receptor family, member 2 DDR2 4921 2
218116_at chromosome 9 open reading frame 78 ; chromosome 9 open
reading frame 78
C9orf78 51759 2
201419_at BRCA1 associated protein-1 (ubiquitin carboxy-terminal
hydrolase)
BAP1 8314 2
225206_s_at Similar to mitochondrial translational release factor 1-like MTRF1L 54516 2
224838_at forkhead box P1 FOXP1 27086 2
228856_at Hypothetical protein MGC2474 MGC2474 65988 2
210825_s_at prostatic binding protein PBP 5037 2
204068_at serine/threonine kinase 3 (STE20 homolog, yeast) STK3 6788 2
33307_at CGI-96 protein CGI-96 27341 2
203032_s_at fumarate hydratase FH 2271 2
218516_s_at inositol monophosphatase domain containing 1 IMPAD1 54928 2
212098_at hypothetical protein LOC151162 LOC151162 151162 2
226967_at hypothetical protein FLJ14768 FLJ14768 84922 2
224616_at dynein, cytoplasmic, light intermediate polypeptide 2 DNCLI2 1783 2
212215_at prolyl endopeptidase-like PREPL 9581 2
218297_at chromosome 10 open reading frame 97 C10orf97 80013 2
238154_at P10-binding protein Cep70 80321 2
224945_at BTB (POZ) domain containing 7 BTBD7 55727 2
242443_at Echinoderm microtubule associated protein like 5 EML5 161436 2
227150_at Metal-regulatory transcription factor 1 MTF1 4520 2
203727_at superkiller viralicidic activity 2-like (S. cerevisiae) SKIV2L 6499 2
225200_at zinc finger, CSL-type containing 2 ZCSL2 285381 2
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222206_s_at nicalin homolog (zebrafish) NCLN 56926 2
226761_at zinc finger protein, subfamily 1A, 4 (Eos) ZNFN1A4 64375 2
210762_s_at deleted in liver cancer 1 DLC1 10395 2
202045_s_at glucocorticoid receptor DNA binding factor 1 GRLF1 2909 2
203864_s_at actinin, alpha 2 ACTN2 88 2
226050_at transmembrane and coiled-coil domains 3 TMCO3 55002 2
200694_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 DDX24 57062 2
202226_s_at v-crk sarcoma virus CT10 oncogene homolog (avian) CRK 1398 2
225793_at Lix1 homolog (mouse) like LIX1L 128077 2
213249_at F-box and leucine-rich repeat protein 7 FBXL7 23194 2
1555730_a_at cofilin 1 (non-muscle) CFL1 1072 2
202732_at protein kinase (cAMP-dependent, catalytic) inhibitor gamma PKIG 11142 2
208962_s_at fatty acid desaturase 1 FADS1 3992 2
213306_at multiple PDZ domain protein MPDZ 8777 2
218020_s_at testis expressed sequence 27 TEX27 60685 2
201440_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 DDX23 9416 2
200734_s_at ADP-ribosylation factor 3 ARF3 377 2
218522_s_at BPY2 interacting protein 1 BPY2IP1 55201 2
218572_at chromatin modifying protein 4A CHMP4A 29082 2
226000_at CTTNBP2 N-terminal like DKFZp547A023 55917 2
232146_at NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1,
6kDa
NDUFC1 4717 2
220841_s_at Abelson helper integration site AHI1 54806 2
45749_at family with sequence similarity 65, member A FAM65A 79567 2
201380_at cartilage associated protein CRTAP 10491 2
219532_at elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3,
yeast)-like 4
ELOVL4 6785 2
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221570_s_at methyltransferase like 5 METTL5 29081 2
201420_s_at WD repeat domain 77 WDR77 79084 2
202470_s_at cleavage and polyadenylation specific factor 6, 68kDa CPSF6 11052 2
225110_at hypothetical protein FLJ10826 FLJ10826 55239 2
202985_s_at BCL2-associated athanogene 5 BAG5 9529 2
202461_at eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa EIF2B2 8892 2
229595_at coiled-coil-helix-coiled-coil-helix domain containing 4 CHCHD4 131474 2
204676_at chromosome 16 open reading frame 51 C16orf51 25880 2
212396_s_at KIAA0090 KIAA0090 23065 2
238688_at Tropomyosin 1 (alpha) TPM1 7168 2
207088_s_at solute carrier family 25 (mitochondrial carrier; oxoglutarate
carrier), member 11
SLC25A11 8402 2
222171_s_at PBX/knotted 1 homeobox 2 PKNOX2 63876 2
212103_at Karyopherin alpha 6 (importin alpha 7) KPNA6 23633 2
218111_s_at cytidine monophosphate N-acetylneuraminic acid synthetase CMAS 55907 2
215185_at hypothetical gene supported by AK024177 LOC441468 441468 2
204577_s_at clusterin associated protein 1 CLUAP1 23059 2
1556764_s_at Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3
dunce homolog, Drosophila)
PDE4D 5144 2
243948_at Echinoderm microtubule associated protein like 5 EML5 161436 2
220230_s_at cytochrome b5 reductase 2 CYB5R2 51700 2
203866_at notchless homolog 1 (Drosophila) NLE1 54475 2
229732_at ZFP-36 for a zinc finger protein HSZFP36 55552 2
228062_at nucleosome assembly protein 1-like 5 NAP1L5 266812 2
228445_at apoptosis-inducing factor (AIF)-like mitochondrion-associated
inducer of death
AMID 84883 2
210418_s_at isocitrate dehydrogenase 3 (NAD+) beta IDH3B 3420 2
202212_at pescadillo homolog 1, containing BRCT domain (zebrafish) PES1 23481 2
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218224_at paraneoplastic antigen MA1 PNMA1 9240 2
217902_s_at hect domain and RLD 2 HERC2 8924 2
203515_s_at phosphomevalonate kinase PMVK 10654 2
201153_s_at muscleblind-like (Drosophila) MBNL1 4154 2
202102_s_at bromodomain containing 4 BRD4 23476 2
1559954_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 DDX42 11325 2
212025_s_at flightless I homolog (Drosophila) FLII 2314 2
200995_at Importin 7 IPO7 10527 2
210896_s_at aspartate beta-hydroxylase ASPH 444 2
226402_at cytochrome P450, family 2, subfamily U, polypeptide 1 CYP2U1 113612 2
213191_at toll-like receptor adaptor molecule 1 TICAM1 148022 2
225359_at DnaJ (Hsp40) homolog, subfamily C, member 19 DNAJC19 131118 2
202919_at preimplantation protein 3 PREI3 25843 2
212904_at leucine rich repeat containing 47 LRRC47 57470 2
226978_at peroxisome proliferative activated receptor, alpha PPARA 5465 2
203252_at CDK2-associated protein 2 CDK2AP2 10263 2
224994_at calcium/calmodulin-dependent protein kinase (CaM kinase) II
delta
CAMK2D 817 2
225406_at twisted gastrulation homolog 1 (Drosophila) TWSG1 57045 2
214999_s_at RAB11 family interacting protein 3 (class II) RAB11FIP3 9727 2
202721_s_at glutamine-fructose-6-phosphate transaminase 1 GFPT1 2673 2
202387_at BCL2-associated athanogene ; BCL2-associated athanogene BAG1 573 2
203692_s_at E2F transcription factor 3 E2F3 1871 2
201379_s_at tumor protein D52-like 2 TPD52L2 7165 2
212458_at sprouty-related, EVH1 domain containing 2 SPRED2 200734 2
227980_at HLA complex group 12 HCG12 493826 2
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200955_at inner membrane protein, mitochondrial (mitofilin) IMMT 10989 2
200974_at actin, alpha 2, smooth muscle, aorta ACTA2 59 2
221732_at calcium activated nucleotidase 1 CANT1 124583 2
236648_at Guanine monphosphate synthetase GMPS 8833 2
205547_s_at transgelin TAGLN 6876 2
225692_at calmodulin binding transcription activator 1 CAMTA1 23261 2
55065_at MAP/microtubule affinity-regulating kinase 4 MARK4 57787 2
203261_at dynactin 6 DCTN6 10671 2
224561_s_at mortality factor 4 like 1 MORF4L1 10933 2
209503_s_at proteasome (prosome, macropain) 26S subunit, ATPase, 5 PSMC5 5705 2
225521_at anaphase promoting complex subunit 7 ANAPC7 51434 2
201263_at threonyl-tRNA synthetase TARS 6897 2
200637_s_at protein tyrosine phosphatase, receptor type, F PTPRF 5792 2
202119_s_at copine III CPNE3 8895 2
222212_s_at LAG1 longevity assurance homolog 2 (S. cerevisiae) LASS2 29956 2
204963_at sarcospan (Kras oncogene-associated gene) SSPN 8082 2
200647_x_at eukaryotic translation initiation factor 3, subunit 8, 110kDa EIF3S8 8663 2
223178_s_at 5'-nucleotidase, cytosolic II-like 1 NT5C2L1 221294 2
222883_at chromosome 1 open reading frame 163 C1orf163 65260 2
203462_x_at eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa EIF3S9 8662 2
218938_at F-box and leucine-rich repeat protein 15 FBXL15 79176 2
218648_at transducer of regulated cAMP response element-binding protein
(CREB) 3
TORC3 64784 2
202695_s_at serine/threonine kinase 17a (apoptosis-inducing) STK17A 9263 2
203458_at sepiapterin reductase (7,8-dihydrobiopterin:NADP+
oxidoreductase)
SPR 6697 2
226002_at GRB2-associated binding protein 1 GAB1 2549 2
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213230_at paraneoplastic antigen HUMPPA 30850 2
222504_s_at COX4 neighbor COX4NB 10328 2
209608_s_at acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A
thiolase)
ACAT2 39 2
226592_at Hypothetical protein LOC286334 LOC286334 286334 2
213766_x_at guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2
226813_at Chromosome 1 open reading frame 57 MGC13186 84284 2
225731_at KIAA1223 protein KIAA1223 57182 2
208678_at ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E isoform 1 ATP6V1E1 529 2
223099_s_at peroxisomal LON protease like LONPL 83752 2
214484_s_at opioid receptor, sigma 1 OPRS1 10280 2
207645_s_at chromodomain helicase DNA binding protein 1-like CHD1L 9557 2
231086_at Beta-site APP-cleaving enzyme 1 BACE1 23621 2
217140_s_at voltage-dependent anion channel 1 VDAC1 7416 2
225492_at CCR4-NOT transcription complex, subunit 3 CNOT3 4849 2
203239_s_at Bobby sox homolog (Drosophila) BBX 56987 2
202914_s_at Rho guanine nucleotide exchange factor (GEF) 11 ARHGEF11 9826 2
200064_at heat shock 90kDa protein 1, beta ; heat shock 90kDa protein 1, beta HSPCB 3326 2
223437_at peroxisome proliferative activated receptor, alpha PPARA 5465 2
223909_s_at histone deacetylase 8 HDAC8 55869 2
229265_at Atrophin 1 DRPLA 1822 2
218816_at leucine rich repeat containing 1 LRRC1 55227 2
209155_s_at 5'-nucleotidase, cytosolic II NT5C2 22978 2
201152_s_at muscleblind-like (Drosophila) MBNL1 4154 2
201478_s_at dyskeratosis congenita 1, dyskerin DKC1 1736 2
224808_s_at chromosome 7 open reading frame 20 C7orf20 51608 2
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206953_s_at latrophilin 2 LPHN2 23266 2
211952_at RAN binding protein 5 RANBP5 3843 2
206388_at phosphodiesterase 3A, cGMP-inhibited PDE3A 5139 2
208660_at citrate synthase CS 1431 2
219737_s_at protocadherin 9 PCDH9 5101 2
223424_s_at zinc finger protein 38 ZNF38 7589 2
1557073_s_at Tau tubulin kinase 2 TTBK2 146057 2
203423_at retinol binding protein 1, cellular RBP1 5947 2
201199_s_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 PSMD1 5707 2
223147_s_at WD repeat domain 33 WDR33 55339 2
210011_s_at Ewing sarcoma breakpoint region 1 EWSR1 2130 2
37201_at inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive
glycoprotein)
ITIH4 3700 2
224729_s_at ATP synthase mitochondrial F1 complex assembly factor 1 ATPAF1 64756 2
205672_at xeroderma pigmentosum, complementation group A XPA 7507 2
36553_at acetylserotonin O-methyltransferase-like ASMTL 8623 2
219244_s_at mitochondrial ribosomal protein L46 MRPL46 26589 2
205665_at tetraspanin 9 TSPAN9 10867 2
243816_at Zinc finger protein 70 (Cos17) ZNF70 7621 2
241206_at Alpha-2-macroglobulin A2M 2 2
221588_x_at aldehyde dehydrogenase 6 family, member A1 ALDH6A1 4329 2
240928_at Chromosome 14 open reading frame 111 C14orf111 51077 2
201059_at cortactin CTTN 2017 2
217842_at LUC7-like 2 (S. cerevisiae) LUC7L2 51631 2
202361_at SEC24 related gene family, member C (S. cerevisiae) SEC24C 9632 2
225853_at glucosamine-phosphate N-acetyltransferase 1 GNPNAT1 64841 2
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1554867_a_at mesenchymal stem cell protein DSC54 LOC51334 51334 2
201056_at Golgi autoantigen, golgin subfamily b, macrogolgin (with
transmembrane signal), 1
GOLGB1 2804 2
218086_at neural proliferation, differentiation and control, 1 NPDC1 56654 2
221606_s_at nucleosomal binding protein 1 NSBP1 79366 2
226896_at coiled-coil-helix-coiled-coil-helix domain containing 1 CHCHD1 118487 2
212102_s_at karyopherin alpha 6 (importin alpha 7) KPNA6 23633 2
230274_s_at Rabaptin, RAB GTPase binding effector protein 1 RABEP1 9135 2
201636_at fragile X mental retardation, autosomal homolog 1 FXR1 8087 2
217917_s_at dynein, cytoplasmic, light polypeptide 2A DNCL2A 83658 2
206050_s_at ribonuclease/angiogenin inhibitor 1 RNH1 6050 2
32402_s_at symplekin SYMPK 8189 2
205803_s_at transient receptor potential cation channel, subfamily C, member
1
TRPC1 7220 2
201327_s_at chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A 908 2
205516_x_at CDKN1A interacting zinc finger protein 1 CIZ1 25792 2
201138_s_at Sjogren syndrome antigen B (autoantigen La) SSB 6741 2
233082_at zinc finger protein 630 ZNF630 57232 2
225144_at bone morphogenetic protein receptor, type II (serine/threonine
kinase)
BMPR2 659 2
222737_s_at bromodomain containing 7 BRD7 29117 2
216976_s_at RYK receptor-like tyrosine kinase RYK 6259 2
203529_at protein phosphatase 6, catalytic subunit PPP6C 5537 2
223328_at SVH protein SVH 83787 2
203724_s_at rap2 interacting protein x RIPX 22902 2
213272_s_at promethin LOC57146 57146 2
220293_at chromosome 14 open reading frame 161 C14orf161 79820 2
225252_at sulfiredoxin 1 homolog (S. cerevisiae) SRXN1 140809 2
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202125_s_at amyotrophic lateral sclerosis 2 (juvenile) chromosome region,
candidate 3
ALS2CR3 66008 2
226090_x_at RAB, member of RAS oncogene family-like 3 RABL3 285282 2
200635_s_at protein tyrosine phosphatase, receptor type, F PTPRF 5792 2
217776_at retinol dehydrogenase 11 (all-trans and 9-cis) RDH11 51109 2
203119_at hypothetical protein MGC2574 MGC2574 79080 2
212818_s_at ankyrin repeat and SOCS box-containing 1 ASB1 51665 2
41113_at zinc finger protein 500 ZNF500 26048 2
202415_s_at hsp70-interacting protein HSPBP1 23640 2
225118_at PR/SET domain containing protein 8 SET8 387893 2
203192_at ATP-binding cassette, sub-family B (MDR/TAP), member 6 ABCB6 10058 2
231765_at zinc finger, FYVE domain containing 20 ZFYVE20 64145 2
218415_at vacuolar protein sorting 33B (yeast) VPS33B 26276 2
1565830_at KIAA1731 KIAA1731 85459 2
1554555_a_at hypothetical protein FLJ21148 FLJ21148 79918 2
214736_s_at adducin 1 (alpha) ADD1 118 2
200758_s_at nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
205066_s_at ectonucleotide pyrophosphatase/phosphodiesterase 1 ENPP1 5167 2
224928_at SET domain-containing protein 7 SET7 80854 2
227587_at hypothetical protein FLJ12949 FLJ12949 65095 2
205008_s_at calcium and integrin binding family member 2 CIB2 10518 2
203837_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 2
223240_at F-box protein 8 FBXO8 26269 2
209316_s_at HBS1-like (S. cerevisiae) HBS1L 10767 2
219188_s_at LRP16 protein LRP16 28992 2
235195_at F-box and WD-40 domain protein 2 FBXW2 26190 2
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218377_s_at chromosome 21 open reading frame 6 C21orf6 10069 2
222841_s_at translocase of inner mitochondrial membrane 22 homolog (yeast) TIMM22 29928 2
212076_at myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
Drosophila)
MLL 4297 2
200816_s_at platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit
45kDa
PAFAH1B1 5048 2
221813_at F-box protein 42 FBXO42 54455 2
200876_s_at proteasome (prosome, macropain) subunit, beta type, 1 PSMB1 5689 2
217737_x_at chromosome 20 open reading frame 43 C20orf43 51507 2
238719_at Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform PPP2CA 5515 2
214168_s_at tight junction protein 1 (zona occludens 1) TJP1 7082 2
213213_at death associated transcription factor 1 DATF1 11083 2
227203_at F-box and leucine-rich repeat protein 17 FBXL17 64839 2
210014_x_at isocitrate dehydrogenase 3 (NAD+) beta IDH3B 3420 2
203937_s_at TATA box binding protein (TBP)-associated factor, RNA polymerase
I, C, 110kDa
TAF1C 9013 2
223398_at chromosome 9 open reading frame 89 C9orf89 84270 2
218199_s_at nucleolar protein family 6 (RNA-associated) NOL6 65083 2
202500_at DnaJ (Hsp40) homolog, subfamily B, member 2 DNAJB2 3300 2
219838_at tetratricopeptide repeat domain 23 TTC23 64927 2
223092_at ankylosis, progressive homolog (mouse) ANKH 56172 2
209895_at protein tyrosine phosphatase, non-receptor type 11 (Noonan
syndrome 1)
PTPN11 5781 2
201247_at sterol regulatory element binding transcription factor 2 SREBF2 6721 2
225277_at solute carrier family 39 (zinc transporter), member 13 SLC39A13 91252 2
223622_s_at hydroxypyruvate isomerase homolog (E. coli) HYI 81888 2
226925_at acid phosphatase-like 2 ACPL2 92370 2
201251_at pyruvate kinase, muscle PKM2 5315 2
218276_s_at salvador homolog 1 (Drosophila) SAV1 60485 2
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59999_at hypoxia-inducible factor 1, alpha subunit inhibitor HIF1AN 55662 2
219338_s_at leucine rich repeat containing 49 LRRC49 54839 2
219427_at FAT tumor suppressor homolog 4 (Drosophila) FAT4 79633 2
203614_at UTP14, U3 small nucleolar ribonucleoprotein, homolog C (yeast) UTP14C 9724 2
203565_s_at menage a trois 1 (CAK assembly factor) MNAT1 4331 2
209428_s_at zinc finger protein-like 1 ZFPL1 7542 2
224699_s_at family with sequence similarity 62 (C2 domain containing)
member B
FAM62B 57488 2
217980_s_at mitochondrial ribosomal protein L16 MRPL16 54948 2
226350_at choroideremia-like (Rab escort protein 2) CHML 1122 2
226209_at NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa NDUFV3 4731 2
217957_at gene trap locus 3 (mouse) GTL3 29105 2
215199_at caldesmon 1 CALD1 800 2
218908_at alveolar soft part sarcoma chromosome region, candidate 1 ASPSCR1 79058 2
203339_at solute carrier family 25 (mitochondrial carrier, Aralar), member 12 SLC25A12 8604 2
214170_x_at fumarate hydratase FH 2271 2
225779_at solute carrier family 27 (fatty acid transporter), member 4 SLC27A4 10999 2
214780_s_at myosin IXB MYO9B 4650 2
225588_s_at hypothetical protein BC009331 LOC92305 92305 2
202098_s_at HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) HRMT1L1 3275 2
207440_at solute carrier family 35 (UDP-galactose transporter), member A2 SLC35A2 7355 2
203078_at cullin 2 CUL2 8453 2
215046_at hypothetical protein FLJ23861 FLJ23861 151050 2
203893_at TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa
TAF9 6880 2
225838_at enhancer of polycomb homolog 2 (Drosophila) EPC2 26122 2
226137_at AT-binding transcription factor 1 ATBF1 463 2
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218061_at male-enhanced antigen 1 MEA1 4201 2
226380_at Protein tyrosine phosphatase, non-receptor type 21 PTPN21 11099 2
201504_s_at translin TSN 7247 2
208767_s_at lysosomal associated protein transmembrane 4 beta LAPTM4B 55353 2
203955_at KIAA0649 KIAA0649 9858 2
46270_at ubiquitin associated protein 1 UBAP1 51271 2
219072_at B-cell CLL/lymphoma 7C BCL7C 9274 2
221647_s_at resistance to inhibitors of cholinesterase 8 homolog A (C. elegans) RIC8A 60626 2
230326_s_at hypothetical protein HSPC138 HSPC138 51501 2
205878_at POU domain, class 6, transcription factor 1 POU6F1 5463 2
40148_at amyloid beta (A4) precursor protein-binding, family B, member 2
(Fe65-like)
APBB2 323 2




283 ; 6038 2
218607_s_at SDA1 domain containing 1 SDAD1 55153 2
242789_at phosphodiesterase 1A, calmodulin-dependent PDE1A 5136 2





225271_at transmembrane protein 63B TMEM63B 55362 2
202622_s_at ataxin 2 ATXN2 6311 2
213133_s_at glycine cleavage system protein H (aminomethyl carrier) GCSH 2653 2
1554679_a_at lysosomal associated protein transmembrane 4 beta LAPTM4B 55353 2
213394_at mitogen activated protein kinase binding protein 1 MAPKBP1 23005 2
218148_at hypothetical protein FLJ13111 FLJ13111 80152 2
235635_at Rho GTPase activating protein 5 ARHGAP5 394 2
203198_at cyclin-dependent kinase 9 (CDC2-related kinase) CDK9 1025 2
226666_at Dishevelled associated activator of morphogenesis 1 DAAM1 23002 2
202397_at nuclear transport factor 2 NUTF2 10204 2
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200778_s_at septin 2 Sep-02 4735 2
226987_at RNA binding motif protein 15B RBM15B 29890 2
216484_x_at
Hepatoma-derived growth factor (high-mobility group protein 1-
like) HDGF 3068 2
1554691_a_at protein kinase C and casein kinase substrate in neurons 2 PACSIN2 11252 2
208680_at peroxiredoxin 1 PRDX1 5052 2
210638_s_at F-box protein 9 FBXO9 26268 2
211256_x_at butyrophilin, subfamily 2, member A1 BTN2A1 11120 2
212128_s_at dystroglycan 1 (dystrophin-associated glycoprotein 1) DAG1 1605 2
203017_s_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 117178 2
1566603_s_at RNA pseudouridylate synthase domain containing 3 RPUSD3 285367 2
202947_s_at glycophorin C (Gerbich blood group) GYPC 2995 2
200913_at
protein phosphatase 1G (formerly 2C), magnesium-dependent,
gamma isoform PPM1G 5496 2
225196_s_at mitochondrial ribosomal protein S26 MRPS26 64949 2
220182_at
solute carrier family 25 (mitochondrial carrier; phosphate carrier),
member 23 SLC25A23 79085 2
221779_at MICAL-like 1 MICAL-L1 85377 2
232649_at Gliomedin COLM 342035 2
223236_at hypothetical protein DKFZp434K1421 DKFZP434K1421 84081 2
229312_s_at G kinase anchoring protein 1 GKAP1 80318 2
35617_at mitogen-activated protein kinase 7 MAPK7 5598 2
212719_at PH domain and leucine rich repeat protein phosphatase PHLPP 23239 2
1554016_a_at hypothetical protein FLJ13154 FLJ13154 79650 2
210306_at l(3)mbt-like (Drosophila) L3MBTL 26013 2
201509_at isocitrate dehydrogenase 3 (NAD+) beta IDH3B 3420 2
212026_s_at exocyst complex component 7 EXOC7 23265 2
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213449_at processing of precursor 1, ribonuclease P/MRP subunit (S. cerevisiae) POP1 10940 2
223701_s_at ubiquitin specific peptidase 47 USP47 55031 2
226696_at retinoblastoma binding protein 9 RBBP9 10741 2
226151_x_at crystallin, zeta (quinone reductase)-like 1 CRYZL1 9946 2
223057_s_at exportin 5 XPO5 57510 2
206113_s_at RAB5A, member RAS oncogene family RAB5A 5868 2
214369_s_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) RASGRP2 10235 2
1555122_at G protein-coupled receptor 125 GPR125 166647 2
225679_at chromosome 14 open reading frame 35 C14orf35 122830 2
218405_at activator of basal transcription 1 ABT1 29777 2
218375_at nudix (nucleoside diphosphate linked moiety X)-type motif 9 NUDT9 53343 2
222801_s_at stromal antigen 3-like FLJ13195 64940 2
202915_s_at family with sequence similarity 20, member B FAM20B 9917 2
222903_s_at cytoplasmic polyadenylation element binding protein 1 CPEB1 64506 2
202862_at fumarylacetoacetate hydrolase (fumarylacetoacetase) FAH 2184 2
201081_s_at phosphatidylinositol-4-phosphate 5-kinase, type II, beta PIP5K2B 8396 2
200001_at calpain, small subunit 1 ; calpain, small subunit 1 CAPNS1 826 2
201632_at eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa EIF2B1 1967 2
208821_at small nuclear ribonucleoprotein polypeptides B and B1 SNRPB 6628 2
219113_x_at dehydrogenase/reductase (SDR family) member 10 DHRS10 51171 2
211051_s_at exostoses (multiple)-like 3 ; exostoses (multiple)-like 3 EXTL3 2137 2
225289_at signal transducer and activator of transcription 3 (acute-phase
response factor)
STAT3 6774 2
225031_at chromodomain helicase DNA binding protein 6 CHD6 84181 2
211467_s_at nuclear factor I/B NFIB 4781 2
200662_s_at translocase of outer mitochondrial membrane 20 homolog (yeast) TOMM20 9804 2
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226764_at hypothetical protein LOC152485 LOC152485 152485 2
201255_x_at HLA-B associated transcript 3 BAT3 7917 2
226202_at zinc finger protein 398 ZNF398 57541 2
44696_at TBC1 domain family, member 13 TBC1D13 54662 2
214687_x_at aldolase A, fructose-bisphosphate ALDOA 226 2
216199_s_at mitogen-activated protein kinase kinase kinase 4 MAP3K4 4216 2
216389_s_at WD repeat domain 23 WDR23 80344 2
226386_at chromosome 7 open reading frame 30 C7orf30 115416 2
209466_x_at pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1)
PTN 5764 2
201162_at insulin-like growth factor binding protein 7 IGFBP7 3490 2
204610_s_at hepatitis delta antigen-interacting protein A DIPA 11007 2
202088_at solute carrier family 39 (zinc transporter), member 6 SLC39A6 25800 2
232662_x_at Chromosome 10 open reading frame 58 C10orf58 84293 2
218229_s_at pogo transposable element with KRAB domain POGK 57645 2
231857_s_at hypothetical protein FLJ21839 FLJ21839 60509 2
202405_at TIA1 cytotoxic granule-associated RNA binding protein-like 1 TIAL1 7073 2
232207_at hypothetical protein LOC285749 LOC285749 285749 2
1555216_a_at LOC440450 LOC440450 440450 2
1553679_s_at vitamin K epoxide reductase complex, subunit 1-like 1 VKORC1L1 154807 2
212590_at related RAS viral (r-ras) oncogene homolog 2 RRAS2 22800 2
201388_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 PSMD3 5709 2
203151_at microtubule-associated protein 1A MAP1A 4130 2
212329_at SREBP cleavage-activating protein SCAP 22937 2
219919_s_at slingshot homolog 3 (Drosophila) SSH3 54961 2
212069_s_at KIAA0515 KIAA0515 84726 2
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228614_at hypothetical protein LOC205251 LOC205251 205251 2
214383_x_at kelch domain containing 3 KLHDC3 116138 2
226082_s_at splicing factor, arginine/serine-rich 15 SFRS15 57466 2
238818_at KIAA1429 KIAA1429 25962 2
219120_at hypothetical protein FLJ21945 FLJ21945 80304 2
218497_s_at ribonuclease H1 RNASEH1 246243 2
1558109_x_at chromosome 20 open reading frame 80 C20orf80 91222 2
208353_x_at ankyrin 1, erythrocytic ANK1 286 2
209055_s_at CDC5 cell division cycle 5-like (S. pombe) CDC5L 988 2
228301_x_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10,
22kDa
NDUFB10 4716 2
200993_at importin 7 IPO7 10527 2
229068_at chaperonin containing TCP1, subunit 5 (epsilon) CCT5 22948 2
203959_s_at zinc finger and BTB domain containing 40 ZBTB40 9923 2
218341_at phosphopantothenoylcysteine synthetase PPCS 79717 2
225457_s_at DKFZP564I1171 protein DKFZP564I1171 25845 2
203933_at RAB11 family interacting protein 3 (class II) RAB11FIP3 9727 2
207629_s_at rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2 9181 2
223811_s_at chromosome 7 open reading frame 20 C7orf20 51608 2
210094_s_at par-3 partitioning defective 3 homolog (C. elegans) PARD3 56288 2
227963_at FLJ35696 protein FLJ35696 388341 2
221822_at hypothetical protein BC011981 LOC112869 112869 2
204381_at low density lipoprotein receptor-related protein 3 LRP3 4037 2
220974_x_at sideroflexin 3 ; sideroflexin 3 SFXN3 81855 2
224940_s_at pregnancy-associated plasma protein A, pappalysin 1 PAPPA 5069 2
208880_s_at chromosome 20 open reading frame 14 C20orf14 24148 2
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225048_at PHD finger protein 10 PHF10 55274 2
209668_x_at carboxylesterase 2 (intestine, liver) CES2 8824 2
213043_s_at thyroid hormone receptor associated protein 4 THRAP4 9862 2
229100_s_at translocase of inner mitochondrial membrane 22 homolog (yeast) TIMM22 29928 2
49077_at protein phosphatase methylesterase-1 PME-1 51400 2
217802_s_at nuclear casein kinase and cyclin-dependent kinase substrate 1 NUCKS1 64710 2
208620_at poly(rC) binding protein 1 PCBP1 5093 2
219576_at hypothetical protein FLJ12649 FLJ12649 79649 2
226297_at Homeodomain interacting protein kinase 3 HIPK3 10114 2
217734_s_at WD repeat domain 6 WDR6 11180 2
218339_at mitochondrial ribosomal protein L22 MRPL22 29093 2
224707_at putative nuclear protein ORF1-FL49 ORF1-
FL49
84418 2
213104_at hypothetical protein MGC24381 MGC24381 115939 2
216511_s_at transcription factor 7-like 2 (T-cell specific, HMG-box) TCF7L2 6934 2
203478_at NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa NDUFC1 4717 2
225267_at karyopherin alpha 4 (importin alpha 3) KPNA4 3840 2
223249_at claudin 12 CLDN12 9069 2
203054_s_at T-cell leukemia translocation altered gene TCTA 6988 2
224690_at chromosome 20 open reading frame 108 C20orf108 116151 2
212441_at KIAA0232 gene product KIAA0232 9778 2
208002_s_at acyl-CoA thioesterase 7 ACOT7 11332 2
226295_at uncharacterized hematopoietic stem/progenitor cells protein MDS028 MDS028 55846 2
201080_at Phosphatidylinositol-4-phosphate 5-kinase, type II, beta PIP5K2B 8396 2
214263_x_at polymerase (RNA) II (DNA directed) polypeptide C, 33kDa POLR2C 5432 2
227573_s_at obscurin-like 1 OBSL1 23363 2
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200684_s_at ubiquitin-conjugating enzyme E2L 3 UBE2L3 7332 2
223315_at netrin 4 NTN4 59277 2
203278_s_at PHD finger protein 21A PHF21A 51317 2
242207_at Chromosome 9 open reading frame 12 C9orf12 64768 2
224763_at ribosomal protein L37 RPL37 6167 2
201076_at NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) NHP2L1 4809 2
202810_at developmentally regulated GTP binding protein 1 DRG1 4733 2
216833_x_at glycophorin B (includes Ss blood group) ; glycophorin E GYPB ; GYPE 2994 ;
2996
2
213943_at twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen
syndrome) (Drosophila)
TWIST1 7291 2
202536_at chromatin modifying protein 2B CHMP2B 25978 2
205133_s_at heat shock 10kDa protein 1 (chaperonin 10) HSPE1 3336 2
211684_s_at dynein, cytoplasmic, intermediate polypeptide 2 DNCI2 1781 2
203512_at trafficking protein particle complex 3 TRAPPC3 27095 2
201135_at enoyl Coenzyme A hydratase, short chain, 1, mitochondrial ECHS1 1892 2
235263_at DKFZp434A0131 protein DKFZP434A0131 54441 2
217564_s_at carbamoyl-phosphate synthetase 1, mitochondrial CPS1 1373 2
212092_at paternally expressed 10 PEG10 23089 2
230660_at SERTA domain containing 4 SERTAD4 56256 2
228002_at isopentenyl-diphosphate delta isomerase 2 IDI2 91734 2
219353_at NHL repeat containing 2 NHLRC2 374354 2
209362_at SRB7 suppressor of RNA polymerase B homolog (yeast) SURB7 9412 2
211950_at retinoblastoma-associated factor 600 RBAF600 23352 2
215464_s_at Tax1 (human T-cell leukemia virus type I) binding protein 3 TAX1BP3 30851 2
203016_s_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 117178 2
226254_s_at KIAA1430 KIAA1430 57587 2
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40560_at T-box 2 TBX2 6909 2
228949_at chromosome 1 open reading frame 139 C1orf139 79971 2
211955_at RAN binding protein 5 RANBP5 3843 2
201817_at ubiquitin protein ligase E3C UBE3C 9690 2
218955_at BRF2, subunit of RNA polymerase III transcription initiation factor,
BRF1-like
BRF2 55290 2
220145_at ASAP FLJ21159 79884 2
225317_at Importin 7 IPO7 10527 2
231130_at acyl-Coenzyme A binding domain containing 6 ACBD6 84320 2
200992_at FK506 binding protein 7 FKBP7 51661 2
218752_at importin 7 IPO7 10527 2
51192_at zinc finger, matrin type 5 ZMAT5 55954 2
211475_s_at slingshot homolog 3 (Drosophila) SSH3 54961 2
1553140_at BCL2-associated athanogene BAG1 573 2
225889_at pelota homolog (Drosophila) PELO 53918 2
219636_s_at AE binding protein 2 AEBP2 121536 2
213058_at armadillo repeat containing 9 ARMC9 80210 2
225772_s_at KIAA1043 protein KIAA1043 23331 2
208742_s_at hypothetical protein MGC14288 MGC14288 84987 2
225135_at sin3-associated polypeptide, 18kDa SAP18 10284 2
225421_at SIN3 homolog A, transcription regulator (yeast) SIN3A 25942 2
228261_at aminoacylase 1-like 2 ACY1L2 135293 2
224749_at mindbomb homolog 2 (Drosophila) MIB2 142678 2
212559_at chromosome 16 open reading frame 9 C16orf9 83986 2
201220_x_at protein kinase, cAMP-dependent, regulatory, type I, beta PRKAR1B 5575 2
217814_at C-terminal binding protein 2 CTBP2 1488 2
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222409_at GK001 protein GK001 57003 2
234921_at coronin, actin binding protein, 1C CORO1C 23603 2
212369_at FLJ26175 protein FLJ26175 388566 2
59697_at zinc finger protein 384 ZNF384 171017 2
202646_s_at RAB15, member RAS onocogene family RAB15 376267 2
214179_s_at cold shock domain containing E1, RNA-binding CSDE1 7812 2
235634_at nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
212309_at purine-rich element binding protein G PURG 29942 2
225038_s_at cytoplasmic linker associated protein 2 CLASP2 23122 2
201754_at surfeit 6 SURF6 6838 2
225863_s_at cytochrome c oxidase subunit VIc COX6C 1345 2
227998_at chromosome 19 open reading frame 12 C19orf12 83636 2
203602_s_at S100 calcium binding protein A16 S100A16 140576 2
221812_at zinc finger and BTB domain containing 17 ZBTB17 7709 2
225268_at F-box protein 42 FBXO42 54455 2
200676_s_at karyopherin alpha 4 (importin alpha 3) KPNA4 3840 2
210574_s_at ubiquitin-conjugating enzyme E2L 3 UBE2L3 7332 2
224560_at nuclear distribution gene C homolog (A. nidulans) NUDC 10726 2
213132_s_at TIMP metallopeptidase inhibitor 2 TIMP2 7077 2
218225_at malonyl-CoA:acyl carrier protein transacylase, mitochondrial MT 27349 2
203038_at signaling intermediate in Toll pathway, evolutionarily conserved SITPEC 51295 2
214876_s_at protein tyrosine phosphatase, receptor type, K PTPRK 5796 2
209465_x_at tubulin, gamma complex associated protein 5 TUBGCP5 114791 2
227449_at pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1)
PTN 5764 2
228397_at EPH receptor A4 EPHA4 2043 2
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225735_at taurine upregulated gene 1 TUG1 55000 2
201030_x_at KIAA1223 protein KIAA1223 57182 2
222704_at lactate dehydrogenase B LDHB 3945 2
235068_at polymerase (RNA) I polypeptide A, 194kDa POLR1A 25885 2
202559_x_at zinc finger, DHHC-type containing 21 ZDHHC21 340481 2
213946_s_at chromosome 1 open reading frame 77 C1orf77 26097 2
225866_at obscurin-like 1 OBSL1 23363 2
212218_s_at brix domain containing 1 BXDC1 84154 2
1554106_at fatty acid synthase FASN 2194 2
219825_at amyotrophic lateral sclerosis 2 (juvenile) chromosome region,
candidate 16
ALS2CR16 130029 2
208316_s_at cytochrome P450, family 26, subfamily B, polypeptide 1 CYP26B1 56603 2
218074_at oculocerebrorenal syndrome of Lowe OCRL 4952 2
227470_at family with sequence similarity 96, member B FAM96B 51647 2
209186_at zinc finger protein 553 ZNF553 197407 2
213361_at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP2A2 488 2
200910_at tudor domain containing 7 TDRD7 23424 2
50376_at chaperonin containing TCP1, subunit 3 (gamma) CCT3 7203 2
228084_at zinc finger protein 444 ZNF444 55311 2
228813_at histone deacetylase 4 HDAC4 9759 2
208696_at chaperonin containing TCP1, subunit 5 (epsilon) CCT5 22948 2
1553995_a_at 5'-nucleotidase, ecto (CD73) NT5E 4907 2
212300_at taxilin alpha TXLNA 200081 2
228992_at Mediator of RNA polymerase II transcription, subunit 28 homolog
(yeast)
MED28 80306 2
228423_at ASAP FLJ21159 79884 2
207732_s_at discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3 1741 2
217608_at p18 splicing regulatory protein P18SRP 285672 2
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225184_at AT rich interactive domain 1B (SWI1-like) ARID1B 57492 2
226319_s_at THO complex 4 THOC4 10189 2
219399_at lin-7 homolog C (C. elegans) LIN7C 55327 2
215096_s_at esterase D/formylglutathione hydrolase ESD 2098 2
212324_s_at vacuolar protein sorting 13D (yeast) VPS13D 55187 2
1555702_a_at ST3 beta-galactoside alpha-2,3-sialyltransferase 3 ST3GAL3 6487 2
200786_at proteasome (prosome, macropain) subunit, beta type, 7 PSMB7 5695 2
1555831_s_at leucine rich repeat containing 41 LRRC41 10489 2
229009_at sine oculis homeobox homolog 5 (Drosophila) SIX5 147912 2
215427_s_at zinc finger, CCHC domain containing 14 ZCCHC14 23174 2
207268_x_at abl interactor 2 ABI2 10152 2
229038_at CWF19-like 1, cell cycle control (S. pombe) CWF19L1 55280 2
211871_x_at guanine nucleotide binding protein (G protein), beta 5 GNB5 10681 2
218089_at chromosome 20 open reading frame 4 C20orf4 25980 2
208619_at damage-specific DNA binding protein 1, 127kDa DDB1 1642 2
204303_s_at KIAA0427 KIAA0427 9811 2
203718_at neuropathy target esterase NTE 10908 2
238515_at Nudix (nucleoside diphosphate linked moiety X)-type motif 16 FLJ31265 131870 2
208765_s_at heterogeneous nuclear ribonucleoprotein R HNRPR 10236 2
205606_at low density lipoprotein receptor-related protein 6 LRP6 4040 2
217225_x_at NODAL modulator 2 NOMO2 283820 2
206355_at guanine nucleotide binding protein (G protein), alpha activating activity
polypeptide, olfactory type
GNAL 2774 2
205412_at acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl Coenzyme A
thiolase)
ACAT1 38 2
219157_at kelch-like 2, Mayven (Drosophila) KLHL2 11275 2
238653_at Leucine-rich repeats and immunoglobulin-like domains 2 LRIG2 9860 2
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208830_s_at suppressor of Ty 6 homolog (S. cerevisiae) SUPT6H 6830 2
221759_at glucose 6 phosphatase, catalytic, 3 G6PC3 92579 2
201186_at
low density lipoprotein receptor-related protein associated
protein 1 LRPAP1 4043 2
200894_s_at FK506 binding protein 4, 59kDa FKBP4 2288 2
212234_at additional sex combs like 1 (Drosophila) ASXL1 171023 2
218442_at tetratricopeptide repeat domain 4 TTC4 7268 2
225560_at protein-O-mannosyltransferase 2 POMT2 29954 2
202932_at v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 YES1 7525 2
213313_at RAB GTPase activating protein 1 RABGAP1 23637 2
226183_at Glycogen synthase kinase 3 beta GSK3B 2932 2
202675_at succinate dehydrogenase complex, subunit B, iron sulfur (Ip) SDHB 6390 2
1554291_at KIAA0701 protein KIAA0701 23074 2
209715_at chromobox homolog 5 (HP1 alpha homolog, Drosophila) CBX5 23468 2
203051_at bromo adjacent homology domain containing 1 BAHD1 22893 2
223370_at pleckstrin homology domain containing, family A PLEKHA3 65977 2
228662_at Suppressor of cytokine signaling 7 SOCS7 30837 2
218997_at polymerase (RNA) I associated factor 1 PRAF1 64425 2
219261_at chromosome 7 open reading frame 26 C7orf26 79034 2
AFFX-HUMGAPDH glyceraldehyde-3-phosphate dehydrogenase GAPDH 2597 2
222800_at tRNA selenocysteine associated protein SECP43 54952 2
231974_at myeloid/lymphoid or mixed-lineage leukemia 2 MLL2 8085 2
209296_at
protein phosphatase 1B (formerly 2C), magnesium-dependent,
beta isoform PPM1B 5495 2
220517_at vacuolar protein sorting 13C (yeast) VPS13C 54832 2
215749_s_at golgi reassembly stacking protein 1, 65kDa GORASP1 64689 2
210986_s_at tropomyosin 1 (alpha) TPM1 7168 2
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220500_s_at RAB, member of RAS oncogene family-like 2B ; RAB, member of






222019_at HLA class II region expressed gene KE2 HKE2 10471 2
212954_at dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 DYRK4 8798 2
203611_at telomeric repeat binding factor 2 TERF2 7014 2
213694_at round spermatid basic protein 1 RSBN1 54665 2
202048_s_at chromobox homolog 6 CBX6 23466 2
210266_s_at tripartite motif-containing 33 TRIM33 51592 2
224727_at hypothetical protein LOC284361 LOC284361 284361 2
209814_at zinc finger protein 330 ZNF330 27309 2
200046_at defender against cell death 1 ; defender against cell death 1 DAD1 1603 2
225658_at hypothetical protein LOC339745 LOC339745 339745 2
217969_at chromosome 11 open reading frame2 C11orf2 738 2
225170_at WD repeat domain 5 WDR5 11091 2
201962_s_at ring finger protein 41 RNF41 10193 2
227270_at hypothetical protein LOC285550 LOC285550 285550 2
208950_s_at aldehyde dehydrogenase 7 family, member A1 ALDH7A1 501 2
218697_at NCK interacting protein with SH3 domain NCKIPSD 51517 2
201581_at thioredoxin domain containing 13 TXNDC13 56255 2
204149_s_at glutathione S-transferase M4 GSTM4 2948 2
224370_s_at calcyphosine 2 ; calcyphosine 2 CAPS2 84698 2
203875_at SWI/SNF related, matrix associated, actin dependent regulator of
chromatin
SMARCA1 6594 2
202136_at zinc finger, MYND domain containing 11 ZMYND11 10771 2
226781_at hypothetical protein HSPC268 HSPC268 154791 2
210142_x_at flotillin 1 FLOT1 10211 2
238929_at Splicing factor, arginine/serine-rich, 46kD SRP46 10929 2
201696_at splicing factor, arginine/serine-rich 4 SFRS4 6429 2
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213286_at zinc finger RNA binding protein ZFR 51663 2
209982_s_at neurexin 2 NRXN2 9379 2
202686_s_at AXL receptor tyrosine kinase AXL 558 2
220968_s_at tetraspanin 9 ; tetraspanin 9 TSPAN9 10867 2
213838_at nucleolar protein 7, 27kDa NOL7 51406 2
221538_s_at plexin A1 PLXNA1 5361 2
204690_at syntaxin 8 STX8 9482 2
225370_at pygopus homolog 2 (Drosophila) PYGO2 90780 2
235196_at Cell division cycle 73, Paf1/RNA polymerase II complex component,
homolog (S. cerevisiae)
HRPT2 79577 2
224993_at hypothetical protein from EUROIMAGE 1669387 LOC56930 56930 2
208774_at casein kinase 1, delta CSNK1D 1453 2
201797_s_at valyl-tRNA synthetase VARS 7407 2
212762_s_at transcription factor 7-like 2 (T-cell specific, HMG-box) TCF7L2 6934 2
221699_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 ; DEAD (Asp-Glu-Ala-
Asp) box polypeptide 50
DDX50 79009 2
218898_at family with sequence similarity 57, member A FAM57A 79850 2
215198_s_at caldesmon 1 CALD1 800 2
208923_at cytoplasmic FMR1 interacting protein 1 CYFIP1 23191 2
AFFX-
HSAC07
actin, beta ACTB 60 2
202220_at KIAA0907 KIAA0907 22889 2
221851_at hypothetical protein BC002926 LOC90379 90379 2
202315_s_at breakpoint cluster region BCR 613 2
223150_s_at protein tyrosine phosphatase, non-receptor
type 23
PTPN23 25930 2
204640_s_at speckle-type POZ protein SPOP 8405 2
222439_s_at thyroid hormone receptor associated protein 3 THRAP3 9967 2
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218105_s_at mitochondrial ribosomal protein L4 MRPL4 51073 2
217913_at vacuolar protein sorting 4A (yeast) VPS4A 27183 2
225103_at mitochondrial ribosomal protein L38 MRPL38 64978 2
219348_at uncharacterized hematopoietic stem/progenitor cells protein
MDS032
MDS032 55850 2
202408_s_at PRP31 pre-mRNA processing factor 31 homolog (yeast) PRPF31 26121 2
200844_s_at peroxiredoxin 6 PRDX6 9588 2
217185_s_at zinc finger protein 259 ZNF259 8882 2
221564_at HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) HRMT1L1 3275 2
225611_at microtubule associated serine/threonine kinase family member 4 MAST4 23227 2
201057_s_at golgi autoantigen, golgin subfamily b, macrogolgin (with
transmembrane signal), 1
GOLGB1 2804 2
212053_at KIAA0251 protein KIAA0251 23042 2
200966_x_at aldolase A, fructose-bisphosphate ALDOA 226 2
214738_s_at NIMA (never in mitosis gene a)- related kinase 9 NEK9 91754 2
201472_at von Hippel-Lindau binding protein 1 VBP1 7411 2
242363_at Dynein, cytoplasmic, intermediate polypeptide 2 DNCI2 1781 2
209702_at fatso FTO 79068 2
227866_at RNA binding motif protein 16 RBM16 22828 2
228480_at VAMP (vesicle-associated membrane protein)-associated protein A,
33kDa
VAPA 9218 2
224163_s_at DNA methyltransferase 1 associated protein 1 DMAP1 55929 2
204166_at KIAA0963 KIAA0963 22904 2
212432_at GrpE-like 1, mitochondrial (E. coli) GRPEL1 80273 2
223469_at hypothetical protein MGC10812 MGC10812 83542 2
208627_s_at Y box binding protein 1 YBX1 4904 2
210208_x_at HLA-B associated transcript 3 BAT3 7917 2
226862_at methyl-CpG binding domain protein 1 MBD1 4152 2
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241872_at SH3-domain GRB2-like (endophilin) interacting protein 1 DKFZp761D221 84251 2





202121_s_at chromatin modifying protein 2A CHMP2A 27243 2
203884_s_at RAB11 family interacting protein 2 (class I) RAB11FIP2 22841 2
212819_at ankyrin repeat and SOCS box-containing 1 ASB1 51665 2
226857_at Rho guanine nucleotide exchange factor (GEF) 19 ARHGEF19 128272 2
218946_at HIRA interacting protein 5 HIRIP5 27247 2
226826_at LSM11, U7 small nuclear RNA associated LSM11 134353 2
212109_at chromosome 16 open reading frame 34 C16orf34 90861 2
208867_s_at casein kinase 1, alpha 1 CSNK1A1 1452 2
227500_at F-box and leucine-rich repeat protein 18 FBXL18 80028 2
222863_at zinc finger and BTB domain containing 10 ZBTB10 65986 2
202355_s_at general transcription factor IIF, polypeptide 1, 74kDa GTF2F1 2962 2
227669_at Brain protein 44 DKFZP564B167 25874 2
226726_at O-acyltransferase (membrane bound) domain containing 2 OACT2 129642 2
212408_at torsin A interacting protein 1 TOR1AIP1 26092 2
226946_at hypothetical protein FLJ30596 FLJ30596 133686 2
223027_at sorting nexin 9 SNX9 51429 2
238906_s_at ras homolog gene family, member J RHOJ 57381 2
217804_s_at interleukin enhancer binding factor 3, 90kDa ILF3 3609 2
222391_at transmembrane protein 30A TMEM30A 55754 2
203262_s_at family with sequence similarity 50, member A FAM50A 9130 2
212402_at KIAA0853 KIAA0853 23091 2
212987_at F-box protein 9 FBXO9 26268 2
208719_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 DDX17 10521 2
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228096_at chromosome 1 open reading frame 151 C1orf151 440574 2
211783_s_at metastasis associated 1 ; metastasis associated 1 MTA1 9112 2
236104_at Heterogeneous nuclear ribonucleoprotein L-like HNRPLL 92906 2
212037_at pinin, desmosome associated protein PNN 5411 2
1555015_a_at zinc finger protein 398 ZNF398 57541 2
201471_s_at sequestosome 1 SQSTM1 8878 2
200802_at seryl-tRNA synthetase SARS 6301 2
203785_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 DDX28 55794 2
235846_at RAD54 homolog B (S. cerevisiae) RAD54B 25788 2
1559946_s_at RuvB-like 2 (E. coli) RUVBL2 10856 2
208806_at chromodomain helicase DNA binding protein 3 CHD3 1107 2
200072_s_at heterogeneous nuclear ribonucleoprotein M ; heterogeneous
nuclear ribonucleoprotein M
HNRPM 4670 2
201594_s_at protein phosphatase 4, regulatory subunit 1 PPP4R1 9989 2
219366_at apoptosis, caspase activation inhibitor AVEN 57099 2
227113_at alcohol dehydrogenase, iron containing, 1 ADHFE1 137872 2
202161_at protein kinase N1 PKN1 5585 2
225232_at myotubularin related protein 12 MTMR12 54545 2
206348_s_at pyruvate dehydrogenase kinase, isoenzyme 3 PDK3 5165 2
204460_s_at RAD1 homolog (S. pombe) RAD1 5810 2
203832_at small nuclear ribonucleoprotein polypeptide F SNRPF 6636 2
205449_at SAC3 domain containing 1 SAC3D1 29901 2
224684_at Sorting nexin 12 SNX12 29934 2
225106_s_at hypothetical protein FLJ10826 FLJ10826 55239 2
201947_s_at chaperonin containing TCP1, subunit 2 (beta) CCT2 10576 2
201155_s_at mitofusin 2 MFN2 9927 2
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225347_at ADP-ribosylation factor-like 10B ARL10B 127829 2
203476_at trophoblast glycoprotein TPBG 7162 2
204104_at small nuclear RNA activating complex, polypeptide 2, 45kDa SNAPC2 6618 2
226820_at FLJ25476 protein FLJ25476 149076 2
224907_s_at SH3-domain GRB2-like endophilin B2 SH3GLB2 56904 2
222526_at GATA zinc finger domain containing 2A p66alpha 54815 2
204383_at DiGeorge syndrome critical region gene 14 DGCR14 8220 2
226481_at Vpr-binding protein VprBP 9730 2
224755_at SM-11044 binding protein SMBP 56889 2
217832_at synaptotagmin binding, cytoplasmic RNA interacting protein SYNCRIP 10492 2
212752_at cytoplasmic linker associated protein 1 CLASP1 23332 2
225076_s_at KIAA1404 protein KIAA1404 57169 2
224473_x_at leucine zipper, putative tumor suppressor 2 ; leucine zipper,
putative tumor suppressor 2
LZTS2 84445 2
214315_x_at calreticulin CALR 811 2
202669_s_at ephrin-B2 EFNB2 1948 2
226976_at Karyopherin alpha 6 (importin alpha 7) KPNA6 23633 2
205300_s_at U11/U12 snRNP 35K U1SNRNPBP 11066 2
213259_s_at sterile alpha and TIR motif containing 1 SARM1 23098 2
222425_s_at polymerase (DNA-directed), delta interacting protein 2 POLDIP2 26073 2
220150_s_at chromosome 6 open reading frame 60 C6orf60 79632 2
216060_s_at dishevelled associated activator of morphogenesis 1 DAAM1 23002 2
226580_at breast cancer metastasis-suppressor 1-like BRMS1L 84312 2
212166_at exportin 7 XPO7 23039 2
209113_s_at high-mobility group 20B HMG20B 10362 2
31846_at ras homolog gene family, member D RHOD 29984 2
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201119_s_at cytochrome c oxidase subunit 8A (ubiquitous) COX8A 1351 2
220198_s_at eukaryotic translation initiation factor 5A2 EIF5A2 56648 2
217816_s_at PEST-containing nuclear protein PCNP 57092 2
207320_x_at staufen, RNA binding protein (Drosophila) STAU 6780 2
214464_at CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA 8476 2
218626_at eukaryotic translation initiation factor 4E nuclear import factor 1 EIF4ENIF1 56478 2
218982_s_at mitochondrial ribosomal protein S17 MRPS17 51373 2
232837_at kinesin family member 13A KIF13A 63971 2
200718_s_at S-phase kinase-associated protein 1A (p19A) SKP1A 6500 2
213405_at RAB22A, member RAS oncogene family RAB22A 57403 2
219467_at hypothetical protein FLJ20125 FLJ20125 54826 2
1553216_at zinc finger protein 41 ZNF41 7592 2
220734_s_at hypothetical protein MGC10334 MGC10334 80772 2
200636_s_at protein tyrosine phosphatase, receptor type, F PTPRF 5792 2
210337_s_at ATP citrate lyase ACLY 47 2
201315_x_at interferon induced transmembrane protein 2 (1-8D) IFITM2 10581 2
217780_at PTD008 protein PTD008 51398 2
224706_at KIAA2013 KIAA2013 90231 2







208964_s_at fatty acid desaturase 1 FADS1 3992 2
200787_s_at phosphoprotein enriched in astrocytes 15 PEA15 8682 2
210474_s_at cell division cycle 2-like 1 (PITSLRE proteins) ; cell division cycle
2-like 2 (PITSLRE proteins)
CDC2L1 ;
CDC2L2
984 ; 985 2
213832_at Clone 24405 mRNA sequence 2
233123_at Solute carrier family 40 (iron-regulated transporter), member 1 SLC40A1 30061 2
202764_at stromal interaction molecule 1 STIM1 6786 2
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222735_at transmembrane protein 38B TMEM38B 55151 2
224659_at selenoprotein N, 1 SEPN1 57190 2
203342_at translocase of inner mitochondrial membrane 17 homolog B (yeast) TIMM17B 10245 2
213224_s_at hypothetical protein LOC92482 LOC92482 92482 2
222551_s_at chromosome 8 open reading frame 33 C8orf33 65265 2
209486_at disrupter of silencing 10 SAS10 57050 2
211855_s_at solute carrier family 25 (mitochondrial carrier, brain), member 14 SLC25A14 9016 2
201391_at TNF receptor-associated protein 1 TRAP1 10131 2
202472_at mannose phosphate isomerase MPI 4351 2
201842_s_at EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 2202 2
212134_at pleckstrin homology-like domain, family B, member 1 PHLDB1 23187 2
202012_s_at exostoses (multiple) 2 EXT2 2132 2
223041_at CD99 antigen-like 2 CD99L2 83692 2
226053_at mitogen-activated protein kinase kinase 7 MAP2K7 5609 2
227378_x_at hypothetical protein MGC13114 MGC13114 84326 2
225405_at Heterogeneous nuclear ribonucleoprotein U-like 2 DKFZp762N1910 221092 2
1554868_s_at PEST-containing nuclear protein PCNP 57092 2
203519_s_at UPF2 regulator of nonsense transcripts homolog (yeast) UPF2 26019 2
204617_s_at adrenocortical dysplasia homolog (mouse) ACD 65057 2
218782_s_at ATPase family, AAA domain containing 2 ATAD2 29028 2
209745_at coenzyme Q7 homolog, ubiquinone (yeast) COQ7 10229 2
223348_x_at melanoma associated antigen (mutated) 1 MUM1 84939 2
218408_at translocase of inner mitochondrial membrane 10 homolog (yeast) TIMM10 26519 2
219186_at zinc finger and BTB domain containing 7A ZBTB7A 51341 2
202180_s_at major vault protein MVP 9961 2
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224467_s_at hypothetical protein MGC13096 ; hypothetical protein MGC13096 MGC13096 84306 2
231200_at family with sequence similarity 61, member B FAM61B 149986 2
201580_s_at thioredoxin domain containing 13 TXNDC13 56255 2
216396_s_at etoposide induced 2.4 mRNA EI24 9538 2
203707_at zinc finger protein 263 ZNF263 10127 2
205146_x_at amyloid beta (A4) precursor protein-binding, family A, member 3
(X11-like 2)
APBA3 9546 2
203607_at inositol polyphosphate-5-phosphatase F INPP5F 22876 2
201945_at furin (paired basic amino acid cleaving enzyme) FURIN 5045 2
212161_at adaptor-related protein complex 2, alpha 2 subunit AP2A2 161 2
221847_at LOC440123 LOC440123 440123 2
219518_s_at elongation factor RNA polymerase II-like 3 ELL3 80237 2
202103_at bromodomain containing 4 BRD4 23476 2
201774_s_at chromosome condensation-related SMC-associated protein 1 CNAP1 9918 2
33494_at electron-transferring-flavoprotein dehydrogenase ETFDH 2110 2
235356_at NHL repeat containing 2 NHLRC2 374354 2








immunoglobulin heavy locus ; immunoglobulin heavy constant alpha 1 IGHA1 283650 18
Immunoglobulin lambda joining 3 IGLC2 3538 14
BCR downstream signaling 1 BRDG1 26228 10
Immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu
polypeptides IGJ 3512 8
membrane-spanning 4-domains, subfamily A, member 1 MS4A1 931 7
CD79A antigen (immunoglobulin-associated alpha) CD79A 973 6
Paired box gene 5 (B-cell lineage specific activator) PAX5 5079 5
membrane-spanning 4-domains, subfamily A, member 1 MS4A1 931 5
major histocompatibility complex, class II, DO beta HLA-DOB 3112 5
complement component 3 C3 718 4
chemokine (C-X3-C motif) receptor 1 CX3CR1 1524 4
toll-like receptor 10 TLR10 81793 4
CD19 CD19 930 4
Ras homolog gene family, member H RHOH 399 3
Spi-B transcription factor SPIB 6689 3
X-box binding protein 1 XBP1 7494 3
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 3
aldehyde oxidase 1 AOX1 316 3
absent in melanoma 2 AIM2 9447 3
Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif)
receptor 5) BLR1 643 3
immunoglobulin heavy constant gamma 1 (G1m marker) IGHG1 3500 3
C-type lectin domain family 2, member D CLEC2D 29121 3
CD79B antigen (immunoglobulin-associated beta) CD79B 974 3
Fas apoptotic inhibitory molecule 3 FAIM3 9214 2
ras homolog gene family, member H RHOH 399 2
ryanodine receptor 1 (skeletal) RYR1 6261 2
chemokine (C-C motif) ligand 13 CCL13 6357 2







interleukin 2 receptor, gamma (severe combined immunodeficiency) IL2RG 3561 2
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 2
sema domain, immunoglobulin domain (Ig) SEMA4D 10507 2






endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 EDG3 1903 3
fibronectin 1 FN1 2335 3
tumor necrosis factor, alpha-induced protein 6 TNFAIP6 7130 3
carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 CHST1 8534 3
peroxidasin homolog (Drosophila) PXDN 7837 2
UL16 binding protein 2 ULBP2 80328 2
chemokine (C-C motif) receptor 1 CCR1 1230 2
solute carrier family 11 (proton-coupled divalent metal ion transporters),
member 1 SLC11A1 6556 2
stabilin 1 STAB1 23166 2







UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 B3GALT2 8707 9
activin A receptor, type IC ACVR1C 130399 4
Matrix metallopeptidase 3 MMP-3 4314 3
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 3
SEC11-like 3 (S. cerevisiae) SEC11L3 90701 3
ryanodine receptor 1 (skeletal) RYR1 6261 2
Cathepsin H CTSH 1512 2
phenylalanine-tRNA synthetase-like, beta subunit FARSLB 10056 2
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 6480 2
Ankyrin repeat and KH domain containing 1 ANKHD1 54882 2
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folate hydrolase (prostate-specific membrane antigen) 1 FOLH1 2346 4
PDZ binding kinase PBK 55872 3
Sulfatase 1 SULF1 23213 3
cathepsin L CTSL 1514 3
phosphodiesterase 4D interacting protein (myomegalin) PDE4DIP 9659 3
hepatocyte growth factor (hepapoietin A; scatter factor) HGF 3082 3
TTK protein kinase TTK 7272 3
apolipoprotein E APOE 348 3
matrix metallopeptidase 14 (membrane-inserted) MMP14 4323 2
ADAM metallopeptidase with thrombospondin type 1 motif, 9 ADAMTS9 56999 2
ADAM metallopeptidase domain 8 ; ADAM metallopeptidase domain 8 ADAM8 101 2
Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform
(calcineurin A alpha) PPP3CA 5530 2
aspartate beta-hydroxylase ASPH 444 2
galactose-3-O-sulfotransferase 4 GAL3ST4 79690 2
bone morphogenetic protein 1 BMP1 649 2
ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 11174 2
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen
binding protein 1) SERPINH1 871 2
procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 PLOD1 5351 2
lysyl-tRNA synthetase KARS 3735 2
c-mer proto-oncogene tyrosine kinase MERTK 10461 2
Insulin receptor INSR 3643 2
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Upregulated Genes GeneSymbol Entrez Gene ID Fold change
activin A receptor, type IC ACVR1C 130399 4
mal, T-cell differentiation protein MAL 4118 3
tumor protein p53 inducible nuclear protein 1 TP53INP1 94241 3
Fas apoptotic inhibitory molecule 3 ; Fas apoptotic inhibitory
molecule 3 FAIM3 9214 2
ELL associated factor 2 EAF2 55840 2
ryanodine receptor 1 (skeletal) RYR1 6261 2
Downregulated Genes GeneSymbol Entrez Gene ID Fold change
angiopoietin-like 4 ANGPTL4 51129 7
Effector cell peptidase receptor 1 BIRC5 332 4
Sulfatase 1 SULF1 23213 3
LIM and senescent cell antigen-like domains 1 LIMS1 3987 3
apolipoprotein E APOE 348 3
pleckstrin homology-like domain, family A, member 2 PHLDA2 7262 2
Appendix H: Apoptotic genes in AAA vs. AOD
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Upregulated Genes GeneSymbol Entrez Gene ID Fold change
homeo box D10 HOXD10 3236 4
homeo box A5 HOXA5 3202 2
DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB1 4189 2
Downregulated Genes GeneSymbol Entrez Gene ID Fold change
angiopoietin-like 4 ANGPTL4 51129 7
plexin domain containing 1 PLXDC1 57125 2
angiopoietin 2 ANGPT2 285 2
stabilin 1 STAB1 23166 2
Fms-related tyrosine kinase 1 (vascular endothelial growth
factor) FLT1 2321 2








Immunoglobulin lambda joining 3 IGLC2 3538 79
Immunoglobulin kappa variable 1-5 ; Immunoglobulin kappa variable 1-5 IGKC 3514 55
immunoglobulin heavy constant mu IGHM 3507 50
immunoglobulin kappa constant ; immunoglobulin kappa constant IGKC 3514 47
immunoglobulin heavy locus ; immunoglobulin heavy constant gamma 1 (G1m
marker)
IGHG1 3492 38
CD79A antigen (immunoglobulin-associated alpha) CD79A 973 36
immunoglobulin heavy locus ; immunoglobulin heavy constant alpha 1  IGHA1 283650 26
Immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu
polypeptides
IGJ 3512 20
SLAM family member 7 SLAMF7 57823 19
BCR downstream signaling 1 BRDG1 26228 17
CD19 antigen CD19 930 15
immunoglobulin lambda locus ; immunoglobulin lambda constant 1 (Mcg marker) IGLC1 28793 14
Fas apoptotic inhibitory molecule 3 ; Fas apoptotic inhibitory molecule 3 FAIM3 9214 13
CD69 antigen (p60, early T-cell activation antigen) CD69 969 12
tumor necrosis factor receptor superfamily, member 7 ; TNFRSF7 939 11
Paired box gene 5 (B-cell lineage specific activator) PAX5 5079 11
cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 10
regulator of G-protein signalling 1 RGS1 5996 9
CD3G antigen, gamma polypeptide (TiT3 complex) CD3G 917 9
lymphocyte transmembrane adaptor 1 LAX1 54900 9
major histocompatibility complex, class II, DO beta HLA-DOB 3112 9
chemokine (C-C motif) receptor 7 ; chemokine (C-C motif) receptor 7 CCR7 1236 8
ras homolog gene family, member H RHOH 399 8
toll-like receptor 10 TLR10 81793 8







Interleukin 7 receptor IL7R 3575 8
lymphocyte antigen 9 LY9 4063 7
chemokine (C-C motif) ligand 3 CCL3 414062 7
chemokine (C-C motif) ligand 5 CCL5 6352 7
regulator of G-protein signalling 1 RGS1 5996 7
cathepsin S CTSS 1520 7
T cell receptor alpha locus TRAC 28755 6
signaling threshold regulating transmembrane adaptor 1 SIT1 27240 6
interferon, gamma IFNG 3458 6
absent in melanoma 2 AIM2 9447 6
T cell receptor beta variable 21-1 TRBV21-1 28566 6
Epstein-Barr virus induced gene 2 (lymphocyte-specific G protein-coupled
receptor)
EBI2 1880 6
SP140 nuclear body protein SP140 11262 6
T cell receptor beta variable 19 ; T cell receptor beta constant 1 TRBV19 28568 5
CD8 antigen, beta polypeptide 1 (p37) CD8B1 926 5
chemokine (C-C motif) ligand 4 CCL4 6351 5
cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 5
zeta-chain (TCR) associated protein kinase 70kDa ZAP70 7535 5
Spi-B transcription factor (Spi-1/PU.1 related) SPIB 6689 5
CD2 antigen (p50), sheep red blood cell receptor ; CD2 antigen (p50), sheep red
blood cell receptor
CD2 914 5
Fc fragment of IgG, low affinity IIIb, receptor (CD16b) FCGR3B 2215 5
CD53 antigen CD53 963 5
interleukin 2 receptor, gamma (severe combined immunodeficiency) IL2RG 3561 5
lymphocyte-specific protein tyrosine kinase LCK 3932 5
CD6 antigen ; CD6 antigen CD6 923 5







lymphocyte antigen 6 complex, locus H LY6H 4062 5
CD3D antigen, delta polypeptide (TiT3 complex) CD3D 915 5
neutrophil cytosolic factor 1 (47kDa, chronic granulomatous disease,
autosomal 1)
NCF1 4687 4
IL2-inducible T-cell kinase ITK 3702 4
killer cell lectin-like receptor subfamily B, member 1 ; KLRB1 3820 4
SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) SH2D1A 4068 4
POU domain, class 2, transcription factor 2 POU2F2 5452 4
integrin, alpha L (antigen CD11A (p180) ITGAL 3683 4
dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 4
Beta-2-microglobulin B2M 567 4
type 1 tumor necrosis factor receptor shedding aminopeptidase regulator ARTS-1 51752 4
lymphotoxin beta (TNF superfamily, member 3) LTB 4050 4
B-cell linker BLNK 29760 4
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G APOBEC3G 60489 4
interleukin 16 (lymphocyte chemoattractant factor) IL16 3603 4
major histocompatibility complex, class II, DM beta ; HLA-DMB 3109 4
FYN binding protein (FYB-120/130) FYB 2533 4
CD48 antigen (B-cell membrane protein) ; CD48 antigen (B-cell
membrane protein)
CD48 962 4
adenosine A3 receptor ADORA3 140 4
major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1 3117 4
coagulation factor III (thromboplastin, tissue factor) F3 2152 4
Guanylate binding protein 5 GBP5 115362 4
major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 3119 4
X-box binding protein 1 XBP1 7494 3
Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide FCER1A 2205 3







lymphocyte-specific protein tyrosine kinase LCK 3932 3
lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of
76kDa)
LCP2 3937 3
FYN binding protein (FYB-120/130) FYB 2533 3
Spleen tyrosine kinase SYK 6850 3
major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 3113 3
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II
antigen-associated)
CD74 972 3
CD180 antigen CD180 4064 3
class II, major histocompatibility complex, transactivator CIITA 4261 3
B-cell linker BLNK 29760 3
interferon regulatory factor 8 ; interferon regulatory factor 8 IRF8 3394 3
interleukin 18 (interferon-gamma-inducing factor) IL18 3606 3
interleukin 12 receptor, beta 1 IL12RB1 3594 3
lysozyme (renal amyloidosis) LYZ ; LILRB1 10859 3
Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of
76kDa)
LCP2 3937 3
CD3E antigen, epsilon polypeptide (TiT3 complex) CD3E 916 3
C-type lectin domain family 2, member D CLEC2D 29121 3
dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 3
transcription factor 7 (T-cell specific, HMG-box) TCF7 6932 3
Tumor necrosis factor (ligand) superfamily, member 8 TNFSF8 944 3
cytotoxic T-lymphocyte-associated protein 4 CTLA4 1493 3
cold autoinflammatory syndrome 1 CIAS1 114548 3
killer cell lectin-like receptor subfamily C, member 4 ; killer cell lectin-like receptor




Arachidonate 5-lipoxygenase ALOX5 240 3
killer cell lectin-like receptor subfamily K, member 1 KLRK1 22914 3







I factor (complement) IF 3426 3
major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 3119 3
major histocompatibility complex, class II, DO alpha HLA-DOA 3111 3
trefoil factor 3 (intestinal) TFF3 7033 3
CD53 antigen CD53 963 3
major histocompatibility complex, class II, DM alpha HLA-DMA 3108 3
CD1C antigen, c polypeptide CD1C 911 3
platelet-activating factor receptor PTAFR 5724 3
Immunoglobulin kappa variable 1-5 IGKC 3514 3
killer cell lectin-like receptor subfamily F, member 1 KLRF1 51348 3
CD79B antigen (immunoglobulin-associated beta) CD79B 974 3
chemokine (C-C motif) receptor 2 ; chemokine (C-C motif) receptor 2 CCR2 1231 3
myeloid cell nuclear differentiation antigen ; myeloid cell nuclear differentiation
antigen
MNDA 4332 3
ring finger protein 125 RNF125 54941 3
CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) CD80 941 3
G-protein signalling modulator 3 (AGS3-like, C. elegans) GPSM3 63940 3
C-type lectin domain family 4, member A CLEC4A 50856 3
tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally
activated glycoprotein 1, 34kDa)
TNFSF4 7292 3
guanylate binding protein 4 GBP4 115361 3
leukocyte specific transcript 1 LST1 7940 3
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) SEMA4D 10507 2
prostaglandin E receptor 4 (subtype EP4) PTGER4 5734 2
Decay accelerating factor for complement (CD55, Cromer blood group system) DAF 1604 2
interleukin 1, beta IL1B 3553 2
Arachidonate 5-lipoxygenase ALOX5 240 2







CD1D antigen, d polypeptide ; CD1D antigen, d polypeptide CD1D 912 2
CD84 antigen (leukocyte antigen) CD84 8832 2
leukocyte specific transcript 1 LST1 7940 2
phosphoprotein associated with glycosphingolipid microdomains 1 PAG1 55824 2
Annexin A1 ANXA1 301 2
chemokine (C-X3-C motif) receptor 1 CX3CR1 1524 2
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen
1; alpha polypeptide)
ITGAL 3683 2
leukocyte specific transcript 1 LST1 7940 2
CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) CD86 942 2
toll-like receptor 1 TLR1 7096 2
leukocyte specific transcript 1 LST1 7940 2
matrix metallopeptidase 25 MMP25 64386 2
Interleukin 24 IL24 11009 2
interleukin 6 receptor ; interleukin 6 receptor IL6R 3570 2
allograft inflammatory factor 1 AIF1 199 2
major histocompatibility complex, class II, DR alpha HLA-DRA 3122 2
nucleotide-binding oligomerization domains 27 NOD27 84166 2
ectodysplasin A EDA 1896 2
tumor necrosis factor (ligand) superfamily, member 7 TNFSF7 970 2
major histocompatibility complex, class I, C HLA-C 3107 2
chemokine (C motif) ligand 1 ; chemokine (C motif) ligand 2 XCL1 ; XCL2 6375 2







clusterin CLU 1191 6
ADAM metallopeptidase domain 33 ADAM33 80332 5
chemokine (C-X3-C motif) ligand 1 CX3CL1 6376 4
histone deacetylase 9 HDAC9 9734 4
amine oxidase, copper containing 3 (vascular adhesion protein 1) AOC3 8639 4
histamine receptor H1 HRH1 3269 4
parathymosin PTMS 5763 4
transcription elongation factor A (SII), 3 TCEA3 6920 3
GTP binding protein overexpressed in skeletal muscle GEM 2669 3
CD27-binding (Siva) protein SIVA 10572 3
transcription elongation factor A (SII), 2 TCEA2 6919 3
mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-
reactive factor)
MASP1 5648 3
histone deacetylase 5 HDAC5 10014 3
toll interacting protein TOLLIP 54472 3
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12)
ITGB1 3688 3
barrier to autointegration factor 1 BANF1 8815 3
protein kinase, interferon-inducible double stranded RNA dependent activator PRKRA 8575 3
fusion (involved in t(12;16) in malignant liposarcoma) FUS 2521 3
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12)
ITGB1 3688 3
histone deacetylase 7A HDAC7A 51564 2
microsomal glutathione S-transferase 3 MGST3 4259 2
Microtubule-associated protein, RP/EB family, member 2 MAPRE2 10982 2
transforming growth factor, beta 1 (Camurati-Engelmann disease) TGFB1 7040 2
nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
myeloid leukemia factor 2 MLF2 8079 2








CD27-binding (Siva) protein SIVA 10572 2
vacuolar protein sorting 45A (yeast) VPS45A 11311 2
IK cytokine, down-regulator of HLA II ; IK cytokine, down-regulator of HLA II IK 3550 2
toll interacting protein TOLLIP 54472 2
eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa EIF2B3 8891 2
Interleukin 17D IL17D 53342 2
zinc finger protein 161 ZNF161 7716 2
annexin A11 ANXA11 311 2
inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) ITIH4 3700 2
tetraspanin 9 TSPAN9 10867 2
ankyrin repeat and SOCS box-containing 1 ASB1 51665 2
hypothetical protein FLJ21148 FLJ21148 79918 2
nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
signal transducer and activator of transcription 3 (acute-phase response factor) STAT3 6774 2
TIA1 cytotoxic granule-associated RNA binding protein-like 1 TIAL1 7073 2
nuclear factor (erythroid-derived 2)-like 1 NFE2L1 4779 2
cytochrome P450, family 26, subfamily B, polypeptide 1 CYP26B1 56603 2
histone deacetylase 4 HDAC4 9759 2
tetraspanin 9 ; tetraspanin 9 TSPAN9 10867 2
ankyrin repeat and SOCS box-containing 1 ASB1 51665 2
sequestosome 1 SQSTM1 8878 2
sterile alpha and TIR motif containing 1 SARM1 23098 2
interferon induced transmembrane protein 2 (1-8D) IFITM2 10581 2








carboxypeptidase Z ; carboxypeptidase Z CPZ 8532 12
tumor necrosis factor receptor superfamily, member 7 TNFRSF7 939 11
CD3G antigen, gamma polypeptide (TiT3 complex) CD3G 917 9
heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 HS3ST3B1 9953 9
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) GZMB 3002 8
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) MMP9 4318 8
Ankyrin repeat and KH domain containing 1 ANKHD1 54882 8
matrix-remodelling associated 5 MXRA5 25878 8
cathepsin S CTSS 1520 7
tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 6
calcium/calmodulin-dependent protein kinase IV CAMK4 814 5
zeta-chain (TCR) associated protein kinase 70kDa ZAP70 7535 5
ADAM metallopeptidase domain 28 ADAM28 10863 5
interleukin 2 receptor, gamma (severe combined immunodeficiency) IL2RG 3561 5
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 26191 5
serine/threonine kinase 4 STK4 6789 5
lymphocyte-specific protein tyrosine kinase LCK 3932 5
FK506 binding protein 11, 19 kDa FKBP11 51303 5
tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 5
dual adaptor of phosphotyrosine and 3-phosphoinositides DAPP1 27071 5
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 ST8SIA4 7903 5
CD3D antigen, delta polypeptide (TiT3 complex) CD3D 915 5
protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
Serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 4
IL2-inducible T-cell kinase ITK 3702 4







carboxypeptidase M CPM 1368 4
dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 4
Matrix-metallopeptidase 3 MMP-3 4314 4
protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
FYN oncogene related to SRC, FGR, YES FYN 2534 4
type 1 tumor necrosis factor receptor shedding aminopeptidase regulator ARTS-1 51752 4
protein tyrosine phosphatase, receptor type, C PTPRC 5788 4
Doublecortin and CaM kinase-like 1 DCAMKL1 9201 4
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 26191 4
Protein kinase C, beta 1 PRKCB1 5579 4
protein phosphatase 2, regulatory subunit B (B56), gamma isoform PPP2R5C 5527 4
serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 4
chromosome 11 open reading frame 17 C11orf17 56672 4
SNF1-like kinase 2 SNF1LK2 23235 3
lymphocyte-specific protein tyrosine kinase LCK 3932 3
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 B3GALT2 8707 3
FYN binding protein (FYB-120/130) FYB 2533 3
Spleen tyrosine kinase SYK 6850 3
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II
antigen-associated)
CD74 972 3
corin, serine peptidase CORIN 10699 3
interleukin 18 (interferon-gamma-inducing factor) IL18 3606 3
Slingshot homolog 2 (Drosophila) SSH2 85464 3
protein kinase C, beta 1 PRKCB1 5579 3
ring finger protein 141 RNF141 50862 3
CD3E antigen, epsilon polypeptide (TiT3 complex) CD3E 916 3
caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 114769 3
serum/glucocorticoid regulated kinase SGK 6446 3







dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 1803 3
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher
1)
PRKAR1A 5573 3
Protein kinase C, eta PRKCH 5583 3
fms-related tyrosine kinase 3 FLT3 2322 3
Membrane-associated ring finger (C3HC4) 1 MARCH-I 55016 3
I factor (complement) IF 3426 3
Ubiquitin specific peptidase 3 USP3 9960 3
napsin B aspartic peptidase pseudogene NAPSB 256236 3
caspase 10, apoptosis-related cysteine peptidase CASP10 843 3
corin, serine peptidase CORIN 10699 3
Bruton agammaglobulinemia tyrosine kinase BTK 695 3
Membrane-associated ring finger (C3HC4) 1 MARCH-I 55016 3
similar to aspartate beta hydroxylase (ASPH) LOC57168 57168 3
protein kinase C, theta PRKCQ 5588 3
protein tyrosine phosphatase, non-receptor type 7 PTPN7 5778 3
A kinase (PRKA) anchor protein (yotiao) 9 AKAP9 10142 3
Death-associated protein kinase 1 DAPK1 1612 3
mitogen-activated protein kinase kinase 6 MAP2K6 5608 3
cathepsin H CTSH 1512 3
carboxypeptidase M CPM 1368 3
membrane-associated ring finger (C3HC4) 1 Mar-01 55016 3
PCTAIRE protein kinase 2 PCTK2 5128 3
RNA binding motif, single stranded interacting protein 1 IRAK3 11213 3
Matrilin 1, cartilage matrix protein MATN1 4146 3
ring finger protein 125 RNF125 54941 3
CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) CD80 941 3







Protein tyrosine phosphatase, non-receptor type 1 PTPN1 5770 3
Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1 51465 2
cathepsin K (pycnodysostosis) CTSK 1513 2
myotubularin 1 MTM1 4534 2
mitogen-activated protein kinase kinase kinase 8 MAP3K8 1326 2
Rap guanine nucleotide exchange factor (GEF) 4 RAPGEF4 11069 2
caspase 8, apoptosis-related cysteine peptidase CASP8 841 2
Slingshot homolog 2 (Drosophila) SSH2 85464 2
Serine/threonine kinase 38 STK38 11329 2
disabled homolog 1 (Drosophila) ; OMA1 homolog, zinc metallopeptidase (S.
cerevisiae)
DAB1 115209 2




CDC14 cell division cycle 14 homolog A (S. cerevisiae) CDC14A 8556 2
kinetochore associated 1 KNTC1 9735 2
DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 4189 2
CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) CD86 942 2
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain
member 1
HERPUD1 9709 2
toll-like receptor 1 TLR1 7096 2
RAB6 interacting protein 2 RAB6IP2 23085 2
Eukaryotic translation initiation factor 5 EIF5 1983 2
matrix metallopeptidase 25 MMP25 64386 2
ribosomal protein L7 RPL7 388401 2
proprotein convertase subtilisin/kexin type 6 PCSK6 5046 2
F-box and WD-40 domain protein 7 (archipelago homolog, Drosophila) FBXW7 55294 2
baculoviral IAP repeat-containing 3 BIRC3 330 2







protein kinase, X-linked PRKX 5613 2
abhydrolase domain containing 7 ABHD7 253152 2
ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) UBE2J1 51465 2
BMP2 inducible kinase BMP2K 55589 2
scavenger receptor class F, member 1 SCARF1 8578 2
Ubiquitin-like domain containing CTD phosphatase 1 MGC10067 134510 2
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) FUT8 2530 2







aortic preferentially expressed gene 1 APEG1 10290 56
ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAMTS8 11095 15
receptor-interacting serine-threonine kinase 4 RIPK4 54101 13
neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 11
caspase 12 pseudogene 1 CASP12P1 120329 9
Proprotein convertase subtilisin/kexin type 7 PCSK7 9159 9
PDZ domain containing RING finger 3 PDZRN3 23024 7
ligand of numb-protein X LNX 84708 6
supervillin SVIL 6840 6
chromosome 9 open reading frame 3 C9orf3 84909 6
V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 2066 6
protease, serine, 35 PRSS35 167681 5
ring finger and FYVE-like domain containing 1 RFFL 117584 5
protein tyrosine phosphatase, non-receptor type 21 PTPN21 11099 5
calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma CAMK2G 818 5
erythrocyte membrane protein band 4.9 (dematin) EPB49 2039 5
Mitochondrial ribosomal protein S6 MRPS6 64968 5
lecithin-cholesterol acyltransferase LCAT 3931 5
ADAM metallopeptidase domain 33 ADAM33 80332 5
integrin-linked kinase ILK 3611 4
chromosome 1 open reading frame 24 C1orf24 116496 4
tubulin tyrosine ligase-like family, member 7 TTLL7 79739 4
heat shock 27kDa protein 1 HSPB1 3315 4
cullin-associated and neddylation-dissociated 2 (putative) CAND2 23066 4
Bone morphogenetic protein receptor, type IB BMPR1B 658 4
methionine sulfoxide reductase B3 MSRB3 253827 4
nucleosome assembly protein 1-like 3 NAP1L3 4675 4







F-box and leucine-rich repeat protein 19 FBXL19 54620 4
transducin (beta)-like 1X-linked TBL1X 6907 4
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) TGM2 7052 4
protein tyrosine phosphatase, receptor type, G PTPRG 5793 4
ankyrin repeat and BTB (POZ) domain containing 2 ABTB2 25841 4
adaptor-related protein complex 2, alpha 1 subunit AP2A1 160 4
CDC14 cell division cycle 14 homolog B (S. cerevisiae) CDC14B 8555 4
OTU domain, ubiquitin aldehyde binding 2 OTUB2 78990 4
mitogen-activated protein kinase kinase 7 MAP2K7 5609 4
ADAM metallopeptidase with thrombospondin type 1 motif, 9 ADAMTS9 56999 4
protein phosphatase 2A, regulatory subunit B' (PR 53) PPP2R4 5524 4
myosin, light polypeptide kinase ; myosin, light polypeptide kinase MYLK 4638 4
chromosome 1 open reading frame 24 C1orf24 116496 4
v-ets erythroblastosis virus E26 oncogene like (avian) ERG 2078 4
heat shock 70kDa protein 2 HSPA2 3306 4
V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 2066 4
G protein-coupled receptor kinase 5 GRK5 2869 3
membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) MPP6 51678 3
Endothelin converting enzyme 1 ECE1 1889 3
ADAM metallopeptidase with thrombospondin type 1 motif, 15 ADAMTS15 170689 3
methionine sulfoxide reductase B2 MSRB2 22921 3
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) SRC 6714 3
natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B) NPR2 4882 3
actin related protein 2/3 complex, subunit 4, 20kDa ARPC4 10093 3
matrix metallopeptidase 16 (membrane-inserted) MMP16 4325 3
carbohydrate (chondroitin 6) sulfotransferase 3 CHST3 9469 3







rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2 9181 3
peptidylglycine alpha-amidating monooxygenase PAM 5066 3
guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 3
Protein tyrosine phosphatase-like (proline instead of catalytic arginine), member a PTPLA 9200 3
adaptor-related protein complex 2, alpha 1 subunit AP2A1 160 3
tripartite motif-containing 47 TRIM47 91107 3
guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 3
methionyl aminopeptidase 1 METAP1 23173 3
transducin (beta)-like 1X-linked TBL1X 6907 3
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) TGM2 7052 3
Insulin-like growth factor 1 receptor IGF1R 3480 3
protein tyrosine phosphatase, non-receptor type 3 PTPN3 5774 3
platelet derived growth factor D PDGFD 80310 3
lysyl-tRNA synthetase KARS 3735 3
HIV-1 Tat interacting protein, 60kDa HTATIP 10524 3
heat shock 27kDa protein 2 HSPB2 3316 3
Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene
homolog, avian)
EGFR 1956 3
protein tyrosine phosphatase, receptor type, D PTPRD 5789 3
microtubule-associated protein 1 light chain 3 alpha MAP1LC3A 84557 3
WNK lysine deficient protein kinase 3 WNK3 65267 3
VAMP (vesicle-associated membrane protein)-associated protein B and C VAPB 9217 3
ribonuclease, RNase A family, 4 RNASE4 6038 3
Supervillin SVIL 6840 3
tubulin, beta 3 TUBB3 10381 3
discoidin domain receptor family, member 1 DDR1 780 3
Bone morphogenetic protein receptor, type IB BMPR1B 658 3
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mitochondrial ribosomal protein L21 MRPL21 219927 3
dual specificity phosphatase 19 DUSP19 142679 3
beta-site APP-cleaving enzyme 1 BACE1 23621 3
myotubularin related protein 2 MTMR2 8898 3
amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) APBB1 322 3
tubulin, beta polypeptide TUBB 203068 3
mitogen-activated protein kinase kinase kinase 6 MAP3K6 9064 3
microtubule associated serine/threonine kinase family member 4 MAST4 23227 3
nuclear protein localization 4 NPL4 55666 3
v-ets erythroblastosis virus E26 oncogene like (avian) ERG 2078 3
EPH receptor A4 EPHA4 2043 3
Protein tyrosine phosphatase, non-receptor type 23 PTPN23 25930 3
protein kinase, cAMP-dependent, regulatory, type II, alpha PRKAR2A 5576 3




Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) MPP6 51678 3
Cyclin-dependent kinase 8 CDK8 1024 3
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 4363 2
calpain 5 CAPN5 726 2
protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) PTPN11 5781 2
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene
homolog, avian)
EGFR 1956 2
COX11 homolog, cytochrome c oxidase assembly protein (yeast) COX11 1353 2
dystroglycan 1 (dystrophin-associated glycoprotein 1) DAG1 1605 2
SCY1-like 1 (S. cerevisiae) SCYL1 57410 2
TRIO and F-actin binding protein TRIOBP 11078 2
chaperonin containing TCP1, subunit 7 (eta) CCT7 10574 2
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laminin, gamma 1 (formerly LAMB2) LAMC1 3915 2
cytoskeleton associated protein 1 CKAP1 1155 2
ring finger protein 150 RNF150 57484 2
MAP/microtubule affinity-regulating kinase 1 MARK1 4139 2
myosin regulatory light chain interacting protein MYLIP 29116 2
Chromosome 9 open reading frame 3 C9orf3 84909 2
H2A histone family, member J H2AFJ 55766 2
Tight junction protein 1 (zona occludens 1) TJP1 7082 2
ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) UBE2M 9040 2
v-akt murine thymoma viral oncogene homolog 2 AKT2 208 2
pregnancy-associated plasma protein A, pappalysin 1 PAPPA 5069 2
hypothetical protein MGC2744 MGC2744 80755 2
Exostoses (multiple) 1 EXT1 2131 2
pyruvate dehydrogenase kinase, isoenzyme 2 PDK2 5164 2
ring finger protein 180 RNF180 285671 2
tripartite motif-containing 28 TRIM28 10155 2
eukaryotic translation initiation factor 4E EIF4E 1977 2
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) SPTAN1 6709 2
prolyl endopeptidase-like PREPL 9581 2
histidyl-tRNA synthetase-like HARSL 23438 2
prefoldin 1 PFDN1 5201 2
Pelota homolog (Drosophila) PELO 53918 2
leucine rich repeat containing 41 LRRC41 10489 2
ST3 beta-galactoside alpha-2,3-sialyltransferase 3 ST3GAL3 6487 2
guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2







BRCA1 associated RING domain 1 BARD1 580 2
ring finger protein 25 RNF25 64320 2
CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA 8476 2
low density lipoprotein receptor-related protein 8, apolipoprotein e receptor LRP8 7804 2
N-myristoyltransferase 1 NMT1 4836 2
Zinc finger, A20 domain containing 1 ZA20D1 56957 2
ribosomal protein L39-like RPL39L 116832 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 DDX1 1653 2
arginyl-tRNA synthetase RARS 5917 2
ubiquitin specific peptidase 20 USP20 10868 2
H2A histone family, member J H2AFJ 55766 2
Protein tyrosine phosphatase, receptor type, D PTPRD 5789 2
RNA binding motif protein 9 RBM9 23543 2
calcium/calmodulin-dependent protein kinase (CaM kinase) II delta CAMK2D 817 2
TRAF2 and NCK interacting kinase TNIK 23043 2
neural precursor cell expressed, developmentally down-regulated 4 NEDD4 4734 2
zinc metallopeptidase (STE24 homolog, yeast) ZMPSTE24 10269 2
eukaryotic translation initiation factor 4 gamma, 1 EIF4G1 1981 2
Heat shock 70kDa protein 4 HSPA4 3308 2
nucleosome assembly protein 1-like 5 NAP1L5 266812 2
cytoskeleton associated protein 1 CKAP1 1155 2
ribosomal protein S27-like RPS27L 51065 2
Janus kinase 2 (a protein tyrosine kinase) JAK2 3717 2
proliferation-associated 2G4, 38kDa PA2G4 5036 2
C-terminal binding protein 1 CTBP1 1487 2







Protein tyrosine phosphatase, receptor type, D PTPRD 5789 2
HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) HRMT1L1 3275 2
mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 2
tubulin, beta 2 TUBB2 7280 2
casein kinase 2, alpha prime polypeptide CSNK2A2 1459 2
v-ets erythroblastosis virus E26 oncogene like (avian) ; v-ets erythroblastosis virus E26
oncogene like (avian)
ERG 2078 2
C-terminal binding protein 1 CTBP1 1487 2
cysteinyl-tRNA synthetase CARS 833 2
discoidin domain receptor family, member 1 DDR1 780 2
par-3 partitioning defective 3 homolog (C. elegans) PARD3 56288 2
AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) AHSA1 10598 2
prefoldin 2 PFDN2 5202 2
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform PPP2CB 5516 2
retinoic acid receptor, alpha ; retinoic acid receptor, alpha RARA 5914 2
sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 2
guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2
fyn-related kinase FRK 2444 2
ubiquitin specific peptidase 47 USP47 55031 2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 NDUFA13 51079 2
Discoidin domain receptor family, member 2 DDR2 4921 2
protein inhibitor of activated STAT, 3 PIAS3 10401 2
vesicle-associated membrane protein 4 VAMP4 8674 2
uronyl-2-sulfotransferase UST 10090 2
ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) UBE2G2 7327 2
S-phase kinase-associated protein 1A (p19A) SKP1A 6500 2
ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 10277 2







carboxypeptidase X (M14 family), member 2 CPXM2 119587 2
MID1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) MID1IP1 58526 2
histone deacetylase 8 HDAC8 55869 2
mitochondrial ribosomal protein L33 MRPL33 9553 2
Supervillin SVIL 6840 2
F-box and WD-40 domain protein 4 FBXW4 6468 2
ring finger protein 180 RNF180 285671 2
mitochondrial ribosomal protein L4 MRPL4 51073 2
methionine sulfoxide reductase B2 MSRB2 22921 2
suppressor of Ty 16 homolog (S. cerevisiae) SUPT16H 11198 2
Eukaryotic translation initiation factor 2C, 2 EIF2C2 27161 2
Lemur tyrosine kinase 2 LMTK2 22853 2
prenylcysteine oxidase 1 PCYOX1 51449 2
ubiquitin specific peptidase 21 USP21 27005 2
isoprenylcysteine carboxyl methyltransferase ICMT 23463 2
gelsolin (amyloidosis, Finnish type) GSN 2934 2
mitogen-activated protein kinase kinase kinase 3 MAP3K3 4215 2
glutaredoxin 2 GLRX2 51022 2
ribosomal protein S23 RPS23 6228 2
ubiquitin specific peptidase 47 USP47 55031 2
ADAM metallopeptidase with thrombospondin type 1 motif, 3 ADAMTS3 9508 2
H2A histone family, member V H2AFV 94239 2
mitochondrial ribosomal protein S18C MRPS18C 51023 2
tripartite motif-containing 56 TRIM56 81844 2
BRCA1 associated protein BRAP 8315 2
dual specificity phosphatase 19 DUSP19 142679 2







pelota homolog (Drosophila) PELO 53918 2
ubiquitin specific peptidase 31 USP31 57478 2
DnaJ (Hsp40) homolog, subfamily C, member 8 DNAJC8 22826 2
alpha-2-macroglobulin A2M 2 2
family with sequence similarity 80, member B FAM80B 57494 2
myosin regulatory light chain interacting protein MYLIP 29116 2
splicing factor, arginine/serine-rich 8 (suppressor-of-white-apricot homolog, Drosophila) SFRS8 6433 2
Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma CAMK2G 818 2
serine/threonine kinase 19 STK19 8859 2
gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2701 2
discoidin domain receptor family, member 2 DDR2 4921 2
prolyl endopeptidase-like PREPL 9581 2
superkiller viralicidic activity 2-like (S. cerevisiae) SKIV2L 6499 2
zinc finger, CSL-type containing 2 ZCSL2 285381 2
actinin, alpha 2 ACTN2 88 2
F-box and leucine-rich repeat protein 7 FBXL7 23194 2
methyltransferase like 5 METTL5 29081 2
serine/threonine kinase 17a (apoptosis-inducing) STK17A 9263 2
guanine nucleotide binding protein (G protein), alpha 11 (Gq class) GNA11 2767 2
ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) UBE2G2 30851 2
bone morphogenetic protein receptor, type II (serine/threonine kinase) BMPR2 659 2
selenocysteine lyase ; NEDD8-conjugating enzyme SCLY 140739 2
cyclin-dependent kinase 9 (CDC2-related kinase) CDK9 1025 2
F-box protein 9 FBXO9 26268 2
dystroglycan 1 (dystrophin-associated glycoprotein 1) DAG1 1605 2
glycophorin C (Gerbich blood group) GYPC 2995 2







protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform PPM1G 5496 2
mitogen-activated protein kinase 7 MAPK7 5598 2
ubiquitin specific peptidase 47 USP47 55031 2
HLA-B associated transcript 3 BAT3 7917 2
mitogen-activated protein kinase kinase kinase 4 MAP3K4 4216 2
SREBP cleavage-activating protein SCAP 22937 2
chaperonin containing TCP1, subunit 5 (epsilon) CCT5 22948 2
rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2 9181 2
chromosome 20 open reading frame 14 C20orf14 24148 2
protein phosphatase methylesterase-1 PME-1 51400 2
heat shock 10kDa protein 1 (chaperonin 10) HSPE1 3336 2
retinoblastoma-associated factor 600 RBAF600 23352 2
ubiquitin protein ligase E3C UBE3C 9690 2
slingshot homolog 3 (Drosophila) SSH3 54961 2
surfeit 6 SURF6 6838 2
F-box protein 42 FBXO42 54455 2
ubiquitin-conjugating enzyme E2L 3 UBE2L3 7332 2
protein tyrosine phosphatase, receptor type, K PTPRK 5796 2
EPH receptor A4 EPHA4 2043 2
chaperonin containing TCP1, subunit 3 (gamma) CCT3 7203 2







SLAM family member 7 SLAMF7 57823 19
Fas apoptotic inhibitory molecule 3 FAIM3 9214 13
tumor necrosis factor receptor superfamily, member 7 TNFRSF7 939 11
CD38 antigen (p45) CD38 952 10
CD3G antigen, gamma polypeptide (TiT3 complex) CD3G 917 9
tumor necrosis factor, alpha-induced protein 3 TNFAIP3 7128 6
serine/threonine kinase 4 STK4 6789 5
Serine/threonine kinase 17b (apoptosis-inducing) STK17B 9262 4
BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 4
tumor protein p53 inducible nuclear protein 1 TP53INP1 94241 4
CD74 antigen CD74 972 3
interleukin 18 (interferon-gamma-inducing factor) IL18 3606 3
caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,
convertase)
CASP1 114769 3
Tumor necrosis factor (ligand) superfamily, member 8 TNFSF8 944 3
BCL2-like 11 (apoptosis facilitator) BCL2L11 10018 3
caspase 10, apoptosis-related cysteine peptidase CASP10 843 3
Death-associated protein kinase 1 DAPK1 1612 3
tumor necrosis factor receptor superfamily, member 18 TNFRSF18 8784 3
interleukin 1, beta IL1B 3553 2
caspase 8, apoptosis-related cysteine peptidase CASP8 841 2
activin A receptor, type IC ACVR1C 130399 2
deoxyribonuclease I-like 3 DNASE1L3 1776 2
Interleukin 24 IL24 11009 2
TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
TIMP3 7078 2







caspase 12 pseudogene 1 CASP12P1 120329 9
clusterin CLU 1191 6
ring finger and FYVE-like domain containing 1 RFFL 117584 5
GULP, engulfment adaptor PTB domain containing 1 GULP1 51454 5
epithelial membrane protein 2 EMP2 2013 4
PRKC, apoptosis, WT1, regulator PAWR 5074 3
BRCA1 associated RING domain 1 BARD1 580 3
B-cell receptor-associated protein 29 BCAP29 55973 3
serine/threonine kinase 17a (apoptosis-inducing) STK17A 9263 3
B-cell receptor-associated protein 29 BCAP29 55973 3
Insulin-like growth factor 1 receptor IGF1R 3480 3
BCL2-like 2 BCL2L2 599 3
tubulin, beta, 2 TUBB2 10383 3
cell division cycle 2-like 1 (PITSLRE proteins) CDC2L1 984 3
BCL2-associated athanogene 3 BAG3 9531 3
tubulin, beta polypeptide ; tubulin, beta polypeptide TUBB 203068 3
poly(rC) binding protein 4 PCBP4 57060 3
peroxiredoxin 2 ; peroxiredoxin 2 PRDX2 7001 3
B-cell receptor-associated protein 29 BCAP29 55973 3
eukaryotic translation elongation factor 1 epsilon 1 EEF1E1 9521 3
Death effector domain containing DEDD 9191 2
nerve growth factor receptor (TNFRSF16) associated protein 1 NGFRAP1 27018 2
mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 2
CD27-binding (Siva) protein SIVA 10572 2
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform PPP2CB 5516 2
sterile alpha motif and leucine zipper containing kinase AZK ZAK 51776 2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 NDUFA13 51079 2
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tumor protein p53 binding protein, 2 TP53BP2 7159 2
nucleolar protein 3 (apoptosis repressor with CARD domain) NOL3 8996 2
death effector domain containing DEDD 9191 2
glutaredoxin 2 GLRX2 51022 2
p8 protein (candidate of metastasis 1) P8 26471 2
modulator of apoptosis 1 MOAP1 64112 2




984 ; 985 2
Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) PTEN 5728 2
tetratricopeptide repeat domain 11 TTC11 51024 2
serine/threonine kinase 3 (STE20 homolog, yeast) STK3 6788 2
apoptosis-inducing factor (AIF)-like mitochondrion-associated inducer of death AMID 84883 2
MAP/microtubule affinity-regulating kinase 4 MARK4 57787 2
serine/threonine kinase 17a (apoptosis-inducing) STK17A 9263 2
voltage-dependent anion channel 1 VDAC1 7416 2
Rabaptin, RAB GTPase binding effector protein 1 RABEP1 9135 2
fragile X mental retardation, autosomal homolog 1 FXR1 8087 2
mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 2
Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform PPP2CA 5515 2
death associated transcription factor 1 DATF1 11083 2
cullin 2 CUL2 8453 2
BCL2-associated athanogene BAG1 573 2
defender against cell death 1 ; defender against cell death 1 DAD1 1603 2
apoptosis, caspase activation inhibitor AVEN 57099 2







type 1 tumor necrosis factor receptor shedding aminopeptidase regulator ARTS-1 51752 4
interleukin 18 (interferon-gamma-inducing factor) IL18 3606 3
plexin domain containing 1 PLXDC1 57125 2






fibroblast growth factor 1 (acidic) FGF1 2246 4
endothelial PAS domain protein 1 EPAS1 2034 4
jagged 1 (Alagille syndrome) JAG1 182 4
fibroblast growth factor 2 (basic) FGF2 2247 3
laminin, alpha 5 LAMA5 3911 3
fibroblast growth factor 2 (basic) FGF2 2247 3
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 ERBB2 2064 3
ribonuclease, RNase A family, 4 RNASE4 6038 3
c-fos induced growth factor (vascular endothelial growth factor D) FIGF 2277 3
endothelial PAS domain protein 1 EPAS1 2034 2
angiogenin, ribonuclease, RNase A family, 5 ; ribonuclease, RNase A family, 4 ANG 283 2
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SAMPLE  C1 GAPDH C2 Bactin C3
C4= AVG
(C2,C3) C4-C1
1 32.8189 28.6413 27.1823
32.9848 28.4601 27.2361
32.9055 28.8244 27.1899
32.9031 28.6419 27.2028 27.9224 4.9807
2 33.2198 26.8973 24.2499
33.2646 27.0835 24.1576
33.2422 27.0738 24.2584
33.2422 27.0182 24.2220 25.6201 7.6221
3 32.4859 26.0773 24.3902
32.2759 26.0622 24.2711
32.4268 26.0640 24.2975
32.3962 26.0678 24.3196 25.1937 7.2025
4 32.7858 26.4507 25.0108
32.4434 26.3243 24.8534
32.2730 26.1930 24.8643
32.5007 26.3227 24.9095 25.6161 6.8847
5 32.1152 27.6957 25.6978
32.4574 27.4853 25.5027
32.1796 27.2469 25.5666
32.2507 27.4760 25.5890 26.5325 5.7182
6 34.4015 28.9730 26.9360
34.6654 29.0286 26.7803
34.9589 28.9822 27.0177
34.6753 28.9946 26.9113 27.9530 6.7223
7 33.0034 27.2454 25.5883
34.0062 27.2610 25.8369
31.4968 27.3853 26.0363
32.8355 27.2972 25.8205 26.5589 6.2766
8 32.6017 27.5042 26.1690
32.9769 27.4086 25.3954
33.8558 27.7803 25.3072
33.1448 27.5644 25.6239 26.5941 6.5507
9 33.5002 27.4201 25.2588
33.1599 27.6935 25.2095
33.4433 28.1190 25.4292
33.3678 27.7442 25.2992 26.5217 6.8461
10 33.7927 27.7750 25.7758
34.2142 27.6481 25.8295
34.3461 28.0045 25.6227
34.1177 27.8092 25.7427 26.7759 7.3417
11 33.1912 27.0128 25.3157
33.1282 27.0389 25.3994
32.6959 27.0723 25.3036
33.0051 27.0413 25.3396 26.1905 6.8147
12 31.1182 28.4114 26.2173
30.8246 28.3351 26.2152
30.7772 28.4564 26.1089
30.9067 28.4010 26.1805 27.2907 3.6160
ADAMTS-9: QRT-PCR RAW DATA
496
AAA
SAMPLE  C1 GAPDH C2 Bactin C3
C4= AVG
(C2,C3) C4-C1
13 33.9345 28.0563 26.4304
33.2021 28.0156 26.3309
33.6546 28.0398 26.3394
33.5971 28.0372 26.3669 27.2021 6.3950
NA
SAMPLES C1 GAPDH C2 Bactin C3
C4 = AVG
(C2,C3) C4-C1
1 32.3159 27.8676 26.0763
31.9773 27.7569 25.9361
32.1139 27.5515 25.8845
32.1357 27.7253 25.9656 26.8455 5.2902
2 29.6901 25.724 22.2915
29.5906 25.4896 22.353
29.6602 25.4302 22.2794
29.6470 25.5479 22.30797 23.9280 5.7190
3 33.2652 27.3042 26.7511
33.398 27.2492 26.229
33.2993 27.7063 26.0831
33.3208 27.4199 26.3544 26.8872 6.4337
4 31.6133 25.4673 23.6737
31.4052 25.7121 23.3977
31.7651 25.6252 23.5224
31.5945 25.6015 23.5313 24.5664 7.0281
5 32.7317 27.0188 24.6658
32.7947 27.0666 24.3919
33.2352 27.1001 24.4837
32.9205 27.0618 24.5138 25.7878 7.1327
6 33.1538 25.9239 24.1413
33.12 26.0085 24.0621
33.2273 26.3428 24.0428
33.1670 26.0917 24.0821 25.0869 8.0801
7 31.0439 24.6079 23.3357
31.0866 24.3444 23.2594
30.9574 24.5506 23.504
31.0293 24.5010 23.3664 23.9337 7.0956
8 31.5041 25.0378 22.8815
31.2687 25.0595 22.6917
31.1799 24.9753 22.62
31.3176 25.0242 22.7311 23.8776 7.4399
ADAMTS-9: QRT-PCR RAW DATA (continued).
497
AOD SAMPLE C1 GAPDH C2 B actin C3
C4 = AVG
(C2,C3) C4-C1
1 33.8577 27.0771 25.1882
33.5836 27.0914 25.1698
33.3438 27.3594 24.5987
33.5950 27.1760 24.9856 26.0808 7.5143
2 31.6256 25.8524 23.9716
32.1118 25.809 23.6967
31.5994 25.7589 23.7727
31.7789 25.8068 23.8137 24.8102 6.9687
3 33.7426 26.9171 25.42
33.2318 27.0025 25.3802
33.4657 26.8578 25.1635
33.4800 26.9258 25.3212 26.1235 7.3565
4 34.4947 27.0749 25.4887
34.7854 26.9697 25.0513
34.5257 27.1162 25.3471
34.6019 27.0536 25.2957 26.1747 8.4273
5 35.1179 26.5472 24.6944
34.7619 26.4802 24.6038
34.625 26.384 24.4912
34.8349 26.4705 24.5965 25.5335 9.3015
6 31.6646 26.7261 25.0028
31.9271 26.7608 24.9524
31.4887 26.723 25.0537
31.6935 26.7366 25.0030 25.8698 5.8237
7 35.9478 27.0304 25.6261
35.1407 27.0908 25.5351
35.4576 27.0548 25.4895
35.5154 27.0587 25.5502 26.3045 9.2109
8 32.1039 25.8611 24.0096
31.9939 25.8855 24.0675
31.8308 25.8872 24.0054
31.9762 25.8779 24.0275 24.9527 7.0235
9 33.3406 28.2577 26.2222
33.1305 28.284 26.033
33.1728 28.2902 26.0866
33.2146 28.2773 26.1139 27.1956 6.0190
10 33.2678 26.5284 24.4353
33.0357 26.5434 24.1411
33.5971 26.517 24.2246
33.3002 26.5296 24.267 25.3983 7.9019
ADAMTS-9: QRT-PCR RAW DATA (continued).
498
AAA
SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 33.3769 27.6593 25.6052
32.8529 27.8416 25.7465
32.2156 27.6540 26.0428
32.8151 27.7183 25.7982 26.7582 6.0569
2 33.3287 27.1822 25.1020
33.3728 27.2291 24.8425
32.4526 27.0099 25.3082
33.0514 27.1404 25.0842 26.1123 6.9391
3 34.4713 29.0198 27.4420
34.7635 28.9490 27.6540
34.2430 28.5780 27.9448
34.4926 28.8489 27.6803 28.2646 6.2280
4 34.5847 26.5070 24.7654
35.1692 26.3552 24.5419
34.3095 26.4610 25.0941
34.6878 26.4411 24.8005 25.6208 9.0670
5 36.3237 27.1587 25.0434
35.8397 27.1265 25.1972
35.7805 26.9038 25.4906
35.9813 27.0630 25.2437 26.1534 9.8279
6 35.6240 29.1832 26.6170
34.8909 29.0685 26.5990
34.6864 29.0432 27.1175
35.0671 29.0983 26.7778 27.9381 7.1290
7 33.3170 28.1248 25.6727
33.1351 27.9396 25.5519
32.6463 27.8572 25.7414
33.0328 27.9739 25.6553 26.8146 6.2182
8 33.4209 28.2741 25.9266
32.9973 28.0849 25.6750
32.4202 27.9657 26.0175
32.9461 28.1082 25.8730 26.9906 5.9555
9 31.8832 27.6665 24.6740
31.9588 27.8047 25.1131
33.8652 28.5579 25.9627
31.9210 28.0097 25.2499 26.6298 5.2912
10 32.2860 26.9148 25.5679
32.4472 27.0924 25.3188
33.1164 27.5023 24.9513
32.6165 27.1698 25.2793 26.2246 6.3920
11 32.1539 27.8387 25.8126
32.1730 27.6061 25.8382
32.1074 27.3876 25.9478
32.1448 27.6108 25.8662 26.7385 5.4063
12 34.0137 28.5958 27.0511
33.9957 28.5322 27.0110
34.0467 28.6432 26.7718
34.0187 28.5904 26.9446 27.7675 6.2512
BMP-6: QRT-PCR RAW DATA
499
AAA
SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 31.5996 27.7207 26.1265
31.2788 27.6130 25.9008
31.4264 27.5997 25.8514
31.4349 27.6445 25.9596 26.8020 4.6329
14 34.1309 28.0618 25.9087
33.7364 28.0427 25.7371
33.3706 27.6394 25.9714
33.7460 27.9146 25.8724 26.8935 6.8525
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 32.9330 25.0994 22.6239
32.5535 25.1613 21.8624
32.4725 25.4525 22.4674
32.6530 25.2377 22.3179 23.7778 8.8752
2 34.0828 25.6989 23.1125
33.6771 25.8848 22.9083
33.5259 25.5091 22.9230
33.7619 25.6976 22.9813 24.3394 9.4225
3 33.7523 26.1569 25.1140
34.2473 26.1605 25.1470
33.4669 26.2515 25.0016
33.8222 26.1896 25.0875 25.6386 8.1836
4 32.4559 23.9207 21.8305
33.0698 23.8038 21.4178
32.3857 24.5730 21.4083
32.6371 24.0992 21.5522 22.8257 9.8115
5 32.6645 26.2694 24.3608
33.5413 26.4458 24.4712
32.5572 26.2939 24.3716
32.9210 26.3364 24.4012 25.3688 7.5522
6 32.7013 24.6410 22.5814
32.9648 25.0041 22.6435
32.6967 24.7671 22.7404
32.7876 24.8041 22.6551 23.7296 9.0580
7 30.6392 24.1397 20.8068
30.9124 24.1158 20.9277
30.3754 24.0508 20.7846
30.6423 24.1021 20.8397 22.4709 8.1714
8 33.8156 26.3132 24.9274
34.4803 26.1942 24.9541
34.4421 25.7688 24.5310
34.2460 26.0921 24.8042 25.4481 8.7979
BMP-6: QRT-PCR RAW DATA (continued).
500
AOD
SAMPLES C1 GAPDH C2 B actin C3 C4 = AVG (C2,C3) C4-C1
1 35.2547 27.0278 25.2553
35.1348 27.0605 25.1219
34.6047 27.1064 25.1766
34.9981 27.0649 25.1846 26.1248 8.8733
2 30.8417 26.1170 24.3772
31.1417 26.3948 24.1835
31.0772 26.2598 24.1477
31.0202 26.2572 24.2361 25.2467 5.7735
3 33.7593 27.8454 25.6122
34.1084 27.7831 25.6606
33.5781 27.5773 25.6713
33.8153 27.7353 25.6480 26.6917 7.1236
4 32.6269 27.1475 25.9176
32.7229 26.7995 25.5791
32.4084 27.3582 25.4227
32.5861 27.1017 25.6398 26.3708 6.2153
5 32.1337 29.0031 26.4356
32.8466 29.1032 26.5558
33.2291 28.9761 26.4317
32.7365 29.0275 26.4744 27.7509 4.9856
6 35.0885 26.1521 24.8653
35.3393 26.1847 24.5956
35.5062 26.1819 24.4566
35.3113 26.1729 24.6392 25.4060 9.9053
7 31.7474 26.1315 24.1087
32.0205 25.9871 24.0408
32.0985 25.9884 23.3121
31.9555 26.0357 23.8205 24.9281 7.0274
8 33.8232 26.9539 25.2487
33.8790 26.9952 25.2379
34.0103 26.8781 25.3167
33.9042 26.9424 25.2678 26.1051 7.7991
9 33.5242 26.3098 24.5545
33.4330 25.9725 24.1300
32.9230 26.3023 24.0141
33.2934 26.1949 24.2329 25.2139 8.0795
10 33.1086 25.7976 23.8429
34.2496 25.7016 23.9169
34.2596 25.5096 24.0126
33.8726 25.6696 23.9241 24.7969 9.0757
11 33.1208 23.3543 22.1173
33.3223 23.4484 22.1517
32.7554 23.3553 22.0651
33.0662 23.3860 22.1114 22.7487 10.3175
BMP-6: QRT-PCR RAW DATA (continued).
501
AAA SAMPLE  C1 GAPDH C2 B actin C3 C4= AVG (C2,C3) C4-C1
1 32.1765 27.5677 26.0718
32.3035 27.5245 25.9007
32.2914 27.9495 26.0044
32.2571 27.6806 25.9923 26.8364 5.4207
2 30.1333 26.9935 25.3750
30.2702 26.8731 25.1023
30.6574 27.0171 25.0114
30.3536 26.9612 25.1629 26.0621 4.2916
3 32.2251 28.5773 27.4115
32.2592 28.3644 27.2813
32.0578 28.3552 26.8337
32.1807 28.4323 27.1755 27.8039 4.3768
4 30.7451 26.3286 24.6993
30.6447 26.3604 24.5749
30.6146 26.2520 24.4304
30.6681 26.3137 24.5682 25.4409 5.2272
5 31.7582 27.0854 25.1718
32.3463 26.9350 25.0572
31.9647 27.0299 25.2590
32.0231 27.0168 25.1627 26.0897 5.9334
6 31.4249 29.1185 26.8822
31.0292 29.1031 26.9648
31.2196 29.0595 26.4490
31.2246 29.0937 26.7653 27.9295 3.2951
7 31.3377 27.9419 25.4877
31.3990 27.6460 25.5129
31.2374 27.5707 25.2917
31.3247 27.7195 25.4308 26.5752 4.7496
8 31.1556 27.7148 25.4925
31.2278 27.6111 25.2447
30.8716 27.8669 25.5133
31.0850 27.7309 25.4168 26.5739 4.5111
9 29.9187 27.2316 24.5851
30.4054 27.1934 24.4609
30.9622 27.2259 24.4616
30.4288 27.2170 24.5025 25.8598 4.5690
10 30.7626 26.3278 24.9281
30.7489 26.3707 24.8005
30.1710 26.7880 24.7564
30.5608 26.4955 24.8283 25.6619 4.8989
11 31.2668 27.5597 25.6125
31.2246 27.3175 25.2351
31.4242 27.2566 25.4791
31.3052 27.3779 25.4422 26.4101 4.8951
12 31.1034 29.0029 26.4184
32.0380 28.2559 26.5910
31.7457 28.5386 26.5029
31.6290 28.5991 26.5041 27.5516 4.0774
CATHEPSIN H: QRT-PCR RAW DATA
502
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 31.0931 27.1923 25.4714
31.2397 27.3273 25.6739
31.1834 27.1157 25.3421
31.1721 27.2118 25.4958 26.3538 4.8183
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 31.6411 25.9706 23.4835
31.7263 25.8346 23.3397
31.5415 26.1397 23.5344
31.6363 25.9816 23.4525 24.7171 6.9192
2 34.0364 27.3143 24.9735
33.3296 27.4106 24.2057
34.0121 27.1971 24.1586
33.7927 27.3073 24.4459 25.8766 7.9161
3 31.0586 27.5593 26.6555
31.3944 27.4605 26.1938
31.2803 27.1992 26.1255
31.2444 27.4063 26.3249 26.8656 4.3788
4 31.5151 25.7583 23.4403
32.2523 25.9829 23.2240
31.9276 25.9217 23.1837
31.8983 25.8876 23.2827 24.5852 7.3132
5 30.7106 28.2357 26.2853
30.3884 28.1565 26.3186
30.6047 28.1425 26.2382
30.5679 28.1782 26.2807 27.2295 3.3384
6 31.3545 25.2697 24.1449
31.5907 25.1079 23.9718
31.3915 25.1797 23.7194
31.4456 25.1858 23.9454 24.5656 6.8800
7 33.2405 26.1636 24.4119
33.1084 26.0321 24.4153
32.5610 26.0519 24.4108
32.9700 26.0825 24.4127 25.2476 7.7224
8 32.0761 25.8905 22.5069
32.1226 26.1003 22.6967
31.9742 25.7506 22.9032
32.0576 25.9138 22.7023 24.3080 7.7496
CATHEPSIN H: QRT-PCR RAW DATA (continued).
503
AOD
SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 32.2024 26.7055 24.9907
33.1191 26.6390 25.0009
32.5743 27.0775 25.2685
32.6319 26.8073 25.0867 25.9470 6.6849
2 29.5736 25.6347 23.8164
30.0775 25.8529 23.7452
30.1542 25.7206 23.8213
29.9351 25.7361 23.7943 24.7652 5.1699
3 33.6592 27.3599 25.5423
34.0097 26.8657 25.1070
34.3542 27.0601 25.0837
34.0077 27.0952 25.2443 26.1698 7.8379
4 31.1261 26.5032 24.9432
31.8691 26.4243 24.6651
31.1008 26.6964 24.6672
31.3653 26.5413 24.7585 25.6499 5.7154
5 30.8757 28.3628 26.4216
31.2599 28.4409 26.0153
31.9860 28.6164 26.1793
31.3739 28.4734 26.2054 27.3394 4.0345
6 31.6889 27.2793 25.4923
31.5374 27.1941 25.2531
31.7940 27.0541 25.1810
31.6734 27.1758 25.3088 26.2423 5.4311
7 30.3448 26.4675 24.5868
30.4135 26.6082 24.7805
30.4708 26.4644 24.4103
30.4097 26.5134 24.5925 25.5530 4.8568
8 34.2729 28.0238 25.9367
35.0448 28.0158 25.7734
35.2062 27.3428 25.7746
34.8413 27.7941 25.8282 26.8112 8.0301
9 31.1478 26.7196 25.2629
30.8827 27.0086 25.1156
31.0552 27.2436 25.2891
31.0286 26.9906 25.2225 26.1066 4.9220
10 31.7525 26.2794 24.4191
32.0377 26.2680 24.5213
32.3872 26.2891 24.9049
32.0591 26.2788 24.6151 25.4470 6.6122
CATHEPSIN H: QRT-PCR RAW DATA (continued).
504
AAA
SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 27.4110 25.5634 24.0383
27.2842 25.5490 23.7237
27.2515 26.0362 23.8222
27.3156 25.7162 23.8614 24.7888 2.5268
2 28.4447 25.0955 23.1873
28.3324 25.0406 23.1539
28.4366 24.9522 23.0123
28.4046 25.0294 23.1178 24.0736 4.3309
3 30.0250 27.0100 25.6002
29.6548 26.8492 25.5773
29.6068 26.7243 25.4295
29.7622 26.8612 25.5357 26.1984 3.5638
4 29.2478 24.4339 22.7899
29.1878 24.6258 22.7357
28.9259 24.6026 22.6202
29.1205 24.5541 22.7153 23.6347 5.4858
5 31.5081 25.1644 23.4378
31.7536 25.2053 23.3627
31.3088 25.1365 23.3334
31.5235 25.1687 23.3780 24.2734 7.2502
6 27.6049 27.1072 24.9013
27.4378 27.1433 24.8476
27.3520 27.0726 24.7625
27.4649 27.1077 24.8371 25.9724 1.4925
7 28.2369 26.0105 23.8204
28.0815 25.9779 23.7152
27.9734 25.7513 23.6585
28.0973 25.9132 23.7314 24.8223 3.2750
8 28.4028 25.8588 23.7512
28.2945 25.9313 23.5084
28.2570 26.0995 23.5335
28.3181 25.9632 23.5977 24.7805 3.5377
9 26.3837 25.2730 22.4660
26.3416 25.2970 22.4104
25.9221 25.2048 22.4879
26.2158 25.2583 22.4548 23.8565 2.3593
10 30.4830 25.1828 23.5611
30.7883 25.1764 23.5555
30.5551 25.2763 23.5587
30.6088 25.2118 23.5584 24.3851 6.2237
11 28.2440 25.8480 23.8479
28.3372 25.8666 23.8686
28.5311 25.9334 23.8875
28.3708 25.8827 23.8680 24.8753 3.4954
12 29.1595 27.1736 25.2426
29.2605 27.1692 25.2253
29.0401 27.1064 25.1665
29.1534 27.1497 25.2115 26.1806 2.9728
CD79A : QRT-PCR RAW DATA
505
AAA
SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 27.2768 26.0749 23.9632
27.2584 26.1223 23.9384
27.2628 26.0029 23.7858
27.2660 26.0667 23.8958 24.9813 2.2848
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 32.8447 24.5994 22.1501
32.4977 24.5331 22.1813
32.5537 24.8661 22.0615
32.6320 24.6662 22.1310 23.3986 9.2335
2 36.6479 25.3072 21.9562
34.3967 24.8114 21.9899
34.5092 24.4916 22.2395
35.1846 24.8701 22.0619 23.4660 11.7186
3 30.7098 25.1976 24.8588
30.7537 25.7629 24.7274
30.2165 25.8087 24.7149
30.5600 25.5897 24.7670 25.1784 5.3816
4 33.5206 23.5991 21.3484
33.4039 24.0255 21.3460
33.2923 23.6644 21.6835
33.4056 23.7630 21.4593 22.6112 10.7945
5 27.4477 25.7675 24.1823
27.4316 25.9747 24.1048
27.5032 25.6856 28.3577
27.4608 25.8093 25.5483 25.6788 1.7821
6 34.7925 22.9819 21.9909
34.9981 22.9278 21.5973
34.1916 23.0197 22.5986
34.6607 22.9765 22.0623 22.5194 12.1414
7 34.3082 23.6380 22.1699
33.9995 23.6444 22.0318
34.0773 23.8504 22.1269
34.1283 23.7109 22.1095 22.9102 11.2181
8 33.9023 23.7568 20.6021
35.2272 23.6767 20.6801
34.0219 23.8708 20.5292
34.3838 23.7681 20.6038 22.1860 12.1979
CD79A : QRT-PCR RAW DATA (continued).
506
AOD
SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 33.3408 25.4637 23.3565
33.4787 25.4730 23.4268
33.3793 25.3681 23.5084
33.3996 25.4349 23.4306 24.4328 8.9669
2 27.5648 24.6939 22.3362
27.5034 24.6598 22.3494
27.5970 24.5232 22.4095
27.5551 24.6256 22.3650 23.4953 4.0597
3 34.7580 25.7235 23.7404
34.6440 25.7747 23.6813
34.1287 25.6110 23.7013
34.5102 25.7031 23.7077 24.7054 9.8049
4 28.3629 25.3451 23.7928
28.4720 25.5467 23.4206
28.4226 25.5069 23.2506
28.4192 25.4662 23.4880 24.4771 3.9421
5 28.1895 27.3443 25.1256
28.1386 27.4329 24.5166
27.6970 27.5032 24.7254
28.0084 27.4268 24.7892 26.1080 1.9004
6 37.0674 25.6428 24.3021
35.9405 25.3436 24.3966
38.6284 25.8219 24.0812
37.2121 25.6028 24.2600 24.9314 12.2807
7 30.2919 25.3771 24.0618
30.0981 25.1514 22.9435
30.2307 25.2074 23.2181
30.2069 25.2453 23.4078 24.3266 5.8804
8 36.9228 26.3388 24.8060
34.8010 26.4489 24.5600
33.8072 26.2013 24.6320
35.1770 26.3297 24.6660 25.4978 9.6792
9 29.0222 25.4770 24.0079
28.9405 25.5263 23.6848
29.0183 26.0122 23.5497
28.9937 25.6718 23.7475 24.7097 4.2840
10 30.7327 25.1709 23.1202
32.3256 25.3002 23.1011
32.1583 25.3010 23.1117
31.7389 25.2574 23.1110 24.1842 7.5547
CD79A : QRT-PCR RAW DATA (continued).
507
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 29.9616 28.6521 26.7632
30.0633 28.5121 26.6328
29.4765 28.4414 26.9396
29.8338 28.5352 26.7785 27.6569 2.1769
2 28.8515 29.0148 26.8070
28.8330 28.8926 26.8848
28.8526 28.8633 26.7901
28.8457 28.9236 26.8273 27.8754 0.9703
3 32.1521 24.8204 23.4856
31.8337 24.7073 23.4596
31.3724 24.7926 28.1650
31.7861 24.7734 23.4726 24.1230 7.6631
4 36.2558 27.2579 25.6928
34.7953 27.2378 25.6339
35.8870 27.2451 25.5789
35.3412 27.2469 25.6352 26.4411 8.9001
5 38.2055 25.9296 24.3822
37.7348 25.9031 24.1271
37.7348 26.1617 23.9325
37.8917 25.9981 24.1473 25.0727 12.8190
6 27.3843 27.5262 25.5412
27.2650 27.5340 25.4284
27.2435 28.0469 25.4493
27.2976 25.4730 25.4730 1.8246
7 30.7445 27.5421 25.6863
30.2088 27.4953 25.5135
30.4542 27.4999 25.3794
30.4692 27.5124 25.5264 26.5194 3.9498
8 27.3179 26.3867 24.6477
27.2870 26.2916 24.5447
27.1412 26.2222 24.3715
27.2487 26.3002 24.5213 25.4107 1.8380
9 28.4699 27.2075 24.7146
28.2575 27.1585 24.4922
28.1549 27.1179 24.4905
28.2941 27.1613 24.5658 25.8635 2.4306
10 29.0540 26.3859 25.1314
28.8105 26.5170 25.0433
29.0016 26.4833 24.9516
28.9554 26.4621 25.0421 25.7521 3.2033
11 30.7197 27.5651 25.1634
30.4710 27.4874 25.2170
30.4844 27.4077 25.1333
30.5584 27.4867 25.1712 26.3290 4.2294
12 26.7280 27.0240 25.7541
26.7278 27.0702 25.3158
26.7327 27.0965 25.7376
26.7295 27.0636 25.6025 25.6025 1.1270
MMP9: QRT-PCR RAW DATA
508
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 31.0333 28.4445 27.2998
30.9748 28.5254 27.1004
31.2917 28.8975 27.2292
31.0999 28.6225 27.2098 27.9161 3.1838
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 31.1668 25.4162 23.2758
31.0349 25.4247 23.2196
31.5223 25.4656 23.2038
31.2413 25.4355 23.2331 24.3343 6.9071
2 32.4260 25.1529 23.8821
32.1697 25.0815 23.8409
31.7569 25.1333 28.5185
32.1175 25.1226 23.8615 24.4920 7.6255
3 38.5511 26.2374 24.7679
38.1593 26.2242 24.4476
38.1593 26.4846 24.2884
38.2899 26.3154 24.5013 25.4084 12.8816
4 29.6525 26.7882 24.5879
29.5438 26.7402 24.4848
29.3985 27.2087 24.4583
29.5316 26.9124 24.5103 25.7114 3.8202
5 30.8313 25.1124 22.9688
30.6340 25.1171 22.8925
31.2055 25.1539 22.8935
30.8903 25.1278 22.9183 24.0230 6.8672
6 30.1208 26.2171 24.2982
29.6311 26.1258 24.2087
29.7360 26.0188 24.1703
29.8293 26.1206 24.2257 25.1732 4.6562
7 29.6126 28.3046 26.3944
29.7059 28.1697 26.2962
29.1714 28.1131 26.5499
29.4966 28.1958 26.4135 27.3047 2.1920
8 30.6871 27.3177 26.1519
30.7233 27.3250 26.0401
30.5108 27.8252 26.0562
30.6404 27.4893 26.0827 26.7860 3.8544
9 34.2093 25.9396 23.1753
33.6651 25.5703 23.2647
33.3931 25.5590 23.1740
33.7558 25.6896 23.2047 24.4472 9.3087
MMP9: QRT-PCR RAW DATA (continued).
509
AOD SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 30.0244 27.1300 25.0167
29.9671 27.0993 24.8779
29.7297 27.5322 24.8455
29.9071 27.2538 24.9134 26.0836 3.8235
2 30.3591 26.5377 24.6547
30.0025 26.4232 24.5475
30.0785 26.3049 24.4900
30.1467 26.4219 24.5641 25.4930 4.6537
3 36.6088 27.5981 26.0766
35.2018 27.5764 26.0332
36.2866 27.5931 25.9760
36.0324 27.5892 26.0286 26.8089 9.2235
4 29.4164 28.7575 26.3730
29.1878 28.9048 26.2536
29.4437 28.8453 26.5427
29.3493 28.8359 26.3898 27.6128 1.7365
5 28.5286 28.6027 26.4395
28.4998 28.4752 26.5076
28.5233 28.4513 26.4406
28.5172 28.5097 26.4626 27.4862 1.0311
6 29.1329 28.3852 26.0793
28.8832 28.5131 25.9488
29.1233 28.4537 26.2020
29.0465 28.4507 26.0767 27.2637 1.7828
7 31.7986 26.9358 25.0850
32.3130 26.8003 25.0177
31.6874 26.9203 25.0540
31.9330 26.8855 25.0522 25.9689 5.9642
8 30.5458 25.8682 24.0209
30.4579 25.8426 23.8165
30.5262 25.8109 23.7707
30.5100 25.8406 23.8694 24.8550 5.6550
9 28.5660 26.2307 24.6721
29.0274 26.4279 24.6558
28.5130 26.4525 24.6475
28.7021 26.3704 24.6585 25.5144 3.1877
10 28.8364 26.9389 25.2421
29.0215 26.4592 25.2680
28.8173 27.1941 25.1792
28.8917 26.8641 25.2298 26.0469 2.8448
MMP9: QRT-PCR RAW DATA (continued).
510
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 36.7902 25.8874 24.0284
35.2824 25.8608 23.8609
34.8027 26.1203 23.9767
35.0426 25.9562 23.9553 24.9558 10.0868
2 33.5384 25.1223 23.4776
33.6037 25.1947 23.3337
33.8400 25.2349 23.4793
33.6607 25.1840 23.4302 24.3071 9.3536
3 34.3269 27.2618 25.9715
34.3846 27.3607 26.0657
33.5651 27.1382 26.0692
34.0922 27.2536 26.0355 26.6445 7.4477
4 34.0512 24.9406 22.9395
33.2909 25.0880 23.0095
33.4770 25.0080 23.2440
33.6064 25.0122 23.0643 24.0383 9.5681
5 37.8807 25.4350 23.6169
37.8000 25.5528 23.5379
45.2594 25.3876 23.6239
37.8000 25.4585 23.5929 24.5257 13.2743
6 36.7953 27.5016 25.1796
36.7953 27.5386 25.0429
36.7953 27.3941 24.9038
36.7953 27.4781 25.0421 26.2601 10.5352
7 40.4999 26.1166 23.7698
40.4999 26.0456 23.8250
40.4999 26.0703 24.0358
40.4999 26.0775 23.8769 24.9772 15.5227
8 33.9614 26.1066 23.8967
34.3082 26.1342 23.9155
34.3671 26.1813 24.2142
34.2122 26.1407 24.0088 25.0748 9.1375
9 36.0579 25.7443 23.0291
36.0970 25.7799 23.4775
35.3753 25.8566 22.8996 24.3781 10.9972
10 33.0504 25.5164 24.1759
33.0161 25.6059 24.0309
33.4348 26.1323 24.0785
33.1671 25.7515 24.0951 24.9233 8.2438
11 36.9704 26.1947 24.2380
39.1457 26.1317 24.2797
37.3352 26.2173 24.1705
37.8171 26.1812 24.2294 25.2053 12.6118
12 36.9704 27.6850 25.5664
36.9704 27.7683 25.6873
36.9704 27.5219 25.5704
36.9704 27.6584 25.6080 26.6332 10.3372
MMP3 : QRT-PCR RAW DATA
511
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 34.9535 26.2764 24.5588
34.0473 26.2345 24.7169
33.6571 26.2144 24.2220
34.2193 26.2418 24.4992 25.3705 8.8488
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 46.8864 25.2567 22.6496
46.8864 25.1551 22.6218
46.8864 25.0051 22.5083
46.8864 25.1390 22.5932 23.8661 23.0203
2 38.2252 25.8957 24.6796
38.2252 25.8906 24.7360
38.2252 25.8215 24.9124
38.2252 25.8693 24.7760 25.3226 12.9026
3 42.3070 25.2567 22.6496
42.6750 25.1551 22.6218
42.0750 25.0051 22.5083
42.3523 25.1390 22.5932 23.8661 18.4862
4 39.0129 24.4271 22.1194
38.9488 24.1875 22.0503
36.9929 24.7712 22.0307
38.3182 24.4619 22.0668 23.2644 15.0538
5 38.0517 26.8602 24.8873
38.9957 26.9421 25.0133
36.1207 26.6347 24.8055
37.7227 26.8123 24.9020 25.8572 11.8655
6 38.0517 23.9782 22.4725
38.9957 23.8451 22.4570
36.1207 23.7878 22.4709
37.7227 23.8704 22.4668 23.1686 14.5541
7 38.0375 25.0769 23.2544
38.0375 25.1609 22.9698
38.0375 25.0551 22.8998
38.0375 25.0976 23.0413 24.0695 13.9680
8 39.0129 24.5236 21.1595
39.0129 24.5058 21.1539
39.0129 24.4660 21.3574
39.0129 24.4985 21.2236 22.8610 16.1519
MMP3: QRT-PCR RAW DATA (continued).
512
AOD SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 49.1274 25.6805 23.7331
49.1274 25.7288 23.6539
49.1274 25.5296 23.7872
49.1274 25.6463 23.7247 24.6855 24.4419
2 31.4277 24.8132 22.9353
31.2524 24.6855 22.6292
31.0605 24.7966 22.5422
31.2469 24.7651 22.7022 23.7337 7.5132
3 47.9726 26.1328 24.3299
44.2159 26.0626 24.2517
44.2159 25.9597 24.1868
45.4681 26.0517 24.2561 25.1539 20.3142
4 37.9100 25.9402 24.0498
37.9100 25.6489 23.8038
37.9100 25.6110 24.2222
37.9100 25.7334 24.0253 24.8793 13.0307
5 47.9726 27.3755 25.1594
44.2159 27.3261 25.2872
44.2159 27.5127 25.4874
45.4681 27.4048 25.3113 26.3581 19.1101
6 37.4631 24.9148 22.2381
37.4631 24.4816 22.2795
37.4631 24.9737 22.1915
37.4631 24.7900 22.2364 23.5132 13.9499
7 38.3659 26.0291 24.3783
38.3659 26.0779 24.2879
38.3659 25.9033 24.2295
38.3659 26.0034 24.2986 25.1510 13.2149
8 34.1710 25.5466 23.4690
34.6147 25.4396 24.0542
34.3382 25.1685 23.3524
34.3746 25.3849 23.6252 24.5051 9.8696
9 44.4763 26.3847 25.0254
44.4763 26.3911 24.7225
44.4763 26.1810 24.8842
44.4763 26.3189 24.8774 25.5982 18.8782
10 35.7865 26.0648 23.8488
36.4678 25.3926 23.6132
35.3236 25.7177 23.8922
35.8593 25.7250 23.7847 24.7549 11.1044
11 35.4743 25.2077 23.1854
36.7317 25.1428 23.1937
36.9200 25.2345 23.2848
36.3753 25.1950 23.2213 24.2082 12.1672





C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 35.7633 28.4319 27.6026
35.9184 28.2965 27.3895
35.2004 28.5638 27.3408
35.6274 28.4307 27.4443 27.9375 7.6899
2 32.7659 27.7650 26.0795
32.5739 27.7673 26.1147
32.2767 27.8539 26.0022
32.5388 27.7954 26.0655 26.9304 5.6084
3 31.0860 27.0904 24.6777
31.0256 27.2074 24.6561
30.8064 27.1066 24.5926
30.9727 27.1348 24.6421 25.8885 5.0842
4 33.1896 28.0354 25.6511
33.3202 28.0519 25.5826
32.9914 28.4614 25.6759
33.1671 28.1829 25.6365 26.9097 6.2574
5 33.7839 27.1304 25.1165
33.2664 26.9483 25.2221
32.7599 27.1204 24.8725
33.2701 27.0664 25.0704 26.0684 7.2017
6 35.0054 26.3293 24.6715
35.5947 26.3202 24.5787
35.0803 26.4001 24.7395
35.2268 26.3499 24.6632 25.5066 9.7203
7 35.2966 26.9475 25.1279
36.0940 26.7891 25.3502
35.2966 26.9565 25.1279
35.5624 26.8977 25.2020 26.0499 9.5126
8 31.3397 27.1519 25.3154
31.3283 27.2454 25.4251
31.0220 26.7775 25.0983
31.2300 27.0583 25.2796 26.1689 5.0611
9 33.4245 27.5148 24.8478
32.9268 27.4644 24.9765
33.8681 27.1018 25.0425
33.4065 27.3603 24.9556 26.1580 7.2485
10 32.0758 27.2562 25.2722
32.2228 27.5099 25.2919
32.3863 27.1620 25.5192
32.2283 27.3094 25.3611 26.3352 5.8931
11 35.3117 27.0382 24.9496
34.5465 26.9072 24.9429
34.5465 27.1699 25.0990
34.8016 27.0384 24.9972 26.0178 8.7838
12 31.5040 28.2997 26.6795
31.7726 28.1369 26.6778
31.3745 28.1474 26.4569
31.5504 28.1947 26.6047 27.3997 4.1507
CD19: QRT-PCR RAW DATA
514
AAA SAMPLE  C1
GAPDH
C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 31.1543 28.6230 26.2193
31.3023 28.8234 26.1310
31.5816 28.8059 26.4912
31.3461 28.7508 26.2805 27.5156 3.8304
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 34.3308 27.6046 26.1575
34.5822 27.5601 26.2102
34.5438 27.3337 26.1864
34.4856 27.4995 26.1847 26.8421 7.6435
2 38.4960 26.0240 23.5627
38.4960 26.0304 23.5545
38.4960 26.1835 23.7382
38.4960 26.0793 23.6185 24.8489 13.6471
3 38.4960 26.2206 22.8729
38.4960 26.1500 22.8269
38.4960 26.5519 22.9846
38.4960 26.3075 22.8948 24.6012 13.8949
4 42.1795 26.9943 24.2702
42.1795 27.1083 24.2679
42.1795 26.8830 24.2085
42.1795 26.9952 24.2489 25.6220 16.5575
5 31.2403 28.2333 26.6507
31.6789 28.2369 26.4499
31.5812 28.3881 26.9866
31.5001 28.2861 26.6957 27.4909 4.0092
6 47.6992 25.0788 23.6566
47.6992 24.8282 23.7371
47.6992 24.6575 23.8089
47.6992 24.8548 23.7342 24.2945 23.4047
7 41.7809 26.0027 23.9830
36.3397 25.8038 23.8678
41.7809 25.7543 23.7932
39.9672 25.8536 23.8813 24.8675 15.0997
8 42.1795 25.5298 23.5991
42.1795 25.3398 23.1623
42.1795 25.8638 23.0803
42.1795 25.5778 23.2806 24.4292 17.7503





C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 34.3144 26.1822 24.3429
34.3279 26.2076 24.1808
33.5463 26.2824 24.2147
34.0629 26.2241 24.2461 25.2351 8.8278
2 41.0127 27.2518 25.4259
42.1123 27.1992 25.3500
40.4973 27.1674 25.4565
41.2074 27.2061 25.4108 26.3085 14.8990
3 32.4501 26.6211 25.0333
33.4156 26.7027 25.0046
32.7001 25.9259 24.9910
32.8553 26.4166 25.0096 25.7131 7.1422
4 38.0093 27.4130 26.0877
38.0093 27.0736 25.4659
38.0093 27.2763 25.7855
38.0093 27.2543 25.7797 26.5170 11.4923
5 39.7602 26.3840 24.5802
39.7602 26.4055 24.4639
39.7602 26.2823 24.4355
39.7602 26.3573 24.4932 25.4252 14.3350
6 46.1954 27.0021 25.0308
42.3772 27.0370 25.2744
42.3772 26.7400 25.1394
42.3772 26.9264 25.1482 26.0373 16.3399
7 31.0948 28.4033 25.7812
31.4516 28.4199 26.0650
31.4278 28.3341 26.1449
31.3247 28.3858 25.9970 27.1914 4.1333
8 31.2661 26.5156 24.5983
31.5752 26.3625 24.5847
31.4059 26.3999 24.6110
31.4157 26.4260 24.5980 25.5120 5.9037
9 36.0828 26.0978 24.1365
36.0828 26.0292 24.1320
36.0828 26.0352 24.0898
36.0828 26.0541 24.1194 25.0868 10.9961
10 42.4981 27.3937 25.9776
42.4981 27.5727 26.0415
42.4981 27.7603 26.1770
42.4981 27.5756 26.0654 26.8205 15.6776
CD19: QRT-PCR RAW DATA (continued).
516
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 34.8003 29.0358 27.1946
34.8761 28.7090 27.1355
35.1314 28.7059 27.0866
34.9359 28.8169 27.1389 27.9779 6.9580
2 37.8347 29.2697 26.9635
37.8734 29.1488 26.8766
38.1624 29.1228 26.8891
37.9568 29.1804 26.9097 28.0451 9.9117
3 34.9066 27.1976 25.3413
36.6187 27.3618 24.8117
35.3758 27.3390 25.2552
35.6337 27.2995 25.1361 26.2178 9.4159
4 36.0813 27.8186 26.0042
36.8950 28.2825 25.9001
35.2944 27.6811 25.9071
36.0902 27.9274 25.9371 26.9323 9.1580
5 35.2873 27.9151 25.5014
34.4574 27.6836 25.5424
34.8213 27.6298 25.5308
34.8553 27.7428 25.5249 26.6339 8.2215
6 36.5730 29.0547 27.9082
38.1038 28.8943 27.7715
37.1168 29.2254 27.6364
37.2645 29.0581 27.7720 28.4151 8.8495
7 34.6980 27.3737 24.9514
34.8518 27.4685 24.7947
33.7768 27.4597 24.6656
34.4422 27.4340 24.8039 26.1189 8.3233
8 35.5089 26.3576 24.2671
35.0727 25.4188 24.4432
34.9770 26.3143 24.3613
35.1862 26.0302 24.3572 25.1937 9.9925
9 31.4317 26.7392 24.7749
32.2018 25.6758 24.6549
31.3693 26.4596 24.7644
31.6676 26.2915 24.7314 25.5115 6.1561
10 34.0312 27.5636 25.6476
33.7233 27.3518 25.3040
33.6727 27.4649 25.2137
33.8091 27.4601 25.3884 26.4243 7.3848
11 35.0267 26.3134 25.2159
37.5269 27.2873 25.2212
34.9496 27.3573 25.2647
35.8344 26.9860 25.2339 26.1100 9.7244
12 34.1888 27.0941 25.2764
34.1538 26.7225 25.2758
34.6669 26.8552 25.1617
34.3365 26.8906 25.2380 26.0643 8.2722
SPEG: QRT-PCR RAW DATA
517
AAA SAMPLE  C1 GAPDH C2 Bactin C3
C4= AVG
(C2,C3) C4-C1
13 34.8702 27.0941 25.6683
35.0979 27.0753 25.5907
34.4038 27.0096 25.8607
34.7906 27.0597 25.7066 26.3831 8.4075
NA SAMPLE C1 GAPDH C2 Bactin C3
C4 = AVG
(C2,C3) C4-C1
1 31.7500 25.2925 24.2226
31.5333 25.1852 24.1546
31.1940 25.2910 23.9760
31.4924 25.2562 24.1177 24.6870 6.8055
2 31.3285 26.4204 24.6258
31.4752 26.3336 24.4400
31.3661 26.3891 24.4012
31.3899 26.3810 24.4890 25.4350 5.9549
3 31.3014 26.0619 23.7883
31.5422 26.0331 23.5892
31.3360 25.9758 23.7142
31.3932 26.0236 23.6972 24.8604 6.5328
4 31.1128 26.0603 22.7446
31.1528 26.0016 22.7234
31.1067 25.9835 22.6203
31.1241 26.0151 22.6961 24.3556 6.7685
5 32.2156 26.9411 24.2319
31.6660 26.6585 24.0387
31.6616 26.4735 24.0024
31.8477 26.6910 24.0910 25.3910 6.4567
6 30.2094 25.4841 23.0783
29.8053 25.3182 23.0164
29.9297 25.3228 23.1185
29.9815 25.3750 23.0711 24.2231 5.7584
7 34.1377 28.6696 26.8438
33.4634 28.4810 26.1362
33.6184 28.5988 26.6796
33.7398 28.5831 26.5532 27.5682 6.1717
8 34.1039 27.7382 26.8042
34.5060 27.6652 26.6331
34.0113 27.7436 26.5311
34.2071 27.7157 26.6561 27.1859 7.0212
SPEG: QRT-PCR RAW DATA (continued)
518
AOD SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 38.2654 29.0966 26.7265
37.5607 28.9370 26.6802
37.1478 28.9877 26.7296
37.6580 29.0071 26.7121 27.8596 9.7984
2 32.1747 27.3036 25.2624
32.6829 27.3543 25.3248
31.9180 27.0563 25.1720
32.2585 27.2381 25.2531 26.2456 6.0130
3 32.8993 26.8596 24.8204
32.9997 26.6325 24.8656
33.1578 26.5424 24.6184
33.0189 26.6782 24.7681 25.7232 7.2958
4 31.9668 27.9780 26.1616
32.1331 27.9244 26.1132
32.2954 27.9237 26.3324
32.1318 27.9420 26.2024 27.0722 5.0596
5 33.1789 26.6141 25.0782
32.8269 26.6485 24.9289
32.5048 26.7061 24.9565
32.8369 26.6562 24.9879 25.8221 7.0148
6 35.2614 26.1334 24.1274
35.9655 26.0578 24.0327
35.1410 26.0277 24.0843
35.4560 26.0730 24.0815 25.0772 10.3788
7 31.1284 26.4501 24.6817
30.8563 26.5243 24.4570
30.8002 26.7515 24.8311
30.9283 26.5753 24.6566 25.6160 5.3124
8 32.7470 26.9116 25.1337
32.7091 26.0148 25.1516
33.0543 26.6437 25.0136
32.8368 26.5234 25.0996 25.8115 7.0253
9 32.3550 26.6946 24.9810
32.1150 25.8308 25.0704
31.9596 26.8524 24.8405
32.1432 26.4593 24.9640 25.7116 6.4316
10 34.7589 27.6640 26.3404
34.8251 27.7343 25.9992
33.8867 27.8043 26.2559
34.4902 27.7342 26.1985 26.9664 7.5239
SPEG: QRT-PCR RAW DATA (continued).
519
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
1 31.3549 25.8814 24.0881
31.4873 26.0554 24.0677
31.4095 26.2949 23.8386
31.4172 26.0772 23.9981 25.0377 6.3796
2 29.3341 25.7907 22.8349
29.3790 25.6801 22.9250
29.0753 25.6937 22.9767
29.2628 25.7215 22.9122 24.3169 4.9460
3 32.2067 25.4784 23.4058
31.7074 25.2970 23.6058
32.1434 25.3190 23.4210
32.0192 25.3648 23.4775 24.4212 7.5980
4 33.3928 24.8086 22.9848
33.3330 24.8463 23.3688
33.4071 24.8259 23.0171
33.3776 24.8269 23.1236 23.9753 9.4024
5 35.0918 25.5146 23.6060
35.0830 25.3623 23.6131
35.3277 25.3152 23.5152
35.1675 25.3974 23.5781 24.4877 10.6798
6 30.7004 27.8090 25.1834
30.2421 27.4701 25.1015
30.2086 27.4253 24.9091
30.3837 27.5681 25.0647 26.3164 4.0673
7 31.7388 26.2894 23.9553
31.8016 26.3291 24.1011
31.6892 26.2539 24.1853
31.7432 26.2908 24.0806 25.1857 6.5575
8 34.8818 27.2421 25.8951
34.4308 27.1881 25.9917
34.2326 27.1423 25.7438
34.5151 27.1908 25.8769 26.5339 7.9812
9 33.6722 26.4120 24.4442
33.7260 26.3752 23.9885
33.5224 26.5257 24.2377
33.6402 26.4376 24.2235 25.3306 8.3097
10 35.3859 25.2894 23.8495
35.3313 25.1800 23.9652
35.1728 25.5695 23.9601
35.2967 25.3463 23.9249 24.6356 10.6611
11 32.6332 26.0154 24.1791
32.4925 26.0655 24.1914
32.3316 25.8232 24.0386
32.4858 25.9680 24.1364 25.0522 7.4336
12 31.8322 27.2560 25.3137
31.8335 27.0635 25.3436
31.6735 27.0005 25.2226
31.7797 27.1067 25.2933 26.2000 5.5798
SPIB TRANSCRIPTION FACTOR: QRT-PCR RAW DATA
520
AAA SAMPLE  C1 GAPDH C2 Bactin C3 C4= AVG (C2,C3) C4-C1
13 31.9408 26.1412 24.3549
31.9001 26.1443 24.2187
32.1484 26.1359 24.1406
31.9964 26.1405 24.2381 25.1893 6.8072
NA SAMPLE C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 34.3453 24.2611 21.6710
34.4124 24.2572 21.7770
34.4124 24.5708 21.8864
34.3900 24.3630 21.7781 23.0706 11.3195
2 38.9587 24.7442 22.1514
37.8992 24.7453 22.1217
38.4290 24.7780 22.0236
38.1641 24.7558 22.0989 23.4274 14.7367
3 39.0313 23.9333 21.6989
38.0470 24.0378 21.6184
38.5392 24.3170 21.6023
38.5392 24.0960 21.6399 22.8680 15.6712
4 30.1151 26.3926 24.4379
30.1162 26.3217 24.4285
30.1146 26.3834 24.3220
30.1153 26.3659 24.3961 25.3810 4.7343
5 38.2665 23.3614 21.7739
37.5670 23.2764 22.0809
37.0595 23.4821 21.8935
37.6310 23.3733 21.9161 22.6447 14.9863
6 36.5005 24.2178 22.2232
38.9081 24.4219 22.6696
37.9127 24.1970 22.2689
37.7738 24.2789 22.3872 23.3331 14.4407
7 36.2506 25.2585 21.0277
36.8617 25.2219 20.7942
36.1132 24.3376 20.9309
36.4085 24.9393 20.9176 22.9285 13.4800
SPIB TRANSCRIPTION FACTOR: QRT-PCR RAW DATA (continued).
521
AOD SAMPLES C1 GAPDH C2 Bactin C3 C4 = AVG (C2,C3) C4-C1
1 30.5982 27.2435 24.8015
30.6213 27.5036 25.0067
30.6477 27.6166 25.0182
30.6224 27.4546 24.9421 26.1984 4.4241
2 35.4631 25.4467 23.8600
37.0471 25.5804 23.7695
36.5378 25.5889 23.8101
36.3493 25.5387 23.8132 24.6759 11.6734
3 31.6634 24.8765 22.4171
31.9341 25.0721 22.7484
31.8763 24.4112 22.6837
31.8246 24.7866 22.6164 23.7015 8.1231
4 44.0526 26.0825 24.0663
44.7060 26.0778 24.0275
44.3793 25.8421 23.9488
44.3793 26.0008 24.0142 25.0075 19.3718
5 32.0017 25.9040 23.6104
31.8062 25.6222 23.5892
32.1376 25.5247 23.9225
31.9818 25.6836 23.7074 24.6955 8.2745
6 31.5699 25.1009 22.7640
31.5699 25.2903 22.7640
31.5699 25.4672 22.7640
31.5699 25.2861 22.7640 24.0251 7.5448
7 36.6355 25.6622 23.8827
37.9414 25.7820 23.8596
37.2885 25.6470 23.7899
37.6149 25.6971 23.8441 24.7706 12.8444
8 33.2784 24.8962 22.6666
33.7799 25.0330 22.8651
33.5292 24.9191 22.6706
33.6545 24.9494 22.7341 23.8418 9.8128
9 38.5343 25.9529 23.8954
46.6118 26.1724 24.1860
42.5731 26.3128 24.0407
42.5731 26.1460 24.0407 25.0934 17.4797
10 36.0111 24.6898 23.2818
37.4123 24.9680 22.9656
36.7117 25.2015 23.1237
36.7117 24.9531 23.1237 24.0384 12.6733
SPIB TRANSCRIPTION FACTOR: QRT-PCR RAW DATA (continued)
